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Preface
The purpose of this book is to provide information on a number of different endocrine systems
that affect animal production, and to describe how these systems can be manipulated or mon-
itored to advantage. A number of excellent endocrinology texts are already available that
describe the function of various endocrine systems, but these texts, for the most part, deal with
human or comparative endocrinology. This book focuses on commercial animals, and
endocrine systems that can affect growth and carcass composition, the production of animal
products (milk, eggs and wool), reproduction efficiency and animal health, behaviour and
welfare are described. Detailed information on the mechanism of action of the endocrine sys-
tems is covered, and an attempt is made to integrate knowledge from similar topics by focus-
ing on common mechanisms and themes (for example, see the discussion of dietary
polyunsaturated fatty acids (PUFA) in Chapter 3, Section 3.7). This information is used to
understand potential methods for altering these systems and, hopefully, to stimulate ideas for
the development of new methods.
The first two chapters cover the essential background information in endocrinology, my
version of ‘Endocrinology 101’, but also include information on the production of hormones
and the methods for manipulating endocrine systems. In the remaining chapters, endocrine
systems that affect some aspect of animal production are described. Each chapter includes an
overview of the problem or application, followed by a description of the endocrine systems
affecting the problem and a discussion of how these systems can be manipulated or monitored
to advantage.
In Chapter 1, the structure and function of hormones and receptors are covered. The main
concepts of endocrinology are reviewed in sufficient depth to provide the necessary back-
ground material for the rest of the book. An attempt was made to avoid excessive detail and
to introduce some potential applications to heighten interest. An initial overview of hormones
and endocrinology is followed by a discussion of the synthesis, release and metabolism of hor-
mones, the intracellular and extracellular mechanisms of hormone action and the integration
of hormone action at the level of the hypothalamus and pituitary.
Chapter 2 covers various endocrine methodologies. The methods that are used to study
how endocrine systems function are described, followed by methods for measuring hormones
and receptors. Methods used for the production of hormones are then described and, finally,
a number of methods for manipulating hormone function are covered.
In Chapter 3, endocrine systems that affect growth rate, feed efficiency and carcass com-
position are described. This includes anabolic steroids and analogues, use of uncastrated
(intact) male pigs and the problem of boar taint, somatotrophin, β-adrenergic agonists, thyroid
hormones, dietary PUFA (linoleic, linolenic, γ-linolenic acid (GLA) and conjugated linoleic
acid (CLA)), leptin, control of appetite by cholecystokinin (CCK), antibiotics, antimicrobials
and other factors, dietary chromium and insulin, and the effects of stress on meat quality.
x
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In Chapter 4, the endocrine effects on animal products other than meat are covered. These
include endocrine effects on mammary gland development and milk production (including
the regulation of mammogenesis, lactogenesis and galactopoiesis), the effects of bovine soma-
totrophin (bST), the factors affecting milk composition, and metabolic diseases related to lac-
tation. This is followed by a discussion of endocrine effects on egg production, including those
on ovary sexual development in chickens, and the regulation of follicular development and
eggshell formation. Finally, wool production and endocrine defleecing are covered.
Chapter 5 is concerned with the endocrine manipulation of reproduction. In the first sec-
tion, sexual differentiation and maturation of mammals are covered, followed by the regula-
tion of the oestrous cycle, pregnancy and parturition. Methods for manipulating reproduction
are then discussed, including manipulation of the oestrous cycle, pregnancy, the postpartum
interval, inducing puberty and advancing cycling in seasonal breeders. The next section cov-
ers endocrine manipulations in aquaculture, including control of reproduction, effects on
growth and nutrient utilization and the effects of stress.
In Chapter 6, the applications of endocrinology in monitoring and manipulating animal
behaviour, health, performance and welfare are described. The control of broodiness in
turkeys and applications of pheromones in vertebrates and insects are discussed first. This is
followed by a section on the effects of stress, including the hormonal responses to stress and
the effects of stress on immune function, reproduction and growth performance. The
endocrine applications in toxicology are covered in the final section, which illustrates that
changes in endocrine function can be used as indicators of endocrine disruptors in the envi-
ronment and food chain.
This text is aimed at senior undergraduate and graduate students in animal science and
veterinary medicine, although others in academia and industry who are interested in applica-
tions of endocrinology in animal production systems should also find it useful. It is based on
a course, ‘Applied Endocrinology’, that has been taught at the Department of Animal and
Poultry Science, University of Guelph, for the past 15 years. It is my hope that it will help to
integrate knowledge of endocrine function in commercial animals and stimulate new ideas
and applications for improving animal production, health and welfare. Constructive criticism
and comments will be most appreciated.
E. James Squires
University of Guelph
jsquires@uoguelph.ca
Preface                                                                      xi
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1.1 Introduction
What is a hormone?
A hormone is a chemical messenger that
coordinates the activities of different cells
in a multicellular organism. Bayliss and
Sterling first used the term in 1904 to de-
scribe the actions of secretin, which is
a hormone produced by the duodenum
to stimulate the flow of pancreatic juice.
The classical definition of a hormone is:
a chemical substance that is synthesized
by particular endocrine glands and then
enters the bloodstream to be carried to
a target tissue, which has specific recep-
tors that bind it. Other mechanisms of hor-
mone delivery also exist (Fig. 1.1).
Neuroendocrine hormones are synthe-
sized by nervous tissue and carried in
the blood to the target tissue; for example,
the various releasing factors that are pro-
duced in the hypothalamus, which travel
to the anterior pituitary via the hypo-
thalamus–pituitary blood portal system.
Neurocrine hormones are released into
the synaptic cleft by neurones that are
in contact with the target cells. Paracrine hor-
mones diffuse to neighbouring cells, while
autocrine hormones feed back on the cell of
origin in a form of self-regulation. At the
other extreme, pheromones are produced by
one animal and released into the environ-
ment to be received by other animals (see
Section 6.2).
Why are hormones necessary?
Hormones are involved in maintaining
homeostasis – consistency of the internal
environment that is maintained for the bene-
fit of the whole organism. Homeostasis was
first recognized by Claude Bernard in the
19th century, who noted that the internal
environment (i.e. the fluid bathing cells) had
to be regulated independently of external
environment. Being able to regulate and
maintain its internal environment gives the
animal freedom from changes in the external
1©CAB International 2003. Applied Animal Endocrinology (E.J. Squires)
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Hormone and Receptor
Structure and Function
Fig. 1.1. Mechanisms of hormone delivery.
Endocrine/neuroendocrine
Paracrine
Autocrine
Blood
stream
Target
tissue
Endocrine
gland
← ←
environment, allowing it to live in changing
or harsh environments. However, there are
metabolic costs associated with maintaining
homeostasis. For example, maintenance of a
constant body temperature allows animals to
function in cold environments, while cold-
blooded animals (poikilotherms) only func-
tion during warm temperatures. The added
energy costs of maintaining deep body tem-
perature above that of the environment
means that warm-blooded animals have a
higher energy requirement for maintenance
than do poikilotherms. 
Homeostasis is maintained by negative
feedback. For example, an endocrine tissue
produces a hormone that affects the produc-
tion of a metabolite by the target tissue. The
metabolite then interacts with the endocrine
gland to reduce the production of the hor-
mone. This forms a cyclic system in which the
levels of the metabolite are maintained at a
particular level. The set point of the system
can be altered to affect the levels of the
metabolite by altering the sensitivity of the
target tissue to the hormone or the sensitivity
of the endocrine gland to negative feedback
from the metabolite (Fig. 1.2).
In addition to maintaining homeostasis,
hormones can also be used to drive change in
an organism. In this case, levels of hormone
increase to some peak, and this occurs by
positive feedback. Positive feedback ampli-
fies the response, so the tissue must be desen-
sitized or turned over to stop the response.
An example of this response is the surge of
luteinizing hormone (LH) that leads to ovula-
tion (see Section 5.1). LH produced by the
pituitary gland stimulates the developing
ovarian follicle to produce oestrogen, which
stimulates the hypothalamus to produce
gonadotrophin releasing hormone and
increase LH production by the pituitary. This
produces a surge of LH, which decreases
only after the follicle ovulates (Fig. 1.3).
How do hormones function?
Hormones cause a trigger effect to modulate
the activity of the target tissue. The effects of
hormones are seen long after levels of the
hormone return to basal values. In contrast,
nervous signals are short lasting and
more immediate. However, nervous signals
can regulate hormone production as
well. Hormones are present in trace amounts
in plasma, usually ranging from 10–9 to
10–6 g ml–1. They are present at all times in
order to maintain receptors in the target tis-
sue and keep the tissue primed for a
2 Chapter 1
Fig. 1.2. Feedback system to regulate hormone
production.
Fig. 1.3. Positive feedback system leading to the LH surge and ovulation.
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response. Hormones are secreted in variable
amounts according to need, and there is a
constant turnover by inactivation and excre-
tion of the hormone. 
The combined effects of more than one
hormone on a biological response can occur in
a number of different ways (Fig. 1.4). The
actions of different hormones are concerted or
additive if they cause the same response and
the combined effect of the hormones is simply
the sum of the separate actions of the individ-
ual hormones. This suggests that the two hor-
mones act by different mechanisms. In some
cases, two hormones can cause the same effect
but the effects due to the different hormones
are non-additive. This implies that the two
hormones may act by the same common mech-
anism. The effects of two different hormones
are synergistic when the combined effect of the
two hormones together is more than the sum
of the separate effects of the individual hor-
mones. Some hormones, for example steroid
hormones and thyroid hormones, can have a
permissive action and have no effect on their
own but must be present for another hormone
to have an effect. A permissive hormone could
act by increasing the number of receptors or
affecting the activity of the second messenger
system for the second hormone. For example,
oestradiol has a permissive action for proges-
terone by inducing the expression of proges-
terone receptors in the oviduct.
What effects are due to hormones?
Hormones cause changes in cellular metabo-
lism, but they do not make a cell do some-
thing it was not previously capable of.
Hormones do not directly cause changes in
gene structure but can activate genes to influ-
ence gene expression and ultimately protein
synthesis. Hormones can alter catalytic rates
of enzymes, by mechanisms such as the
phosphorylation and dephosphorylation of
proteins. Hormones can also alter membrane
permeability to affect transport processes
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Fig. 1.4. Concerted, non-additive, synergistic and permissive action of hormones.
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and ion movements, alter muscle contraction,
exocrine secretion and water permeability.
These general mechanisms can cause a
variety of effects in the animal. Hormones can:
• cause morphological changes, such as the
differences in body shape between males
and females;
• act as mitogens to accelerate cell division
or alter gene expression to trigger differen-
tiation of cells;
• stimulate the overall rate of protein syn-
thesis or the synthesis of specific proteins;
• be involved in stimulating smooth muscle
contraction; for example, oxytocin stimu-
lates contraction of the myoepithelium in
the mammary gland for milk ejection;
• affect exocrine secretions; for example,
secretin, a peptide hormone from intestinal
mucosa, stimulates pancreatic secretions;
• control endocrine secretions, and a number
of trophic hormones from the anterior
pituitary can stimulate or inhibit hormone
secretion from target organs;
• regulate ion movements across mem-
branes and control permeability to water;
for example, antidiuretic hormone (ADH,
vasopressin) increases water reabsorption
by the kidney; and
• have a dramatic effect on behaviour, such
as sex-related behavioural characteristics,
maternal behaviour, nesting activity and
broodiness (see Chapter 6).
How is hormone action selective?
The method of hormone delivery to the target
cells and the presence of specific receptors in
the target cells determine the selectivity of
hormone action. For example, the hypophy-
seal–portal system linking the hypothalamus
to the pituitary delivers releasing hormones
from the hypothalamus directly to the target
cells in the anterior pituitary. Smaller quanti-
ties of hormone are needed since there is less
dilution of the hormone in selective delivery
systems compared to hormones that reach
their target via the peripheral circulation.
Many hormones are linked to carrier proteins
in the blood, which stabilize the hormone and
increase its half-life in the circulation. For
example, sex hormone binding globulin is
synthesized in the liver and binds testos-
terone and oestradiol in the circulation with a
high affinity. However, the main factor that
determines the sensitivity of a particular tis-
sue to a hormone is whether or not the tissue
contains the specific receptor for the hormone
– the tissue will not respond to the hormone
unless it has enough of the specific receptor.
Receptors are specific proteins present in
target cells that bind a particular hormone
and initiate a response. Receptors are nor-
mally present in small numbers (10,000 mol-
ecules per cell). There are two general types,
cell-surface receptors (Fig. 1.5) and intracellu-
lar receptors (Fig. 1.6). Peptide and protein
hormones generally do not enter the cell, but
interact with cell-surface receptors. For some
cell-surface receptors, a second messenger
system is needed to transmit the hormone
response signal from the outside to the inside
of the cell. This involves the activation of a
protein kinase, which phosphorylates spe-
cific proteins within the cell to alter their
function. Steroid hormones and thyroid hor-
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Fig. 1.5. Action of hormones via cell-surface receptors.
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mones enter the cell to interact with intracel-
lular receptors and regulate gene expression. 
Types of hormones 
The major structural groups of hormones are:
• steroids;
• proteins, polypeptides and glycoproteins;
• amino-acid derivatives (especially deriva-
tives of tyrosine); and
• fatty acids and derivatives, such as
prostaglandins.
The structures of some non-protein hor-
mones are given in Fig. 1.7.
Location of endocrine glands
The location of the key endocrine glands is
given in Fig. 1.8. Table 1.1 lists the hormones
produced by these glands and their func-
tions. Applications involving many of these
hormones are covered in this text and the rel-
evant sections are listed in Table 1.1.
1.2 Synthesis, Release and
Metabolism of Hormones
Synthesis of protein hormones
Peptide and protein hormones consist of a
linear chain of amino acids. As with any pro-
tein, the specific sequence of the different
amino acids determines the primary struc-
ture and nature of the protein. The amino-
acid sequence information for a protein is
contained in the sequence of bases (A,C,G,T)
in the coding region of the gene that codes for
the protein. A three-base sequence codes for
one amino acid; this is known as the genetic
code. This code is copied from DNA into
mRNA by transcription and the mRNA is
used to direct protein synthesis by the
process of translation (Fig. 1.9).
Signal peptides are short sequences of
15–30 hydrophobic amino acids located at the
amino-terminal (beginning) of proteins. The
presence of a signal sequence (S) directs the
newly synthesized protein into the endoplas-
mic reticulum and then to export from the
cell. Other proteins enter the cytosol and
from there are directed to the mitochondria
(M) or nucleus (N), or to other sites within
the cell. Proteins move between the various
compartments by vesicular transport. The
uptake of proteins by particular vesicles is
controlled by the sorting signal sequences in
the proteins (Fig. 1.10). A program (SignalP)
for identifying signal peptides and their
cleavage sites has been described by Nielsen
et al. (1997) and can be accessed online
(http://www.cbs.dtu.dk/).
Newly synthesized protein hormones
containing signal sequences are known as
prehormones. Some peptide hormones are
synthesized as part of a larger precursor,
called a prohormone. Examples of prohor-
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Fig. 1.6. Action of hormones via intracellular receptors.
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Fig. 1.7. Structures of representative non-protein hormones.
Triiodothyronine (3,5,3’-Triiodothyronine, T3)
mones include proparathyroid hormone, the
precursor of parathyroid hormone and pro-
insulin, which is the precursor of insulin. Pro-
opiocortin is the precursor of several trophic
peptide hormones produced in the anterior
pituitary. The newly synthesized prohor-
mone with a signal peptide is known as a
preprohormone (Fig. 1.11).
A number of hormones, including thy-
roid stimulating hormone (TSH), follicle
stimulating hormone (FSH) and LH, have
sugar units attached to the amino-acid side-
chains, and are known as glycoproteins.
After protein synthesis, the preprohormone
moves from the endoplasmic reticulum to the
Golgi apparatus, where sugar residues are
attached to asparagine, serine and other
amino-acid side-chains in a process called
glycosylation. These sugar units can form
complex branched chains. From the Golgi
apparatus, the proteins are packaged into
secretory vesicles and the active hormone is
generated by cleavage of the prohormone
sequences. The secretory granules fuse with
the plasma membrane to release their con-
tents by exocytosis when the cell is stimulat-
ed. For more information on the mechanisms
of protein secretion, see the review by
Blázquez and Shennan (2000).
Synthesis of steroid hormones
Steroid hormones are produced in the
gonads and the adrenal gland. The gonadal
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Fig. 1.9. Transcription of DNA to RNA and transla-
tion of RNA into protein.
Fig. 1.8. The location of key endocrine glands in
cattle: 1, pineal; 2, hypothalamus; 3, pituitary; 4,
thyroid; 5, parathyroid; 6, pancreas; 7, adrenal; 8,
kidney; 9, ovary (testis in males).
Fig. 1.10. Role of signal peptides in directing the movement of proteins within cells. A typical signal
sequence (S) is: M-M-S-F-V-S-L-L-L-V-G-I-L-F-W-A-T-E-A-E-Q-L-T-K-C-E-V-F-Q- (a patch of hydropho-
bic amino acids is underlined). The signal (M) for importing into the mitochondria is: M-L-S-L-R-Q-S-I-R-
F-F-K-R-A-T-R-T-L-C-S-S-R-Y-L-L-. The signal (N) for importing into the nucleus is: P-P-K-K-K-R-K-V-.
Endoplasmic
reticulum
Cell
surface
Secretory
vesicles
steroids include the progestins, oestrogens
and androgens. Progesterone is a major prog-
estin, which prepares the lining of the uterus
for implanting of the ovum and is involved in
the maintenance of pregnancy. Oestrogens,
such as oestradiol, are involved in the devel-
opment of female secondary sex characteris-
tics and in the ovarian cycle. The androgens
are involved in the development of male sec-
ondary sex characteristics. Testosterone is a
major androgen. The adrenal cortex produces
glucocorticoids and mineralocorticoids.
Cortisol, a major glucocorticoid, promotes
gluconeogenesis and fat and protein degra-
dation. Aldosterone, a major mineralocorti-
coid, increases absorption of sodium,
chloride and bicarbonate by the kidney to
increase blood volume and blood pressure.
The synthesis of steroid hormones
occurs on the smooth endoplasmic reticulum
and in the adrenal mitochondria. Cholesterol
is the precursor of all steroid hormones and is
present as low-density lipoprotein (LDL) in
plasma. Many of the steps in the biosynthesis
of steroids involve an electron transport
chain in which cytochrome P450 is the termi-
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Table 1.1. Summary of hormones produced by various endocrine glands and their functions.
Relevant book
Endocrine glands Hormones produced Physiological response sections
Hypothalamus TRH TSH and PRL by anterior pituitary See Section 1.4 for
GnRH LH and FSH interaction between
CRH ACTH, β-endorphin, stress hypothalamus and
GHRH and GH-RIH GH pituitary
PRF and PIF PRL
MRF and MIF MSH
Anterior pituitary GH Somatomedin by liver Section 3.4
(adenohypophysis) PRL Mammary gland/lactogenesis Section 4.1
TSH Thyroid hormone Section 3.6
FSH E2, follicular growth/spermatogenesis Sections 4.2, 5.1
LH E2 and P4, ovulation/androgen Section 5.1
ACTH Adrenal steroids Sections 3.12, 6.3
MSH Melanogenesis
β-endorphin Analgesic
Posterior pituitary Oxytocin Milk ejection Section 1.4
(neurohypophysis) Vasopressin Antidiuretic hormone
Pineal Melatonin Seasonality, gonad function Section 5.1
Parathyroid PTH Calcium and phosphorus metabolism Sections 4.1, 4.2
Thyroid T4 and T3 Metabolic rate Section 3.6
Adrenal cortex Cortisol, corticosterone, Carbohydrate metabolism, Sections 3.12, 6.3
(outer part) aldosterone sodium retention
Adrenal medulla (Nor)Epinephrine Alarm reactions Sections 3.5, 6.3
Gonads Androgens, oestrogens Sexual development/behaviour Sections 3.2, 3.3,
Progestins Pregnancy 4.1, 5.1, 5.2
Inhibin FSH
Relaxin/oxytocin Parturition
Pancreas Insulin, glucagon Blood glucose Section 3.11
Gastrointestinal Gastrin, GIP, secretin HCl and bicarbonate Section 3.9
tract CCK Pancreatic enzymes
Motilin, neurotensin Gastric activity
VIP Blood flow
Kidney Erythropoietin Blood cell formation
Various tissues Eicosanoids Smooth muscle Section 3.7
Growth factors Growth and differentiation Sections 4.1, 4.3
nal electron acceptor and carries out hydrox-
ylation reactions. The overall scheme is
shown in Fig. 1.12.
The conversion of cholesterol to preg-
nenolone (Fig. 1.13) involves removal of the
C6 side chain from cholesterol by hydroxyla-
tion at C20 and C22 and cleavage of this bond
by desmolase (P450 side-chain cleavage).
This step occurs in adrenal mitochondria and
is stimulated by adrenocorticotrophic hor-
mone (ACTH).
Pregnenolone is then converted to prog-
esterone by oxidation of the 3-hydroxy to
a 3-keto group and isomerization of the
∆5 double bond to a ∆4 double bond.
Progesterone is converted to cortisol by
hydroxylation at C17, C21 and C11.
Progesterone is converted to aldosterone
by hydroxylation at C21 and C11, and oxida-
tion of the C18 methyl to an aldehyde
(Fig. 1.14).
Progesterone is converted into andro-
gens by hydroxylation at C17 and cleavage of
the side-chain to form androstenedione (an
androgen). The 17-keto group is reduced to a
hydroxyl to form testosterone. Androgens are
converted into oestrogens by loss of the C19
methyl group and aromatization of the A
ring. The formation of oestrogens from
androgens is catalysed by the aromatase
enzyme CYParom (CYP19) (Fig. 1.15).
Synthesis of eicosanoids
The eicosanoid hormones include
prostaglandins, prostacyclins, thrombox-
anes and leukotrienes. They are locally pro-
duced within cell membranes and have
autocrine and paracrine effects. They stimu-
late inflammation, regulate blood flow and
blood pressure, affect ion transport and mod-
ulate synaptic transmission. They are synthe-
sized from 20 carbon fatty acids, such as
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Fig. 1.11. Structure of insulin illustrating the sig-
nal peptide and pro-sequence.
Fig. 1.13. Conversion of cholesterol to pregnenolone.
Fig. 1.12. Overall pathways of steroid hormone
synthesis (see Fig. 1.7 for structures of these
steroids).
arachidonic acid (20:4) derived from mem-
brane lipids (Fig. 1.16).
The enzyme cyclooxygenase (COX)
catalyses the first step in the conversion of
arachidonate to prostaglandins and throm-
boxanes. Non-steroidal anti-inflammatory
drugs (NSAIDs), such as aspirin, ibuprofen
and acetaminophen, inhibit COX and reduce
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Fig. 1.14. Metabolism of pregnenolone to aldosterone.
Fig. 1.15. Metabolism of progesterone to androgens and oestrogens.
the production of prostaglandins and throm-
boxanes. Prostaglandin E2 (PGE2) and F2α
(PGF2α) control vascular smooth muscle
activity. Prostaglandin I2 (PGI2) is produced
by the blood vessel wall and is the most
potent natural inhibitor of blood platelet
aggregation. Thromboxanes such as TXA2 are
produced by thrombocytes (platelets) and are
involved in the formation of blood clots and
the regulation of blood flow to the clot.
Leukotrienes are made by leukocytes and are
extremely potent in causing vasocontraction
and inducing vascular permeability.
Synthesis of thyroid hormones
Synthesis of thyroid hormones occurs in the
thyroid gland. The synthesis is stimulated by
thyrotrophin (TSH) released from the anteri-
or pituitary. Thyrotrophin is released in
response to thyrotrophin releasing hormone
produced from the hypothalamus. Thyroid
hormones are synthesized by iodination of
tyrosine residues in the thyroglobulin pro-
tein. Proteases in lysosomes degrade thy-
roglobulin to release triiodothyronine (T3)
and thyroxine (T4) (Fig. 1.17).
Hormone release
Steroids are not stored but released immedi-
ately to diffuse out of the cell. Protein and
peptide hormones are stored in granules
within the gland and are released in response
to various stimuli. Trophic hormones can
stimulate hormone release: for example TSH,
which stimulates the release of thyroxine.
The trophic hormones FSH and LH stimulate
the synthesis and release of gonadal steroids,
while ACTH stimulates the synthesis and
release of adrenal steroids (see Section 1.4).
Hormones can be released in response to
nervous stimuli from environmental cues
such as light, smell, sound and temperature.
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Fig. 1.16. Synthesis of eicosanoids.
Arachidonic acid
Prostacyclin I2 (PGI2)
This neuroendocrine transduction illustrates
the integration of the nervous and endocrine
systems. Hormones are also released in
response to levels of various metabolites. For
example, intracellular glucose levels control
glucagon and insulin secretion, amino acids
stimulate somatotrophin release and increase
uptake of amino acids, while extracellular
Ca2+ regulates parathyroid hormone and cal-
citonin secreting cells. These effects are all
examples of stimulus–response coupling.
Metabolism and excretion of hormones 
Hormones must be metabolized rapidly and
removed so that feedback mechanisms can
operate and hormones can regulate cellular
functions. Removal or inactivation follows
exponential decay kinetics (Fig. 1.18). The
half-life of the hormones in the circulation is
a measure of the longevity of hormone
action. Many synthetic hormones and hor-
mone analogues are designed to have a
longer half-life and thus be effective for
longer periods of time than natural hor-
mones.
Peptide hormones are degraded by pep-
tidases, such as the cathepsins in lysosomes,
which split the peptide bonds in the mol-
ecule. Exopeptidases degrade protein from
the carboxy-terminal end or the amino-termi-
nal end. Endopeptidases, such as trypsin and
chymotrypsin, degrade the protein at internal
sites with some specificity. Trypsin hydro-
lyses peptide bonds where the carboxyl
group is from lysine or arginine, while for
chymotrypsin the carboxyl group in the pep-
tide bond comes from phenylalanine, trypto-
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Fig. 1.17. Synthesis of thyroid hormones.
Fig. 1.18. Inactivation of hormones follows expo-
nential decay.
H
or
m
on
e 
co
nc
en
tr
at
io
n
phan or tyrosine. Deamination or reduction
of disulphide bonds (e.g. insulin) can also
inactivate proteins. This occurs in kidney,
liver and in target cell lysosomes.
Steroid hormones are bound to protein
carriers in blood, such as serum albumin or
steroid-binding globulin, which are necessary
since steroids are lipophilic. Binding to protein
carriers also increases the half-life of steroids.
Physiologically, only 5–10% of the hormone is
present in the free or unbound form.
Steroids are degraded by a two-phase
process in the liver and in the kidney. This
process inactivates the steroids and makes
them more water soluble for excretion. In
phase one, enzymes such as cytochrome P450
(CYP) add functional groups such as hydroxyl
groups. These metabolites are then conjugated
to glucuronic acid or sulphates by transferase
enzymes (Fig. 1.19). These more water-soluble
metabolites are excreted by the kidney in the
urine or by the liver in the bile salts.
1.3 Receptors and Hormone Action
Hormones interact with receptors located
either on the cell surface or inside the cell to
initiate their effects on the target tissue.
Binding of hormones to cell-surface receptors
activates intracellular enzyme systems to
alter cell function. Hormones that cross the
cell membrane act by binding to intracellular
receptors. The hormone–receptor complex
then interacts with DNA to affect expression
of specific genes.
Extracellular receptors
Extracellular receptors are large macromol-
ecules located on the outer surface of the
plasma membrane in target tissues. For
example, the insulin receptor has a molecular
mass of 200–400 kDa, consisting of two
α-subunits of 130 kDa and two β-subunits of
90 kDa linked by disulphide bonds. Usually,
there are separate receptors for each hormone
and the function of the cell (i.e. the cell type)
dictates whether a particular receptor will be
present on a cell and the number of receptors
present. Experimental evidence that a hor-
mone receptor is located on the cell surface
includes:
1. Demonstrating that antibodies against the
receptor can block hormone action;
2. Limited proteolysis of intact cells would be
expected to destroy the receptor and remove
the hormone response;
3. Coupling the hormone to a large molecule
that cannot enter the cell and demonstrating
that the effect of the hormone is still present;
and
4. Demonstrating that the receptor is present
in a plasma membrane preparation produced
by subcellular fractionation (100,000 g pellet). 
Hydrophobic regions on the receptor protein
interact with lipid in the membrane. The
receptor can be solubilized with detergents
and purified by affinity chromatography
using the hormone bound to a column
matrix. Receptors can be glycoproteins and
contain carbohydrate residues. Experimental
tools to demonstrate this are:
1. Treat the receptor preparation with neur-
aminidase or β-galactosidase to remove the
sugar residues. This inhibits binding of the
hormone.
2. Concanavalin A (ConA; a protein from jack
bean that binds to a D-glucosyl residues) can
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Fig. 1.19. Structure of steroid sulphates and glucuronides.
be used to inhibit hormone binding. In addi-
tion, ConA can be used for affinity chro-
matography of glycoproteins (see Section 2.2,
Chemical assays).
Second messenger systems
Some hormones interact with a cell-surface
receptor and stimulate the synthesis of intra-
cellular second messenger compounds. The
hormone does not enter the cell to elicit a
response but stimulates one of two main
pathways:
1. The adenylate cyclase–cAMP–protein
kinase A pathway or the related guanylate
cyclase–cGMP-dependent protein kinase
pathway; and
2. The calcium-dependent phospholipase
C–protein kinase C pathway. 
In the first system, hormone binding to the
receptor activates the enzyme adenylate
cyclase or guanylate cyclase, which synthe-
size either cAMP or cGMP. These second
messengers activate protein kinase A. In the
second system, binding of the hormone to the
receptor activates phospholipase C, which
splits phosphatidylinositol in the cell mem-
brane to inositol phosphate and diacylgly-
cerol. The inositol phosphate increases levels
of intracellular calcium, which, together with
the diacylglycerol, activates protein kinase C. 
Both protein kinase A and protein kinase
C can phosphorylate and activate various
intracellular proteins to alter cellular metabo-
lism. These proteins are inactivated by
removing the phosphate using the enzyme
phosphoprotein phosphatase.
Adenylate cyclase–cAMP–protein kinase
A pathway
The enzyme adenylate cyclase catalyses the
formation of cAMP from ATP. cAMP acti-
vates protein kinases which phosphorylate
intracellular proteins to alter their activity
(Fig. 1.20). The formation of cAMP is an
amplification step that increases the effective
hormone concentration, since one adenylate
cyclase enzyme catalyses the formation of
many cAMP molecules. The enzyme phos-
phodiesterase degrades cAMP to AMP by the
following reaction:
ATP → cAMP → AMP
Adenylate Phosphodiesterase
cyclase
Several properties of cAMP make it suitable
as a second messenger. It is derived from ATP
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Fig. 1.20. Cyclic AMP second messenger system.
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but is chemically stable. ATP is ubiquitous
and cAMP is formed from it in a single reac-
tion. Since cAMP is not a metabolic precursor,
but an allosteric regulator, it can be controlled
independently of metabolism. cAMP is a
small and easily diffusable molecule and it
has a number of functional groups that allow
specific binding to regulatory subunits of
protein kinases.
Experimentally, the involvement of
cAMP as a second messenger can be deter-
mined if physiological levels of hormone
increase cAMP in cells and cAMP production
precedes the physiological effect. The hor-
mone should also stimulate adenylate cyclase
activity in broken cells. Treatment with
exogenous cAMP or its analogues, such as
dibutyryl cAMP and 8-bromo cAMP (Fig.
1.21) should produce the hormone response.
Phosphodiesterase inhibitors, such as theo-
phylline, caffeine or isobutylmethylxanthine
(IBMX), will decrease cAMP clearance and
potentiate the response. Adenylate cyclase
can be activated by treatment with the diter-
pene, forskolin (Fig. 1.22), which binds direct-
ly with the catalytic subunit to permanently
activate it.
A number of different hormones act via
the cAMP second messenger system (Table
1.2). The substrates for cyclic AMP-depend-
ent protein kinases include triglyceride
lipase, which is involved in the regulation of
lipolysis, phosphorylase b kinase in the regu-
lation of glycogenolysis, cholesterol ester
hydrolase in the regulation of steroidogenesis
and fructose 1,6-diphosphatase in the regula-
tion of gluconeogenesis. These latter
enzymes are all activated by phosphoryla-
tion. Enzymes that are inactivated by phos-
phorylation include pyruvate kinase in the
regulation of glycolysis and gluconeogenesis,
glycogen synthase in the regulation of glyco-
gen synthesis, and 3-hydroxy-3-methylglu-
taryl-CoA reductase in the regulation of
cholesterol biosynthesis.
Guanyl cyclase–cGMP-dependent protein
kinase pathway
The cGMP system is similar to the cAMP sys-
tem, but may act in opposition to cAMP. This
is known as the yin–yang hypothesis. For
example, activation of the cAMP-dependent
kinases results in smooth muscle relaxation,
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Fig. 1.21. cAMP and its analogues and phosphodiesterase inhibitors.
while activation of the cGMP-dependent
kinases results in smooth muscle contraction.
Levels of cGMP are normally 10–50 times
lower than those of cAMP. 
GENOMIC ACTIONS OF CAMP. Activating pro-
tein kinase A and subsequent phosphoryla-
tion of intracellular proteins can cause
immediate cellular responses, such as modifi-
cation of metabolic pathways and regulation
of ion flows and muscle contraction.
However, cAMP can also have effects on gene
transcription by protein kinase A activation
of the cAMP-responsive-element binding
protein (CREB), or modification of the struc-
tural proteins in chromatin. Activated CREB
binds to specific cAMP-responsive elements
in the regulatory regions of certain genes to
activate gene expression.
Calcium-dependent phospholipase
C–protein kinase C system
The primary intracellular effector in this
pathway is calcium, which activates a calci-
um-dependent protein kinase C. Hormone
binding activates phospholipase C, which
catalyses the hydrolysis of phosphatidylinos-
itol-4,5-bisphosphate to produces inositol-
1,4,5-phosphate (IP3) and diacylglycerol
(DAG) (Fig. 1.23). Inositol-1,4,5-phosphate
and its metabolite, inositol-1,3,4,5-tetra
kisphosphate (IP4), increase intracellular Ca
2+
by activating calcium channels at the endo-
plasmic reticulum and cell surface.
Diacylglycerol activates protein kinase C by
increasing its affinity for Ca2+, and protein
kinase C then phosphorylates cellular pro-
teins to regulate their activity (Fig. 1.24). 
In both of these systems, the receptor is
discrete from the enzyme system that it acti-
vates; both ‘float’ in the cell membrane lipid.
The receptor interacts with the adenylate
cyclase or phospholipase C via an intermedi-
ate G-protein. The G-protein is activated by
binding GTP and inactivated when the GTP-
ase activity converts the GTP to GDP. G-
protein function can be studied using a non-
hydrolysable form of GTP or cholera toxin,
both of which inhibit the GTP-ase activity.
The Ras oncogene codes for a permanently
active G-protein, which might explain its role
in the development of cancer. G-proteins act
to couple cell-surface receptors for hormones,
neurotransmitters, odorants and photons of
light to effector molecules such as ion chan-
nels or enzymes that generate second mes-
senger molecules.
An example of the stimulus response
coupling due to this system is the effect of
gonadotrophin releasing hormone (GnRH).
GnRH is produced by the hypothalamus and
causes LH and FSH release by the anterior
pituitary. GnRH increases cellular Ca2+ levels
and affects inositol metabolism. LH release is
Ca2+ dependent and an increase in intracellu-
lar Ca2+ causes a release of LH. 
Calcium also binds to calmodulin to
form an active complex. Calmodulin is a
heat-stable globular protein of molecular
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Fig. 1.22. Forskolin, an activator of adenylate
cyclase.
Table 1.2. Hormones that act via the adenylate cyclase–cAMP–protein kinase A pathway.
Glucagon Chorionic gonadotrophin
Vasopressin Parathyroid hormone
Thyrotrophin (TSH) Calcitonin
Adrenocorticotrophic hormone (ACTH) Luteinizing hormone releasing hormone (LHRH)
Luteinizing hormone (LH) Thyrotrophin releasing hormone (TRH)
Follicle stimulating hormone (FSH) Secretin
mass 16 kDa and is a calcium-dependent reg-
ulatory protein found in all eukaryotic cells.
It controls intracellular Ca2+ and binds four
Ca2+ ions per molecule to form an active com-
plex. This complex acts as an allosteric regula-
tor of protein kinase C and other enzymes. It
also controls the activity of cellular filamentous
organelles (via actin and myosin) responsible
for cell motility, exoplasmic flow (hormone
secretion) and chromosome movement.
Experimental tools used to determine
the involvement of the calcium-dependent
phopholipase C–protein kinase C system are: 
1. Increase intracellular Ca2+ levels using
Ca2+-selective ionophores (A23187) or lipo-
somes loaded with Ca2+.
2. Decrease intracellular Ca2+ by chelating
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Fig. 1.24. Calcium-dependent protein kinase C second messenger system.
Fig. 1.23. Action of phospholipase C.
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with EGTA, using Ca2+-channel blockers, or
inorganic Ca2+ antagonist (La3+).
3. Use phorbol esters (tetradecanoylphorbol
acetate (TPA)), which resemble diacylglycerol
(Fig. 1.25, see structure inside dashed lines),
to activate protein kinase C. 
4. Inhibit phospholipase C with U73122; the
inactive analogue, U73343, is used as a posi-
tive control.
INTERACTION OF CAMP AND CA2+ PATHWAYS.
There is a considerable amount of ‘cross-talk’
between the different secondary messenger
systems. Ca2+ binds to calmodulin and this
complex can bind to phosphodiesterase to
activate it and decrease cAMP levels. Protein
kinase A, which is activated by cAMP, can
phosphorylate some Ca2+ channels and
pumps and alter their activity to affect intra-
cellular calcium levels. Protein kinase C can
be phosphorylated by protein kinase A to
change its activity. Protein kinase C and pro-
tein kinase A can phosphorylate different
sites on the same protein, so that its activity is
regulated by both cAMP and Ca2+.
Tyrosine kinase receptors: catalytic
receptors
The tyrosine kinase receptors do not use a
second messenger system to activate a sepa-
rate protein kinase, but have a kinase domain
as part of the receptor structure. The activat-
ed receptor phosphorylates tyrosine residues
in its kinase domain and can then phospho-
rylate other proteins, and is thus called a
tyrosine kinase receptor. The receptor con-
sists of a transmembrane domain, an extra-
cellular domain for hormone recognition and
a cytoplasmic domain that transmits the reg-
ulatory signals and contains ATP binding
sites. The cytoplasmic domain has a C-termi-
nal tail with autophosphorylation sites. The
phosphorylated receptor acts as a kinase
enzyme and phosphorylates substrates.
These phosphorylated substrates transmit
several regulatory signals into the cell. 
There are three main classes of tyrosine
kinase receptors (Fig. 1.26). The class I receptor
(e.g. epidermal growth factor (EGF) receptor)
is a monomeric transmembrane protein with
intracellular and extracellular domains on the
same molecule. The extracellular domain con-
tains two cysteine-rich repeat regions. The
class II receptor (e.g. insulin receptor) is a
heterotetrameric receptor in which the two
α-subunits and the two β-subunits are linked
by disulphide bonds. The class III receptor
(e.g. receptors for platelet-derived growth fac-
tor (PDGF) or nerve growth factor (NGF)) is a
monomeric protein with cysteine residues
over the extracellular domain. The intracellu-
lar domain has unique amino acid inserts in
the middle of the kinase domain.
Hormone binding causes dimerization
of the monomeric receptors (Fig. 1.27). The
kinase domains in the monomers are then
phosphorylated and activated by their part-
ner. The kinases can then phosphorylate and
activate other proteins. The receptors also
interact with proteins containing SH2
domains that bind to phosphotyrosines. The
amino-acid sequence next to the phospho-
tyrosines specifies which protein, containing
an SH2 domain, can bind to receptor. The SH2
domain protein can be attached to a different
enzymatic domain or be a linker molecule
that binds to other enzyme molecules that
could not normally bind to the receptor. In
this way, linker molecules can bind a number
of different specific molecules to bring them
together to produce the desired biological
effect. For example, the appropriate kinase
and phosphatase can be held in position so
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Fig. 1.25. Tetradecanoylphorbol acetate (TPA) or
phorbol 12-myristate 13-acetate (PMA). The out-
lined area has a structure similar to that of diacyl-
glycerol.
that a protein (receptor, ion channel, etc.) is
activated by the kinase in the presence of the
appropriate signalling molecule and deacti-
vated by the phosphatase when the
signalling molecule is absent. The role
of SH2 domain proteins is described in a
popular press article by Scott and Pawson
(2000).
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Fig. 1.26. Types of tyrosine kinase receptors.
Fig. 1.27. Mechanism of action of tyrosine kinase receptors.
CYTOKINE RECEPTORS. Receptors for cytokines
(growth hormone (GH), prolactin, erythro-
poietin, interferons and interleukins) do not
have intrinsic kinase activity (Fig. 1.28). The
GH receptor exists as a monomer when it is
not bound to hormone. The binding of hor-
mone causes dimerization of the receptor and
binding of Janus kinase (JAK) tyrosine
kinase, which phosphorylates the receptor to
activate it. Phosphotyrosines act as docking
sites for intracellular signalling molecules,
such as STATs (signal transducers and activa-
tors of transcription), which activate various
genes.
RECEPTOR SERINE KINASE. Receptor serine
kinases include receptors for transforming
growth factor-β (TGFβ), activin and inhibin.
These peptide growth factors are involved in
the control of cell proliferation and differenti-
ation. The existence of these receptors was
demonstrated by chemical cross-linking of
radiolabelled hormone to cell-surface pro-
teins on responsive cells. 
The binding of hormone results in for-
mation of a heterodimer of receptors I and II.
Serine residues on RI are phosphorylated by
RII to activate the complex (Fig. 1.29).
Termination of hormone action 
After hormones interact with receptors, they
cluster together, and this triggers vesicu-
larization of membrane and endocytosis.
The receptors may then be degraded by lyso-
mal enzymes or the receptor can be recycled.
The hormone at the cell surface can be
degraded by serum enzymes. The cyclic
nucleotides are degraded by phosphodi-
esterases and the phosphorylated proteins
are dephosphorylated by phosphoprotein
phosphorylase.
Intracellular receptors
Steroid and thyroid hormones operate via
intracellular receptors. In 1966, Toff and
Gorski identified oestrogen receptors, using
radiolabelled hormone, and showed that the
receptor was only present in target cells.
Receptors for glucocorticoids (GR), mineralo-
corticoids (MR) and androgens (AR) are
found predominantly in the cytoplasm, while
receptors for thyroid hormone (TR), oestrogen
(ER), progesterone (PR), retinoic acid (RAR)
and 1,25-hydroxy vitamin D3 (VDR) are pre-
dominantly in the nucleus. Receptors for
steroid hormones act as transcription factors
to regulate the transcription of target genes.
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Fig. 1.28. Mechanism of action of cytokine receptors.
Steroid hormone receptors move
between the nucleus and cytoplasm and, in
the absence of hormone, are bound to the 90
kDa heat-shock protein complex (Hsp90).
(TR, RAR and VDR do not bind Hsp90.)
Binding of the hormone to the recep-
tor results in release of the Hsp90 com-
plex and translocation of the hormone–
receptor complex to the nucleus. A dimer of
the hormone–receptor complex then interacts
with hormone-responsive elements on
specific genes to affect DNA transcrip-
tion. This exposes template sites on DNA,
either directly or by influencing pre-existing
repressor molecules, to increase the initiation
sites for RNA polymerase and increase tran-
scription (Fig. 1.30). These actions of steroid
hormones occur over a much longer time
frame (hours) compared to peptide hor-
mones.
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Fig. 1.29. Mechanism of action of receptor serine kinases.
Fig. 1.30. Mechanism of action of steroid hormones.
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Steroid hormones can also affect the
extent of mRNA degradation. The effects of
steroid hormones can be determined experi-
mentally by:
1. Measuring steady-state levels of mRNA by
Northern blotting. Levels would increase
with increased synthesis or decreased degra-
dation of mRNA.
2. In order to separate synthesis from degra-
dation, a nuclear run-on assay can be used to
measure the rate of mRNA synthesis.
3. Actinomycin D (an inhibitor of RNA tran-
scription) and puromycin (an inhibitor of
protein synthesis) can be used to inhibit the
effects of steroid hormones. 
Steroid hormones can affect the response to
other hormones. This can be through synthe-
sis of receptors or protein kinases to increase
hormone response or phosphoprotein phos-
phatases, which are antagonistic to cyclic
nucleotide actions.
Structural and functional domains of
nuclear receptors 
Nuclear receptors have common structural
domains involved in DNA binding and hor-
mone binding (Fig. 1.31). Other regions are
involved in dimerization of the receptor and
translocation of the receptor to the nucleus. 
The ligand-binding domain is the
region where the hormone binds to the recep-
tor. Sequence diversity in this region gives
the specificity of the receptor for the hor-
mone. The DNA-binding domain of the
receptor is comprised of 60–70 amino acids
arranged in ‘zinc fingers’. This region is
where the hormone–receptor complex binds
to hormone-responsive genes to stimulate
transcription (Fig. 1.32).
Binding sites of the hormone–receptor
complex on DNA
Hormone target genes contain specific
hormone-responsive elements (HREs), which
are involved in binding to the hormone–recep-
tor complex. Identification of these sequences
in a gene suggests that hormones regulate the
gene. The sequences are usually in the
5’ regions, but may also be in the introns or the
3’ region. All HREs have a similar structure,
consisting of pairs of hexamers arranged as
inverted palindromes, with one side of the
palindrome having the complementary
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Fig. 1.31. Structural domains of intracellular receptors.
Ligand binding
sequence to the other side. The complemen-
tary sequences are separated by a defined
number of intervening bases. Steroid receptors
bind to the HREs as homodimers, with the axis
of symmetry over the centre of the palindrome.
Receptors for thyroid hormone (TR) and vita-
min D (VDR) bind to their HREs as het-
erodimers along with the RXR receptor
(named for binding to 9-cis retinoic acid).
Recent evidence has shown that the polyunsat-
urated fatty acid docosahexaenoic acid (DHA)
binds to the RXR receptor in vivo, which may
explain the vital role of DHA in development.
Only two types of consensus hexamers
are used. The steroid receptors (GR, MR, AR
and PR) bind to 5’-AGAACA-3’, while the ER,
RXR, TR and VDR bind to 5’-AGGTCA-3’. The
residues in the P box of the DNA-binding
domain of the receptor determines which type
of HRE consensus sequence is recognized by
the receptor. The spacing between the pairs of
hexamers in the palindrome varies from one to
five nucleotides for different receptors.
Organization of nuclear chromatin and
the nuclear matrix
CHROMATIN. The DNA in eukaryotic cells is
tightly associated with protein in the form of
chromatin (Fig. 1.33). Chromatin exists as a
string of nucleosomes, which are composed
of 146 bp of DNA wrapped around a core of
eight histones. Histones are small, basic pro-
teins that are rich in arginine, lysine and his-
Hormone and Receptor Structure and Function 23
Fig. 1.32. DNA-binding domains of intracellular receptors. The P-box sequences define the specificity of
receptor binding to DNA. The sequences are: ER, EGCKA; TR, EGCKG; RAR, EGCKG; GR, GSCKV;
PR, GSCKV.
Fig. 1.33. Nucleosome structure of chromatin.
tidine. The histone core of the nucleosome
consists of two each of H2A, H2B, H3 and H4,
and this complex is coated with positive
charges that interact with the negatively
charged DNA. Histones H3 and H4 are very
similar between species, with a difference of
only two amino acids in H4 and four amino
acids in H3 found between pea and calf thy-
mus. An additional histone (H1) is involved
in the packaging of the individual nucleo-
somes to form condensed chromatin. There
are no changes in the histones that are related
to cell function and they are not involved in
binding of the hormone–receptor complex to
chromatin.
DNA that is highly condensed is often
inactive, with transcription taking place in
the more loosely packed regions of the
genome, which can be detected by their
hypersensitivity to nucleases or chemical
probes. The histones in active chromatin are
highly acetylated, which removes a positive
charge on lysine and reduces the binding to
DNA and the packing density of the chro-
matin. The binding of a steroid hormone–
receptor complex produces hypersensitive
sites in chromatin allowing the binding of
other transcription factors to initiate gene
transcription.
Chromatin also contains non-histone
proteins or acidic proteins. The acidic pro-
teins are rich in aspartic acid and glutamic
acid. Many types of acidic proteins are pres-
ent, and their composition varies between tis-
sues. One group of these, the non-histone
high-mobility group (HMG) proteins, has
been implicated in the regulation of tran-
scription by enhancing the binding of steroid
hormone receptors to their target sites on
DNA. In particular, HMG-1 and HMG-2 bind
to specific DNA structures and they can also
modify and stabilize the structure of DNA, to
aid in the assembly of protein complexes at
the promoter. They thus act to increase the
sequence-specific binding of steroid hormone
receptors to DNA and increase transcription
of steroid hormone responsive genes.
However, HMG-1/2 do not stimulate bind-
ing of non-steroid nuclear receptors, such as
VDR, RAR and RXR (for further details, see
Boonyaratanakornkit et al., 1998). 
The increase in initiation sites caused by
binding of steroid hormone–receptor com-
plexes to DNA can be demonstrated using
inhibitors of free RNA polymerase, such as
rifampicin or α-amanitin. In this experiment
(Fig. 1.34), RNA polymerase is added to chro-
matin, which then binds to available initia-
tion sites. Rifampicin is then added, which
binds to and inhibits the excess RNA poly-
merase not bound to chromatin. Nucleotides
are then added to start transcription and,
after one copy is made, RNA polymerase is
inhibited. The number of copies of RNA tran-
scribed is a measure of the number of initia-
tion sites on the chromatin.
NUCLEAR MATRIX. The nuclear matrix is a
three-dimensional skeletal network that
exists in the nucleus. It is isolated by extract-
ing nuclei with Triton X-100 detergent, fol-
lowed by treatment with DNase I and 2 M
NaCl. The matrix allows the nucleus to be
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Fig. 1.34. Experiment to illustrate that steroid
hormone receptor binding increases RNA
polymerase initiation sites in target genes.
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organized into different domains for DNA
replication, transcription and RNA splicing.
The nuclear matrix is analogous to the
cytoskeleton, which is involved in the intra-
cellular transport of molecules in the cytosol,
for example the movement of hormone–
receptor complexes to the nucleus. 
Specific, high-affinity steroid receptors
have been found to be associated with active-
ly transcribed genes that are also associated
with the nuclear matrix. The interaction of
receptors with the nuclear matrix is hormone
dependent. The nuclear matrix may thus pro-
vide a mechanism whereby the hormone–
receptor complex binds to specific DNA
sequences. Acceptor proteins for receptors
have been identified associated with the
matrix, and specific domains of the receptors
are involved in matrix binding. Release of
receptors from the matrix may be ATP
dependent. Nuclear matrix proteins of 10–17
kDa have been identified that cause specific
high-affinity binding of the progesterone and
oestrogen receptor to genomic DNA. These
acceptor proteins are expressed only in tis-
sues that are responsive to progesterone.
The nuclear matrix is also involved in
the organization of DNA, DNA replication,
heterogeneous nuclear RNA (hnRNA) syn-
thesis and processing. It may play a role as a
communication network from one part of the
cell to another, in the transport of molecules
(e.g. chromosomes during replication), and
as a framework for reactions. For more infor-
mation on nuclear acceptor sites for the pro-
gesterone receptor, see Spelsberg et al. (1996).
IDENTIFICATION OF DNA REGULATORY SEQUENCES.
DNA sequences that are important in regulat-
ing gene expression can be identified using
an in vitro system (Fig. 1.35). The experimen-
tal method involves:
1. Linking the regulatory sequences of inter-
est to a test gene and transfecting the gene
construct into a cell line. For measuring hor-
mone-responsive elements, the cell line must
also contain the receptor for the hormone. 
2. The activity of the test gene is measured in
the presence of hormone and receptor.
3. The sequences of interest are then gradual-
ly deleted and the effect of the deletion on
expression of the test gene is measured. 
Deletion of important regulatory
sequences will dramatically affect the level of
gene expression. For example, deletion of
sequences important in activation of the gene
by a hormone–receptor complex will elimi-
nate the stimulation of gene transcription by
the hormone. Deletion of repressor regions
will result in increased activity of the test
gene.
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Fig. 1.35. System for identifying regulatory elements in genes.
IDENTIFICATION OF DNA-BINDING PROTEINS. The
binding of protein factors to DNA can be
determined by DNase footprinting and elec-
trophoretic mobility shift assays (Fig. 1.36).
These techniques can be used to determine
sequences that are involved in
hormone/receptor binding.
DNase footprinting assays begin by
labelling a double-stranded DNA sequence
that contains the region of DNA (promoter)
suspected of binding protein factors. The
labelled DNA is then incubated with a source
of binding protein, such as an extract of
nuclei from cells in which the promoter func-
tions. A control incubation is carried out with
a source of protein that does not bind the
DNA. This is followed by limited digestion
with DNase I to introduce approximately one
nick in each DNA molecule. The DNA frag-
ments are separated by denaturing polyacryl-
amide gel electrophoresis to generate a
‘ladder’ of DNA fragments. The region of the
DNA probe bound by the protein is protected
from DNase digestion and this results in a
hole or ‘footprint’ in the ladder.
The electrophoretic mobility shift assay is
used to confirm that a small region (25 bp) of
DNA binds to protein. A labelled DNA probe
is incubated with a source of binding protein,
such as a nuclear extract, and the mixture is
separated by non-denaturing gel elec-
trophoresis to preserve DNA–protein com-
plexes. The unbound DNA probe has a low
molecular weight and moves rapidly through
the gel, while the DNA–protein complex is of
much larger size and is ‘shifted’ to a higher
region of the gel. The specificity of binding of
protein to the labelled probe is confirmed by
the absence of the labelled higher molecular
weight band when an excess of the same
DNA that is unlabelled is included. An unre-
lated oligonucleotide should have no effect.
Integration of peptide and steroid
hormone actions
The classic descriptions of peptide and
steroid hormone actions described above are
not the whole story. Steroid hormones can
also cause rapid effects by acting at the cell
surface and not only longer-term effects on
gene transcription by binding to intracellular
receptors. For example, plasma sex hormone
binding globulin (SHBG) is involved in the
transport of androgens and oestrogens in the
blood, and it regulates the amount of free sex
steroids that are released to the target cells. In
addition, a SHBG receptor is present on the
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Fig. 1.36. DNase footprinting and electrophoretic mobility shift assays.
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surface of target cells. SHBG can bind to its
receptor at the cell surface and then bind free
steroids, to activate a cAMP second messen-
ger system. In this way, the SHBG modulates
the effects of sex steroids acting on receptors
within the cells. Steroids that bind to the
SHBG but do not activate the second messen-
ger system act as antagonists. The actions of
SHBG have been reviewed (Fortunati, 1999).
In addition to gonadal steroids, rapid, non-
genomic effects for glucocorticoids, miner-
alocorticoids, vitamin D3 and thyroid
hormone are also known. For further infor-
mation on the rapid non-genomic effects of
steroid hormones, see the review by
Falkenstein et al. (2000).
Steroid hormones can also affect the
activity of protein hormones by stimulating
the synthesis of protein hormone receptors on
the cell surface, or by affecting the synthesis of
protein kinases or other intracellular proteins
that are involved in the action of peptide hor-
mones. As mentioned previously, production
of cAMP by the action of protein hormones
can also have effects on gene transcription.
This occurs by phosphorylation and activa-
tion of the cAMP-responsive-element binding
protein (CREB) by protein kinase A or by
modification of the structural proteins in
chromatin. Many hormone-responsive genes
have specific cAMP-responsive elements in
their regulatory regions. Activated CREB
binds to these regions to activate gene expres-
sion. For more information, see the texts by
Stryer (1995) and Nelson and Cox (2000).
1.4 Pituitary–Hypothalamic
Integration of Hormone Action
Structure–function relationship of
pituitary and hypothalamus
The hypothalamus is a part of the brain loca-
ted below the third ventricle above the
median eminance. The pituitary gland or
hypophysis is located below the hypothala-
mus in a hollow pocket of the sphenoid bone
known as the ‘sella turcica’ and is linked to
the hypothalamus. The pituitary gland con-
sists of two distinct lobes, the posterior pitu-
itary or neurohypophysis and the anterior
pituitary or adenohypophysis. The posterior
pituitary is nervous tissue that develops as an
outgrowth of the diencephalon. It receives
hormones that are made in the magnocellular
neurones in the hypothalamus and are trans-
ported along the axons to the posterior pitu-
itary. The anterior pituitary is glandular
tissue, and is subdivided into pars distalis
and pars intermedia. It is the ‘master gland’,
which produces a number of trophic releas-
ing hormones that stimulate hormone release
by target tissues (Fig. 1.37).
The hypothalamus is innervated with
many neurones from other parts of the body,
and receives signals from cells such as baro-
receptors and osmoreceptors and other envi-
ronmental cues. It produces releasing
hormones and release inhibiting hormones,
which are delivered to the anterior pituitary
by the hypothalamic–pituitary portal system.
Release from the posterior pituitary is by
direct nervous stimulation, from other neu-
rones in the hypothalamus to the neurones
that produce the posterior pituitary hor-
mones. The release of hormones from the
hypothalamus and pituitary is pulsatile
because of the pulsatile firing of nerves. 
Releasing factors or release inhibiting
factors produced by specific neurones in the
hypothalamus regulate release of hormones
from the anterior pituitary. These factors are
produced in very small amounts and are
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Fig. 1.37. Organization of the pituitary and hypo-
thalamus.
delivered from the hypothalamus to the ante-
rior pituitary by the hypothalamic–
hypophyseal portal system (Fig. 1.37).
Release of hormones by the posterior
pituitary is under direct nervous control. The
posterior pituitary gland has nerve endings
with bulbous knobs that lie on the surfaces of
capillaries. Vasopressin or ADH (antidiuretic
hormone) and oxytocin are secreted into the
capillaries by exocytosis from the neurones
that produce them (Fig. 1.38).
Posterior pituitary hormones
Oxytocin and vasopressin are the two hor-
mones that are released from the posterior
pituitary. Oxytocin causes contraction of
smooth muscles. These include the myo-
epithelial cells for milk let down in the mam-
mary gland, and in the myometrium for the
contraction of the uterus for parturition.
Vasopressin, also known as antidiuretic hor-
mone, stimulates reabsorption of water from
the distal tubular kidney to maintain blood
osmolarity when blood volume or blood pres-
sure is decreased. Both vasopressin and oxy-
tocin are polypeptides containing nine amino
acids with a disulphide bridge between two
cysteines in the molecule (Fig. 1.39).
These two hormones are almost identi-
cal, except that in vasopressin, phenylalanine
and arginine replace isoleucine and leucine of
the oxytocin molecule. They are synthesized
as preprohormones in the cell bodies of spe-
cific neurones in the hypothalamus. The pro-
hormones are cleaved to active hormones
during fast axonal transport from the cell
body down the axon in the posterior pitu-
itary and before they are released into the cir-
culation (Fig. 1.38). They are released in
response to changes in osmotic or barometric
pressure, pain, fright or stress, adrenal insuf-
ficiency, hypoxia or cardiac failure.
Anterior pituitary hormones
The anterior pituitary produces a number of
trophic hormones that cause hormone release
from target tissues (Table 1.3). Hormones of
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Table 1.3. Hormones of the anterior pituitary.
Number of
Hormone amino acids Structure
GH 191 Single-chain proteins with 2–3 disulphide bonds
PRL 199
TSH 211 Glycoproteins, 2 subunits with common α-subunit
FSH 210
LH 204
ACTH 39 Short, linear-chain peptides
MSH 13/22
β-LPH 91
Fig. 1.38. Hormone production and axonal trans-
port by nerve cells. RER, rough endoplasmic
reticulum.
the anterior pituitary are proteins or glyco-
proteins. They have longer half-lives than
releasing hormones produced by the hypo-
thalamus. They are made in specific cells
(thyrotrope, gonadotrope, corticotrope,
melanotrope, somatotrope, mammotrope) in
the anterior pituitary gland.
Hypothalamic control of pituitary
hormone secretion
The control of pituitary hormone release by
the hypothalamus (Fig. 1.40) has been
demonstrated by a number of experiments.
These include:
1. Placing a mechanical barrier between the
hypothalamus and the pituitary, or ectopic
transplantation of the pituitary gland
(to another site that has a good blood supply,
see Section 2.1). This will either decrease
or enhance secretion of certain pituitary
hormones.
2. Pharmaceutical agents that affect neuro-
transmitter production, or electrical stimula-
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Fig. 1.39. Structures of oxytocin, vasopressin and their preprohormones.
Fig. 1.40. Regulation of pituitary hormone
release.
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tion of discrete hypothalamic sites, can affect
the release of pituitary hormones. 
3. Hypothalamic extracts injected into an
intact animal affect pituitary secretions. 
4. Releasing factors have been localized to
specific hypothalamic neurones, and levels of
these factors are higher in the hypothalamic–
pituitary portal system than in the systemic
circulation. 
5. Antisera to hypothalamic releasing hor-
mones lead to enhanced or inhibited pitu-
itary hormone secretion (for example, see
immunization against GnRH, Section 3.3).
Hypothalamic releasing and
release-inhibiting hormones
The function of the releasing and inhibitory
hormones from the hypothalamus is to con-
trol the secretion of the anterior pituitary hor-
mones. For each type of anterior pituitary
hormone there is usually a corresponding
hypothalamic releasing hormone; for some of
the anterior pituitary hormones there is also a
corresponding hypothalamic inhibitory fac-
tor (Table 1.4).
The hypothalamic releasing hormones
are generally made as a larger prohor-
mone, which is cleaved later to form active
peptide hormones. Using labelled antibodies,
it can be demonstrated that specific neurones
make different releasing hormones. The
releasing hormone precursors are made in
cell bodies and transported down the axons
to the nerve endings for storage. They are
released by exocytosis of granule contents
(excretion of substances through the
cell membrane) into the hypothalamic–
pituitary portal blood system in response to
electrical signals from other neurones.
Chemical signals for release include metabo-
lite levels and other hormones such as steroid
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Table 1.4. Hypothalamic hormones.
Releasing Target tissue and
hormone Trophic hormone hormone Ultimate effect
TRH (thyrotrophin TSH (thyrotrophic ↑ T4 and T3 from Regulates metabolic rate
releasing hormone) hormone) thyroid
PRL (prolactin) Mammary gland Synthesis of milk
GnRH LH (luteinizing hormone) Ovary Affects ovulation
(gonadotrophin FSH (follicle stimulating Ovary Affects gonadal
releasing hormone) hormone) development
CRH or CRF ACTH ↑ Adrenocortical Response to stress
(corticotrophin (adrenocorticotrophic steroids from adrenal
releasing hormone) hormone) cortex
β-LPH (β-lipotrophin Analgesia in stress
degrades to β-endorphin neurotransmitter
[Met]enkephalin
GHRH and GH (somatotrophin)) ↑ Somatomedin Increased growth
GH-RIH production by liver
(growth hormone
releasing hormone,
and growth hormone
release-inhibiting
hormone)
MRF, MIH MSH (melanocyte Melanocytes ↑ Skin pigmentation
(melanocyte stimulating stimulating hormone)
hormone releasing
and inhibiting hormones)
PRH and PIH PRL (prolactin) Mammary gland Synthesis of milk
(prolactin releasing
and inhibiting hormones)
hormones or small molecules that can cross
the blood–brain barrier.
The releasing and inhibiting hormones
produced by the hypothalamus are all simple
peptides or proteins. They range in size from
three amino acids for TRH (pyro-E-H-P-
amide), ten amino acids for GnRH (pyro-E-
H-W-S-Y-G-L-R-P-G-amide), 14 amino acids
for GH-RIH, 41 amino acids for CRH and 44
amino acids for GHRH.
Some hormones (e.g. GH, MSH, PRL) are
under tonic inhibition by release inhibiting
hormones. These hormones are needed early
in life, but as the hypothalamus matures and
becomes more active, the hormones that are
‘driven’ by releasing hormones increase,
while GH and MSH decrease.
Control of hormone release 
Electrical (nervous) stimulus in response to
environmental or internal signals causes the
release of releasing hormone by the hypo-
thalamus. The releasing hormone is pro-
duced in nanograms and is delivered to the
pituitary by the portal system. This causes
the release of trophic hormone by the anter-
ior pituitary in microgram amounts. The
trophic hormone then causes release of the
milligram amounts of the ultimate hormone
by the target gland. Note that each step in
this process produces an amplification of the
response. The overall scheme of the regula-
tion of metabolic hormones is given in Fig.
1.41 and the regulation of reproductive hor-
mones is given in Fig. 1.42.
Hormone secretion from the pituitary
gland occurs in an episodic or rhythmic man-
ner. This is regulated by the biological clock
in the suprachiasmatic nucleus of the hypo-
thalamus. This may prevent the down regu-
lation of receptors that would occur in
response to a continuous level of hormone
secretion. For example, the levels of cortisol
are highest in the morning and decrease in
the afternoon and evening. Secretion of
somatotrophin is more pulsatile in females
than in males. The pulse frequency, pulse
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Fig. 1.41. Overview of regulation of metabolic hormones.
amplitude and average hormone levels can
be calculated using a pulse detection algo-
rithm, ‘Pulsar’, developed by Merriam and
Wachter in 1982. The nature of this pulsatile
release is very important. For example, dif-
ferences in the frequency of GnRH release by
the hypothalamus differentially affect the
subsequent release of LH and FSH by the
pituitary.
The release of hormones by the anterior
pituitary is regulated by feedback control.
There is a short feedback loop from the ante-
rior pituitary to the hypothalamus and a long
feedback loop of the ultimate hormone on the
CNS, hypothalamus or anterior pituitary
(Fig. 1.40).
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Fig. 1.42. Overview of regulation of reproductive hormones.
Questions for Study and Discussion
Section 1.1 Introduction
1. What is the definition of a hormone?
2. Why are hormones necessary?
3. How do hormonal systems function and what are the effects of hormones?
4. How are hormones selective?
5. Why are there both intracellular and extracellular receptors?
6. What are the different chemical structures of hormones?
7. Where are the different hormones produced and what are their physiological roles?
Section 1.2 Synthesis, Release and Metabolism of Hormones
1. Describe the mechanism for the synthesis of protein hormones and the process of movement and
processing of newly synthesized protein in the cell.
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2. Describe the synthesis of steroid hormones.
3. Describe the synthesis of eicosanoid hormones and thyroid hormones.
4. Discuss factors that regulate hormone release and hormone metabolism and excretion.
Section 1.3 Receptors and Hormone Action
Protein hormones
1. Outline the chemical nature of receptors.
2. Describe the cAMP and cGMP second messenger systems.
3. Outline the calcium/diacylglycerol–protein kinase C-dependent signalling pathway.
4. Describe methods to determine whether the cAMP- or calcium-dependent pathways are involved
in any system.
5. Outline the mechanisms of action of tyrosine kinase receptors, cytokine receptors and serine
kinase receptors.
Steroid hormones
1. Discuss the actions of steroid hormones in the cell. What is the time frame for steroid hormone and
peptide hormone action?
2. Describe the structure of steroid hormone receptors.
3. Discuss the potential role of the nuclear matrix and nuclear chromatin in hormone action.
4. Describe experiments to identify DNA sequences involved in hormonal regulation of gene expres-
sion.
Section 1.4 Pituitary–Hypothalamic Integration of Hormone Action
1. Illustrate the position of the brain, hypothalmus and pituitary gland. (a) Outline the integration of
hormonal systems with the hypothalamus. (b) Describe the integration of hypothalamic and pituitary
function (nervous/pituitary–hypothalamic portal system).
2. What is the nature of the hypothalamic releasing and release inhibiting hormones (function and
structure)?
3. What hormones are produced by the posterior pituitary gland (structure, synthesis and function)?
What stimulates their release and how is this regulated?
4. What are the properties of the hormones produced by the anterior pituitary gland? How is their
release regulated?
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2.1 Methods for Studying Endocrine
Function 
It is necessary to first characterize an
endocrine system and understand how it
functions. This knowledge of the endocrine
system can then be used to improve or moni-
tor animal performance, health and welfare.
In broad terms, this involves identifying the
endocrine tissue and target organs and deter-
mining the physiological effects of hormone
and their significance to the animal. The
detailed information needed includes:
1. The chemical structure of the hormone (for
example protein, steroid, amino acid or fatty
acid derivative);
2. The details of the biosynthesis, storage and
secretion, and the stimulus for secretion of
the hormone;
3. The transport of the hormone and the
mechanism of hormone action in the target
cell; and
4. The pathways of metabolism, inactivation
and excretion of the hormone.
Model systems 
A number of in vivo and in vitro model sys-
tems can be used to study endocrine systems.
Models range from the whole animal, to iso-
lated perfused organs, tissue slices, isolated
cells in culture and subcellular fractions (Fig.
2.1). The model system of choice for a partic-
ular study depends on what information is
needed and what level of organization is
needed to achieve the objectives of the study.
For example, the overall effects of an
endocrine system on animal performance
would need to be studied in a whole animal,
while the mechanism of action of the hor-
mone might best be studied in an isolated cell
system.
Whole animal model
Experiments using the whole animal have
the advantage of measuring in vivo produc-
tion and uptake of hormones by various
organs. The true ‘in vivo’ function and effect
on the animal can be established in the whole
animal model. The net effects on the whole
animal are determined and the interplay
35
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among individual organs can be examined.
However, whole animal experiments have
the disadvantages of high cost for animals
and reagents and high biological variability
among different animals. Biological variabili-
ty can be reduced somewhat by using highly
inbred lines of animals with a similar genetic
make-up.
The classical methods used to study
endocrine tissues are whole animal studies in
which organs are removed and replaced. The
approach is to remove the organ, note the
effects on the animal and then replace the
organ. Sham-operated animals, in which the
surgery is performed up to the point that the
organ would be removed but the animal is
left intact, act as controls (Fig. 2.2).
Organs can be removed surgically; for
example, adrenalectomy or removal of the
adrenals, which would result in lowered
plasma adrenal steroids and lower plasma
sodium, along with other effects. In the case
of paired organs, such as the adrenals and
gonads, removal of one organ causes the
other to increase in size to compensate for the
lost capacity. This can be from hypertrophy
(increase in cell size) or hyperplasia (increase
in cell number). Note that hyperplasia can be
distinguished from hypertrophy by an
increase in the DNA content of the tissue.
Another example of surgical removal of
organs is hypophysectomy or removal of the
pituitary (hypophysis). Hypophysectomy
demonstrates that the endocrine system is
under pituitary control. For example, in the
winter flounder Pseudopleuronectes ameri-
canus, a hypophysectomized fish turns grey
due to a lack of melanocyte stimulating hor-
mone (MSH) from the pituitary. 
Organs can also be inactivated by treat-
ment with chemicals or by removing the
nervous stimulation of the tissue. Examples
of chemical inactivation include treatment
with alloxan, which destroys the islet cells in
the pancreas that produce insulin. Cobalt
chloride treatment destroys the glucagon-
secreting cells. This is particularly useful
when surgical removal is impossible, as in
the islets of Langerhans, which are scattered
throughout the pancreas. An example of
removal of nervous stimulation to an organ,
called deafferentation, is vagotomy or dis-
ruption of the vagus nerve to the gastrin-
producing cells of the stomach. Normally the
vagus nerve stimulates gastrin secretion in
anticipation of food or distension of the stom-
ach. Gastrin stimulates HCl and pepsinogen
secretion into the stomach.
To confirm that the endocrine response is
due to a particular tissue, the tissue can be
placed back in the animal and a reversal of
the effects from removal of the tissue should
be seen. In these studies, it is necessary to
control for rejection of the implanted tissue
and the use of highly inbred strains may min-
imize these problems. Tissues can be trans-
planted to an ectopic site, which is well
supplied with blood, for example beneath the
kidney capsule, or within the orbit of the eye.
A variant of this is parabiosis, in which the
blood supplies of two animals are connected
together. One animal is treated and the effects
in the other animal are noted to demonstrate
that blood-borne factors are causing the
effect. An extract of the gland can also be
injected to check for the presence of the hor-
mone by measuring the endocrine response.
The extract is then purified to obtain separate
compounds with hormonal activity.
In whole animal studies where the
effects of various hormones are studied in
vivo, the following issues should be
addressed:
1. What animal would be used? Is a smaller
but still relevant animal model available (e.g.
sheep instead of cattle)? Inbred strains or spe-
cific genetic crosses?
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2. What dose of hormone would be used?
Is this a physiological or pharmacological
level?
3. What is the appropriate physiological state
(e.g. age, maturity, reproductive status)?
4. What is the appropriate route of adminis-
tration (in the feed, by injection – implant or
multiple injection)?
5. What are the potential interactions or side-
effects of the treatment?
6. What variable will be measured?
7. What are the advantages and disadvan-
tages of this model?
Isolated organs or tissues
An isolated perfused organ system is useful
for determining the overall metabolic effects
on an organ, for example the effects of
insulin/glucagon on glucose metabolism. It
could also be used to study hormone produc-
tion by an organ in response to blood-borne
signals such as tropic hormones or levels of
metabolites. The blood vessels supplying and
draining the organ or tissue are cannulated
and the vascular system is perfused with a
modified blood cocktail that is continuously
oxygenated and recirculated (Fig. 2.3). The
system has the advantages of lack of effects
from endogenous hormones and neural
influences, as it isolates the effects of other
tissues in the animal. The system is also easi-
ly manipulated and sampled. The disadvan-
tages of the system are that surgical skill
is required, and since it is not in vivo, it
can sometimes be difficult to maintain organ
viability.
Another version of this is the use of iso-
lated organs or tissues in situ. In this model,
catheters are placed in the blood vessels sup-
plying and draining the organ or tissue, and
the organ is left in the circulation and not
removed from the animal. Blood samples can
be taken from the arterial and venous
catheters to determine what effects the organ
has on levels of hormones or metabolites. Test
compounds can be supplied to the organ via
the arterial catheter and the effects on the
organ noted. An example of this would be the
in vivo catherization of the vessels supplying
the mammary gland in dairy cattle. Separate
catheters are placed in the external pudental
arteries supplying the two sides of the mam-
mary gland. This split-udder design allows
one side of the mammary gland to be used
for a treatment, while the other side is used as
a control (see Section 4.1). 
With the organ perfusion/infusion
model, the following factors should be con-
sidered:
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1. What is the appropriate animal (species,
strain, etc.) to use to study the effect?
2. How will the hormone be given in the per-
fusion/infusion?
3. What dose will be used, and how long will
the treatment be carried out?
4. What is the appropriate physiological state
(age, maturity, reproductive status, etc.)?
5. What dependent variables will be meas-
ured?
6. What are the advantages and disadvan-
tages of this experimental approach?
In vitro models
In vitro models are useful for studying the
details of the endocrine effects on specific tis-
sues or cell types, but they suffer from sever-
al limitations. First, the tissue being studied
tends to be in a catabolic state when studied
in vitro. Thus, although particular biochemi-
cal pathways can be studied by in vitro meth-
ods, the results are qualitative rather than
quantitative. Secondly, the results can also be
dramatically affected by the composition of
the incubation medium. The presence of par-
ticular hormones or metabolites can alter the
activity of metabolic pathways. Thirdly, the
concentration of hormones used may be
pharmacological rather than physiological
and thus the results obtained in vitro can dif-
fer dramatically from the results in vivo.
The next lower level of organization is
the use of thin tissue slices that are incubat-
ed in an appropriate medium containing nec-
essary metabolites and oxygen for the cells to
remain viable. This has the advantage of
being technically easier than perfusion, not
requiring blood cells, and allowing for the
study of different areas of the same organ.
However, the slices must be very thin so that
oxygen can penetrate through to the cells on
the interior of the slice, and there are many
damaged cells on the surface of the slice. 
Isolated cells have the advantage of
being a more defined system that can be used
to study hormone actions on particular genes
at the cellular level, including the effects of
cellular growth factors or studying the con-
trol of gene expression (hormone-responsive
elements, etc., see Section 1.3). Various
inhibitors can be used to determine the mech-
anism of action of hormones within the cell.
Cell culture uses fewer animals, and usually
many treatments can be performed from one
preparation of cells. Various types of cells can
be isolated, so that the contribution of differ-
ent cell types to the overall metabolism of a
tissue can be studied. However, cell culture is
not an in vivo system and the culture condi-
tions are critical (for example, the presence of
serum), so that artefacts can be produced
inadvertently if the conditions are not con-
trolled carefully.
Isolated cells can be prepared by treating
a tissue with collagenase to break down the
connective tissue and release the cells. The
viability of the cells is determined by their
exclusion of the dye Trypan Blue and the cells
can be used in a primary cell culture system.
The disadvantages of primary tissue culture
are that cell viability and receptor/enzyme
functions change over the time that the cells
are in culture. An alternative to primary cell
culture is to use established immortalized
cell lines that have been derived from carci-
nomas from a particular tissue and species of
animal. Many of these can be obtained com-
mercially (for example from the American
Type Culture Collection). Other cell lines
have been immortalized experimentally by
transforming primary cells with a tumour-
inducing virus or chemicals. An example of
this is the MAC-T3 cell line derived from
mammary alveolar cells transfected with
large T antigen. Immortalized cell lines pro-
duce a stable long-term system. However,
they may not have the same properties as
freshly isolated primary cells, so results
obtained using these cells should be inter-
preted with caution.
With the cell culture model system, the
following points should be considered:
1. What is the appropriate cell type? Is a pri-
mary cell culture or immortalized cell line
appropriate?
2. What are the appropriate conditions for
cell culture? Can a defined medium be used
or is serum required? What culture surface is
required (e.g. collagen-coated plates or plas-
tic)? Is a feeder cell line required in co-
culture?
3. What is the appropriate duration of treat-
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ment? Is cell viability and response to hor-
mones maintained (e.g. receptors main-
tained)?
4. What are the appropriate end-point meas-
urements (e.g. specific proteins produced,
cell growth, etc.)?
5. What is the appropriate dose of hormone
for culture conditions (physiological versus
pharmacological)?
6. What are the advantages and disadvan-
tages of this experimental model?
Various subcellular fractions can be pre-
pared by homogenizing cells or tissue in
buffer and then centrifuging the homogenate
at different speeds (differential centrifuga-
tion). These fractions can be used to study
specific processes; for example, membrane
transport using membrane vesicles, or
enzyme activities, or structure/function rela-
tionships of molecules involved in endocrine
responses. The advantages of subcellular
fractions are their usefulness for detailed bio-
chemical studies and that they represent a
well-defined system. However, this system
can produce artefacts, particularly if high lev-
els of compounds are used, so the results may
not reflect what is found in an in vivo system.
Use of inhibitors and agonists
A number of inhibitors can be used to deter-
mine the mechanism of action of hormones,
particularly in studies using cell culture or
subcellular fractions. These include inhibitors
of the synthesis of DNA, RNA and protein,
metabolic inhibitors, receptor agonists and
antagonists and compounds that affect mem-
brane transport.
Inhibitors of RNA synthesis include
actinomycin D, which intercalates with the
double helix of DNA to prevent transcription,
and rifampicin, which inhibits the initiation
of transcription. Inhibitors of protein synthe-
sis include cycloheximide and puromycin.
Cycloheximide inhibits the peptidyl trans-
ferase activity of the 60S ribosomal subunit.
Puromycin resembles the aminoacyl termi-
nus of aminoacyl-tRNA and joins to the car-
boxyl group of the growing peptide chain,
causing it to dissociate from the ribosome,
resulting in premature termination of the
growing amino-acid chain.
Inhibitors of microtubules and microfil-
aments include colchicine and cytochalasin
B. Colchicine is a plant alkaloid that inhibits
microtubule assembly by binding with tubu-
lin. It inhibits insulin secretion, suggesting
that microtubules may function in the secre-
tion of this hormone. Cytochalasin B is a fun-
gal metabolite that specifically interferes with
microfilament function without affecting
microtubule integrity. It inhibits secretion of a
number of hormones, suggesting that fila-
mentous organelles may be involved in the
secretory process of these hormones.
A number of hormone antagonists and
agonists are available. Cyproterone acetate
antagonizes testosterone binding at androgen
receptors and can be used to reduce aggres-
sion and to treat prostatic hypertrophy.
Dexamethasone is a synthetic glucocorticoid
agonist that is widely used. Chlorpromazine
and ergot alkaloids (e.g. ergocryptine) are
dopamine receptor antagonists. Spirono-
lactone is an aldosterone receptor antagonist
and saralisin is an angiotension II receptor
antagonist. Thiouracil inhibits the uptake
of iodide and synthesis of thyroid hormone
in the thyroid gland.
The methylxanthines, theophylline and
caffeine, are phosphodiesterase inhibitors,
which elevate intracellular cAMP levels by
inhibiting degradation of cAMP. A number of
cAMP analogues are also available, including
dibutyryl cAMP and 8-bromo cAMP.
Forskolin is an activator of adenylate cyclase
and phorbol ester activates protein kinase C
(see Section 1.3).
Metabolic inhibitors include iodo-
acetic acid, which blocks glycolysis, and
2-deoxyglucose, which inhibits glucose
uptake and utilization within cells. Inhibitors
that affect ATP formation include dinitrophe-
nol, which uncouples oxidative phosphoryla-
tion, and oligomycin, which prevents
mitochondrial phosphorylation of ADP to
ATP.
The cytotoxic agent alloxan destroys the
beta cells of the pancreas that secrete insulin,
while cobalt chloride destroys the alpha cells
of the pancreas that secrete glucagon.
Ion transport can be affected by treat-
ment with ionophores, which span biological
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membranes to carry ions into cells. The
ionophore A23187 is used to increase intra-
cellular Ca2+, and valinomycin has a high
specificity for K+ transport. Verapamil is a
calcium-channel antagonist.
Liposomes can be used as transport
vehicles that fuse with the cell membrane and
transfer the contents into the cytoplasm.
Liposomes that incorporate specific proteins
can be potentially targeted to different cells.
This provides a novel method of studying the
mechanisms of stimulus–secretion coupling,
particularly as it relates to the release of a
chemical messenger.
Use of antibodies 
Antibodies (Ab) are produced by animals as
a defence against foreign compounds, called
antigens (Ag). Antibodies are widely used in
endocrine studies and can be prepared by
injecting hormones or receptors obtained
from one species into another species. 
Immune response
There are two types of immune responses,
the cell-mediated response and the humoral
response (see Section 6.3). The cell-mediated
response is involved in the destruction of
‘self’ cells gone wrong, such as infected or
cancerous cells, and is carried out by cyto-
toxic T lymphocytes. The humoral response
is the generation of soluble antibodies against
foreign antigens.
The humoral response is due to B lym-
phocytes, which are precommitted to
respond to a limited number of antigens. The
initial exposure to an antigen produces the
primary immune response, in which specific
B cells that respond to particular antigen
divide and differentiate (Figs 2.4 and 2.5).
The majority of the responding B cells
become memory cells and others become
antibody-producing plasma cells. Thus, there
is only a small production of Ab from the pri-
mary response. The secondary immune
response occurs upon subsequent exposure
to the same antigen. This results in a rapid
proliferation and differentiation of memory
cells into antibody-producing plasma cells
and high antibody titres (a titre is the highest
dilution of serum that gives a measurable
Ab response). A large number of different
antibody-producing cells are generated, and
each of these produces a unique antibody
directed against a particular epitope on the
surface of the antigen. Thus, the immuniza-
tion process generates a mixture of antibod-
ies, called a polyclonal antibody preparation.
To elicit an antibody response, the sub-
stance (Ag) must be recognized as foreign
(non-self), and be large (for example, pro-
teins) and complex in structure (not a
homopolymer such as polylysine). A hapten
is a low molecular weight compound that can
react with an antibody but is unable to induce
antibody formation by itself. It must be
attached to a larger molecule, such as keyhole
limpet haemocyanin (KLH) that will readily
be recognized as foreign, to be antigenic.
Protein hormones are usually antigenic since
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Fig. 2.4. The humoral response to foreign antigens.
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their structures differ between species.
Steroid hormones have a low molecular
weight and their structure is the same in dif-
ferent species, so they need to be linked to a
large protein to make them antigenic.
Normally an adjuvant is given with the
antigen to enhance the immune response. A
classic adjuvant is Freund’s complete adju-
vant, which is an emulsion of water in oil
containing killed bacteria. It causes a slow
continuous release of antigen and local irrita-
tion, which stimulates macrophage activity
but can cause discomfort for the animals. 
Detection and purification of antibodies
The presence of antibody in plasma can be
detected using immunodiffusion (Ouchter-
lony) plates (Fig. 2.6). Serum containing anti-
bodies (antiserum) is placed in one well of an
agar plate and the antigen is placed in an
adjacent well. The presence of an immuno-
precipitate between the two wells indicates
that the antibodies are present. The antibod-
ies can be purified by affinity chromatogra-
phy, using protein A to purify the IgG
fraction or by linking the antigen to a support
such as Sepharose to fractionate different
antibodies in a polyclonal mixture.
Monoclonal antibodies
Antibodies produced in vivo are polyclonal,
since they are produced from more than one
B-cell clone. It is possible to produce antibod-
ies from one clone (monoclonal antibody) to
increase specificity, since a monoclonal anti-
body recognizes only one particular hapten
(Fig. 2.7). Once a mouse has been immunized
with the antigen, the spleen is removed, and
the cells are isolated. The antibody-produ-
cing cells are then fused with a myeloma cell
line to produce immortalized hybridoma
cells. The individual hybridoma cell clones
are then purified to produce cell lines that
produce one particular monoclonal antibody.
The cell line that produces the monoclonal
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Fig. 2.5. Primary and secondary responses to
antigen exposure.
Fig. 2.6. Ouchterlony immunodiffusion
experiment. Fig. 2.7. Production of monoclonal antibodies.
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antibody with the desired specificity is then
used to produce large amounts of antibody.
A selection process is used to isolate the
hybridoma cells from the unfused myeloma
cells and spleen cells. The myeloma cell line
is missing the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT) from
the purine salvage pathway. The cells are
grown in HAT medium, containing hypoxan-
thine, thymidine and the synthetic folic acid
analogue aminopterin, which blocks the
thymidylate synthetase enzyme and forces
the cells to use the purine salvage pathway.
The unfused myeloma cells cannot survive
under these conditions and unfused spleen
cells cannot last more than a few days in cul-
ture. Thus, only the hybridoma cells that
express the HGPRT from the spleen cells sur-
vive in the HAT medium.
Use of antibodies to identify the site of
hormone synthesis or target tissue
Antibodies against hormones can be tagged
with a fluorescent, enzyme, or electron-dense
probe and used to identify hormone-produ-
cing or target cells. Labelled antibodies will
accumulate in cells containing the hormone,
which is the antigen to that antibody. For
example, in immunocytochemistry, labelled
antibody is applied to histological sections of
tissue. In immunoenzyme histochemistry,
an enzyme that gives a colour reaction is cou-
pled to the antibody to increase the sensitivi-
ty of detection. Antibody binding is detected
using fluorescent light microscopy, or elec-
tron-dense probe via electron microscopy.
Labelled hormone can also be used to
localize areas of hormone binding.
Radiolabelled hormone is injected and the
tissue is sampled, fixed and the label is
detected by autoradiography. This involves
exposing the tissue to X-ray film and allow-
ing the decay of radioisotope to produce
spots on the exposed film. A related tech-
nique, in situ hybridization, is used to detect
the presence of mRNA for a hormone or
receptor in a particular cell type. In this case,
the tissue section is exposed to a radiola-
belled DNA probe for the hormone or recep-
tor, and the binding of the probe to the tissue
section is determined by autoradiography.
Antibodies can also be used to neutralize
the effect of a hormone or to modulate hor-
mone action, as described in Section 2.3.
2.2 Measurement of Hormones and
Receptors
Assay of hormones
Assays for hormones are used primarily to
measure the levels of hormones in plasma or
tissue extracts. An assay must meet several
criteria and be validated to be of use. The
assay should be calibrated with a standard of
known activity (Fig. 2.8). The standard must
be tested at a number of concentrations to
demonstrate that the response in the assay is
proportional to the amount of hormone. A
plot of the response in the assay versus the
concentration of standard is known as a stan-
dard curve. The slope of the line gives the
response factor that is used to convert the
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Fig. 2.8. Typical standard curve.
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response in the assay that is obtained with a
sample to the concentration of hormone in
the sample.
Sufficient replicates should be done to
demonstrate reproducibility; this is deter-
mined by a low coefficient of variation (CV =
standard deviation/mean). The assay must
be sensitive, usually in the picogram to
nanogram range for plasma hormones. The
standard and unknown should be measured
at the same time and under the same condi-
tions as the samples. There should be near
100% recovery of standard added to extract,
and this recovery should be consistent
between samples. A comparison of standard
curves obtained with pure standard in buffer
to a sample spiked with standards should
show that the curves are parallel. This paral-
lelism of standard curves needs to be validat-
ed for each tissue type (for example, plasma
will be different from muscle) to demonstrate
that the response in the assay is not depend-
ent on the sample matrix (Fig. 2.9). The assay
should also be simple, of low cost and suit-
able for routine use. The measure used in the
assay must also relate to hormone activity.
This is important when the assay is based on
structural components of hormones that may
not be related to activity.
What does all this mean? In order to use
an assay, you first determine the response in
the assay for different amounts of a pure ref-
erence hormone. Construct a standard curve
by plotting the response in the assay versus
the amount of added hormone and deter-
mine the equation of the line. When you
measure the response in the assay with an
unknown sample, use the equation from the
standard curve to determine the amount of
hormone in the unknown. To check for paral-
lelism, prepare additional standard curves by
adding the pure reference hormone to the
sample matrix you are using.
Types of hormone assays
BIOASSAYS. The bioassay is the primary
method for measuring the amount of a hor-
mone, since it is based on measuring the
physiological responses caused by the hor-
mone. Whole animals, or tissue preparations
utilizing an organ or tissue that is naturally
responsive to the hormone, can be used.
Some examples of bioassays are listed in
Table 2.1.
The parameter or response measured in
the bioassay should be specific for the hor-
mone. An example is the pregnancy test, in
which urine from the test subject is injected
into rats or rabbits and the effect on the
ovaries is noted. Human chorionic
gonadotrophin (hCG) in the positive test
causes ovaries to turn from being normally
pale yellow to pink, due to increased blood
flow. The response should also be directly
controlled by the hormone and not depend-
ent on the presence of other factors for a
response. Otherwise, these other factors may
also contribute to variability in the response
parameter. The response should also be easi-
ly measured, such as an increase in weight.
The parameter can be electrophysiological.
For example, in measuring olfaction in fish,
the trans-membrane potential in neurosecre-
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Fig. 2.9. Example of parallelism in standard curves.
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tory neurones in the hypothalamus is record-
ed with microelectrodes. The magnitude of
the electrical potential is a measure of the
response of the fish to various compounds.
The disadvantages of bioassays include:
1. A lack of sensitivity, particularly with
whole animal studies, which require a lot of
hormone to produce a response.
2. Poor reproducibility due to the wide vari-
ability in response that is obtained with dif-
ferent animals.
3. High cost and difficulty of use for animals
and animal preparations. 
However, in spite of these factors, any type of
assay for hormones must be correlated with
hormone activity as determined by some sort
of bioassay.
In recent years, hormone activity has
been assessed using in vitro systems consist-
ing of hormone receptors coupled to a
‘reporter’ activity by genetic engineering.
Binding of the hormone to the receptor turns
on the reporter and this is easily measured.
Examples of this approach are the oestrogen
receptor coupled to luciferase, which is an
enzyme from the firefly that produces a fluo-
rescent product. This system has been used to
measure binding of oestrogenic ‘endocrine
disruptor’ compounds in the environment to
the oestrogen receptor, to assess their poten-
tial biological activity (see Section 6.4).
Similarly, the growth hormone secretagogue
receptor (GHS-R, see Section 3.4) coupled to a
fluorescent reporter gene, aequorin, has been
used to screen for compounds that bind to
the GHS-R. This approach is particularly use-
ful in measuring binding between two differ-
ent receptors for a particular hormone. For
example, corticotrophin releasing hormone
(CRH) acts via two classes of receptors,
CRHR1 and CRHR2 (see Section 6.3). These
receptors have been cloned and expressed in
cells in culture, to be used as a bioassay sys-
tem for compounds that bind specifically to
one form of the receptor.
CHEMICAL ASSAYS. Chemical assays for hor-
mones are based on some aspect of the struc-
ture of the particular hormone. Sometimes it
is possible to take advantage of unique
aspects of the hormone structure to design a
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Table 2.1. Some examples of bioassays (adapted from Hadley, 2000).
Hormone Assay system Responses monitored
In vivo systems
Insulin Fasted rodent ↓ Blood glucose
FSH Immature hypophysectomized rodent ↑ Weight of follicular size of ovaries
TSH Any vertebrate ↑ Thyroid uptake of 131I and release
of [131I]T4 and [131I]T3 from thyroid
Thyroxine Larval amphibian Metamorphic change
Somatotrophin Tibia test (rat) ↑ Width of epiphysial (cartilage) plate
Oxytocin Rat uterus ↑ Contraction
Parathormone Parathyroidectomized rat ↑ Ca2+ in plasma
Oestrogens Castrated or immature rodent Vaginal cornification
Androgens Castrated or immature rodent ↑ Weight of prostate and seminal vesicles
Prolactin White squab pigeon ↑ Height of crop sac epithelium
Chorionic Female frog Induced ovulation
gonadotrophin Galli–Mainini male frog test Induced spermatogenesis
Ascheim–Zondek test, mature rodent Formation of haemorrhagic follicles and
or rabbit corpora lutea
In vitro systems
Melanotrophins Frog skin ↑ Darkening of skin, melanosome
dispersion
Melanoma cells ↑ Tyrosinase activity, melanin production
Corticotrophin Perfused adrenal ↑ Synthesis and release of cortisol
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simple and specific measure. For example,
one assay method for thyroxine is to measure
total protein-bound iodine. Uptake of 125I can
also be used to measure biosynthesis of thy-
roxine in the thyroid gland. However, chemi-
cal assays that test for functional groups on
the hormone molecule that may not be
involved with activity can give false results
compared to biological activity.
The solubility and stability of the hor-
mone are related to its chemical nature. If the
hormone is soluble in organic solvents, it is
likely a steroid or other hydrophobic mol-
ecule; while if it is soluble in water, it is more
polar and probably a protein or amino-acid
derivative. Protein hormones can also be
inactivated by heating, changing the pH or
digestion with proteases.
One form of chemical assay involves
purifying the hormones by chromatography
and then measuring the amount of hormone.
Separation of compounds by chromatography
depends on the differential partitioning of the
compounds between the stationary phase (the
material in the column) and the mobile phase
that is flowing through the column.
Liquid chromatography. Purification by chro-
matography can be achieved using open-
column chromatography, but high perform-
ance liquid chromatography (HPLC) is more
commonly used as an analytical technique.
HPLC uses high-resolution columns contain-
ing very uniform particles. These columns
can separate very similar molecules with
high efficiency, and normally operate under
high pressure. The column is connected to a
detector, which measures some chemical
characteristic of the column effluent, such as
the absorbance of ultraviolet or visible light,
fluorescence, refractive index, conductivity,
radioactivity or even a molecular mass (using
a mass spectrometer). The typical arrange-
ment of a chromatography system is shown
in Fig. 2.10.
The types of chromatography columns
include:
1. Ion exchange (either anion or cation),
which separates molecules based on charge;
2. Adsorption (normal phase) chromatogra-
phy, which is similar to thin-layer chro-
matography in that it works by surface
adsorption of molecules to silica and is used
to purify small organic molecules; and
3. Hydrophobic interaction (reverse phase),
which separates by relative polarity or
hydrophobicity, with the polar compounds
eluting first from the column. Common
reverse-phase columns are C18 and C4,
which are used for separating small
hydrophobic molecules such as steroids,
drugs and amino acids, and phenyl, which is
used for proteins. 
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Fig. 2.10. Typical chromatography system.
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In these types of chromatography, separation
of the various compounds is achieved by
changing the composition of the mobile
phase over time. The compounds that are
tightly bound to the column are removed by
changing the pH, ionic strength or percent-
age of organic solvent in the mobile phase,
usually as a gradient. A group of compounds
with a similar chemistry can also be separat-
ed using an isocratic system with no changes
in the mobile phase during the chromato-
graphic run. 
Size exclusion or gel filtration chro-
matography separates molecules based on
their size and shape. Small molecules enter
the pores in the gel matrix and are retained
on the column, while the larger molecules are
excluded from the gel and elute first in the
initial void volume. Gel filtration is not usu-
ally of high enough resolution for analytical
work, but it is useful in preparative work for
large molecules such as proteins. Another
type of liquid chromatography is affinity
chromatography. This uses a ligand attached
to the column matrix that binds specifically
the compound of interest, giving a one-step
purification procedure. An example of this
would be to attach an antibody or binding
protein to the column matrix and then apply
a crude hormone preparation to the column.
The hormone binds to the protein on the col-
umn and the other compounds pass through
the column. The pure hormone is then eluted
with a high salt or pH gradient. The types of
liquid chromatography systems are summa-
rized in Table 2.2.
Gas chromatography. Gas chromatography
(GC) separates compounds by adsorption or
partitioning between the gaseous mobile gas
phase and the liquid or solid stationary
phase. The partitioning is dependent on tem-
perature, so the temperature is increased dur-
ing the run to elute the low boiling
compounds first and the high boiling com-
pounds last. Compounds must be volatile to
be separated by GC, so charged groups are
normally derivatized to make them less
polar. Common detectors for GC are thermal
conductivity (TCD) and flame ionization
detectors (FIDs). The FID is sensitive over a
large range of concentrations, but destroys
the sample. With the FID, the effluent from
the column passes through a hydrogen/air
flame that produces ions from organic mol-
ecules present in the effluent. The ions are
collected on an electrode to produce an elec-
trical signal. With the TCD, organic mol-
ecules in the column effluent change the ther-
mal conductivity of the carrier gas, which
changes the resistance of an electrically heat-
ed wire or thermistor. This change in resist-
ance is converted to an electrical signal. The
TCD is not as sensitive as a FID, but does not
destroy the sample.
Mass spectrometry can be used to identi-
fy the molecular weight, structure and posi-
tion of functional groups of small molecules.
The mass spectrometer produces charged
ions from the sample, consisting of parent ion
and fragments of original molecule, and then
sorts these ions by mass/charge ratio in a
magnetic field. The relative numbers and the
mass/charge ratio of each ion is characteristic
of a particular compound and can be used to
identify the structure of the compound. A
mass spectrometer can be linked to a GC
(GC-MS) or HPLC (HPLC-MS) to identify the
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Table 2.2. Liquid chromatography systems.
Type Separation principle Usage
Ion exchange Net charge Proteins, charged molecules
Reverse phase Relative hydrophobicity C18 – small hydrophobic molecules
Phenyl – proteins
Normal phase Surface adsorption Small organics
Size exclusion Molecular size and shape Large molecules (proteins, etc.)
Affinity Specific binding affinity Unlimited
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compounds that are separated by the chro-
matography. 
Electrophoresis. Proteins can be separated by
electrophoresis, usually on polyacrylamide
gels. Native or non-reducing gels separate
intact protein molecules based on charge,
while gels containing sodium dodecyl sul-
phate (SDS) separate molecules based on
their molecular weight. SDS coats proteins
and gives them an overall negative charge, so
the migration of the protein in the gel is
affected by the molecular weight and not the
charge of the protein. After electrophoresis,
the gels are stained to visualize all the pro-
teins. The proteins can also be transferred or
blotted to a solid membrane support and
stained with a specific antibody that recog-
nizes the protein of interest. This is known as
Western blotting. A protein band can also be
cut from a gel, the protein eluted from the gel,
and a partial amino-acid sequence deter-
mined. This information can be used to iden-
tify the protein and to produce DNA
oligonucleotide probes as a first step in
cloning the protein. Capillary electrophoresis
is a high-resolution analytical method useful
for separating a variety of compounds. It uses
just a few nanolitres of sample for capillary
tubes with internal diameters of 20–100 µm.
COMPETITIVE BINDING ASSAYS. The competitive
binding assay is based on specific binding of
a hormone by a protein (usually a specific
antibody). A fixed amount of labelled hor-
mone and a fixed amount of a binding pro-
tein are used, along with a variable amount of
unlabelled hormone. An equilibrium is estab-
lished between the amount of unlabelled hor-
mone and labelled hormone that is
complexed with the binding protein (see
equation at top of page). 
The proportion of labelled versus unla-
belled hormone bound to the antibody at
equilibrium depends on the amount of unla-
belled hormone present in the assay. The
amount of bound label decreases with
increasing amount of unlabelled hormone.
Since we can only measure the amount of
labelled hormone bound to the protein, we
use this to determine how much unlabelled
hormone was present in the assay.
The procedure involves first preparing
standard curves to determine the useful con-
centrations of binding protein. A series of
standard curves are produced using a fixed
amount of binding protein for each curve,
with the same amount of radioactive hor-
mone throughout, and adding various
amounts of unlabelled hormone. The amount
of labelled bound hormone is plotted on the y
axis (linear scale), with the concentration of
unlabelled hormone on the x axis (log scale).
The amount of binding protein that gives a
moderate slope from 10–90% saturation is
used for subsequent assays (Fig. 2.11).
The hormone concentration in a test
sample is determined by adding the sample
to the binding protein and labelled hormone
mixture. The amount of labelled hormone
bound is measured and the hormone concen-
tration can be determined from the standard
curve.
ASSAY REQUIREMENTS. Competitive binding
assays require specific, high-affinity binding
of hormone and the absence of non-specific
interfering substances in the assay. Sometimes
there are substances present in physiological
fluids that affect binding of hormone to the
binding protein and it may be necessary to
partially purify the hormone and remove the
interfering substances before assay.
Several types of binding proteins can
potentially be used in competitive binding
assays. Hormones bind to receptors with
high affinity and specificity, and it is possible
to use target-tissue plasma membrane or
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*labelled hormone (fixed amount)
+ + specific binding protein (fixed amount)
unlabelled hormone (variable amount)
↓
*labelled hormone– → unlabelled hormone–
protein complex ← protein complex
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intact cells as a source of binding protein. The
hormone binds to its own receptor and the
specificity of binding can be checked by com-
petition with other hormones to replace
labelled hormone. However, a purified
source of the binding protein is needed and
this is usually accomplished with a high titre
of antibodies. It is also possible to quantitate
the number of receptor binding sites if a
known concentration of hormone is used.
This is known as Scatchard analysis (see
below). 
Proteins present in blood serum, such as
specific globulins that bind hormones, can
also potentially be used in competitive bind-
ing assays, but the binding affinity and speci-
ficity is usually not adequate. Most often,
specific antibodies are used as binding pro-
teins and the assays are then called
immunoassays. Immunoassays are a popular
method for assay of protein hormones.
Antibodies to steroids are generated using
the steroids conjugated to an antigenic pro-
tein at a site on the steroid that leaves the
unique functional groups on the steroid
available as haptens for antibody production. 
Competitive binding assays require effi-
cient methods to separate bound hormone
from free hormone. These methods must not
change the binding equilibrium, and should
be simple and efficient so that a number of
samples can be processed at the same time. A
second antibody can be used to precipitate
the primary antibody–hormone complex,
leaving unbound hormone in solution.
Alternatively, the free hormone can be
adsorbed on a solid phase material, such as
charcoal with a coating of albumin or dex-
tran. Bound and free hormone can also be
separated using column chromatography
with gel filtration media such as Sephadex;
convenient spin columns are available for
separating different-sized molecules. A most
convenient way of separating bound from
free hormone is to link the binding hormone
to a solid support, such as glass beads, filter
paper, or the assay tube. This latter format is
referred to as a solid-phase assay (Fig. 2.12).
Labels used for immunoassays can be
radioactive, fluorescent or an enzyme that
produces a colour change. A radioimmuno-
assay (RIA) can use steroids labelled with 14C
or 3H; 125I can be used to label steroids or
tyrosine residues of protein by mild oxida-
tion. A fluorescence immunoassay (FIA) uses
a fluorescent label such as fluorescein isothio-
cyanate, which has an excitation maximum at
485 nm and emission maximum at 525 nm. In
the enzyme-linked immunosorbent assay
(ELISA or EIA), an enzyme such as alkaline
phosphatase or horseradish peroxidase is
coupled to the hormone. The enzyme cataly-
ses the hydrolysis of substrates that produce
a coloured product, such as BCIP/NBT (5-
bromo-4-chloro-3-indoyl phosphate/nitro
blue tetrazolium) for alkaline phosphatase
and TMB (3,3’,5,5’-tetramethylbenzidine) for
peroxidase. The extent of colour change is
used to quantitate the amount of labelled
hormone–antibody complex that is present.
As an alternative to the competitive
immunoassays, an antibody sandwich
ELISA can be used to measure hormone con-
centrations. In this format, a capture antibody
is bound to a solid support (tube or microtitre
plate) and incubated with unlabelled hor-
mone (standard or in a sample). This is then
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Fig. 2.11. Standard curves for competitive binding
assays.
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followed by incubation with a second indica-
tor antibody against the hormone that is con-
jugated to an enzyme. The activity of the
enzyme is then measured. The amount of
hormone bound to the capture antibody is
estimated from the enzyme activity on the
bound indicator antibody.
Measurements of hormone–receptor
binding 
Hormones bind to receptors with high affini-
ty (10–9 M) and receptors are normally highly
specific for binding a particular hormone.
The affinity of hormone binding to its recep-
tor and the effective number of receptors
present in a cell can be determined by equi-
librium binding experiments and Scatchard
analysis. Scatchard analysis is similar to a
competitive binding assay, but is used to
measure the characteristics of receptors
instead of the amount of hormone. For this
analysis, specific (low capacity, high affinity)
binding of hormone to receptors must be
determined separately from non-specific
(high capacity, low affinity) binding of hor-
mone to other components of the system.
A saturation binding curve is first gener-
ated by incubating labelled hormone with a
receptor preparation (membrane or nuclear
fraction). The bound hormone is separated
from the free hormone and the amount of
hormone binding is measured. The total
binding is the amount of radioactivity bound
to the receptor preparation and includes hor-
mone that is bound to receptors as well as
non-specific binding of hormone. The non-
specific binding is determined by including a
large amount of unlabelled hormone
(100–1000 times excess) to saturate all the
specific receptor sites. When radioactive hor-
mone is added, there are no specific receptors
available for binding, so the binding is now
due to the large number of non-specific sites
available. The specific binding is determined
as the difference between non-specific and
total binding (Fig. 2.13).
The binding of hormone (H) to its recep-
tor (R) to form a hormone–receptor complex
can be described by the equation:
R + H ↔ RH
The equilibrium association constant (Ka) and
the dissociation constant (Kd) are defined as:
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Fig. 2.12. Example of solid-phase competitive immunoassay. The steps are coupling of specific
antibody to a solid support, addition of the sample and radiolabelled hormone, and washing to remove
soluble compounds followed by counting the bound radioactivity.
Attachment of antibody support
Addition of sample and radiolabelled hormone
Wash to remove unbound labelled hormone and
count radioactivity
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hormone
Unlabelled
hormone
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Ka = [RH] = 1/Kd
[R][H]
The ratio of bound to free hormone (B/F) is
given by:
B/F = [RH] = Ka[R] 
[H]
The total number of receptors (Rt) is given by:
[Rt] = [R] + [RH]
Combining these equations:
B/F = Ka([Rt] – [RH]) = –Ka[RH] + Ka[Rt]
The data from the saturation binding curve is
plotted, comparing the ratio of specifically
bound to free hormone (y variable) versus
hormone specifically bound to the receptor
preparation (RH or B) (x variable). The slope
of the line is –Ka, the x-intercept is Rt and the
y intercept is Ka[Rt].
The dissociation constant for the RH
complex (Kd) is a measure of the binding
affinity of the receptor for the hormone.
When the concentration of hormone equals
the Kd, one-half of the receptors are occupied.
A small Kd indicates a high affinity of the
receptor for the hormone, since a low amount
of hormone is needed to get a response. The
Kd for steroid receptors is in the range of
10–8–10–10. As an approximation, 20 times the
Kd is enough to saturate the receptor. At the x
intercept, all of the hormone is in the bound
form since the bound/free ratio = 0, and this
indicates the number of receptors present
(Fig. 2.14).
Competition binding
A competition or displacement experi-
ment measures the ability of a test factor to
displace the hormone from its receptor. A sin-
gle concentration of labelled hormone is incu-
bated with increasing concentrations of the
test factor, F, and the ability of factor F to
compete for binding with labelled hormone
is measured. The Kd for factor F is calculated
by:
Kd(F) = IC50(F)/(1 + [H]/Kd(H))
where IC50(F) is the concentration of F that
displaces 50% of bound H. Most factors will
not compete with H for binding as the
binding of hormone to receptor is very spe-
cific and high affinity. This is useful for meas-
uring the binding of hormone analogues to
receptors.
Receptor cooperativity is seen when
binding of hormone to one receptor affects
binding of subsequent hormone molecules.
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Fig. 2.13. Saturation binding curve for hormone–
receptor binding.
Fig. 2.14. Scatchard plot of hormone–receptor binding.
Slope = –Ka = –1/Kd
x intercept is Rt = total number of
receptor sites
Scatchard plot equation B/F = Ka[Rt] – Ka[B]
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This is seen as a curve in the Scatchard plot.
Positive cooperativity indicates that the ini-
tial binding of hormone enhances further
binding, and is seen as an upward curve in
the Scatchard plot. This may be important in
sensitizing a system for a hormone response.
Negative cooperativity is seen when the ini-
tial binding reduces further binding and pro-
duces a downward curve in the Scatchard
plot. It may provide a mechanism for desen-
sitizing a tissue to abnormal hormone levels.
This is seen with receptors for insulin, TSH
and nerve growth factor.
Regulation of receptor number repre-
sents another endocrine control mechanism.
A number of factors affect the receptor
number, including cellular development,
differentiation and age. There can be either
up or down regulation of receptor num-
bers. Hormones can induce synthesis (up
regulation) of their own receptors; for
example, prolactin induces liver receptors.
Insulin down regulates its receptors in lym-
phocytes. Changes in receptor number and
affinity can be determined by Scatchard
analysis.
When one hormone regulates the recep-
tor number of another hormone, this is het-
erospecific regulation. This is a mechanism
for hormones to act in sequence to amplify or
diminish response to other hormones.
Homospecific regulation occurs when a hor-
mone regulates levels of its own receptor; this
prevents hyperstimulation of cells in patho-
logical states. 
2.3 Methods for the Production of
Hormones 
One of the common methods for manipulat-
ing endocrine function is to treat animals
with a source of exogenous hormones.
Reliable and inexpensive sources of hor-
mones are needed to provide the hormones
that can be administered to animals. Very
early work used tissue extracts, which were
very crude and contained a mixture of hor-
mones and degradation products. In later
work, the hormones were isolated and puri-
fied and their structure determined, so that
usable amounts of the hormone could be syn-
thesized. 
Steroids and non-protein hormones
Epinephrine was isolated by Oliver and
Shafer from adrenal glands and then synthe-
sized in 1895. In 1919, thyroxine was purified
by Kendal from thyroid glands of swine; in
1926, Harrington showed it to be a derivative
of tyrosine. Insulin was crystallized by Abel,
who demonstrated that it was a protein.
Oestrogen was the first steroid to be isolated;
Doisy and Butenandt did this from human
pregnancy urine. Later, Doisy in 1935 and
MacCorquodale in 1936 isolated 12 mg of
oestradiol-17β from 4 tonnes of sows’ ovaries.
In 1931, Butenandt isolated androsterone
from male urine and in 1934, progesterone
was isolated from sow ovaries by four differ-
ent groups. In 1935, testosterone was isolated
from testes by David and co-workers, who
demonstrated that it could be synthesized
from cholesterol. In the period of 1936 to
1942, adrenal hormones were isolated by
many workers in the US and Europe. From
20,000 slaughter-house cattle, 100 kg of adre-
nal glands were obtained and used to isolate
300 mg each of 29 steroids. Hench and co-
workers demonstrated that cortisone could
be partially synthesized and used it to clini-
cally improve rheumatoid arthritis.
Afterwards, it was found that microor-
ganisms such as Rhizopus and Aspergillus
could metabolize steroids to useful com-
pounds. These can be used as bioreactors for
the synthesis of steroids. Natural sources of
steroids include plant steroids, which are
usually conjugated to sugar residues, and
bile salts. Hyodeoxycholic acid from bile salts
of swine has been used to synthesize proges-
terone and testosterone.
Steroids all have a cyclopentanoperhy-
drophenanthrene nucleus consisting of four
fused rings, labelled A, B, C and D, and can
be members of the pregnane, androstane or
estrane families (Fig. 2.15). Different steroids
have different functional groups or double
bonds on the four rings. The trivial names
and systematic names of common steroids
are given in Table 2.3.
Synthetic steroids that are more potent
steroid derivatives or inhibitors have been
chemically synthesized (Fig. 2.16). These can
be longer lasting since they are degraded
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more slowly; for example diethylstilbestrol
(DES) is a long-lasting oestrogenic com-
pound. Ethinyl oestradiol and norethindrone
are used as contraceptive steroids.
Dexamethasone is a synthetic glucocorticoid
and promegesterone (R5020) is a synthetic
progestogen. Other compounds are receptor
antagonists. Clomiphene and tamoxifen bind
to oestrogen receptors to block them.
Tamoxifen has also been shown to have
oestrogenic effects. Mifepristone (RU-486) is
a progesterone antagonist that is used clini-
cally to induce abortions.
Protein and peptide hormones
Peptide hormones are named based on their
endocrine activity rather than their chemical
structure. The structure of a particular pep-
tide hormone can vary in different species,
while a particular steroid hormone has the
same structure regardless of the species in
which it is found. For example, growth hor-
mones from pigs and cattle are different,
since they have a different amino-acid
sequence. However, progesterone isolated
from pigs or cattle is the same molecule.
Because of this species specificity, peptide
hormones must be isolated from the same, or
very similar, species for biological activity.
They have a higher molecular weight than
steroids and this makes structure elucidation
more difficult. Proteins are also easily
degraded by cellular proteases and this can
result in a number of protein fragments being
produced during the isolation procedure.
Historically, White and colleagues first
crystallized prolactin in 1937. In 1953, the
structures of oxytocin and vasopressin were
determined, and these peptides were then
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Fig. 2.15. Pregnane, androstane and estrane steroid structures. Pregnane (C21) indicates a steroid
structure with methyl groups at C-13 and C-10 and a two-carbon-atom side-chain attached at the C-17
position. Androstane (C19) indicates a steroid structure with methyl groups at both the C-13 and C-10
positions. Estrane (C18) indicates a steroid structure with a methyl group attached at C-13 in addition to
the 17 carbon atoms of the ring structure.
Table 2.3. Systematic names of vertebrate steroids.
Class name Trivial name Systematic name
Glucocorticoids Cortisol (hydrocortisone) 11β, 17α, 21-Trihydroxy-pregn-4-ene-3,20-dione
Corticosterone 11β, 21-Dihydroxy-pregn-4-ene-3,20-dione
Mineralocorticoids Aldosterone 11β, 21-Dihydroxy-pregn-4-ene-3,20-dione-18-al
11-Deoxycorticosterone 21-Hydroxy-pregn-4-ene-3,20-dione
Androgenic steroids Dehydroepiandrosterone 3β-Hydroxy-androst-5-ene-17-one
Testosterone 17β-Hydroxy-androst-4-ene-3-one
Oestrogenic steroids Oestradiol 1,3,4(10)-Oestratriene-3,17β-diol
Progestens Pregnenolone 3β-Hydroxy-pregn-5-ene-20-one
Progesterone Pregn-4-ene-3,20-dione
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synthesized by du Vigneaud. Sanger deter-
mined the structure of insulin, and it was
synthesized in the 1960s. Glucagon was crys-
tallized by Staub, and sequenced in 1957 by
Bromer and colleagues.
Determination of amino-acid sequence
Peptide and protein hormones consist of a
linear chain of amino acids, with the
sequence of the amino acids determining the
primary structure of the protein. Short pep-
tides can be sequenced directly, but long
chains are divided up into smaller chains by
enzymatic digestion to obtain overlapping
fragments, which are then sequenced. 
Peptides can be sequenced from the
amino-terminal end by Edman degradation
(Fig. 2.17). This process is now done by auto-
mated methods. The amino-end terminal
amino acid of the peptide is first labelled with
phenylisothiocyanate and then the labelled
amino acid is removed by mild acid hydroly-
sis. The labelled amino acid that is released
by hydrolysis is identified by chromatogra-
phy. The cycle is then repeated with the
shortened peptide.
Peptides and proteins can also be
sequenced using matrix-assisted laser de-
sorption ionization–time of flight mass spec-
trometry (MALDI-TOF). This is used
especially in the field of proteomics, to
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Fig. 2.16. Synthetic steroids and steroid antagonists.
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sequence a large number of proteins that are
expressed in a variety of biological samples.
This type of mass spectrometry generates
overlapping short peptide fragments and
determines their molecular weights. The
sequence of amino acids is deduced from
these molecular weight measurements.
The amino-acid sequence can also be
determined from the DNA sequence, and this
is particularly useful for large peptides and
proteins (Fig. 2.18). First, the sequence of
10–20 amino acids is determined from the
amino-terminal end of the protein, and then a
DNA oligonucleotide primer encoding these
amino acids is synthesized. In cases where
more than one codon is used for an amino
acid, degenerative primers are designed using
the codon combinations that are commonly
used for this amino acid. The mRNA is isola-
ted from a tissue that expresses the protein,
and complementary DNA (cDNA) is pro-
duced from the mRNA by reverse transcrip-
tion. The primers can be used to amplify the
cDNA encoding the protein directly, by poly-
merase chain reaction (PCR). Alternatively,
the total cDNA from the tissue can be inserted
into a plasmid or phage vector to produce a
cDNA library. The library can then be
screened using the oligonucleotide primers
(or with antibodies if an expression vector is
used) to isolate a full-length cDNA encoding
the protein hormone. The sequence of the
cDNA is determined and the amino-acid
sequence is then deduced from it.
Peptide and protein synthesis
The chemical synthesis of peptides involves
the formation of peptide bonds between
amino acids that are arranged in a specific
sequence. Since amino acids are at least
bifunctional, with both an amino group and a
carboxyl group, the groups that are not
involved in the formation of peptide bond
must be protected (Fig. 2.19). The carboxyl
and amino ends, as well as selective side-
groups not involved in the desired peptide
bond, are first blocked and then the peptide
bond is formed. The desired blocking group
is then removed from the peptide and the
next amino acid is added.
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Peptide
React with phenylisothiocyanate to label
NH2 terminus
Remove NH2-terminal amino acid by
mild acid hydrolysis
Identify liberated amino acid by chromatography
Fig. 2.17. Determination of amino-acid sequence
of proteins by Edman degradation.
Fig. 2.18. Strategies for deducing amino-acid sequence from cDNA.
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The chemical synthesis of larger pep-
tides (Merrifield synthesis) uses a solid-phase
support to assemble the peptide in a manner
that is analogous to the function of a ribo-
some in the cell (Fig. 2.20). This improves the
recovery and efficiency of peptide synthesis.
The disadvantages of chemical synthesis are
the high cost for equipment and reagents, the
limitations of peptide size (~30 amino acids)
and the low recovery of the peptide from the
synthesis.
Examples of peptides that have been made
by solid-phase synthesis include bradykinin (9
residues), vasopressin (9 residues), valino-
mycin (12 residues), neurotensin (13 residues),
β-endorphin (31 residues), corticotrophin (39
residues), ferredoxin (55 residues) and β-
lipotrophin (91 residues). 
Non-peptide mimics of peptides
A large number of biologically important
peptides are known, but small peptides are
limited in their usefulness as hormone sup-
plements. Peptides have a poor bioavailabil-
ity, since they are rapidly degraded by
proteases and have a limited ability to pene-
trate membranes. To overcome these prob-
lems, non-peptide compounds, called
peptidomimetics or peptoides, have been
developed to act as agonists or antagonists
for peptide hormones. These non-peptide
compounds mimic the three-dimensional
structure of the hormone ligand and an
unlimited variety of compounds can be made
with various biological activities (for exam-
ple, see Fig. 2.21). Different libraries of chem-
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Fig. 2.19. Strategies for the chemical synthesis of peptides.
Fig. 2.20. Merrifield synthesis of bradykinin.
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ical structures can be developed based on a
core ‘privileged structure’ that mimics impor-
tant parts of peptides (for more information
see Patchett and Nargund, 2000). Often small
alterations in the molecule, such as alkyl sub-
stituents or changes in the stereochemistry,
change the biological activity from agonistic
to antagonistic.
The earliest examples of these hormone
analogues were based on morphine and rela-
ted opioids, which mimic the biological activ-
ity of the enkephalins, natural peptide
analgesics. In fact, the structure–activity rela-
tionships of the opioids were determined
before their receptor was characterized. More
recently, non-peptide analogues for the
growth hormone secretagogues (GHS) and
cholecystokinin (CCK) (see Sections 3.4 and
3.9) have been developed using functional
screening assays. GHS analogues were devel-
oped based on structural elements in the
hexapeptide growth hormone releasing pep-
tide (GHRP) that were thought to be critical
for bioactivity. A large number of compounds
were then screened for their effectiveness in
releasing growth hormone from a rat pitu-
itary cell assay. Similarly, agonists for the
CCKA receptor were screened for their effec-
tiveness in contracting a gall bladder prepa-
ration. Once biologically active compounds
are found, the pharmacokinetic parameters
are measured to determine the in vivo effec-
tiveness of the compounds. For further infor-
mation, see the review by Sugg (1997).
Production of recombinant proteins 
An efficient method for producing large pep-
tides or proteins uses recombinant DNA tech-
niques (Fig. 2.22). For the in vitro production
of proteins, the DNA sequences encoding
protein are isolated (as cDNA or genomic
DNA) and put into a vector, such as a plas-
mid, which is transfected into bacteria or a
eukaryotic cell line. The cells are then grown
to produce the protein, which is then puri-
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Fig. 2.21. Some examples of non-peptide mimics of hormones.
Fig. 2.22. Production of proteins in vitro using
recombinant DNA techniques.
Isolate DNA sequence for proteins
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Grow cells and harvest protein
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fied. The use of efficient promoters, and hav-
ing more than one copy of the gene, can
increase the production of the protein.
Purification of recombinant proteins can
be simplified by adding a signal peptide to
the gene so the protein is exported from the
cells. The protein is then harvested from the
culture medium, which reduces the number
of compounds that have to be removed dur-
ing the purification. 
A common method for expression of
recombinant proteins is to produce proteins
as fusion products to stabilize the protein,
make the protein more soluble, or act as con-
venient tags for purification by affinity chro-
matography. The fusion protein can then be
cleaved after the purification to produce the
recombinant protein. Examples of fusion pro-
teins include β-galactosidase, bacterial alka-
line phosphatase, chloramphenicol acetyl
transferase, green fluorescent protein (GFP),
glutathione-S-transferase, luciferase and
polyhistidine. More recently, a small 24-bp
FLAG sequence, which contains the rare five-
amino-acid recognition sequence for entero-
kinase (Asp–Asp–Asp–Asp–Lys ↓ X) has been
used. The small FLAG peptide is particularly
useful as it may not affect the function, secre-
tion or transport of the fusion protein and
thus may not need to be removed.
Recombinant protein hormones can also
be produced in vivo using transgenic animals.
This involves creating a transgenic animal that
produces the desired protein and deposits it in
milk, eggs or semen so it can be easily har-
vested. This may be a cost-effective method
overall, but it requires considerable effort to
first generate the appropriate transgenic ani-
mal that produces the recombinant product.
The advantages of recombinant DNA
technology methods for producing proteins
include the lower cost overall, high efficiency
and the production of a higher-purity, consis-
tent product. The disadvantages are that an
appropriate DNA construct must first be pro-
duced and that simple bacterial systems can-
not always be used. In some situations, the
‘pro’ and signal sequences must be removed
from the cDNA, and this may affect the fold-
ing of the polypeptide chain and reduce the
activity. Bacteria use methionine for the ini-
tial amino acid, so any protein produced in a
bacterial system will begin with methionine.
Eukaryotic systems (e.g. yeast) must also be
used if post-translational modifications of the
protein, such as glycosylation, are necessary.
There is also the possibility of degradation of
foreign polypeptides when they are
expressed in a cell.
2.4 Manipulation of Endocrine
Function
The earliest use of hormones to enhance pro-
duction in farm animals involved feeding
iodinated proteins to dairy cows to increase
milk production, and using diethylstilbestrol
(DES) and dienesterol in broilers for
enhanced fat. In the USA, DES was used from
1954 in beef cattle and sheep to increase
growth efficiency and lean yield, but its use
was banned in 1972 due to potential car-
cinogenicity in humans. In 1958, oestradiol
benzoate/testosterone implants were
approved for heifers, and in 1969, zeranol
implants were approved. The USA approved
bovine somatotrophin (bST) for improving
milk production in dairy cattle in 1993.
Hormone delivery methods
Hormones can be administered as feed addi-
tives if the compounds are not degraded by
the digestive system or rapidly metabolized
and eliminated. Examples of these orally
active compounds are β-agonists (see Section
3.5), or the synthetic progestagen, melenge-
strol acetate (MGA, Section 3.2). In this case,
there is a potential safety concern for feed
mill workers from exposure to hormones in
the dust. Hormones that are not orally active
can be administered as single or multiple
injections, usually as subcutaneous or intra-
muscular injections. Multiple injections result
in a pulsatile delivery of hormone, while a
single dose produces high levels that
decrease over a period of time (Fig. 2.23).
Hormones can be given as a suspension in
oils or waxes to give a more sustained release
than hormone in aqueous solution.
Hormones can be delivered with sus-
tained-release devices that are implanted in
the animal. This gives an initial rapid release
of hormone that may be above the optimal
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concentration and which decreases gradually
(Fig. 2.23). Subsequent implants can be given
as the concentration of hormone drops below
the effective dose. The hormone composition
of the implants could also be varied as the
animal develops. Sustained-release devices
have the advantage of being less labour
intensive than multiple injections.
Types of sustained-release devices
Growth-promoting implants have been used
extensively in cattle in North America since
the early 1970s. These are implanted in the
base of the ear, usually with a large-bore nee-
dle. The matrix of implants can be composed
of lactose (short acting), cholesterol (long act-
ing), or a large polymer of polyethylene gly-
col. Silastic tubing impregnated with the
hormone can also be used, and in this case
the length of the tubing controls the dose. The
progesterone-releasing intrauterine device
(PRID), which is used for synchronizing
oestrus (see Section 5.1), is an example of
delivering hormone to the site of action.
Osmotic minipumps (Alzet®) can be used for
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Fig. 2.23. Administration of hormones: pulsatile release versus single injection.
Maximum effective dose
Maximum effective dose
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the experimental delivery of hormones. Skin
patches could also be used for uptake of the
hormone through the skin.
The potential problems of using
implants are that protein hormones, such as
growth hormone, can form insoluble aggre-
gates over time, so that not all the hormone is
released. The hormone can also degrade over
time, and may need to be stabilized. The im-
planting technique can also cause abscesses
and expelled or crushed implants.
Pulsatile release of hormone
The pulsatile versus continuous mode of
administration can affect the hormone
response. Insulin, somatostatin, GH, PTH
and LH are secreted in pulses, and pulsatile
delivery of these hormones gives the opti-
mum biological effect. This may be due to the
suppression of natural hormone secretion
from continuous administration of large
doses of hormone. Receptor numbers can
also be down regulated by negative feedback,
or the dimerization of receptor can be
decreased by continuous high concentrations
of hormone (see Section 1.3).
Pulsatile release can be obtained from
implants. Implanted mechanical pumps can
be used, but these are expensive and may
require surgery. A number of experimental
controlled release systems have also been
described (Medlicott and Tucker, 1999). 
Bulk eroding systems (Fig. 2.24) consist
of a mixture of microspheres made of differ-
ent formulations of polylactic acid/glycolytic
acid polymers, which degrade to release hor-
mone at different rates. 
Surface eroding systems (Fig. 2.25) com-
prised of poly(ortho) ester and polyanhy-
dride matrices degrade rapidly from the
surface. More than one matrix composition
can be used in layers (with hormone and then
without hormone) to obtain pulsatile release
of hormone. The composition of the surface
layer can be varied to produce a mixture of
microspheres that degrade at specified rates
to produce a series of pulses of hormone
release.
In osmotically controlled systems (Fig.
2.26), the outside of the implant is coated
with a water-insoluble polymer with a water-
soluble pore-former; the interior contains
hormone and the osmotic agent. Pores are
created to allow water to move inside by
osmotic pressure, to rupture the implant and
release a pulse of hormone.
Enzymatically activated liposomes can
be prepared containing phospholipase A2
with hormone on the inside. The liposome is
encapsulated in alginate–poly-lysine. Once
the capsule dissolves, the phospholipase
degrades the liposomes to release the hor-
mone in a pulse. Triggered pulsatile delivery
systems can also be designed to release hor-
mone by exposure to various chemicals, pH
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Fig. 2.24. Bulk eroding systems for the pulsatile release of hormones.
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change, temperature, electric pulses or mag-
netic fields.
Hormone residues
Hormone residues in edible tissues are a con-
cern when exogenous hormones are used.
The acceptable daily human intake (ADI) per
unit of body weight is the dose that gives no
hormone effect in the most sensitive animal
model divided by 100. The potential daily
intake (PDI) is the average intake of animal
tissue times the residue level. The PDI must
be less than the ADI for approval of the hor-
mone treatment protocol. 
Usually physiological concentrations of
hormone are desired when hormones are
given. Higher (pharmacological) doses may be
detrimental and act through negative feedback
to reduce the effect of the hormone. There are
also differences between individuals and time
of day effects on hormone activity. The effec-
tive dose of hormone depends on how rapidly
the hormone is inactivated. Differences in
metabolism among different animals may
affect the extent of hormone activity.
Potentially, delivery systems can be
devised to target particular cells and direct
compounds to particular tissues where they
are biologically active. The compound could
be chemically modified to a derivative that is
activated at the target site. Specific carriers
can be utilized, such as liposomes, micro-
spheres, nanoparticles, antibodies, cells (e.g.
erythrocytes and lymphocytes), and macro-
molecules. Alternatively, compounds can be
coupled to a hormone for delivery to the tar-
get tissue of the hormone. For example, in
vivo treatment of ewes with a GnRH agonist
coupled to a cytotoxic agent (pokeweed
antiviral antigen) decreased the ability of the
pituitary gland to secrete LH (Nett et al.,
1999). This could provide a novel approach to
sterilizing animals. A conjugate of a lytic
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Fig. 2.25. Surface eroding systems for the pulsatile release of hormones.
Fig. 2.26. Osmotically controlled system for the pulsatile release of hormones.
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peptide (hecate) coupled to a segment of the
β-chain of LH selectively killed cultured cells
expressing the LH receptor, including
prostate cancer cells. 
Immunomodulation of hormone action
Antibodies can be generated to enhance or
repress hormone action. The immunoneutral-
ization of hormone action can be achieved by
active or passive immunization. Some appli-
cations for the immunoneutralization of hor-
mone action are summarized in Table 2.4. For
active immunization, antibodies are generat-
ed within the animal by immunizing with the
hormone. Some animals may not respond to
the immunization procedure and generate
high antibody titres, so there is reduced effect.
For passive immunization, purified antibod-
ies against hormone are infused into the ani-
mal. This requires a source of purified
antibody and is suitable for short-term
reversible immunization. Antibodies can also
be raised against hormone receptors, to inhib-
it or stimulate hormone action (anti-idiotypic
antibodies). For example, see Erlanger and
Cleveland (1992) for a method for producing
monoclonal auto-anti-idiotypic antibodies.
Antibodies are immunoglobulins (Igs)
that are present in the γ-globulin fraction of
plasma proteins. They are comprised of two
light polypeptide chains (23 kDa) and two
heavy polypeptide chains (50–70 kDa).
Disulphide bonds join the chains into a ‘Y’
configuration, with the variable (V) regions
located at the distal ends of the ‘Y’. The hyper-
variable regions in the V regions have binding
sites that are specific for particular antigens;
these sites are called idiotypes. The constant
(C) regions next to the variable regions are
distinctive for each Ig type (Fig. 2.27).
TYPES OF IMMUNOGLOBULINS. IgM is the first
antibody type formed after primary immu-
nization and it acts to protect the intravascu-
lar space from disease. IgG is formed after
IgM levels decrease and in the secondary
immune response. It is the most prevalent
serum antibody and is also found in the
extravascular space. IgA is found in mucous
secretions and is an early antibacterial and
antiviral defence. IgE is found in respiratory
and gastrointestinal tract mucous secretions,
and may be involved in the allergic response.
Anti-idiotypic antibodies naturally exist
against idiotypes in another antibody and
these are important in the regulation of B-cell
function. Secondary antibodies that are
directed against primary antibodies to a hor-
mone can also be produced. Some of these
secondary antibodies will be specific for the
idiotypic region and these are called anti-
idiotypic antibodies. Anti-idiotypic antibod-
ies can have hormonal activity, with the
Endocrine Methodologies 61
Table 2.4. Applications of immunoneutralization of hormone action.
Production parameter Immunogen Mode of action
Increased fertility of sheep Oestrogen – ‘fecundin’ Decreased feedback from oestradiol →
increased LH → increased ovulation
Inhibin Increased FSH → increased ovulation
Reduced libido – bulls Decreased GnRH → decreased gonadal
Contraception – wildlife GnRH function
Immunocastration – pigs
Increased growth and lean Somatostatin Increased GH due to decreased somatostatin
carcass
Manipulation of oestrus in Melatonin Remove inhibition of reproductive activity in
horses seasonal breeders
Decreased carcass fat Adipocyte membranes Decreased development of adipose tissue
Reduced boar taint in Androstenone Binding of Ab to androstenone did not decrease
uncastrated male pigs accumulation in fat
Wool follicles in sheep Epidermal growth factor Increased EGF weakens wool fibre

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added advantage of no hormone residues in
the edible tissues from treatment. The hor-
monal activity from anti-idiotypic antibodies
made by active immunization will be main-
tained longer than a hormone implant and
may be longer acting (more stable) than hor-
mone treatment. The disadvantage of this
procedure is that it is necessary to first gener-
ate, test and purify a primary antibody, which
is then used to generate the secondary anti-
idiotypic antibody. Also, the anti-idiotypic
antibody may not have hormonal activity.
Examples of anti-idiotypic antibodies
that have been studied include: anti-β-ago-
nist anti-idiotypic antibody, which can act as
β-agonists to improve growth and carcass
lean; and anti-GH anti-idiotypic antibody, to
stimulate milk production in dairy cattle.
Anti-idiotypic antibodies can also be tagged
with a label (enzyme, chemiluminescent or
fluorogenic) and used in non-competitive
immunoassays.
Transgenic animals
Uses for transgenic animals
A transgenic animal is an animal that con-
tains exogenous genes or gene modifications.
These genes can be from different species and
novel gene constructs can be used.
Transgenic animals can be produced by
inserting new gene(s) or by modifying the
expression of existing genes. Interrupting the
expression of particular genes can make gene
‘knockouts’ and these are useful in determin-
ing the physiological role of particular gene
products. Specific genes can be targeted for
knockout by the use of gene constructs that
are highly homologous to the target gene, but
which contain a mutation that interrupts the
function of the gene. The mutation is intro-
duced into the target gene by the process of
homologous recombination.
New genes can be used to modify hor-
mone responses and thus affect the perform-
ance, growth or health of the animal. Genes
for improved growth include GH and the
insulin-like growth factors (IGFs). Disease-
resistance genes could be used to improve the
health and performance of animals.
Improved productivity could also come from
genes that allow better utilization of feeds or
alternative feeds. 
Transgenic animals can also be used as
bioreactors, to produce a valuable protein
product that is deposited in the milk, eggs,
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Fig. 2.27. Structure of  antibodies.
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semen, etc. This allows the custom synthesis
of valuable products such as protein hor-
mones, antibodies and vaccines (Table 2.5).
Transgenic animals can be used as model
systems to study hormone function. This
includes molecular aspects of hormone/gene
interaction and cis- and trans-acting factors
involved in gene regulation in vivo. They can
also be used to identify genes important in
development, to identify factors responsible
for tissue-specific gene expression and to
study genes involved with disease.
Gene constructs can be made by linking
the control region of interest to a marker gene
that is easy to measure (Table 2.6). The
expression of these test genes can be studied
first in tissue culture. A transgenic animal is
then made to determine the physiological
significance of expression of particular genes
and how hormones control the genes.
Production of transgenic animals
Production of a transgenic animal requires a
gene to transfer, an efficient method for trans-
ferring the gene and an appropriate cell type
to receive the transgene. The gene of interest
is first identified and isolated. It is then
linked to appropriate control elements so that
it is expressed in the appropriate cell type in
the animal and at the right time in develop-
ment. These control elements can be found in
other genes that are expressed in the tissue of
interest. A gene transfer methodology is used
to transfect a cell type that gives rise to the
germ line. The potential cell types and gene
transfer methods are summarized in Table
2.7. Transfection of somatic cells will not pro-
duce transgenic offspring, but can be used for
transient gene expression in an existing ani-
mal.
There are a number of problems and
challenges in generating transgenic animals.
The number of copies of the transgene that
are incorporated is difficult to control. Many
promoters that are used do not tightly control
the expression of the transgene, so that the
transgene may be constitutively expressed.
The site of integration can affect transgene
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Table 2.5. Projects using transgenic farm animals as bioreactors (from Pinkert and Murray, 1999).
Product Use Commercializing firm(s)
α1-Antitrypsin Hereditary emphysema/cystic fibrosis PPL
α-Glucosidase Glycogen storage disease Pharming
Antibodies Anti-cancer CellGenesys, Genzyme, Ligand
Antithrombin III Emboli/thromboses Genzyme
Collagen Rheumatoid arthritis Pharming
CFTR Ion transport/cystic fibrosis Genzyme
Factor IX Blood coagulation/haemophilia Genzyme, PPL
Fibrinogen Tissue sealant development ARC, PPL
Haemoglobin Blood substitute development Baxter
Lactoferrin Infant formula additive Pharming
Protein C Blood coagulation ARC, PPL
Serum albumin Blood pressure, trauma/burn treatment Pharming
Tissue plasminogen activator Dissolve fibrin clots/heart attacks Genzyme
Tissues/organs Engineered for xenotransplantation Alexion, Baxter, CTI, Novartis
CFTR, cystic fibrosis transmembrane conductance regulator.
Table 2.6. Marker genes used for gene function
studies.
GFP Green fluorescent protein
β-GAL β-Galactosidase
CAT Chloramphenicol acetyltransferase
ALP Alkaline phosphatase
ADH Alcohol dehydrogenase from Drosophila
LUC Luciferase
NEO Resistance to antibiotic G418
HPRT Resistance to methotrexate
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expression, and the integration site is usually
random except for targeted gene insertions
by homologous recombination. The activities
of other genes in the region of the transgene
affect the expression of the transgene, and the
expression can be inhibited if the transgene
inserts in an area of inactive chromatin.
Including buffer sequences, such as matrix
attachment regions, around the transgene can
shield it from these effects. The integration of
the transgene can also disrupt other endoge-
nous genes by non-targeted insertional muta-
genesis. This can give clues about the
function of endogenous genes if the effect is
not lethal.
Further details on various applications
of transgenic animals can be found in
Houdebine (1996, 2000).
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Table 2.7. Methods for gene transfer.
Cell type Methodology
Single-cell fertilized ovum Microinjection
Embryonic stem cells CaPO4, DEAE-dextran, polybrene, PEG, DMSO
Primordial germ cells Electroporation
Unfertilized ova Liposomes
Spermatozoa and spermatogonia Particle bombardment
Retroviral vectors
Nuclear transfer
Questions for Study and Discussion
Section 2.1 Methods for Studying Endocrine Function
1. Describe a classical endocrine experiment in whole animals to identify endocrine tissues.
2. Discuss the use of various in vivo and in vitro methods.
3. How are antibodies raised and how can you make a hormone more antigenic?
4. How can you use antibodies to identify endocrine glands or target tissues?
5. Describe the use of various inhibitors as tools to study hormone function.
Section 2.2 Measurement of Hormones and Receptors
1. What are the requirements for assay methods?
2. Describe bioassays. What are the advantages and disadvantages of bioassays?
3. Describe chemical assays. What are the advantages and disadvantages of chemical assays?
4. How can you determine the chemical composition of a hormone (steroid versus protein)? What
methods are useful for purifying and measuring protein versus steroid hormones?
5. Describe the different types of chromatography for analytical use.
6. Describe the principle and methods of competitive binding assays for the measurement of hor-
mones.
7. Describe the types of binding proteins and labels that can be used for competitive binding assays.
8. Describe Scatchard analysis; how does it differ from competitive binding assays for hormones?
Section 2.3 Methods for the Production of Hormones
1. What are the sources of steroid hormones? Describe the structure of steroid hormones and their
synthetic analogues.
2. How is the sequence of short peptide hormones determined and how can they be synthesized?
3. How are protein hormones produced?
4. What is the relative purity of steroid versus protein hormone preparations?
DMSO, dimethylsulphoxide; PEG, polyethylene glycol.
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5. What is the relative purity of hormone preparations from recombinant and natural sources?
Section 2.4 Manipulation of Endocrine Function
1. Discuss the advantages and disadvantages of different methods for delivering hormones.
2. Outline the method and application of immunoneutralization of hormones.
3. Discuss the use of anti-idiotypic antibodies to mimic hormone action.
4. How are transgenic animals made and how can they be used to affect endocrine function?
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3.1 Overview
Growth is an increase in body weight and
size due to an increase in the number of cells
(hyperplasia) or an increase in the size of cells
(hypertrophy). Growth can occur from
increased deposition of protein, measured as
an increase in nitrogen retention in the car-
cass, as well as increased lipid deposition.
Protein deposition is regulated by the balance
between protein synthesis and protein degra-
dation; lipid deposition is regulated by the
balance between lipogenesis versus lipolysis. 
Hormones can differentially affect the extent
of deposition of muscle and fat, which affects
the lean yield of the carcass. Hormones can
also affect feed intake, feed conversion effi-
ciency (the ratio of feed:gain), growth per-
formance (the rate of gain) and dressing
percentage (the ratio of carcass weight:live
weight) (Fig. 3.1). In addition, hormones can
affect various aspects of meat quality, includ-
ing tenderness, juiciness, flavour and water-
holding capacity. These hormones are
discussed in detail in the following sections
of this chapter.
The hormones affecting growth are cov-
ered first in this chapter, starting with ana-
bolic steroids and then discussing issues
related to castration of pigs and removal of
these anabolic hormones. The effects of soma-
totrophin, β-adrenergic agonists, thyroid hor-
mones and dietary polyunsaturated fatty
acids (PUFAs) on growth rate, feed efficiency
and carcass composition are then covered.
This is followed by a discussion of the many
effects of leptin, and then factors such as
cholecystokinin that affect appetite are cov-
ered. After a short discussion of the use of
antimicrobials, the potential effects of dietary
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Fig. 3.1. Summary of hormones affecting growth and carcass composition. CCK, Cholecystokinin; NPY,
neuropeptide Y; ST, somatotrophin; β-AA, β-adrenergic agonists; PUFA, polyunsaturated fatty acids; T3,
triiodothyronine; Cr, chromium.
chromium and the effects of stress on meat
quality are presented.
Many of these factors are interrelated
and it is important not to disregard meat
quality, for example, when manipulating hor-
mones to improve growth and feed efficiency.
Similarly, it is important to stimulate suffi-
cient bone growth to maintain bone integrity
and carrying capacity of the increased skele-
tal mass. For example, treatment of growing
pigs with porcine somatotrophin (pST, see
Section 3.4) can result in cartilage damage
and decreased bone strength. Abnormal
skeletal development is a major cause of mor-
tality and downgrading of broiler chickens.
This problem is more prevalent in meat-type
birds and turkeys than in laying hens and is
probably linked to rapid growth.
The increase in knowledge of hormonal
effects on various aspects of growth has led
to strategies for increasing the lean content in
carcasses and improving feed efficiency and
growth rate. Improved feed efficiency means
that more meat is produced from less feed,
which can lower the cost of production and
reduce the amount of land necessary for
grazing animals. More efficient utilization of
feed also means that a lower amount of waste
products, such as nitrogen, will be produced
in the urine and faeces, thus reducing the
impact of intensive production systems.
However, public perceptions that exogenous-
ly administered hormones are bad, regardless
of the available scientific data, can make the
commercial application of these compounds
difficult.
Effects on growth, feed efficiency and
lean yield
Many hormones, including growth hormone,
thyroid hormones, catecholamines, insulin,
glucocorticoids and sex steroids, affect
growth and the metabolic processes involved
in the synthesis and degradation of body tis-
sues. The result is a shift in the metabolism to
direct more nutrients into muscle with fewer
nutrients either deposited into fat or excre-
ted. In contrast to the short-term regulation of
metabolism for the maintenance of homeo-
stasis, endocrine regulation of growth
involves long-term endocrine changes. The
hormonal regulation of metabolism is affect-
ed by nutrition and by the normal cycles of
endogenous hormone secretion and sensitiv-
ity in the animal. It is important to consider
these factors to maximize the response of ani-
mals to exogenously administered hormones.
For further information, see Sejrsen and
Vestergaard-Jensen (1990).
The young, growing animal produces
mostly muscle mass with little fat, but as the
animal continues to grow, the body fat con-
tent increases. Thus, the particular endocrine
systems affecting growth depend on the
species, sex and stage of maturity of the ani-
mal. Treatment with growth modifiers to
increase protein deposition is less effective in
young animals, when the inherent capacity
and efficiency of protein deposition is
greater, than it is in older animals that are
closer to their mature body size. 
Protein synthesis and deposition are
increased by the intake of dietary protein or
limiting amino acids, such as lysine, in the
growing pig. When energy is not limiting,
there is a linear response of protein synthesis
to intake of dietary protein, or the first limit-
ing amino acid, up to a plateau that is deter-
mined by the inherent capacity of the animal
for protein deposition (Fig. 3.2). The slope of
this linear response is a measure of the effi-
ciency of use of dietary amino acids for pro-
tein synthesis. Endocrine manipulations to
affect growth could act by increasing the
maximal response plateau of growth, which
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Fig. 3.2. Effects of efficiency versus inherent
capacity for protein deposition.
would increase the requirements for dietary
amino acids. Alternatively, the efficiency of
amino-acid use for protein synthesis could be
increased, which would not dramatically
increase the dietary requirements of amino
acids. Increased efficiency of utilization of
dietary amino acids may occur through a
decrease in amino-acid catabolism in the
liver, which can be measured as a decrease in
levels of plasma urea nitrogen.
The effects of endocrine manipulations
on increasing protein synthesis versus
decreasing protein catabolism have been
determined in vivo using labelled amino
acids. The dilution of isotope and uptake of
amino acids can be measured by arterio-
venous differences with blood flow measure-
ments across the hind limb of an animal. The
release of free amino acids produced from
protein catabolism would result in a dilution
of the specific activity of the labelled amino
acid in the venous blood. Uptake of amino
acids for protein synthesis would be meas-
ured as a decrease in the amount of labelled
amino acids in the venous compared to the
arterial blood, with no change in specific
activity.
Genetics plays an important role in the
hormonal response of an individual animal,
and a large proportion of the genetic selection
effort to date has been directed to improving
muscle development and the partitioning of
nutrients away from fat. This has been more
successful in poultry and swine, partly
because of the shorter generation time, com-
pared to cattle. However, selection for
increased muscle mass has resulted in some
metabolic problems. For example, selection
for increased breast muscle in turkeys has led
to problems with pale, soft, exudative (PSE)
meat and various cardiovascular problems,
such as round heart disease and sudden
death syndrome. Selection for decreased fat
in swine has reduced some organoleptic
qualities and affected flavour and eating
quality. Selection for increased muscle devel-
opment in certain breeds of pigs caused an
increase in porcine stress syndrome (PSS).
Selection for double muscling in cattle results
in pale meat due to lower myoglobin and fat
contents, and double-muscled cattle are more
susceptible to stress. It is important to include
meat quality and health status attributes in
selection programmes to reduce these prob-
lems.
3.2 Anabolic Steroids and Analogues
Male cattle, pigs and sheep are traditionally
castrated, even though intact (uncastrated)
males are more efficient at producing lean
meat (muscle) than castrates. Cattle are cas-
trated to reduce the undesirable aggressive
behaviour of males and to produce a more
consistent carcass with improved tenderness
and finish. During sexual development at
8–12 months of age, the collagen content
increases in the muscles of bulls, which can
decrease meat tenderness. Male pigs are cas-
trated to prevent objectionable odours and
flavours (boar taint) in the meat (see Section
3.3); male sheep also tend to have undesirable
odours when raised to heavier weights.
Female animals tend to produce carcasses
with less muscle mass and increased fat con-
tent than carcasses from intact males. For
these reasons, animals have been treated with
a variety of steroid hormones to improve lean
growth or produce more consistent, high-
quality carcasses. Females can be treated with
androgens to improve muscle growth and
decrease carcass fat. Intact males can be treat-
ed with oestrogenic compounds to increase
carcass fat and meat tenderness, and to
decrease aggressive behaviour. Castrates can
be treated with a combination of oestrogens
and androgens to produce the most desirable
growth rate and carcass composition.
Anabolic steroids have been used in both
human and veterinary medicine for over 30
years. They have been used in the treatment
of debilitating conditions such as starvation,
recovery after surgery and from extreme
trauma, such as burns. They have also been
used by competing athletes, such as body-
builders. The use of anabolic steroids in
equine athletes began in the 1960s, but by the
1970s it was decided that the presence of ana-
bolic steroids at the time of racing constituted
doping.
Anabolic steroids are used therapeutical-
ly in horses to increase appetite and protein
retention during recovery from injuries and
to reduce the catabolic effects of cortico-
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steroid therapy. Anabolic steroids have been
reported to stimulate erythropoiesis and
have been recommended for the treatment of
certain types of anaemia.
Anabolic steroids are sometimes used
illegally in horses to increase stamina and to
modify behaviour, to increase aggression and
‘sharpness’ for racing. There are few scienti-
fic studies and much anecdotal information
on the effects of anabolic steroid use in hor-
ses. Racing results are affected by a variety of
factors, such as track conditions, weather,
other horses and the racer/driver, so deter-
mining the effects of doping with anabolic
steroids is difficult. For more information, see
Snow (1993).
The term ‘anabolic’ refers to compounds
that increase nitrogen retention. A number of
different types of compounds, including
insulin, growth hormone, β-agonists and
steroids, exert anabolic effects. Steroid hor-
mones currently used as anabolic agents (Fig.
3.3) include testosterone, oestradiol and
progesterone, as well as steroid analogues
such as zeranol and synthetic steroids such as
trenbolone acetate (TBA) and melengestrol
acetate (MGA). Zeranol is an oestrogenic
compound produced from the mycotoxin
zearalenone. TBA is a synthetic androgen,
which has 10–50 times the anabolic proper-
ties of testosterone with reduced secondary
androgenic effects. MGA is an orally active
progestagen used for suppressing oestrus
and improving the rate of gain and feed effi-
ciency in heifers. Corticoids can also be
administered to finishing animals. Oxandro-
lone is a synthetic analogue of testosterone
that has been used in human studies. For fur-
ther information about the use of anabolic
steroids in animal production, see Lone
(1997).
Modifications of the structure of testos-
terone by alkylation at the 17α position pro-
duces orally active preparations. However,
the most commonly used anabolic steroids in
horses have modifications at the C19 or C18
position. These include nandrolone (deca-
durabolin or 19-nortestosterone), which is
also popular for human bodybuilding, tren-
bolone, which is used in cattle, and
methanedieone (methandrostenolone or
Dianabol®). Stanazol (Winstrol®) and bolde-
none are intended primarily for horses (Fig.
3.4).
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Fig. 3.3. Steroids and steroid analogues used as anabolic agents.
These compounds can be esterified at the
17α hydroxyl group and administered intra-
muscularly in an oil formation for sustained
activity. Dosage levels are 0.55–1.1 mg kg–1
body weight per injection period. The length
of the ester chain affects the rate of absorp-
tion and duration of activity. Esters of acetic
and propionic acid last for several days,
esters of phenylpropionic, cyclopentylpropi-
onic and undecylenic acid last 2–4 weeks and
esters of lauric, decanoic and heptanoic acid
last several months. Once absorbed, the
esters are hydrolysed to produce the free
steroids. Stanazol is not esterified, as the
pyrazole group on the A ring gives it a
1-week duration of activity. 
For use in meat-producing animals, the
goal is to maximize the anabolic effects of
growth-promoting compounds, while redu-
cing their androgenic effects. The term ‘ana-
bolic’ refers to the tissue-building properties
of the compound, including the increase in
muscle mass (nitrogen retention) and
decrease in body fat. The term ‘androgenic’
refers to the increased development of male
sexual characteristics by the compound,
including behavioural changes and the
development of the reproductive tract.
Steroid derivatives have been synthesized
with specific androgenic and anabolic activi-
ties, which are determined by a bioassay
using castrated rats. The effects of the com-
pound on the myotrophic activity in levator
ani muscle is used as a measure of anabolic
activity, while the effects on the development
of the prostate or seminal vesicles are used as
a measure of androgenic activity. The ratio of
anabolic to androgenic activity is the Q value
for the compound. These Q values can vary
among different laboratories due to non-
standardized methods that are used in their
determination. The levator ani muscle may
also be an androgen-dependent muscle, so
true measures of anabolic activity should be
based on whole-body nitrogen retention
studies.
Mechanism of action 
Androgens increase protein synthesis and
decrease fat deposition in adipose tissue.
Anabolic steroids increase the retention of
dietary nitrogen as body protein and increase
muscle mass through hypertrophy rather
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Fig. 3.4. Anabolic steroids used in horses.
than hyperplasia. Increased body protein can
be the result of increased protein synthesis or
decreased protein degradation. Anabolic
steroids can act by a direct mechanism
through the androgen receptors, or by indi-
rect methods. Indirect mechanisms include
modulating the production of other hor-
mones, such as growth hormone, thyroid
hormone and insulin. For more information,
see Sheffield-Moore (2000).
Direct effects
The direct effects of androgens are mediated
by interaction with the androgen receptor
(AR, see Fig. 3.5). A large number of different
androgenic compounds have been developed
that are known as selective androgen recep-
tor modulators (SARMs). However, only one
androgen receptor has been identified and
cloned. The AR gene is located on the X chro-
mosome and codes for a protein of 918 amino
acids. As a member of the nuclear receptor
family of transcription factors, it contains
protein domains that can activate or repress
activity. These domains are exposed upon
hormone binding to allow interactions with
various co-activators or co-repressors. These
include cAMP-responsive-element binding
protein (CBP/p300), glucocorticoid receptor
interacting protein 1 (GRIPI), androgen
receptor co-activator (ARA) 54, 55 and 70 and
transactivator protein (TAT)-interacting pro-
tein (Tip60). The binding of these co-activator
proteins is believed to enhance the stability of
the pre-initiation complex. Some factors
(CBP/p300) have intrinsic histone acetyl
transferase activity, which will disrupt nucleo-
some structure and increase the rate of tran-
scription initiation (see Section 1.3).
The differential effects of androgens in
various tissues may be due to differences in
the levels of cofactors that affect the AR, or
the presence of unique AR-interacting pro-
teins such as ARIP-3, which is specific to
testis. In addition, the binding of a particular
SARM to the AR may cause a unique confor-
mational change that exposes particular
domains that allow the interaction of specific
cofactors. This would lead to the selective
regulation of individual genes in specific tis-
sues by the AR. Ongoing research will lead to
the development of SARMs with selective
preferences for individual tissues or activi-
ties. For more information on SARMs, see
Negro-Vilar (1999), and for oestrogen recep-
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Fig. 3.5. Mechanism of action of the androgen receptor.
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tor modulators, see Cosman and Lindsay
(1999).
Testosterone can undergo irreversible
reduction by the 5α-reductase enzyme in
some tissues to form 5α-dihydrotestosterone,
which can be further metabolized to 17-
ketosteroids and polar metabolites that will
have different binding characteristics to the
AR. The aromatization of androgens with a
∆-4-3-keto group to oestrogens may also be
important in some tissues, since oestrogen-
like effects will be produced. The aromatase
reaction can be blocked by removal of the
C19 methyl function (as in nandrolone) or
modification of the A ring (as in oxandrolone
and stanazol). 
Androgens have a primary effect on
skeletal muscle through binding to specific
receptors on the muscle. Because the activity
of the 5α-reductase enzyme is low in skeletal
muscle, testosterone is the major hormone for
androgen action in muscle. Increased num-
bers of androgen receptors are found during
the muscle hypertrophy seen with increased
exercise or treatment with oxandrolone,
which is a synthetic analogue of testosterone
that cannot be aromatized to oestrogens. 
The number of free androgen receptors
is higher in females and castrates compared
to intact males. An oestrogen receptor has
also been identified, and the free form of this
receptor is present in higher amounts in
males than in females. Steroids bind to recep-
tors in the cytoplasm, and the hormone–
receptor complex enters the nucleus to
stimulate the transcription of hormone-
specific genes. This increases the synthesis of
myofibril and sarcoplasmic proteins to
increase the overall muscle mass.
Testicular feminization (Tfm) or andro-
gen insensitivity syndrome (AIS) is an X-
linked recessive gene defect in the androgen
receptor that results in a male pseudo
hermaphrodite. Virtually all androgen-
responsive tissues in Tfm individuals are not
responsive to testosterone due to the lack of a
functional AR. Female carriers have the Tfm
gene defect on one X chromosome and a nor-
mal AR on the other chromosome. These car-
riers have an androgen responsiveness that is
intermediate between that of normal and Tfm
animals.
Indirect effects
Androgens can function indirectly by
increasing the production of GH or IGF-I,
and prior exposure to androgens can prime
cells for the secondary actions of IGF-I.
Glucocorticoids may increase the production
of IGF-binding proteins to decrease IGF
bioactivity. Anabolic steroids also reduce the
production of LH and testosterone, delay
sexual maturation and reduce testicular
growth and spermatogenesis in bulls. 
There appears to be a reciprocal relation-
ship between testosterone (an anabolic hor-
mone) and cortisol (a catabolic hormone) in
bulls. Anabolic steroids could potentially act
as antagonists of the catabolic action of glu-
cocorticoids, by decreasing the concentration
of the glucocorticoids, or by displacing the
glucocorticoids from their receptors. Studies
in vitro have shown that testosterone has a
high affinity for the glucocorticoid receptor
and could thus prevent the normal protein
catabolic action of glucocorticoids.
There is some evidence that anabolic
agents with oestrogenic activity increase the
blood levels of insulin to promote growth.
Oestrogens increase growth rate and feed
efficiency in ruminants without the loss of
desired carcass characteristics. Insulin has
anabolic effects on adipose and skeletal mus-
cle, while thyroid hormone (T3) has a catabol-
ic effect on adipose tissue and an anabolic
influence over skeletal muscle.
Delivery systems
Anabolic agents can be given to cattle in three
ways:
1. Oral administration by addition to the
feed. This requires an orally active hormone
(e.g. MGA) and higher levels are needed to
stimulate growth performance.
2. Repeated intramuscular injections can be
used, but this is labour intensive and results
in high levels of hormones at the injection
site.
3. Implants containing the steroids can be
used for sustained release of the hormone.
Implants are normally placed behind the ear,
which is a desirable site since it is eliminated
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after slaughter. Steroids can be formulated
into a compressed pellet that has a life span
of 90–120 days of activity before completely
degrading. Silastic rubber implants can also
be used to provide a slow and continuous
release for 200–400 days. Some commercially
available implants are listed in Table 3.1.
The general principle for use of anabolic
steroids is to supplement with the hormone
that is deficient for the particular animal. In
cattle, the expected improvement in growth
rate is about 15% and in feed efficiency about
8% from the use of anabolic steroids. Growth
responses are likely to be greater in steers
than in intact males or females, which
already have a source of endogenous hor-
mones. Androgenic compounds are more
effective in females, while oestrogens are
more effective in males. A combination of
androgen and oestrogen or progestagen and
oestrogen is given to castrated males. 
A combination of androgen and oestro-
gen can be given to intact males to inhibit tes-
ticular function. Implanting zeranol in bulls
from birth to slaughter decreases carcass mas-
culinity, improves fat cover to an acceptable
finish and improves meat quality and palata-
bility. Steers implanted with trenbolone and
oestradiol have weight gains similar to those
of intact bulls. Treatment with a combination
of androgen and oestrogen or androgen alone
increases protein accretion and decreases fat
content. Treatment with oestrogens or an
oestrogen/progestagen combination increas-
es fat deposition, particularly in uncastrated
males. Treatment of bulls with TBA and
oestradiol increases tenderness and lowers
the connective tissue content, while not affect-
ing the juiciness and flavour of steaks.
A conservative approach using mild
oestrogens ensures marbling with a slight
growth response. An intermediate approach
using a mild combination of androgens and
oestrogens gives improved growth with a
slight depression on marbling. An aggressive
approach using a strong combination of
androgens and oestrogens gives maximum
improvement in growth with very poor mar-
bling and negative effects on finishing. Mild
oestrogens include zeranol, which produces a
5% decrease in marbling, and the combina-
tion of oestrogen and progesterone, which
gives a 10% decrease in marbling. Treatment
with the strong androgen TBA gives a
20–25% decrease in marbling. 
The efficacy of growth promoters is also
affected by nutrition. Cattle implanted with
anabolic steroids require higher levels of
dietary protein or nitrogen to sustain the
higher growth rates. The level of response
may be dependent on the initial nutritional
status, level of live weight gain, age, dose and
length of treatment. Higher response is found
in cattle that are already growing at a rapid
rate, since growth in each animal is limited
by its genetic potential. In larger-framed cat-
tle, the average daily gain (ADG) should be
higher than 1.8–2.0 kg day–1 for anabolic
treatment to be effective. Anabolic treatment
does not affect the digestibility of feed,
although feed intake and feed efficiency may
increase. Sufficient levels of dietary protein
and essential amino acids are needed to sus-
tain the higher growth rates. Anabolic agents
are ineffective in the early treatment of intact
males, while castrates and females can be
treated with anabolic agents at any age. The
response to repeat implants is reduced with
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Table 3.1. Steroid anabolic agents used as implants (from Unruh, 1986).
Trade name Chemical name
Compudose® Oestradiol 17β
Ralgro® Zeranol
Synovex -S® Oestradiol 17β benzoate + progesterone
Synovex-H® Oestradiol 17β benzoate + testosterone propionate
Finaplix® Trenbolone acetate
Revalor® Oestradiol 17β + trenbolone acetate
Forplix® Zeranol + trenbolone acetate
each sequential implant. Intramuscular injec-
tion of synthetic hormones must be repeated
every 10–15 days for 8–10 weeks. 
Weights of the liver and spleen are
increased in steers implanted with anabolic
agents. Treatment with corticoids alters thy-
mus, thyroid and adrenal glands and lowers
the levels of lymphocytes and neutrophils.
These alterations in the immune system can
result in health disorders, such as respiratory
illness or infection in finishing animals.
Treatment of intact males with oestrogenic
compounds decreases testicular maturation
and spermatogenesis. Growth-promoting
implants are not recommended for replace-
ment heifers because of possible detrimental
effects on fertility. 
Anabolic agents produce similar
responses in growth and carcass composition
of sheep as in cattle. The results in pigs have
been mixed, with few consistent beneficial
effects found. Anabolic treatment of fish with
methyltestosterone is used to induce sex
reversal and promote growth (see Section
5.2). Salmon treated with methyltestosterone
had 20–33% higher daily gain, 18–19%
improved feed conversion ratio and 19–34%
lower ammonia excretion than untreated fish.
Safety issues 
Anabolic agents have had a very significant
impact on beef production in North America
since they were first licensed for use in the
early 1950s. In the early years, the synthetic
stilbenes, diethylstilbestrol, hexestrol and
dienestrol, were used. These were subse-
quently banned in the EU, the USA and
Canada because of their potential carcino-
genic activity. Since December 1988, there has
been a complete ban on the use of hormonal-
type growth promoters in the EU. Consumers
generally consider the use of hormones in
meat production to be a very high risk.
However, in 1999 the Food and
Agriculture/World Health Organization
(FAO/WHO) Joint Expert Committee on
Food Additives (JECFA) reviewed the use of
oestradiol, progesterone and testosterone in
meat production and declared that they were
safe. The no observed effects limits (NOELs)
for oestradiol, progesterone and testosterone
are 5 µg kg–1 BW, 3.3 mg kg–1 BW and 1.7 mg
kg–1 BW, respectively. Using a safety factor of
100, this limits the acceptable daily intake
(ADI) to 50 ng kg–1 BW, 30 µg kg–1 BW and
2 µg kg–1 BW for oestradiol, progesterone and
testosterone, respectively. The theoretical
maximum daily intakes for these compounds
can be calculated from data on tissue levels of
these compounds in treated animals and con-
sidering that an individual would consume
300 g muscle, 100 g liver, 50 g kidney and 50 g
fat per day. These calculations show that the
theoretical daily maximum intakes are sub-
stantially less than the ADI from consuming
meat from treated animals. For more infor-
mation, see Waltner-Toews and McEwen
(1994).
The ADI values for oestradiol used by
the FAO/WHO report have been questioned,
based on new data for oestrogen production
and clearance in prepubertal boys, with an
ADI of 0.04–0.1 µg day–1. This implies that the
additional dose of oestrogen from consuming
meat from implanted animals could equal the
production rate in prepubertal boys.
However, natural levels of oestradiol 17β are
significantly higher in meat from animals in
late pregnancy than from steers with a hor-
monal implant. There are also high levels of
natural steroids in meat from intact males
and in the milk from pregnant cows. Levels
of natural oestrogens found in plants and
plant products, such as soybean oil, are sev-
eral orders of magnitude higher than in beef
from implanted animals (see Section 6.4).
The maximum residue levels (MRLs) for
TBA, zeranol and MGA are 2.0 µg kg–1 mus-
cle, 70 µg kg–1 and 25 µg kg–1 tissue, respec-
tively. A 48 h withdrawal time for MGA is
prescribed. The USDA and Agriculture and
Agrifood Canada maintain drug testing pro-
grammes. There were some instances of high
levels of zeranol in 1988 and 1989, but other-
wise tests for zeranol, TBA and MGA were
negative between 1988 and 1993.
Detection of anabolic steroid use in hor-
ses is based on levels in urine or blood, with
initial screening by immunoassays and con-
firmation by GC/MS. However, colts natural-
ly produce testosterone and 19-nortes-
tosterone, so it is more difficult to detect use
of these steroids. A ratio of oestrane-3,17-diol
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to 5(10)-oestrene-3,17-diol levels greater than
one indicates that doping with nandrolone
has occurred (Houghton et al., 1986).
Anabolic steroid treatment will reduce
cycling in mares and sperm production and
testis size in stallions. In humans, a number
of anabolic steroids have been shown to be
hepatotoxic. High doses of anabolic steroids
can increase the risk of severe coronary heart
disease, decrease high-density lipoprotein
(HDL) while increasing low-density lipopro-
tein (LDL), and reduce the immune response.
3.3 Use of Intact (Uncastrated)
Male Pigs
Advantages and problems of intact
male pigs
Raising intact male pigs instead of castrates
for pork production offers several advan-
tages, due to the natural production of ana-
bolic hormones by intact males. Overall
production costs are substantially lower for
intact males than for castrates. The labour
costs for castration are eliminated, along with
death losses and temporary decreases in per-
formance usually seen following castration.
Intact males have better feed conversion effi-
ciency than castrates, and may sometimes
grow faster than castrates. As a result, the
overall output of nitrogen in manure is less
with intact males than with castrates. Intact
males may also be more resistant to diseases
that negatively affect performance. 
Intact male pigs, compared to other
sexes, have a slightly lower dressing percent-
age (2–2.5%) but higher lean content (5–7%).
Intact males have about 5% less separable fat
than castrates, with gilts being intermediate.
The total fat content of soft tissues is about
30% lower in intact males than in barrows.
Decreased backfat in intact males would
result in a higher grading for carcasses, but
carcass grade may be underestimated unless
special equations are used for carcass grading
systems for intact males. The low intramus-
cular fat content, which can affect the flavour
and texture of the meat, may be of some con-
cern in intact males if it is lower than the
2–3% level recommended for optimum sen-
sory quality. Intramuscular fat levels can be
higher for gilts than for intact males, but
breed differences are more pronounced than
sex differences. Meat cuts from intact males
are more appealing to the consumer because
of the decrease in intermuscular fat.
There are important differences between
sexes in the fatty tissue composition, as well
as in the composition of the lipid fraction of
the fat. The back fat from intact males con-
tains more water, more protein and less lipid
than that from castrates and gilts. The lipid
fraction of intact male back fat contains more
unsaturated fatty acids than that of castrates,
with that of gilts being intermediate. The
high level of unsaturation of intact male fat is
mainly due to the higher levels of linoleic
(18:2) and linolenic (18:3) acids, with a lower
level of palmitic acid (16:0). 
The lower fat content and different fatty
acid composition of carcasses from intact
males has its advantages as well as disadvan-
tages. Intact male meat, with its lower level of
fat and a healthier balance of fatty acids,
offers a greater nutritional value and may be
more appealing to consumers. The leanness
of the meat has been found to be the most
important visual criterion in purchasing
pork. On the other hand, fat from intact males
is softer, due to the high level of unsaturation,
and more easily separates from the other tis-
sues. This causes difficulties in handling by
meat packers and decreases the quality of the
cuts. Also, since unsaturated fatty acids are
more susceptible to oxidation, intact male fat
turns rancid faster than that of gilts and cas-
trates. However, the degree of saturation of
fatty acids in the intact male fat can be
manipulated by dietary means. Reducing the
level of unsaturated fatty acids or increasing
the energy level in swine diets via carbohy-
drates decreases the level of unsaturation of
fatty acids in the fatty tissue. The poorer
quality of fat in boars is a result of the lean-
ness of the animals and thus is more impor-
tant in very lean genotypes.
The processing characteristics of pork
from intact males differ very little from that
of the other sexes, with the main difference
being the slightly lower processing yields.
Intact males are considered to be more
aggressive and therefore potentially more
susceptible to the development of PSE (pale,
soft, exudative) and DFD (dark, firm, dry)
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conditions in meat. While the frequency of
PSE meat is not higher for intact males, they
do show a greater tendency for producing
DFD meat. Thus, care should be exercised
during preslaughter handling of intact males.
Avoiding mixing of unfamiliar animals, min-
imizing lairage time and using good han-
dling practices would reduce the amount of
stress and consequently the incidence of
DFD. Such measures would also reduce the
incidence of skin damage, which is another
problem associated with higher aggressive-
ness of intact males. Sometimes fighting
results in only superficial skin blemishes, but
in other cases it can cause major carcass
bruising and consequently financial losses
from increased carcass trim. The incidence of
carcass and skin damage varies considerably
between slaughter plants, and major prob-
lems are likely to occur where good pre-
slaughter practices are not exercised. 
A clear disadvantage of intact male car-
casses is the higher bone content. Both gilts
and barrows have lower bone percentage and
consequently lower deboning losses. Due to
the much higher fat content in castrates, the
lean yield for intact males is higher, despite
intact males having more bone. The bone
content in pig carcasses is strongly affected
by the breed. The dressing percentage is also
lower in intact male pigs than in castrates,
due to the presence of a developing genital
tract. For more information on meat quality
in intact male pigs, see the review by Babol
and Squires (1995).
Particularly in European countries, ani-
mal welfare concerns are putting more and
more pressure on the pig production chain to
abandon castration. Avoiding surgical castra-
tion without anaesthetic undoubtedly
improves the welfare of the animals in the
short term, although increased aggression
may occur with intact males as they approach
market weight. As the males approach sexual
maturity, there can also be excessive ‘riding’
or mounting, which results in decreased feed
consumption and poorer growth perform-
ance.
Avoiding castration would also lower
the costs of swine breeding programmes,
since the breeding stock could be selected at
an older age and the non-selected animals
could be sold for meat at a normal market
price.
Although the problems with meat quali-
ty may be significant, particularly in lean
strains of pigs, the main reason that prevents
the production of intact males is the presence
of an offensive odour, called boar taint, in
their fatty tissue. Boar taint is present in only
a small portion of carcasses and a high per-
centage of people are not sensitive to it. Intact
males are used to some extent for meat pro-
duction in several countries including
Denmark, Great Britain, Spain and Australia.
However, in most countries, including
Canada, all male pigs intended for meat pro-
duction are castrated at a very young age to
avoid the potential consumer dissatisfaction
from boar taint in the carcasses. Under the
current Canadian pork carcass grading sys-
tem, a carcass from an intact male pig (boar)
is not graded and is assigned an index of 67.
This compares to a normal grade of 100 for a
market hog, making boar carcasses worth
about one-third less than a similar carcass
from a gilt or castrate. 
Effects of sex steroid hormones
The natural sex steroid hormones produced
in the testes account for the increase in
growth rate and lean meat yield of intact
male pigs compared to castrates. The most
predominant androgens in the testis of the
pig are 5-androstenediol, dehydroepiandro-
sterone (DHEA) and testosterone. These
steroids (and their metabolites 5α-dihy-
drotestosterone (DHT) and oestrogen) stimu-
late the development of the reproductive
tract and secondary sex characteristics,
including actions in the central nervous sys-
tem. In addition, these steroids have dram-
atic anabolic effects to stimulate muscle
growth, nitrogen retention, phosphorus
retention and bone growth, and cause the
redistribution of nutrients away from the
synthesis of subcutaneous fat. This results in
an enhanced growth rate and feed conversion
efficiency, along with a reduced backfat thick-
ness and increased lean content of carcasses
from intact males compared to females or
castrates.
The biological effects of androgens are
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mediated by their interaction with specific
receptors inside the cells of the target tissues
(see Section 3.2). In some tissues DHT is the
active androgen that binds to the receptor,
while in other tissues it is testosterone.
Synthetic anabolic steroids, such as nan-
drolone decanoate, oxandrolone and
stanozolol, have high anabolic activity in
skin, muscle and bone but have minimal
androgenic activity. These effects may be due
to competition between these anabolic
steroids and endogenous glucocorticoids for
their receptors in non-reproductive tissues.
Anti-androgen compounds, such as cypro-
terone acetate and flutamide, act by binding
to the androgen receptor, thus preventing
binding of the active androgen. Oestrogen
has also been shown to be involved in the
development of secondary sex characteristics
in the boar. 
The testicular synthesis of both the sex
steroid hormones and the androst-16-ene
steroids (responsible for boar taint) is
induced in vivo by administration of lutein-
izing hormone (LH), human chorionic
gonadotrophin (hCG) and by sexual stimula-
tion. The production and secretion of testos-
terone by the testis is controlled by the release
of LH from the anterior pituitary gland,
which in turn is regulated by gonadotrophin
releasing hormone (GnRH) produced by the
hypothalamus (Fig. 3.6). As the animal
approaches sexual maturity, levels of GnRH
rise and stimulate the release of LH into the
circulation. The binding of LH to specific
receptors on the surface of the Leydig cells
stimulates the synthesis of steroidogenic
enzymes and thus increases the production of
androgens and androst-16-ene steroids.
Steroid hormone production can be blocked
by the use of GnRH agonists, which cause a
down regulation of the number of GnRH
receptor sites, and with GnRH antagonists,
which block the binding of GnRH to its
receptor. Analogues of LH that block LH
action also cause decreased production of
both androst-16-ene steroids and androgens.
Production of antibodies that bind GnRH or
LH and thus inhibit their activity, so called
‘immunocastration’, will also result in
decreased androst-16-ene steroid and andro-
gen production.
Description of boar taint
Boar taint is the presence of off-odours and
off-flavours found predominantly, but not
exclusively, in meat of some intact male pigs.
The main compounds responsible for boar
taint (Fig. 3.7) are 5α-androst-16-en-3-one
(androstenone) and 3-methylindole (skatole).
There is some evidence that they cannot com-
pletely account for the occurrence of boar
taint as determined by a trained sensory
panel. Intact males near sexual maturity, as
judged by the length of the bulbourethral
glands, with low levels of androstenone and
skatole still had significant boar taint odour
and flavour scores. It may be that other fac-
tors related to sexual maturity also contribute
to boar taint. The presence of 4-phenyl-
3-buten-2-one in fat has been shown to
increase the perception of androstenone and
skatole in fat (Solé and García-Regueiro,
2001).
Androstenone is synthesized in boar
testes and is released into the bloodstream
(Fig. 3.8). It is removed by a specific binding
protein which is a member of the lipocalin
family, in the salivary gland (see Section 6.2;
Marchese et al., 1998) and released into the
saliva, where it acts as a pheromone, induc-
ing a mating response in oestrous sows. Due
to its hydrophobicity, androstenone also
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Fig. 3.6. Regulation of androst-16-ene steroid
synthesis.
accumulates in adipose tissue, causing a
urine-like odour when heated. Androstenone
is metabolized in the liver, although the
details of this metabolism are not known.
Skatole is produced by bacterial degra-
dation of tryptophan in the hindgut. It is
absorbed from the gut, metabolized in the
liver, partially excreted with the urine and
partially deposited in the fatty tissue (Fig.
3.9). It produces a faecal-like odour and a bit-
ter taste.
At usual slaughter weights, the inci-
dence of boar taint is very variable, ranging
from 10 to 75% in different studies. Because
of the large variation in the incidence of boar
taint, and because of the variety of culinary
habits between countries, the acceptability of
meat from intact males can be quite inconsis-
tent in consumer surveys.
Cut-off levels that define a limit between
untainted and tainted samples have been
proposed for androstenone and skatole from
sensory assessments by trained panels. Cut-
off levels for skatole are considered to be 0.20
or 0.25 p.p.m., while cut-off levels for
androstenone range between 0.5 and 1 p.p.m.
For more information, see the reviews by
Bonneau (1998) and Bonneau et al. (2000).
Measurement of boar taint
The existence of quick, cheap and reliable
methods for the assessment of boar taint on
the slaughter line would enable the sorting of
carcasses according to levels of boar taint. A
quick ‘soldering iron’ method, or ‘sniff test’,
which involves heating fat directly on the car-
cass, has poor repeatability and is not realis-
tic in industrial conditions with up to 1000
carcasses processed per line per hour. 
A number of different methods have
been developed for measuring the levels of
skatole and androstenone in carcasses (see
Chapter 2 for a discussion of methods for
measuring hormones). Immunological meth-
ods, including radioimmunoassay (RIA),
have been developed for androstenone, and
enzyme-linked immunosorbent assay
(ELISA) has been developed for skatole and
androstenone. The commercial usefulness of
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Fig. 3.7. Compounds responsible for boar taint.
Fig. 3.8. Overview of androstenone metabolism.
Sex pheromone
in saliva
immunological methods can be limited by
the long time required to develop equilibri-
um binding with the antibody and the
requirement for extraction of the fat samples.
These factors can also introduce a significant
amount of variation in these assays, with
coefficients of variation of more than 10%
commonly found. Chromatographic meth-
ods, such as high-performance liquid chro-
matography (HPLC) and gas
chromatography (GC, see Section 2.2), have
been used for measuring skatole and
androstenone. Chromatographic methods
can have the advantage of measuring a num-
ber of related compounds at one time, and
are usually quite specific and not affected by
interfering compounds. However, they can
be time consuming, technically difficult,
expensive and prone to equipment failure.
Careful extraction of the samples is required
for chromatographic analysis, both to ensure
good resolution of the samples and to main-
tain the useful life of the chromatography
columns. This makes these methods more
suitable for use in experimental analysis
rather than for the routine analysis of boar
taint compounds on a slaughter line.
Colorimetric methods for the analysis of ska-
tole and the 16-androstene steroids have also
been described. 
None of these methods is practical
enough to be used on the slaughter line, as
they involve either complicated extraction
procedures, or the use of sophisticated and
expensive equipment or costly materials, or
are too time consuming or unable to handle a
large-enough capacity of samples. A colori-
metric method for skatole, developed in
Denmark, has been used for sorting carcasses
in slaughter plants. However, the equipment
is quite expensive and has a limited capacity.
The detection of compounds causing taint
instantaneously on the slaughter line, using
probes such as immunosensors, electronic
sensors or chemical sensors, would be ideal.
Immunosensors couple antibody–antigen
reactions to an electronic signal generated by
a transducer. Electronic sensors have been
used in ‘electronic noses’ and are composed
of semiconductors whose characteristics
change when a particular substance is
adsorbed on to the surface. Various types of
electronic sensors have been investigated for
detection of boar taint, and artificial noses
have been shown to simulate the response of
a laboratory panel to boar taint (Annor-
Frempong et al., 1998). Further work is need-
ed in this area to develop commercially
useful methods for detecting boar taint.
Use of tainted meat in processed
products
Heat processing can reduce the levels of boar
taint in processed meat products. Products
produced from tainted meat that were not
heated during processing, such as dry
sausages, dry cured hams and cured bellies,
were usually evaluated as having a stronger
odour than that of controls made from non-
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Fig. 3.9. Overview of skatole metabolism.
tainted meat. However, cooked products,
such as cooked hams, luncheon meat, frank-
furters and cooked sausages, were acceptable
unless they were prepared from very strong-
ly tainted meat. An important factor influenc-
ing the acceptability of processed meat from
intact males is the way it is consumed. If it is
heated immediately prior to consumption,
the perception of the odour is enhanced and
the taint is more easily detected. Another way
of utilizing tainted meat is to dilute it with
non-tainted material and to use flavour-
masking substances such as spices.
Metabolism of androstenone and skatole
The extent of skatole and androstenone accu-
mulation in carcasses is controlled by the bal-
ance between the processes that produce
these compounds and processes that are
involved in degrading and removing the
compounds.
The 16-androstene steroids (including
androstenone) are synthesized in the testis
from pregnenolone in a reaction that is cata-
lysed by cytochrome P450C17 along with
cytochrome b5 and the associated reductases.
The biosynthetic pathway is given in Fig.
3.10. Cytochrome b5 has been cloned from a
number of species, including pig. Levels of
the cytochrome b5 protein and total
cytochrome b5 mRNA are correlated with the
rate of androstenone synthesis. This suggests
that levels of cytochrome b5 in the testis could
be used as a marker to reduce boar taint from
androstenone.
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Fig. 3.10. Biosynthesis of androgens and androst-16-ene steroids.
The 5α-reductase enzyme catalyses the
final step in the synthesis of androstenone,
which is the reduction of the ∆4 double bond
in 4,16-androstadien-3-one. Thus, inhibition
of this enzyme could reduce the synthesis of
androstenone. However, this enzyme is also
responsible for the conversion of testosterone
to dihydrotestosterone, which is the ultimate
androgen in some tissues. Multiple forms of
the 5α-reductase enzyme exist and a specific
isoform has been identified in pig testis for
the synthesis of androstenone. It may there-
fore be possible to reduce boar taint from
androstenone by inhibition of this isoform
without affecting the biological actions of
androgens (Cooke et al., 1997). 
Skatole is produced by gut bacteria that
degrade tryptophan from undigested feed or
from the turnover of cells lining the gut of the
pig. Skatole is absorbed from the gut and
then metabolized primarily in the liver. The
major metabolites (Fig. 3.11) that are formed
by phase I metabolism are 6-hydroxyskatole,
indole-3-carbinol, 3-hydroxy-3-methyloxin-
dole (HMOI), 3-hydroxy-3-methylindolenine
(HMI) and 3-methyloxindole (3MOI). The
key enzymes in the phase I metabolism of
skatole are CYP2E1 and CYP2A6. High levels
of activity of these enzymes and the produc-
tion of 6-hydroxyskatole and HMOI are neg-
atively correlated with skatole accumulation
in fat, while production of HMI was positive-
ly correlated with skatole levels in fat (Diaz
and Squires, 2000). The phase II metabolism
of skatole metabolites by phenol sulphotrans-
ferase (PST) is also negatively correlated with
skatole levels in fat. Thus, pigs with high lev-
els of these liver enzymes will be able to
metabolize skatole rapidly and clear it from
the body. Pigs with low levels of these
enzymes can have high levels of skatole in
the fat due to insufficient capacity to metabo-
lize skatole. This becomes a problem if the
amount of skatole absorbed from the gut, or
the manure in the environment, is high. 
Factors affecting boar taint 
The extent of boar taint from skatole and
androstenone is affected by a number of fac-
tors, including diet and management factors
and genetic factors. Efficient methods for
controlling boar taint are needed before intact
males can be used for pork production. If the
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Fig. 3.11. Hepatic metabolism of skatole.
incidence of boar taint in intact male pig pop-
ulations is sufficiently low and effective
detection methods for boar taint were avail-
able, tainted carcasses could be sorted out on
the slaughter line to be used in processed
products. 
Diet and management
There is a wide variation among different
animals in fat skatole levels at slaughter.
Because bacteria in the gut produce skatole,
feeding and rearing factors affect skatole pro-
duction, while genetic factors affect skatole
metabolism. Swine diets with a high fibre
content or high level of non-digestible carbo-
hydrates provide the energy needed for
increased proliferation of bacteria, so that
tryptophan can be used for protein synthesis
rather than being degraded to skatole. Wet
feeding and an unlimited water supply can
lower skatole levels in fat. Wet feeding of
boars on a low protein diet with virginia-
mycin as a growth enhancer in fully slatted
pens reduced the level of boar taint. Feeding
pigs a mixture of inulin and bicarbonate for a
few days before slaughter results in a sharp
reduction in fat skatole levels. The addition of
zinc bacitracin or zeolite to the diet is effec-
tive in reducing fat skatole levels. Finally,
withholding feed on the evening prior to
slaughter has been shown to reduce fat ska-
tole levels. These modifications of the gut
microbes can dramatically reduce skatole
production. Environmental factors, such as
raising pigs on slatted floors, decrease skatole
levels compared to animals on concrete,
probably because the animals were less dirty.
Thus, a proper control of the environment
and diet may reduce fat skatole levels sub-
stantially.
Diet and management factors do not
affect fat androstenone levels, unless they
affect the sexual maturity of the intact male at
slaughter.
Genetic factors
Androstenone synthesis increases during
puberty, along with increased production of
the androgens and oestrogens, which are
responsible for the better growth perform-
ance of intact males. The same regulatory sys-
tems appear to control the synthesis of all tes-
ticular steroids, so it is very difficult to
decrease androstenone without affecting
androgens and oestrogens as well. However,
there is a wide variation among different
intact males in the accumulation of
androstenone in fat. Levels of androstenone
also vary among breeds of pigs, with Durocs
having dramatically higher levels than
Yorkshire, Landrace or Hampshire breeds
and Large White breeds having higher levels
than Landrace breeds. 
The sexual maturity and age of the ani-
mal at slaughter weight, as well as the gen-
etic potential for androstenone production,
affect the synthesis of androstenone. Both
mechanisms are genetically determined and
this explains the high heritability of fat
androstenone content, with heritability esti-
mates ranging from 0.25 to 0.87 (Willeke,
1993). However, selection experiments
against androstenone also decreased the pro-
duction of androgens and oestrogens, and
delayed puberty in the gilts of a ‘low
androstenone’ line. 
A significant effect of different haplo-
types of swine lymphocyte antigen (SLA) and
the microsatellite marker S0102 on
androstenone level in fat has been proposed.
This suggests that a quantitative trait locus
(QTL) for androstenone is located on chro-
mosome 7 between these two markers. Other
work, based on a selection experiment for
low androstenone, proposed a major two-
allele gene affecting androstenone levels in
fat that was distinct from the SLA system
(Fouilloux et al., 1997). Thus it appears that
there are at least two major genetic effects on
androstenone accumulation in fat. One of
these may be related to the expression of
cytochrome b5 and the potential for
androstenone production, while the other
may be related to other factors, such as the
development of sexual maturity. Genetic
markers for low androstenone may be devel-
oped in the future and used in marker-assist-
ed selection breeding programmes for low
androstenone pigs.
Genetic factors also affect the accumula-
tion of skatole in fat. High skatole levels in
boars may be related to a higher anabolic
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potential and increased turnover of intestinal
cells, which increases skatole formation in the
hindgut. The differences that are seen in the
activities of the key enzymes in skatole
metabolism (CYP2E1, CYP2A6 and PST)
mean that the potential for degrading blood
skatole is decreased in some intact male pigs.
Genetic markers are needed which can iden-
tify those animals expressing high levels of
these enzymes. These markers could be used
in marker-assisted selection programmes for
low-skatole pigs. 
Immunological methods to control
boar taint
A number of immunological approaches
could potentially be used to reduce boar taint
from androstenone. Attempts have been
made to remove 5α-androstenone by active
immunization against the steroid, but it was
still deposited in the body tissues. The
removal of the androst-16-ene steroids would
not adversely affect growth performance,
since they show little or no anabolic activity. 
Castrating pigs at 2 or 3 weeks before
slaughter reduces androstenone content in fat
to levels similar to those in castrates and gilts.
However, surgical castration of older animals
cannot be used in practice. Interfering with
testicular function can also reduce boar taint.
Antagonists or agonists for GnRH can be
used to interfere with gonadotrophin produc-
tion. Another approach is the immunocastra-
tion of male pigs by immunizing against LH
or GnRH at an appropriate age. This yields
the anabolic effects of the androgens early in
life but shuts down all steroid biosynthesis
before the synthesis of androst-16-ene
steroids at sexual maturity. The performance
of immunized animals depends on the
response to the vaccine (Turkstra et al., 2002).
Immunocastration also results in a reduction
of fat skatole content to what is found in cas-
trates. A vaccine for immunocastration
(Improvac®) is commercially available in
Australia (Dunshea et al., 2001). Two doses of
vaccine (2 ml of 200 µg ml–1 GnRH conjugate)
are given at an interval of at least 4 weeks.
The second dose should be given 4–5 weeks
before slaughter. The vaccine is administered
at the base of the ear with a special vaccinator
designed to prevent accidental needle sticks.
Whether or not the technique is commercial-
ly viable and accepted in other countries
remains to be determined. However, the
main problem might be the acceptability of
the technique by the general public. Workers
accidentally injected with the vaccine may
also raise antibodies against GnRH and
become sterile.
3.4 Somatotrophin
Somatotrophin or growth hormone (ST, GH)
is the most important peptide hormone
affecting growth. Experiments in the 1930s
demonstrated that rats injected with alkaline
extracts of pituitary gland gained more
weight and had more muscle and less fat
than controls. In 1945, growth hormone was
isolated from anterior pituitary and experi-
ments evaluating the effects of crude prepa-
rations of porcine growth hormone (pST)
began in pigs. However, prior to the 1980s,
studies with domestic livestock and commer-
cial application of ST were limited because ST
had to be extracted from pituitary glands of
slaughtered animals. Thus, there was a very
limited supply of ST, and what was available
varied greatly in quality. Subsequently,
advances in recombinant DNA technology
made it possible to produce large quantities
of high-purity ST.
Somatotrophins from domestic livestock
contain 191 amino acids and there is a high
degree of sequence homology between STs
from different species (Table 3.2). There are 18
differences in amino-acid sequence between
porcine ST (pST) and bovine ST (bST), but
only two differences between bST and ovine
ST (oST). Chicken ST (cST) has only 77%
sequence identity to bST. There are consider-
able sequence differences between human ST
(hST) and bST or pST, so that pituitary prepa-
rations from farm animals are not active in
humans. Variants of ST are produced by the
pituitary gland and four major variants of
bST have been identified.
Treatment of pigs with pST increases
protein accretion and decreases fat deposi-
tion in boars, barrows and gilts in both poor
and improved genotypes. The response to
pST can vary according to initial body
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weight, length of treatment, breed, sex, dose
of pST and diet composition. Maximally
effective doses can increase average daily
gain by 10–20%, improve feed efficiency by
15–30%, decrease feed intake by 10–15%,
decrease lipid accretion by 70% and increase
protein deposition by 50%. A daily dose of
30–69 µg kg–1 body weight given between
50 kg and slaughter improves growth rate,
feed conversion efficiency and lean content
by 22%, 20% and 10%, respectively, while
decreasing carcass fat by 30%. Since pST
stimulates protein deposition in all tissues, a
slight decrease in dressing percentage may be
found due to an increase in weight of the
internal organs. There are no detrimental
effects on meat tenderness from pST treat-
ment. However, treatment of pigs with pST
has been reported to reduce chondrocyte
metabolism and compromise cartilage, bone
and joint development in growing animals
(He et al., 1994).
Bovine ST (bST) is less effective in grow-
ing cattle than pST is in pigs. Daily gain, feed
efficiency and carcass lean content in grow-
ing cattle are improved by 12%, 9% and 5%,
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Table 3.2. Amino-acid sequence of somatotrophins from various species.
–30 –20 –10 0 10 20 30
Porcine (pST) MAAGP RTSALLAFAL LCLPWTREVG AFPAMPLSSL FANAVLRAQH LHQLAADTYK
Bovine (bST) MMAAGP RTSLLLAFAL LCLPWTQVVG AFPAMSLSGL FANAVLRAQH LHQLAADTFK
Sheep (oST) MMAAGP RTSLLLAFTL LCLPWTQVVG AFPAMSLSGL FANAVLRAQH LHQLAADTFK
Human (hST) MATGSR TSLLLAFGLL CLPWLQEGSA FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE
Chicken (cST) MAPGS WFSPLLIAVV TLGLPQEAAA TFPAMPLSNL FANAVLRAQH LHLLAAETYK
Turkey MAPGS WFSPLLIAVV TLGLPQGAAA TFPTMPLSNL FTNAVLRAQH LHLLAAETYK
Duck MAPGSW FSPLFITVIT LGLQWPQEAA TFPAMPLSNL FANAVLRAQH LHLLAAETYK
Carp MARV LVLLSVVLV SLLVNQGRAS DNQRLFNNAV IRVQHLHQLA AKMINDFEDS
40 50 60 70 80 90
Porcine (pST) EFERAYIPEG QRYSIQNAQA AFCFSETIPA PTGKDEAQQR SDVELLRFSL LLIQSWLGPV
Bovine (bST) EFERTYIPEG QRYSIQNTQV AFCFSETIPA PTGKNEAQQK SDLELLRISL LLIQSWLGPL
Sheep (oST) EFERTYIPEG QRYSIQNTQV AFCFSETIPA PTGKNEAQQK SDLELLRISL LLIQSWLGPL
Human (hST) FEEAYIPKEQ KYSFLQNPQT SLCRSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV
Chicken (cST) EFERTYIPED QRYTNKNSQA AFCYSETIPA PTGKDDAQQK SDMELLRFSL VLIQSWLTPV
Turkey EFERTYIPED QRYTNKNSQA AFCYSETIPA PTGKDDAQQK SDMELLRFSL VLIQSWLTPM
Duck EFERSYIPED QRHTNKNSQA FCYSETIPAP TGKDDAQQKS DMELLRFSLV LIQSWLTPVQ
Carp LLPEERRQLS KIFPLSFCNS DYIEAPAGKD ETQKSSMLKL LRISFHLIES WEFPSQSLSG
100 110 120 130 140 150
Porcine (pST) QFLSRVFTNS LVFTGTSDRVY EKLKDLEEGI QALMRELEDG SPRAGQILKQ TYDKFDTNLR
Bovine (bST) QFLSRVFTNS LVFGTSDRVY EKLKDLEEGI LALMRELEDG TPRAGQILKQ TYDKFDTNMR
Sheep (oST) QFLSRVFTNS LVFGTSDRVY EKLKDLEEGI LALMRELEDV TPRAGQILKQ TYDKFDTNMR
Human (hST) QFLRSVFANS LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS
Chicken (cST) QYLSKVFTNN LVFGTSDRVF EKLKDLEEGI QALMRELEDR SPRGPQLLRP TYDKFDIHLR
Turkey QYLSKVFTNN LVFGTSDRVF EKLKDLEEGI QALMRELEDR SPRGPQLLRP TYDRFDIHLR
Duck YLSKVFTNNL VFGTSDRVFE KLKDLEEGIQ ALMRELEDRS PRGPQLLKPT YDKFDIHLRN
Carp TVSNSLTGNP NQLTEKLADL KMGISVLIQA CLDGQPNMDD NDSLPLPFED FYLTMGENNL
160 170 180 190
Porcine (pST) SDDALLKNYG LLSCFKKDLH KAETYLRVMK CRRFVESSCA F
Bovine (bST) SDDALLKNYG LLSCFRKDLH KTETYLRVMK CRRFGEASCA F
Sheep (oST) SDDALLKYNG LLSCFRKDLH KTETYLRVMK CRRFGEASCA F
Human (hST) HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F
Chicken (cST) NEDALLKNYG LLSCFKKDLH KVETYLKVMK CRRFGESNCT I
Turkey SEDALLKNYG LLSCFKKDLH KVETYLKVMK CRRGESNCN I
Duck EDALLKNYGL LSCFKKDLHK VETYLKVMKC RRFGESNCTI
Carp RESFRLLACF KKDMHKVETY LRVANCRRSL DSNCTL
respectively, and in sheep by 18%, 14% and
10%, respectively, by bST treatment. Carcass
fat content was decreased by 15% in sheep
and cattle by bST treatment. The lipolytic
effects of ST contribute to improved feed effi-
ciency while maintaining growth rate. As a
result, feed costs are lower and carcass grade
is improved. Results with chickens have
been mixed, but this may be because of the
mode of delivery. Episodic administration of
cST to older birds markedly improved
growth performance, while continuous infu-
sion had no effect. ST is largely ineffective in
promoting growth or altering metabolism
during the early posthatch period, when the
bird is already growing rapidly and the rate
of fat deposition is low (Vasilatos-Younken,
1995).
Bovine ST has dramatic effects on milk
production and is approved for use in the
dairy industry in the USA. This aspect is dis-
cussed in Section 4.1.
Control of ST release
ST release from the anterior pituitary gland is
regulated by hormones produced in the
hypothalamus (Fig. 3.12). ST release is stimu-
lated by growth hormone releasing hormone
(GHRH) and decreased by somatostatin (SS).
ST release occurs in a pulsatile pattern and
this pattern is thought to be regulated by the
feedback of ST on periventricular neurons in
the hypothalamus to cause the release of SS.
The production of SS suppresses the activity
of the GHRH neurons in the arcuate nucleus
and subsequently decreases the release of ST
by the pituitary. The decrease in ST then
reduces the negative feedback on the hypo-
thalamus, which increases GHRH production
to increase ST release from the pituitary. This
cycle of events results in a pulsatile release of
ST. For more information, see the review by
Müller et al. (1999).
Somatostatin exists as both 14 amino-
acid (SS-14) and 28 amino-acid (SS-28) forms
that interact with different receptors. SS-14 is
the predominant form and has the same
sequence in different species. Somatostatin is
expressed in the brain and in specialized D
cells in the gastrointestinal tract and pancre-
atic islets. It acts to inhibit the secretion of
most hormones and, in addition to its
endocrine effects, can act locally as a
paracrine or autocrine regulator. In the stom-
ach, SS inhibits the release of gastrin and
hydrochloric acid, while in the pancreatic
islets, SS regulates the secretion of glucagon
and insulin. Androgens stimulate while
oestrogens decrease the production of SS in
the brain; this may, in part, explain the differ-
ences in ST secretion patterns between males
and females.
Octapeptide analogues of SS are
octreotide (Fig. 3.13), lanreotide and
vapreotide, and these are used for the treat-
ment of acromegaly and to decrease gastric
secretions.
There are five major forms of SS
receptors that vary in their tissue dis-
tribution. SS receptors are coupled to several
populations of K+ channels and their
activation causes hyperpolarization of the
cell membranes, leading to decreased
action potential and decreased intracellular
calcium.
GHRH was first isolated from pancreatic
islet tumours. It is a 44 amino-acid peptide
that is part of a family of brain–gut peptides
which includes glucagon, glucagon-like pep-
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Fig. 3.12. Regulation of growth hormone release.
tide I, vasoactive intestinal polypeptide,
secretin and gastric inhibitory peptide. In
addition to regulating secretion of ST, GHRH
has been implicated in promoting sleep and
increasing appetite, particularly for protein.
ST secretion also increases during rapid eye
movement (REM) sleep.
Pulsatile GHRH release can be stimula-
ted by activation of the growth hormone sec-
retagogue receptor (GHS-R) in the arcuate
nucleus of the hypothalamus. The GHS-R is
expressed in both the anterior pituitary and
central nervous system and is highly con-
served across species. The GHS-R is not acti-
vated by GHRH or somatostatin, but binds a
number of peptide analogues of Leu- and
Met-enkephalins known as growth hormone
releasing peptides (GHRPs). GHRP-6 (His–D-
Trp–Ala–D-Phe–Lys–NH2) was one of the
first analogues developed as a potent stimu-
lator of pulsatile ST secretion, but the GHRPs
had low oral bioavailability of about 0.3%.
Other non-peptide derivatives were devel-
oped (Fig. 3.14) and L-692,429 was the first of
these, with 4% bioavailability in humans.
Later, the spiropiperidine MK-0677 was
developed to have good bioavailability and a
longer half-life, being effective for 24 hours.
The benzolactam L-739,943 has similar bio-
logical and pharmacokinetic properties but
different structure from MK-0677. The ben-
zylpiperidine L-163,540 has a shorter half-life
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Fig. 3.13. Structure of octreotide, an analogue of
somatostatin.
Fig. 3.14. Growth hormone secretagogues.
and is used for finer control over ST and
IGF-I levels. For more information of growth
hormone secretagogues, see Smith et al. (1996,
2001).
Ghrelin is a 28 amino-acid peptide that
binds to the GHS-R to stimulate ST release. It
has an n-octanoly ester on serine 3 that is nec-
essary for biological activity. Ghrelin is pro-
duced in the stomach, kidney and placenta,
and is the only endogenous GHS-R ligand yet
isolated that stimulates GHRH release.
Intracerebroventricular injections of ghrelin
stimulated feeding and weight gain in rats.
Ghrelin blocked the action of leptin
(see Section 3.8) in reducing feed intake,
suggesting that there is a competitive interac-
tion between ghrelin and leptin in regula-
ting feed intake. Ghrelin also regulates gas-
tric acid secretion by activating the vagus
system.
Binding of GHRH to its receptors on
somatotrophs increases intracellular levels of
cAMP. Somatostatin binds to subtype-2
receptors and hyperpolarizes the somato-
troph membranes to inhibit ST release.
GHRP-6 acts by stimulating phospholipase C
to increase levels of diacylglycerol and IP3,
thereby mobilizing cellular calcium and stim-
ulating protein kinase C (see Section 1.3). The
presence of GHRP-6 along with GHRH
potentiates the increase in cAMP due to
GHRH alone, indicating that there is some
interaction between the different signal trans-
duction pathways. Co-administration of
GHRH and ghrelin gives a synergistic effect
on ST secretion.
Plasma levels of ST and the pulse ampli-
tude for ST are higher in women than in men,
but the pulse frequency is the same in males
and females (Fig. 3.15). The amplitude and
number of oscillations of ST release decline
during ageing. Decreased levels of ST are
associated with a reduced nitrogen balance
and a decline in body condition and muscle
tone. The decrease in ST may be due to a
decrease in the endogenous ligand(s) of the
GHS-R during ageing. Chronic oral admini-
stration of MK-0677 once daily to dogs pro-
duces a sustained physiological pattern of
pulsatile ST release. However, stimulation of
GH release by isolated pituitary cells in vitro is
not sustained, with desensitization occurring
within a few minutes. Administration of L-
dopa to old rats also restores the amplitude of
ST release to what is seen in young animals. It
has been suggested that GHS-R ligands may
modulate dopamine release from hypothala-
mic neurons to affect pulsatile release of ST.
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Fig. 3.15. Age and gender effects on the pattern of growth hormone secretion (redrawn from Smith et
al., 1996).
Mechanism of action of ST
Somatotrophin affects a wide range of
somatogenic and metabolic processes to
increase lean tissue growth. It has two dis-
tinct types of effects: direct and indirect. The
direct effects are due to ST binding to recep-
tors on target cells, and these include effects
on carbohydrate, lipid, protein and mineral
metabolism. The indirect somatogenic effects
of ST are those related to cell proliferation,
and these are mediated by insulin-like
growth factor-I (IGF-I), which is a potent
mitogen with some sequence similarities to
insulin.
Direct effects
ST RECEPTORS. The biological actions of ST
begin with ST binding to its receptor on the
cell surface. The ST receptor is a transmem-
brane protein of 634–638 amino acids with a
molecular mass of about 70 kDa. The free
receptor exists in the cell membrane as a
single-chain monomer, while the activated
receptor complex consists of a receptor dimer
that is bound to a single ST molecule. The ST
receptor is a member of a superfamily of
cytokine receptors, which includes prolactin,
erythropoietin, interferons and interleukins
(see Section 1.3). 
The differential effects of pulsatile versus
continuous infusion of ST may be due to
effects on the ST receptors. Continuous expo-
sure to high levels of ST may cause down reg-
ulation of the number of ST receptors. High
levels of ST may also prevent the dimeriza-
tion of the ST receptor, since the receptor
monomers will be bound to different mol-
ecules of ST and will not form active dimers.
In contrast, at low levels of ST a single ST
molecule will be more likely to bind to two
ST receptor monomers to form an activated
complex (see Fig. 1.28).
A growth hormone binding protein
(GHBP), which is essentially the extracellular
domain of the ST receptor which is also pro-
duced from the ST receptor gene, is present in
plasma of many species. GHBP enhances the
growth promoting effects of ST, probably by
increasing the half-life of ST in the circulation.
METABOLIC EFFECTS. The metabolic effects of ST
are summarized in Table 3.3.
There is a dramatic decrease in lipid
accretion in ST-treated animals. This allows
more nutrients, such as glucose, to be avail-
able for increased growth of lean tissue, and
improves commercial production efficiency
by reducing the proportion of nutrients used
for the synthesis of body fat. The effects of ST
on lipid metabolism are chronic rather than
acute. When animals are in positive energy
balance, ST reduces the rate of lipogenesis,
while lipolysis is increased in animals under
negative energy balance. In growing pigs, ST
decreases the uptake of glucose for lipid syn-
thesis by adipocytes through decreased syn-
thesis of the glucose transporter protein,
GLUT4. ST also decreases the synthesis of
lipogenic enzymes, including fatty acid syn-
thase and acetyl-CoA carboxylase. ST also
decreases the stimulatory effects of insulin on
glucose uptake and utilization by adipocytes
and increases the lipolytic responses to
adrenaline. ST treatment of pigs decreases
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Table 3.3. Summary of metabolic effects of somatotrophin.
Tissue type Metabolic effect
Skeletal muscle Increased protein synthesis/accretion
Adipose tissue Increased lipolysis, decreased glucose uptake and lipid synthesis
Liver Increased glucose output
Intestine Increased calcium and phosphorus uptake
Mammary gland Increased milk synthesis by increased uptake of nutrients and increased blood flow
Various tissues Decreased amino-acid and glucose oxidation; increased oxidation of free fatty
acids; decreased effects of insulin
glucose utilization by adipose tissue from
40% to 7% of the whole-body glucose
turnover. 
The protein anabolic effect of ST occurs
almost exclusively by increasing protein syn-
thesis, with no measurable effects on protein
catabolism. Alterations in tissue response to
other endocrine factors, such as insulin, may
also be important. Sufficient levels of plasma
amino acids are needed to sustain the
increased level of protein synthesis.
Maintenance energy requirements are also
10–20% higher in pST-treated pigs, because of
increased protein synthesis in muscle and in
visceral tissues such as liver and gut. 
In growing pigs, pST treatment increases
the apparent efficiency of use of dietary pro-
tein for protein deposition by 25–50%,
depending on growth stage, quality of
dietary protein and the sex of the pig. Young
pigs that are less than about 40 days of age
have little response to pST treatment, since
they are already growing rapidly with a high
efficiency of utilization of dietary protein.
The rate of protein deposition is increased by
16%, 25% and 74% in gilts and barrows in the
weight ranges of 10–20 kg, 20–55 kg and
55–100 kg, respectively. There is no effect of
pST on protein digestibility, and only a mar-
ginal increase in the dietary protein require-
ment for 25–60 kg pigs. Increases in protein
deposition from pST treatment are greater in
finisher pigs weighing 60–90 kg, and this
increases the dietary protein requirement.
This is especially important in boars of
improved genotypes that already have a high
efficiency of use of dietary protein. Thus, pST
acts by separately increasing the efficiency of
amino-acid utilization and the maximal rate
of protein accretion. Decreased levels of plas-
ma urea nitrogen and the activity of lysine α-
ketoglutarate reductase are seen following ST
treatment, which suggests that oxidation of
amino acids is reduced.
Indirect effects
The major role of ST in stimulating growth is
mediated via insulin-like growth factor-I
(IGF-I, see also Section 4.1). High blood levels
of IGF-I decrease the secretion of ST by direct
negative feedback action on the pituitary and
also by stimulating SS production by the
hypothalamus.
IGF-I is synthesized in the liver along
with its major binding protein, IGFBP3, and
the third member of the ternary binding com-
plex, the acid-labile subunit. Local synthesis
of IGF-I in muscle and adipose tissue may
also be important. IGF-I is a single polypep-
tide chain of about 7500 Da and the sequence
of human, porcine and bovine IGF-I is identi-
cal. There are at least six binding proteins for
IGF-I, and almost all of the IGF-I is bound to
binding proteins that modulate the interac-
tions of IGF with its target tissues. IGF-I
interacts with type I and type II receptors that
differ in structure, specificity and signalling
mechanism. The type I receptor is similar to
the insulin receptor, while the type II receptor
is a monomeric protein.
IGF-I stimulates the proliferation of
chondrocytes or cartilage cells, to increase
bone growth. It also increases the prolifera-
tion of satellite cells, which fuse with the
myofibre and contribute to muscle fibre
growth. It also stimulates amino-acid uptake
and protein synthesis. A related polypeptide,
IGF-II, may also be important in the control
of muscle growth.
Although some of the effects of pST are
mediated by IGF-I, treatment of finisher pigs
with IGF-I does not affect growth. Treatment
of finisher pigs with the potent analogue LR3
IGF-I reduces growth rate, the amplitude of
endogenous pST pulsatile release and plasma
levels of IGF-I and its major plasma-binding
protein. Thus negative feedback limits the
effectiveness of IGF-I treatment in finisher
pigs. In neonatal pigs, LR3 IGF-I infusion
increases growth of the gut and visceral tis-
sues, particularly in pigs under nutritional
stress. 
Peptide growth factors may be orally
active in the neonatal pig and could poten-
tially be added to diets of early weaned or
supplemental fed piglets to improve health
and growth rate. 
Delivery/dose effects
Porcine ST was approved in 1994 for use in
pigs in Australia, using daily injections of 3–5
mg per pig for finishing pigs, starting at 35
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days before slaughter. So far, it has not been
approved for use in other countries. ST is not
orally active and most studies have used
daily injection as a practical means of deliv-
ery of pST. The ADG and rates of protein and
ash accretion are maximally stimulated at a
daily pST dose of about 100 µg kg–1 BW.
However, rates of lipid accretion and
feed:gain ratio decrease in a more linear man-
ner up to a dose of 200 µg kg–1 BW. For more
information, see Etherton and Smith (1991).
The most investigated formulation for
pST delivery has been the implant, with the
goal of a one-time treatment that provides
pST for the entire finishing period. Sustained-
release implants have been designed to deliv-
er approximately 2 mg of pST per day for 42
days. The implants consist of recombinant
pST having an N-alanyl residue linked to the
natural pST sequence in a solution of 49.5%
1 M sodium phosphate, 49.5% glycerol and
1% Tween 20. Pigs treated with these
implants had increased efficiency of gain
through decreased feed consumption, but the
rate of gain was not increased. It appears that
the large peaks in pST caused by daily injec-
tion are necessary to activate the physiologi-
cal processes related to growth. 
Administration of ST to rats by constant
infusion produces a male pattern of response
in liver enzymes, while a pulsatile delivery
elicits a female response. In chickens, the
pulse amplitude of ST in plasma is high at
early ages during rapid growth and decreas-
es at older ages when growth rate is
decreased. 
Growth hormone secretagogues (GHS)
such as MK-0677 have been used in humans
as an alternative to injectable ST. They have
the advantage of oral dosing and producing a
pulsatile, physiological ST profile. However,
the GHS-R pathway is subject to negative
feedback, so the sustained supraphysiologi-
cal levels of ST that can be obtained with ST
or GHRH injection are not possible with GHS
treatment.
A slow-release oil-based formulation of
zinc methionyl bST (Sometribove®) is avail-
able, which improved growth performance
and increased carcass leanness in lambs
when administered weekly or once every 2
weeks. Equine ST (EquiGen®) is also used as
an aid to improve nitrogen retention in aged
horses (at least 15 years of age). The recombi-
nant product is expressed in Escherichia coli
and has an additional N-terminal methion-
ine. It has been shown to decrease plasma
urea nitrogen and urinary nitrogen, indica-
ting that it increased protein synthesis
and/or decreased protein breakdown. The
recommended dose is 10–20 µg kg–1 BW
day–1 for 42 days, starting at 10 µg kg–1 BW
day–1 for the first week and then increasing to
20 µg kg–1 BW day–1 for weeks 2–6. ST is
given by deep muscular injection, rotating
the site between the neck, pectoral muscle
and rump. Recombinant bST has also been
shown to increase growth rate and improve
feed efficiency and protein deposition in both
young and older salmonid fish. 
Immunization against somatostatin has
also been used to increase the secretion of ST.
Some work on developing anti-idiotypic anti-
bodies for ST has also been done (see Section
2.4). Transgenic animals with ST genes (pigs,
fish) have also been generated.
Safety/quality aspects
ST is a natural protein that is destroyed by
cooking and rapidly broken down in the gut,
so the potential threat from residues should
be small. A slight reduction in meat tender-
ness in pigs treated with pST may be due to
decreased intramuscular fat content.
3.5 β-Adrenergic Agonists
β-Adrenergic agonists (β-AA) are synthetic,
orally active phenethanolamine derivatives
that are related to the naturally occurring cat-
echolamines, dopamine, noradrenaline (nor-
epinephrine) and adrenaline (epinephrine).
Noradrenaline functions both as a neuro-
transmitter in the sympathetic nervous sys-
tem and an endocrine hormone produced by
the adrenal medulla. It is biosynthesized
from tyrosine in the adrenal medulla and is
present in plasma at 2–5 times the levels of
adrenaline and dopamine. Adrenaline is syn-
thesized by methylation of noradrenaline.
Catecholamines regulate a variety of
physiological functions, including the speed
and force of heart contractions, motility and
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secretions from various parts of the gastroin-
testinal tract, bronchodilation, salivary gland
and pancreas secretions, brown adipose tis-
sue metabolic activity, blood vessel dilation
and contraction, uterine contraction and
spleen capsule contraction. This wide range
of processes is regulated by the presence of
distinct groups of α- and β-receptors in
different tissues. Adrenaline is more potent
than noradrenaline for α-receptors. Nor-
adrenaline is more potent than adrenaline for
β1-receptors. 
Mechanism of action
In stressful situations, the sympathetic nerv-
ous system stimulates the release of the cate-
cholamines, adrenaline and noradrenaline,
from the adrenal medulla (see Sections 3.12
and 6.3). These hormones act on α- and β-
receptors that are located in many different
tissues to produce the ‘fight or flight’
response. Activation of the β-receptors
increases the availability of metabolic fuels
(glucose and fatty acids) and the dilation of
airways increases the oxygen availability.
Catecholamines stimulate the activity of
glycogen phosphorylase and inhibit glycogen
synthase to increase the conversion of glyco-
gen to glucose in muscle. These effects are
also stimulated by the β-AA analogue isopro-
terenol, and inhibited by the β-receptor
antagonist, propanolol. Catecholamines stim-
ulate lipolysis and inhibit lipogenesis in adi-
pose cells and these effects can be blocked
with β-adrenergic receptor antagonists.
β-AAs have been used in the treatment
of asthma since the 1970s because of their
ability to relax smooth muscle in the airways.
They are given in small doses directly into
the airways using an inhaler, so that little of
the drug enters the circulation to affect other
tissues. β-AAs are also effective as reparti-
tioning agents that alter nutrient metabolism,
to produce dramatic increases in lean and
decreases in adipose tissue growth. 
β-AA structures
Several synthetic analogues of adrenaline
and noradrenaline have been investigated for
their effects on increasing skeletal muscle
growth and decreasing the fat content of car-
casses. β-AAs have the same overall struc-
ture, but individual compounds may have
quite different chemical and pharmacokinetic
properties. In order to be biologically active,
β-AAs must have a substituted six-mem-
bered aromatic ring, a hydroxyl group on the
β carbon and a positively charged nitrogen
on the ethylamine side-chain. A bulky R
group on the side-chain confers specificity for
the β-receptor. The substituents on the aro-
matic ring at the 3 and 4 carbons are impor-
tant, since they can form hydrogen bonds to a
serine hydroxyl in the β-receptor.
Substituting the hydroxyl groups on the aro-
matic ring for halogen atoms prevents the
rapid catabolism and deactivation of β-AA.
Common β-AAs include cimaterol, clen-
buterol, ractopamine and L-644,969 (Fig.
3.16). Each of these compounds may have
multiple actions on various aspects of nutri-
ent metabolism, which may vary in different
species. The positive response to protein
accretion is largely confined to skeletal mus-
cle. Clenbuterol and cimaterol act by binding
primarily to β2-receptors, while ractopamine
is reported to also bind to β1-receptors in
muscle. Stimulation of β1-receptors in heart
muscle can result in tachycardia. Most β-AA
compounds bind to more than one type of
β-adrenergic receptor.
β-AA receptors
Most tissues have a mixture of α- or β-adren-
ergic receptors, with different amounts of
each receptor type present in different tissues
and in different species. Cloning of β-AA
receptors has confirmed the existence of α1-,
α2- and β1-, β2- and β3-receptors. β-AA recep-
tors within a species have about 50% amino-
acid sequence homology, while individual
β-AA subtypes have 75% sequence homology
across species. The β-AA receptors are glyco-
sylated with an approximate molecular mass
of 65,000 Da.
Some tissues have predominantly one
particular receptor subtype. For example, rat
heart has primarily β1-receptors, while
guinea-pig tracheal muscle has primarily β2-
receptors. These tissues were used to classify
the specificity of different β agonists and
Manipulation of Growth and Carcass Composition 91
antagonists for different receptor types. For
example, the compound CGP 20712A is a
specific β1-receptor antagonist, ICI 118,551 is
a specific β2 antagonist and SR 59,230A is a
specific β3 antagonist. Isoproterenol is a uni-
versal β receptor agonist. Compounds with a
high degree of specificity for a particular
receptor subtype were then used to classify
different tissues for the receptor subtypes
present. However, there are species differ-
ences in the effectiveness of different β-AAs
for subtypes of β-receptors. There may also
be differences in the cellular distribution of
the different β-receptor subtypes.
Heart contractility is stimulated primari-
ly by β1-receptors, although β2-receptors are
also present in heart muscle in some species.
In cattle and sheep, skeletal muscle and
adipose tissue have β2-AA receptors. Theβ3-receptor subtype is the predominant
receptor in brown and white adipose tissue in
rats and in brown adipose tissue in the
bovine fetus. It is pharmacologically different
from β1 and β2 and is not as readily inactivat-
ed by phosphorylation. Adipocytes in cattle
and sheep have predominantly β2-AA recep-
tors.
Binding of β-AA to its receptor activates
the Gs-protein, and the α-subunit of the Gs-
protein then activates adenylate cyclase. The
cAMP produced by adenylate cyclase acti-
vates protein kinase A to release its catalytic
subunit to phosphorylate and activate a num-
ber of intracellular proteins (see Section 1.3).
These include hormone-sensitive lipase, the
rate-limiting enzyme responsible for triacyl-
glycerol degradation in adipocytes. The
CREB (cAMP-response-element binding pro-
tein) is also phosphorylated by protein kinase
A and subsequently binds to the cAMP
response element in the regulatory region of
genes to stimulate gene transcription. Acetyl-
CoA carboxylase, which is the rate-limiting
enzyme for fatty acid biosynthesis, is inhibit-
ed by phosphorylation (Fig. 3.17).
The β-AA receptor is eventually inacti-
vated by uptake and metabolism of the β-AA.
Noradrenaline and adrenaline are catabo-
lized by catechol-o-methyl transferase, which
is an enzyme that methylates the hydroxyl
groups on the aromatic ring, and by deami-
nation by monoamine oxidase. The β-AA
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Fig. 3.16. Structures of β-adrenergic agonists.
Fig. 3.17. Mechanism of action of β-adrenergic
agonists.
↓
↓
↓
receptor can also be inactivated by phosphor-
ylation of the receptor after β-AA binding by
protein kinase A. Chronic stimulation with β-
AA also reduces the number of β-AA recep-
tors.
Physiological responses to β-AA
The effects of β-AA are generally greatest in
cattle and sheep and least in chickens, with
pigs being intermediate; but the results are
quite variable (Table 3.4). This may be due to
the fact that some species, such as broiler
chickens, have been intensively selected for
growth and are closer to the biological maxi-
mum growth rate. There may also be differ-
ences in the ability of different β-AAs to
activate receptors in different species. 
β-AAs increase muscle growth in both
obese and lean genotypes of swine, but the
genotype differences are not eliminated by
β-AA treatment. The effects of β-AA on
growth performance and carcass composition
are much smaller in young pigs and rumi-
nants that are not laying down fat at a fast
rate compared to market-weight animals. It is
not known whether this is due to low recep-
tor numbers or increased desensitization of
receptors in younger animals.
Carcass fat is reduced by 20–30% in cat-
tle and sheep, with less dramatic improve-
ments of about 10% in pigs. Small but
significant improvements in dressing per-
centage and feed conversion are found.
β-AAs are also effective in poultry, but the
effects are less than those seen in mammals.
Cimaterol reduces carcass fat by 10% in
female broilers and by 5% in male broilers.
Dose-dependent improvements in growth
and carcass composition are also found in
ducks and turkeys.
The effects of β-AA on metabolism are
summarized in Fig. 3.18. Insulin regulates the
rate of lipogenesis, and β-AAs reduce the rate
of lipogenesis through a reduction in the
number of insulin receptors and in the bind-
ing of insulin to adipocytes. β-AAs also act
directly on adipose tissue via the β-receptor
to stimulate lipolysis or decrease lipogenesis.
Increased lipolysis by β-AA results in acutely
increased levels of non-esterified fatty acids
in the plasma of pigs and cattle.
β-AA treatment causes muscle hypertro-
phy rather than hyperplasia. The response is
greater in type II fibres (fast contracting,
mixed glycolytic–oxidative) than in type I
fibers (slow contracting, oxidative). Long-
term treatment with β-AAs may increase the
proportion of type II fibres in a muscle.
β-AA treatment can also increase blood
flow to the skeletal muscle and thereby
increase the availability of energy and amino
acids required for protein synthesis.
Increased blood flow to the adipose tissue
may help to remove the non-esterified fatty
acids produced from lipolysis.
The effects of β-AA on muscle metabo-
lism are probably mediated by direct effects,
rather than indirect effects on other
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Table 3.4. Effects of oral β-AA in different species (% change) (from Mersmann, 1998).
Animal Weight gain Feed consumption Gain/feed Muscle Fat
Cattle +10 –5 +15 +10 –30
Sheep +15 +2 +15 +25 –25
Pigs +4 –5 –5 +4 –8
Chicken +2 +2 +2 –7
Fig. 3.18. Metabolic effects of β-adrenergic
agonists.
endocrine systems, since the effects of β-AA
are also seen in hypophysectomized or
severely diabetic rats. Thus, the mode of
action of β-AA is by direct receptor-mediated
stimulation of muscle growth. Treatment
with β-AA can both increase protein synthe-
sis and decrease the degradation of muscle
protein. Increased levels of mRNAs for mus-
cle-specific proteins, such as myosin light
chain and α-actin, as well as reduced activity
of calpains and other specific proteolytic sys-
tems, have been reported. 
Dry matter intake is commonly reduced
after initial exposure to β-AAs, but this
returns to normal after a short period. The
repartitioning effects of β-AA occur in both
feed-restricted and adequately fed animals,
but the increase in growth rate is only seen in
well-fed animals. 
The increased protein deposition with
β-AA is accompanied by a proportional
increase in dietary protein requirements, and
no response to ractopamine was found in
pigs when dietary crude protein levels were
less than 140 g kg–1. At higher dietary protein
levels, the maximal protein deposition rate is
23% higher in ractopamine-treated gilts com-
pared to controls. This suggests that β-AAs
increase the maximum rate of protein deposi-
tion. Sufficient levels of dietary energy are
required to sustain the increased rate of pro-
tein deposition with β-AA treatment.
However, maintenance energy requirements
are not increased by β-AA. This may be
because the energy requirements of increased
muscle mass are offset by decreased energy
requirements of a smaller visceral mass.
An important advantage of β-AAs is that
they stimulate protein deposition primarily in
skeletal muscle, while pST stimulates protein
deposition and growth in all tissues. The
increased energy and protein required for
muscle synthesis comes from both increased
utilization of dietary energy and protein and
from turnover of other body tissues, such as
liver, kidneys and gut. The weight of the liver,
heart and gut are often reduced by β-AA treat-
ment. There is little or no effect of β-AA on
bone weight in ruminants, but β-AA treat-
ment results in decreased bone weight in pigs.
Thus the dressing percentage (carcass:offal
ratio) is increased by β-AA treatment.
The effects of β-AA on meat quality can
vary with the different β-AAs used, the
species, dose and length of treatment.
Overall, the anabolic effects of β-AA tend to
increase meat toughness, as measured by
shear force values. Trained sensory panels
found decreased tenderness in beef, but not
in pork. Other objective measures of meat
quality, including pH, colour, drip loss and
protein solubility, are not affected. There is
some risk of developing DFD meat, due to
the decreased muscle glycogen and plasma
glucose at slaughter (see Section 3.12).
Delivery/dose
The effects of β-AA are dose dependent, with
a tendency for reduced effects at very high
doses. Doses of 5 µg kg–1 BW resulted in peak
plasma levels of 0.5 ng ml–1 of clenbuterol
after 3–5 h in cattle, with plasma levels
increasing to 2 ng ml–1 as the treatment was
continued. Doses of 50–80 µg kg–1 BW of
salbutamol resulted in plasma levels of about
5 ng ml–1. For pasture-fed cattle, use of β-AA
is impractical, since β-AAs are not available
as implants.
The response to β-AA decreases over
time if they are administered at a constant
rate on a daily basis. The initial marked
responses to β-AA peaks at 14 days after
treatment and then is greatly decreased by 21
days of treatment. This occurs through
densensitization of receptors and uncoupling
of receptors with the adenyl cyclase system
and down regulation of receptor numbers in
the cell membrane. Thus, a relatively short
treatment time towards the end of the finish-
ing period will maximize the response to
β-AA.
A withdrawal period can reduce the
overall effectiveness of β-AA treatment. The
withdrawal period should be kept relatively
short (about 5 days), since compensatory
growth of adipose tissue is seen after with-
drawal of β-AA, while muscle mass is main-
tained.
Safety aspects
The oral potencies of different β-AAs can dif-
fer by as much as three orders of magnitude,
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due to differences in the structures, pharma-
cokinetics and metabolism of the different β-
AAs. β-AAs that have halogenated aromatic
ring systems, such as clenbuterol, are meta-
bolized by both oxidative and conjugative
pathways and have a long half-life. β-AAs
that have hydroxylated aromatic rings are
metabolized solely by conjugation and have a
short half-life. The metabolism occurs in the
liver and in the intestine during absorption. 
The β-AAs are all orally active, in con-
trast to ST and most anabolic steroids. β-AAs
are also heat stable and are not destroyed by
cooking. This increases concern about the
potential effects of residues of β-AA in meat.
Half-life estimates for plasma cimaterol in
steers was 54 min, and for plasma clenbuterol
in veal calves it was 18 h for the initial distri-
bution phase and 55 h for the terminal half-
life. These estimates are much larger than for
adrenaline. The very long half-life for clen-
buterol means that high concentrations can
accumulate in liver and adipose tissue. The
effective therapeutic dose for clenbuterol is
10–20 µg, with a no observed effects limit
(NOEL) of 2.5 µg day–1. In contrast, the effec-
tive dose for other common β-AAs is
2000–10,000 µg. These less potent β-AAs sug-
gest that safe and effective use of β-AAs may
be possible. For more information on tissue
residues for β-AAs, see the review by Smith
(1998).
Ractopamine was approved for use in
swine in the USA in December 1999; other-
wise β-AAs are not approved for use in mod-
ifying the growth of animals raised for meat.
In Canada and Europe, clenbuterol is
approved only for therapeutic use as a bron-
chodilator in horses and calves, and for toco-
lysis to prevent premature birth in cows.
Because of its high potency, clenbuterol has
been used illegally in cattle, and this led to
the hospitalization of 135 people in Spain in
1990 after clenbuterol poisoning caused by
calf liver contaminated with 160 and 291
µg kg–1 of clenbuterol. The symptoms include
muscle tremors, cardiac palpitations, nerv-
ousness, headache, muscular pain, dizziness,
nausea, vomiting, fever and chills. The high-
est accumulation of clenbuterol occurs in pig-
mented tissues, such as hair and the retina in
the eye, due to binding with melanin. This
finding can be used as a highly sensitive test
for detecting residues of clenbuterol in these
tissues up to 60 days after treatment.
Intensive monitoring programmes have
shown a decrease in the illegal use of clen-
buterol in The Netherlands, Germany,
Northern Ireland and Spain by the mid 1990s.
In the USA, clenbuterol has been used illegal-
ly for some show-ring animals, to accentuate
muscle definition and reduce subcutaneous
fat. For more information on the illegal use of
β-AAs in Europe and the USA, see the
reviews by Kuiper et al. (1998) and Mitchell
and Dunnavan (1998).
Alternative approaches for using growth
promoters
The effect of combined use of growth pro-
moters depends on the mode of action of the
different compounds. An additive effect can
be expected when two growth promoters act
via different mechanisms. Anabolic steroids
and β-adrenergic agonists increase meat yield
by reducing protein degradation, while ST
increases protein synthesis more than protein
degradation. Studies in pigs and veal calves
combining ST treatment with β-AAs showed
additive effects on feed efficiency and loin
eye area from the two treatments.
Vaccines can potentially be used to
mimic the effects of β-AA and ST, without the
need to administer natural or synthetic hor-
mones. This might alleviate concerns about
the use of hormonal growth promoters and
also make it feasible to improve growth in
animals on extensive grazing systems. 
Antibodies can be raised against natural
hormones to block their effects. Targets for
this research have been somatostatin, which
blocks ST release, and ACTH, which stimu-
lates release of the catabolic hormone, corti-
sol. Antibodies can also be generated which
bind to a hormone to increase the activity of
the hormone. This might occur by protecting
the hormone from degradation and increas-
ing the biological half-life or improving the
delivery to the target tissue. This has been
demonstrated with ST and IGF-I. Antibodies
can also be directed to the target tissues to
block the receptors of catabolic hormones, or
stimulate the receptors of anabolic hormones
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(anti-idiotypic antibodies, see Section 2.4), as
has been demonstrated for β-AA. Antibodies
can also be developed which destroy cells.
An example would be removing fat cells to
prevent the accumulation of lipid. So far,
these approaches are still under develop-
ment. Since antibodies are proteins that will
be inactivated by cooking, there should be
significantly less concern about residues in
meat from this immunological approach.
3.6 Thyroid Hormones
Thyroid hormones regulate two main types
of processes. First, they affect metabolic path-
ways to modulate oxygen consumption,
basal metabolic rate and lipid, carbohydrate
and protein metabolism. There are also indi-
rect effects due to altering the levels of other
hormones. Secondly, thyroid hormones trig-
ger cell differentiation and maturation in a
number of tissues and indirectly affect
growth. These effects on metabolism and cell
differentiation are interrelated.
Synthesis and metabolism
Thyroid hormone is synthesized in the folli-
cles of the thyroid gland. The precursor of
thyroid hormones is a large glycoprotein
called thyroglobulin, which contains iodina-
ted tyrosine residues. These residues are cou-
pled to form iodinated thyronine, mainly in
the form of tetraiodothyronine or thyroxine
(T4, see Section 1.2). Hydrolysis of thyroglo-
bulin causes the release of T4. Thyroid hor-
mones are highly hydrophobic and are
bound to transthyretin, as well as other pro-
teins, for transport and stabilization in the
blood. T4 is converted to the most biological-
ly active form of thyroid hormone, tri-
iodothyronine (T3), outside the thyroid gland
by the action of the type I and type II 5’-deio-
dinases (Fig. 3.19). T4 and T3 are metabolized
to the inactive diiodotyrosine (3,3’-T2) by the
type III 5’-deiodinase enzyme. The deiodi-
nase enzymes have been cloned and shown
to be selenium-dependent enzymes with
active selenocysteine residues. A potent
inhibitor of the type I enzymes is 6-propyl-2-
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Fig. 3.19. Metabolism of thyroid hormones.
thiouracil (PTU), while all of the deiodinase
enzymes are inhibited by iopanoate. The
tissue-specific expression patterns of these
enzymes suggest that they play an important
role in the local and systemic availability of
active T3. Thyroxine can also be deaminated
to form inactive tetraiodothyroacetate, or
conjugated to glucuronides by UDP-
glucuronyl transferase and then excreted. For
more information on deiodinase enzymes,
see the review by Köhrle (2000).
Thyroid hormone release and synthesis
is stimulated by thyrotrophin (TSH), which is
synthesized in the basophilic thyrotrophs of
the pars distalis in the adenohypophysis. The
amino-acid sequence of TSH is highly con-
served and TSH from mammalian sources
stimulates thyroid activity in most verte-
brates. TSH interacts with receptors in the
thyroid follicular cells to activate adenylate
cyclase and increase cAMP production,
resulting in increased synthesis and release of
thyroid hormones. Thyroid hormones exert a
negative feedback on TSH secretion.
Thyroid hormones act via two different
mechanisms. There is a direct action of T4,
reverse T3 (rT3) or T2 on the plasma mem-
brane or on subcellular organelles. T3 also
acts by binding to nuclear receptors and
affecting gene expression. There are two
main classes of receptors (c-erb Aα and
c-erb Aβ) encoded by different genes.
Different forms exist within these classes.
Most are stimulatory, while others, such as
the c-erb Aβ2 in the pituitary gland, which is
responsible for the negative feedback of T3 on
TSH synthesis, are inhibitory. The expression
of some forms of thyroid hormone receptors
(e.g. β1) is developmentally regulated. For
more information on the mechanism of action
of thyroid hormone receptors, see Zhang and
Lazar (2000).
Metabolic effects
The effects of thyroid hormones on metabo-
lism and growth and development are sum-
marized in Fig. 3.20. Thyroid hormones
increase heat production and oxygen utiliza-
tion by heart, liver, kidney and pancreas. In
chickens, a precocial species, there is an
increase in thyroid activity in the perihatch
period in response to cooling, while doves,
an altricial species, show little thermoregula-
tory development until 1–2 weeks after
hatching. At older ages in chickens, the con-
version of T4 to T3 is increased by short-term
cold exposure and decreased by warm tem-
peratures. Noradrenaline also plays an
important regulatory role on non-shivering
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Fig. 3.20. Effects of thyroid hormones on metabolism, growth and development. BMR, basal metabolic
rate.
thermogenesis, and thyroid hormones play a
permissive role for this action of cate-
cholamines by increasing the number of β-
adrenergic receptors.
The maximal rate of stimulation of the
basal metabolic rate (BMR) by thyroid hor-
mone, as measured by oxygen consumption,
is 100–150% in humans. Heat production
involves stimulation of the Na+/K+ ATPase
ion pump. The thermogenic effects of thyroid
hormones are mediated through both short-
term (minutes) and long-term (hours) effects
on mitochondria. The short-term effects are
due to T3 binding to c-erb Aα1 isoform p28
on the inner mitochondrial membrane.
Inhibitors of protein synthesis do not affect
these short-term effects, which can also be
demonstrated in isolated mitochondria, so
they do not involve gene transcription. The
long-term effects occur at the nuclear level,
and include changes in phospholipid
turnover and increased synthesis of uncou-
pling protein, which increase proton leakage
at the inner membrane. T3 binds to c-erb Aα1
isoform p43 in the inner mitochondrial
matrix to stimulate mitochondrial genome
transcription. T3 is also involved in the pro-
duction of new mitochondria, by activating
both nuclear and mitochondrial genome
expression. 
In the liver, T3 stimulates the synthesis of
malic enzyme, which converts malate to
pyruvate and provides NADPH for lipogen-
esis. Thyroid hormones also increase glucose
transport and storage. Insulin increases the
effects of T3, but has little effect by itself,
while glucagon is inhibitory. The effects are
not seen on malic enzyme in non-hepatic tis-
sues, indicating that tissue-specific factors are
important. In chickens, malic enzyme does
not increases in response to T3 during the
perihatch period when the lipid supply from
the yolk is high, but only after the birds begin
to feed in the early posthatch period, when
carbohydrate from the diet becomes the pri-
mary energy source.
Thyroid hormones affect not only
growth, but also carcass composition.
Thyroid hormones increase the activity of
lipoprotein lipase to increase the mobiliza-
tion of triacylglycerol stored in adipose tissue
and increase the levels of non-esterified fatty
acids. Low levels of thyroid hormones in
poultry are associated with increased fatness,
while hyperthyroidism reduces abdominal
fat. Similarly, pigs exposed to high tempera-
tures have decreased levels of thyroid hor-
mones and increased uptake and storage of
triacylglycerols in adipose tissue. 
Levels of T3 decrease during fasting and
increase again during refeeding. This is due
to changes in the conversion of T4 to T3, as
well as changes in TSH release from the pitu-
itary. The levels of dietary carbohydrate
affect both of these factors.
Effects on growth and development
Thyroid hormones are necessary for proper
growth and development, and a deficiency in
thyroid hormones results in severe growth
retardation. Hypothyroidism during early
stages of development results in deficiencies
in somatic, neural and sexual development
and decreased metabolic rate (termed cre-
tinism in humans). Inadequate thyroid hor-
mone production leads to high levels of TSH
and hypertrophy of the thyroid gland, to
cause goitre. This was traditionally observed
in humans when dietary iodine was inade-
quate. Thyroid deficiency also results in
decreased wool growth in sheep and hair
growth in a number of different species.
It has been known for a long time that
thyroid hormones are necessary for meta-
morphosis in tadpoles, and this is the basis
for a bioassay for endocrine disruptor chemi-
cals that affect thyroid hormones (see Section
6.4). In the rat, plasma T3 and T4 increase dur-
ing the first 3 weeks after birth and then
decrease to adult levels. Supplementation of
broiler chicken diets with T3 at 0.1 mg kg
–1
diet stimulated growth, while higher levels
(0.3 mg kg–1 diet) depressed growth. Levels of
T3 can also be affected by altering the seleni-
um status of broilers, since this affects the
activity of the deiodinase enzymes. It is like-
ly that increases in heat production and basal
metabolic rate from increased levels of T3
lower feed efficiency and growth (Jianhua et
al., 2000). 
There is an interaction between ST and
thyroid hormones. Thyroid hormones are
required for secretion of ST and for its sys-
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temic actions. Both thyroxine and ST increase
the production of muscle proteins and there
is a synergistic action of both hormones on
muscle and whole-body growth. In birds,
conversion of T4 to T3 is increased by pul-
satile administration of ST but not by contin-
uous ST administration. 
Mitochondria have been implicated in
the control of cellular proliferation and apop-
tosis. T3 affects mitochondrial biogenesis and
activity, and thus is involved in the differenti-
ation and maturation of various cell types.
These include neurones and glial cells of the
central nervous system. Levels of T3 are
maintained in the brain during periods of
hypothyroidism by increases in the activities
of the type I 5’-deiodinase enzymes that con-
vert T4 to T3 and decreases in the activity of
the type III 5’-deiodinase enzymes that con-
vert T3 to diiodotyrosine. T3 is also a major
regulator of myoblast differentiation. For
more information, see the review by
Wrutniak-Cabello et al. (2001).
3.7 Dietary Polyunsaturated Fatty
Acids
Polyunsaturated fatty acids (PUFAs) are
important components of cell membranes
that influence membrane function, signal
transduction, eicosanoid metabolism and
gene expression. The number and position of
the double bonds in the fatty acid (for exam-
ple 18:2, n-3 means an 18-carbon fatty acid
with 2 double bonds starting at carbon 3
counting from the methyl end of the mole-
cule) has dramatic effects on its biological
activity. Animals cannot insert double bonds
into fatty acids beyond carbon 9 from the car-
boxyl end of a fatty acid. Thus, both linoleic
acid (LA, 18:2, n-6) and α-linolenic acid
(ALA, 18:3, n-3) are essential PUFAs that
must be obtained from the diet. These fatty
acids are converted through desaturation and
elongation reactions to longer-chain n-3 and
n-6 fatty acids.
Mechanism of action
PUFAs and their metabolites are involved in
regulating the expression of enzymes
involved in lipid and carbohydrate metabo-
lism (Fig. 3.21). PUFAs cause decreased lipid
synthesis in the liver, increased fatty acid oxi-
dation in the liver and skeletal muscle and
increased synthesis of glycogen. Thus,
PUFAs act as repartitioning agents, increas-
ing the oxidation of fatty acids rather than
storage as triacylglycerols and increasing glu-
cose storage as glycogen.
PUFAs are also involved in the control of
adipogenesis. Activation of adipocyte genes
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Fig. 3.21. Metabolic effects of dietary PUFA. PPAR, Peroxisome proliferator-activated receptor; SREBP,
sterol regulatory elements binding protein; HNF, hepatic nuclear factor; PK, pyruvate kinase; FAS, fatty
acid synthase; GLUT4, glucose transporter 4; SCD, stearoyl-CoA desaturase; UCP, uncoupling protein.
Hepatic lipogenesis
(malic enzyme, acetyl-CoA carboxylase,
PK, FAS, GLUT4, S14, SCD1)
Adipose tissue lipogenesis
(SCD1, FAS, GLUT4, lipoprotein lipase)
leading to adipocyte differentiation is stimu-
lated by a metabolite of PGD2 (15-deoxy-
prostaglandin J2) interacting with the
peroxisome proliferator-activated receptor γ
(PPARγ). Adipocyte differentiation is inhibit-
ed by PGF2α interacting with a cell-surface
receptor and altering intracellular calcium
levels. The balance between these two path-
ways determines the overall effect of PUFA
metabolites on adipocyte differentiation.
Fatty acids can regulate gene expression
by activating nuclear transcription factors,
including PPARα, β and γ, hepatic nuclear
factor (HNF4α), NFκB, and sterol regulatory
elements binding protein (SREBP1c). The
PPAR bind responsive elements (PPRE) on
DNA as a heterodimer with the retinoid X
receptor (RXR) to increase gene expression
(see Chapter 1). PPARα is activated by lipid
catabolic fibrate drugs and PUFA to increase
expression of genes involved in lipid trans-
port, oxidation and thermogenesis, including
carnitine palmitoyltransferase, peroxisomal
acyl-CoA oxidase and uncoupling protein 3.
For further details, see the reviews by Sessler
and Ntambi (1998) and Clarke (2001).
PUFAs inhibit hepatic lipogenesis by
decreasing the expression of enzymes
involved in glucose metabolism and fatty
acid biosynthesis. Malic enzyme, acetyl-CoA
carboxylase, L-type pyruvate kinase, fatty
acid synthase (FAS), glucose transporter 4
(GLUT4), S14 protein and stearoyl-CoA
desaturase (SCD1) in the liver are decreased
by PUFAs. The expression of SCD1, FAS,
GLUT4 and lipoprotein lipase in adipose tis-
sue are also decreased by PUFAs. The sup-
pression of lipogenesis is not mediated by
PPAR, but through decreased levels of tran-
scription factor SREBP1c and by reducing the
DNA-binding activity of other transcription
factors. PUFAs can affect both the level of
gene transcription and mRNA stability.
Nuclear transcription factors (TF) can be
activated by direct binding of fatty acids,
fatty acyl-CoA or oxidized fatty acids, and
responsive elements have been identified
in the promoter regions of several PUFA-
regulated genes. Alternatively, cell-surface
receptors linked to G-proteins can be activat-
ed by eicosanoids that are produced by the
metabolism of PUFA, or intracellular calcium
levels can be regulated by oxidized fatty
acids. This can result in intracellular sig-
nalling cascades and subsequent activation of
transcription factors (Fig. 3.22).
Linoleic acid, linolenic acid and
γ-linolenic acid
Linoleic acid (LA, 18:2, n-6) and α-linolenic
acid (ALA, 18:3, n-3) are essential dietary
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Fig. 3.22. Mechanism of action of dietary PUFA on transcription factors (adapted from Duplus et al.,
2000).
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polyunsaturated fatty acids (PUFAs) that are
converted by elongation and desaturation
reactions to other n-6 and n-3 fatty acids,
respectively. LA is ultimately metabolized to
arachidonic acid (AA), which is the precursor
of 2-series prostaglandins and 4-series
leukotrienes (see Section 1.2). Dihomo-γ-
linolenic acid (DGLA), an intermediate in the
formation of AA, is converted into 1-series
prostaglandins and 3-series leukotrienes.
ALA is metabolized to eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA). EPA
is converted into the 3-series prostaglandins
and 5-series leukotrienes. This is summarized
in Fig. 3.23.
Changes in the metabolism of the n-3
and n-6 fatty acids can alter the structural
properties of cell membranes, such as fluidity
and permeability. This can affect the activity
of ion channels and membrane proteins. In
addition, the availability of 20-carbon precur-
sors for the synthesis of prostaglandins and
leukotrienes can have dramatic endocrine
effects. The ∆6 desaturase enzyme catalyses
the conversion of LA to γ-linolenic acid
(GLA), which is the rate-limiting step in the
n-6 reaction cascade. The activity of the ∆6
desaturase is increased by insulin, and inhib-
ited by epinephrine, cortisol, thyroxine,
glucagon, saturated fat and ageing. Thus,
dietary supplementation with GLA may be
necessary to provide sufficient precursors for
the synthesis of DGLA and the series-1
prostaglandins. GLA is found in natural plant
oils, including evening primrose oil (9%),
borage oil (23%) and blackcurrant oil (18%). 
The n-3 and n-6 PUFAs have opposing
physiological functions and their balance is
important for normal growth and develop-
ment. The n-6 and n-3 pathways are believed
to share the same enzymes, so an increase in
LA results in an increase in AA and a
decrease in the formation of the n-3 fatty
acids, EPA and DHA. Along with the total
amount of fatty acids available, the n-6/n-3
ratio affects the formation of the long-chain
PUFAs. The affinity of the enzymes is higher
for the n-3 fatty acids, and efficient conver-
sion of ALA to long-chain n-3 PUFAs can
occur at a 4:1 ratio of LA to ALA in the diet.
Since the longer chain n-3 PUFAs are the
most biologically active, dietary supplemen-
tation with DHA and EPA is necessary if the
metabolism of ALA is impaired. Good
dietary sources of DHA and EPA are various
marine oils, while ALA is found in flax,
canola (rapeseed), perilla and soybean oils.
The n-3 fatty acids have been implicated
in the prevention and management of coro-
nary heart disease and hypertension. n-3
fatty acids stabilize myocardial membranes
electrically, resulting in decreased suscepti-
bility to ventricular arrhythmia and reducing
the risk of sudden death. DHA is essential for
growth and functional development of the
brain in infants, and deficiencies of DHA are
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Fig. 3.23. Metabolism of n-3 and n-6 fatty acids.
associated with many types of mental dis-
ease. The n-3 fatty acids have potent anti-
inflammatory effects, and high doses of n-3
fatty acids can reduce plasma triacylglycerol
levels.
As the levels of DHA and EPA increase,
the levels of AA decrease in cell membranes
of platelets, erythrocytes, monocytes, neu-
trophils and liver cells. This decreases the lev-
els of the eicosanoids produced from AA that
enhance platelet aggregation, immunosup-
pression and the development of inflamma-
tion and allergic reactions. These include
PGE2, thromboxane A2 (a potent platelet
aggregator and vasoconstrictor), leukotriene
B4 (an inducer of inflammation and leucocyte
adherence and chemotaxis), and thrombox-
ane A3 (a weak platelet aggregator and vaso-
constrictor). There is also increased
production of prostacyclin PGI3 and mainte-
nance of PGI2 (both active vasodilators and
inhibitors of platelet aggregation) and
increased levels of leukotriene B5 (a weak
inducer of inflammation and chemotaxis).
Thus, an increase in the formation of
eicosanoids from AA increases the formation
of blood clots, increases blood viscosity and
vasoconstriction and increases inflammation.
The appropriate balance of n-6/n-3 fatty
acids in the diet is important. Deficiencies of
the n-6 fatty acids have been linked with
depressed growth, impaired immune func-
tion, cardiovascular disease, diabetes and
cancer. However, the diets of Western coun-
tries have high levels of LA, which has been
promoted for its cholesterol-lowering effects,
so deficiencies are unlikely, except under con-
ditions where there is decreased activity of
the ∆6 desaturase enzyme.
Supplementation with GLA, an n-6 PUFA
that has the same number of double bonds as
ALA, has similar physiological effects to sup-
plementing with n-3 PUFA. GLA supplemen-
tation increases tissue levels of DGLA and the
1-series prostaglandins, particularly PGE1,
which has anti-inflammatory and immuno-
regulating properties. Levels of AA are not
increased since the levels of the ∆5 desaturase
are low. DGLA competes with AA for the
cyclooxygenase enzyme and thus further
lowers the synthesis of the pro-inflammatory
series-2 prostaglandins from AA. GLA sup-
plementation also lowers blood pressure and
plasma cholesterol. GLA supplementation
has also been shown to decrease the accumu-
lation of body fat in rats. For more informa-
tion on GLA, see the review by Wu and
Meydani (1996).
Applications
Supplementing diets with n-3 fatty acids may
be effective in treating metabolic diseases of
poultry, including ascites and sudden death
syndrome (heart attack) in broilers and
turkeys. Ascites is caused by an imbalance
between the oxygen requirements of the bird
for growth and metabolism and the delivery
of oxygen to the tissues, resulting in tissue
hypoxia. This increases the haematocrit and
blood viscosity, which leads to pulmonary
hypertension and hypertrophy of the right
ventricle of the heart. Eventually, the atrio-
ventricular valve fails, causes backpressure
and ascites fluid leakage from the liver.
Supplementing broiler diets with 5% flax oil
decreased blood viscosity and reduced the
incidence of ascites. The addition of flaxseed,
flax oil or other sources of n-3 fatty acids to
layer rations reduces the accumulation of fat
in the liver of laying hens. In addition, sup-
plementing animal diets with n-3 fatty acids
not only improves the health of the animals
but also provides a good dietary source of
n-3 fatty acids for human consumption. 
A major limitation to supplementing ani-
mal diets with PUFA is the potential for
increased lipid peroxidation and rancidity;
these problems have been at least partly
addressed by increasing levels of vitamin E
and other antioxidants. n-3 Fatty acids can also
lead to ‘fishy’ odours and taste. n-3-Enriched
eggs are now produced commercially by
including flax in layer rations, and it has been
demonstrated that cows’ milk can be enriched
with n-3 fatty acids. Research on enriching the
n-3 content of meat from poultry, pigs and cat-
tle without adversely affecting the stability
and organoleptic properties is continuing.
Conjugated linoleic acid
Conjugated linoleic acid (CLA) refers to a
group of isomers of linoleic acid (cis-9, cis-12
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octadecadienoic acid), the most biologically
important being cis-9, trans-11 CLA (also
known as rumenic acid) and trans-10, cis-12
CLA (Fig. 3.24). CLA has a broad range of
biological activities, including anti-cancer
effects, regulation of energy partitioning and
nutrient metabolism, reduction of the cata-
bolic effects of immune challenge, and reduc-
tion in blood lipids and prevention of
atherosclerosis. Many of these effects have
been demonstrated in animal models and
have not yet been shown conclusively in
humans. From an animal production point of
view, CLA acts as an effective repartitioning
agent in pigs, to increase feed efficiency,
decrease back fat and increase lean muscle in
the carcass.
CLA was first isolated from grilled beef
and can be formed by heating linoleic acid in
the presence of a base. CLA is produced bio-
logically by the biohydrogenation of linoleic
and linolenic acid by rumen microbes, and
various CLA isomers are found in milk,
cheese and beef. The cis-9, trans-11 isomer is
the predominant form of CLA produced by
rumen microbes. Most feeding trials with ani-
mals use a mixture of cis-9, trans-11 CLA and
trans-10, cis-12 CLA in approximately equal
amounts, with other isomers at considerably
lower levels. Some commercial preparations
may contain isomers with conjugated double
bonds at carbon 8, 10, 11 or 13, and this may
affect the biological activity. Trans-vaccenic
acid (trans-11-C18:1) is the major trans fatty
acid of rumen fermentation. It can be con-
verted in mammalian tissues to cis-9, trans-11
CLA by the ∆9 desaturase enzyme.
Metabolic effects of CLA isomers
Dietary CLA increases feed efficiency and
decreases body fat with a lesser increase in
lean content. CLA at 0.5% in the diet of mice
decreased body fat by approximately 60%
and increased whole-body protein. Results in
pigs and poultry have been less dramatic.
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Fig. 3.24. Structures of linoleic acid and conjugated linoleic acids.
Pigs fed diets containing 1% CLA tended to
have about a 6% improvement in feed effi-
ciency, 7% less subcutaneous fat and 2.5%
more lean, with no difference in rate of gain
compared to controls. In chickens, CLA sup-
plementation reduced abdominal fat content,
but also reduced feed intake and growth rate.
In mice, the decrease in body fat has been
attributed to the trans-10, cis-12 CLA isomer.
This CLA isomer reduced lipoprotein lipase
and decreased intracellular levels of triacyl-
glycerol and glycerol in adipocytes. It also
reduces the expression of stearoyl-CoA desat-
urase in adipocytes and depresses milk fat
synthesis in cows. CLA also increases carnitine
palmitoyltransferase, which is a rate-limiting
enzyme in the β-oxidation of fatty acids. CLA
also enhanced noradrenaline-induced lipoly-
sis and hormone-sensitive lipase activity.
Trans-10, cis-12 CLA also reduces the
secretion of apolipoprotein B and triacylgly-
cerol in the human hepatoma HepG2 cell
line, which would explain the role of CLA in
the prevention of atherosclerosis. CLA sup-
plementation in rabbits reduced LDL choles-
terol and the incidence of aortic plaques, and
did not affect HDL cholesterol.
The trans-10, cis-12 CLA isomer is also
likely to be responsible for many of the effects
of CLA on the immune system, including
enhancing the immune system, reducing the
catabolic effects of immune stimulation, and
reduced production of PGE2 and leukotriene
B4. CLA appears to shift the immune
response from a TH2-type response (allergic
reactions) to a TH1-type response (cell-medi-
ated functions; see Section 6.3). 
CLA is an effective inhibitor of carcino-
genesis, and both CLA isomers may be equal-
ly effective in this regard. Fish oil is usually
required at about 10% of the diet to exert a
beneficial effect, while CLA is effective at lev-
els of 1%. The anticarcinogenic effect of CLA
may be due to a decrease in the production of
PGE2 and an increase in tissue levels of retinol.
The CLA-induced increase in growth in
young rodents may be due to cis-9, trans-11
CLA and this may be blocked by the trans-10,
cis-12 CLA isomer. The cis-9, trans-11 CLA is a
potent and high-affinity ligand for the perox-
isome proliferator-activated receptor α
(PPAR-α, see above). PPAR-α is found in
liver, skeletal muscle, spleen, kidney and
brown adipose tissue, and is involved in
increasing lipid catabolism and reducing
fatty acid synthesis. CLA supplementation
produces antidiabetic effects, including lower
plasma glucose, insulin and free fatty acids. 
Mechanism of action of CLA
The effects of CLA may be due to alterations
in eicosanoid metabolism and reduced syn-
thesis of PGE2. The isomers of CLA are elon-
gated and desaturated in the same manner as
linoleic acid to produce CLA-derived
eicosanoids. This can reduce the conversion
of arachidonic acid into PGE2 and thereby
alter eicosanoid signalling pathways.
Reduced levels of prostaglandins, such as
PGE2, will decrease the synthesis and action
of tumour necrosis factor-α (TNF-α) and
interleukin 1 (IL-1). These cytokines induce
the inflammatory response in immune cells,
catabolism in skeletal muscle, changes in cell-
surface proteins and increase the production
of the intestinal peptide cholecystokinin,
which induces anorexia (see Section 3.9).
TNF-α is a key mediator in many chronic
pathological conditions, including cachexia
(physical wasting), atherosclerosis, carcino-
genesis and obesity. Some of the effects of
CLA may be due to reduced activity of
TNF-α. For more information on the mecha-
nism of action of CLA, see Pariza et al. (2000).
CLA preparations
It is apparent that the different isomers of
CLA have different biological properties. It is
thus essential that the isomer composition of
commercially available preparations of CLA
be known. Early preparations of CLA, pro-
duced by alkali isomerization during the first
half of the 1990s, consisted of approximately
20–40% of cis-9, trans-11 and trans-10, cis-12
CLA, with the remainder consisting of other
positional isomers. The CLA products avail-
able starting in 2000 are almost entirely the
two desired isomers. The different CLA iso-
mers can be measured as fatty acid methyl
esters by gas chromatography or HPLC using
silver-impregnated columns.
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Enhancement of cows’ milk with CLA is
hampered by the dramatic decrease in milk
fat caused by supplementation of diets with
CLA. This is due to a decrease in fatty acid
synthesis and desaturation of fatty acids by
CLA. For more information on CLA in milk,
see the review by Parodi (1999).
Further studies are needed with single
isomers of CLA to determine their effects in
commercial animals and humans.
3.8 Leptin
Leptin is a 16 kDa protein hormone produced
by white adipose tissue, and is the product of
the obese (ob) gene. Leptin secretion is higher
in subcutaneous than omental adipocytes. It
is thought to function as an ‘adipostat’ and
long-term regulator of energy reserves in the
form of adipose tissue in the animal. When
there is a lot of adipose tissue, production of
leptin increases to activate the satiety centres
in the hypothalamus and reduces food
intake. Conversely, when adipose tissue
reserves decrease due to limited availability
of food, leptin levels decrease and appetite
increases. Leptin is thus an important regula-
tor of appetite, whole-body energy balance
and body composition. Leptin is also impor-
tant in metabolic adaptation to starvation, by
regulating metabolic rate and inhibiting
reproductive and thyroid function (Fig. 3.25).
Plasma leptin varies in a pulsatile man-
ner, with approximately 30 pulses in 24 h in
humans. There is also a diurnal rhythm in
leptin levels, with highest levels at 01.00
hours and lowest levels at 11.00 hours, but
varying the timing of meals can alter this
rhythm.
Leptin is mutated and inactive in the
homozygous obese (ob/ob) mouse; leptin
treatment of these mice reduces feed intake
and body weight by about 40% after 33 days
of treatment. Pair-fed (ob/ob) mice that are
not treated with leptin lose significantly less
weight than those treated with leptin. Body
weight loss from leptin treatment is due
almost exclusively to loss of adipose tissue,
with lean mass unaffected. Leptin treatment
of normal wild-type mice also reduces feed
intake and body fat.
Up to six different serum-binding pro-
teins for leptin have been identified. The
amount of the binding proteins is reduced
and the percentage of free and unbound lep-
tin is increased in obesity.
Leptin receptors 
Leptin receptors are located in the hypothala-
mus as well as on peripheral target tissues.
Spontaneous mutations in the leptin recep-
tors in the db/db mice and fa/fa rats result in
inactive leptin receptors and severe obesity
that is resistant to leptin treatment. The
receptor has been cloned from a variety of tis-
sues and is similar to the class I cytokine
receptor family, which includes growth
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Fig. 3.25. Metabolic effects of leptin.
hormone, prolactin, interleukin-6 and
leukaemia inhibitory factor. This receptor
does not have an intrinsic tyrosine kinase
activity, but acts by association with cytoplas-
mic Janus kinases (JAK, see Section 1.3). The
receptor exists in multiple forms with a com-
mon extracellular sequence and a variable-
length cytoplasmic domain. Alternate
splicing of the mRNA from a single gene pro-
duces the six isoforms of the leptin receptor.
The short form of the receptor (OB-Ra) in
the choroid plexus is thought to act as a trans-
port protein to allow leptin to cross the
blood–brain barrier. The kidney is the major
site of leptin metabolism and clearance. A
short form of the leptin receptors in the adre-
nal medulla may be involved in adrenaline
secretion. The long form of the leptin receptor
(OB-Rb) is found in areas of the hypothalamus
that have been implicated in the regulation of
appetite and body weight, namely the arcu-
ate, dorsomedial, ventromedial and paraven-
tricular nuclei. The effects of leptin on food
intake may be mediated in part by inhibiting
the actions of neuropeptide Y (NPY), which is
a potent stimulator of food intake. For more
information, see the reviews by Ahima and
Flier (2000) and Fried et al. (2000).
Involvement in energy metabolism and
reproduction
Leptin treatment of ob/ob mice decreases
serum insulin and glucose and increases oxy-
gen consumption, locomotor activity and
body temperature to that found in normal
wild-type mice. Leptin is more effective in
the ob/ob mice than in normal animals, and
even the highest dose did not cause metabol-
ic indices to exceed normal levels. These
effects may be mediated by the sympathetic
nervous system, through the effects of nor-
adrenaline on brown adipose tissue.
Catecholamines and β-agonists decrease lep-
tin levels in the long term. Leptin levels are
also increased by high-fat diets. Insulin and
glucocorticoids act synergistically to increase
leptin levels over the long term.
Leptin also causes local tissue effects that
are mediated by mitochondrial uncoupling
proteins (UCPs). It stimulates synthesis of
UCP mRNA and protein in muscle and adi-
pose tissue. The UCPs increase proton leak-
age through the inner mitochondrial mem-
brane and thus uncouple oxidative
phosphorylation and ATP synthesis from
mitochondrial electron transport, with the
energy released as heat.
Females with poor body condition do
not reproduce well, and leptin may act to sig-
nal the reproductive system that sufficient
body fat is present to support a pregnancy.
Leptin treatment increases sexual develop-
ment in both male and female ob/ob mice,
resulting in increased serum LH and ovary
and uterine weights in females, and
increased serum FSH, testes and seminal
vesicle weights and sperm counts in males.
Levels of leptin are 2–4 times higher in
women than in men, and leptin levels
increase near puberty in girls but not in boys.
Leptin production is decreased by androgens
(testosterone and dihydrotestosterone) but
not by oestrogens.
Leptin levels vary during fetal develop-
ment and are correlated with fetal size.
Leptin may be involved in signalling nutrient
availability and in regulating growth and
development of the fetal–placental unit dur-
ing embryonic development.
Leptin stimulates secretion of ST and
restores pulsatile ST secretion after fasting. It
decreases GHRH receptors but increases
growth hormone secretagogue receptors
(GHS-R) in isolated pituitary somatotrophs.
Thus leptin decreases GHRH stimulation
while increasing GHS stimulation of ST
secretion.
Direct effects
Leptin has direct effects on a variety of tis-
sues, and this has been shown in isolated
cells and tissues treated with physiological
levels of leptin in vitro. It reduces lipid syn-
thesis and increases lipolysis in isolated
adipocytes and fat pads. Leptin reduces the
effect of insulin on stimulating gluconeogen-
esis in HepG2 liver cells and reduces insulin
secretion by pancreatic islets. It stimulates
fatty acid oxidation and decreases triacyl-
glycerol synthesis in muscle. Glucose uptake
and glycogen synthesis is stimulated in
myotubes by leptin. 
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Applications
Leptin can affect nutrient intake and carcass
composition, including the level and rate of
fattening. This, together with the effects on
reproductive efficiency, makes leptin of inter-
est to animal producers. Leptin and its recep-
tors are potential candidate genes for the
development of genetic markers for improve-
ments in animals. Since leptin decreases the
efficiency of energy utilization by increasing
thermogenesis, the use of leptin antagonists
may improve feed utilization and increase
the efficiency of animal production. Leptin
has broad effects on reproductive processes
and may be useful for inducing early puber-
ty in young, thinner animals and to reduce
the interval from parturition to oestrus. For
more information, see the reviews by
Hossner (1998) and Houseknecht et al. (1998).
3.9 Cholecystokinin and Appetite
Mechanism of action
The capacity of pigs for growth is limit-
ed to some extent by the amount of feed they
consume, so methods for increasing appetite
should increase weight gain and shorten the
time taken to reach slaughter weight. Feed
intake is increased by stimulation of the later-
al hypothalamic nuclei, while stimulation of
the ventral medial hypothalamus decreases
feed intake. Cells within these regions have
glucoreceptors that monitor blood glucose
levels to control feed intake. Other hormones
or metabolites may also affect the feeding
and satiety centres in the hypothalamus. One
such hormone is cholecystokinin (CCK),
which is a peptide hormone produced by the
duodenal mucosa. The transfer of digesta
(particularly amino acids, HCl and certain
fatty acids) from the stomach to the duode-
num stimulates its release and causes empty-
ing of the gall bladder and release of
pancreatic enzymes. CCK or a related pep-
tide also acts as an important satiety signal to
reduce food intake, so interfering with CCK
function can be used to increase food intake.
CCK is structurally related to gastrin
(Fig. 3.26) and the common C-terminal pen-
tapeptide is present in a wide range of
species. The tyrosine at residue 7 from the
carboxy-terminal of CCK is sulphated, and
the sulphated form of the hormone binds 160
times more strongly to the CCK receptor
(CCKA) than the non-sulphated form. The
gastrin receptor (CCKB) does not require sul-
phated hormone for activation and subse-
quent stimulation of acid secretion in the
stomach. CCK exists in a number of forms,
from a 33-amino-acid polypeptide in the gas-
trointestinal (GI) tract to the 8-amino-acid C-
terminal peptide (CCK-8) that is found in the
central nervous system (CNS). CCK-8 is
inhibitory to food intake as well as stimulat-
ing pancreatic secretions and gall-bladder
contraction.
Synthetic analogues of CCK inhibit food
intake as well as induce gall-bladder contrac-
tion and release of pancreatic enzymes, sug-
gesting that these functions are regulated by
a common mechanism. Satiety signals are
transferred to the hypothalamus via the
vagus nerve, but there is also evidence that
CCK acts locally within the ventral medial
hypothalamus. This is another example,
along with somatostatin and ghrelin, of a
hormone that has actions in both the gut and
brain.
Other hormones involved in satiety are
leptin and neuropeptide Y (NPY). NPY is a
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Fig. 3.26. Structures of gastrin and cholecystokinin.
36-amino-acid peptide found in the peripher-
al nervous system and in the brain. Feed
restriction increases transcription and trans-
lation of NPY and intracerebroventricular
administration of NPY increases appetite. A
related peptide YY (PYY) is localized in
endocrine cells of the intestinal mucosa. NPY
and PYY are also involved in regulating
blood flow, motility and electrolyte secretions
in the intestine. Leptin administration
decreases feed intake, and this occurs at least
in part by decreased activity of NPY. Leptin
receptors have been co-localized with NPY
neurons in the arcuate nucleus of the hypo-
thalamus. Animals that do not produce func-
tional leptin (such as ob/ob mice) or
functional leptin receptors overexpress NPY
and are hyperphagic. This has led to the pro-
posal that NPY is the major mediator of the
actions of leptin.
Other peptides, such as galanin and
orexins, also influence feed intake. For
more information on endocrine signals regu-
lating food intake, see the review by Bray
(2000).
Applications
Differences in plasma levels of CCK have
been found in pigs with different genetic
potential for feed intake. This suggests that
satiety effects of CCK are involved in the
genetic differences between lines of pigs for
feed intake. Decreased production of CCK
has been found in humans with bulimia ner-
vosa. Increased levels of CCK, or sensitivity
to CCK, have been implicated in age-related
anorexia. CCK may also prove useful in the
control of obesity in humans.
Immunizing pigs, but not sheep, against
CCK-8 increased growth rate by about
10% and feed intake by 8%, with no change in
carcass composition. Antibody titres were
highly variable and were correlated with
weight gain (McCauley et al., 1995).
Treatment of pigs and immature rainbow
trout with a CCKA receptor antagonist (MK-
329, see Fig. 3.27) increased feeding behav-
iour, feed intake and weight gain. For an
example of work on developing non-peptide
ligands for the CCK receptor, see Bernad et al.
(2000).
3.10 Antibiotics, Antimicrobials and
Other Factors
Antibiotic use for enhancing meat production
began in the 1940s, when it was discovered
that they improved growth rate by 4–20%
and feed conversion efficiency by 4–10% if
used in small amounts in the diet of pigs and
poultry. These effects may be greater in
younger than in older animals. There are no
significant effects on carcass quality, such as
length and depth of the carcass, fat content
and dressing percentage.
Since the effects of antibiotics may not be
seen in germ-free animals, it is thought that
they may improve growth and feed efficiency
by changing the intestinal microflora. This
may, in turn, reduce the production of toxins,
decrease the destruction of nutrients and
increase the absorptive capacity of the intes-
tinal mucosa. There may also be direct effects
of antibiotics on the metabolism of the ani-
mal. Antibiotics may reduce low-level and
sub-chronic infections and thus cause
increased growth performance.
In ruminants, antibiotics can affect
rumen fermentation and improve digestibili-
ty of feeds. Many of these antibiotics are
ionophores, which are also effective coc-
cidiostats in poultry. Improvements in daily
gain of 15–25% and feed conversion efficien-
cy of 3–16% are seen with beef cattle fed these
antibiotics. The extent of the effects are
dependent on diet, with greater improve-
ments in grazing animals eating low-quality
forages compared to those fed high-energy-
concentrate diets.
A number of factors can affect the eco-
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Fig. 3.27. Structure of a CCKA receptor antago-
nist (MK-329).
nomic advantages of using growth
enhancers. Responses in feed conversion and
growth rate obtained in controlled experi-
ments may not be obtained under field con-
ditions. One exception would be the use of
antimicrobial growth enhancers in the feed,
which can give greater responses in commer-
cial use due to the higher bacterial challenge
and feed variability that is likely under pro-
duction conditions. The economic benefits
can also be affected by the duration of
treatment that is necessary. Changes in
health status, either positive or negative, may
result in effects that continue long after treat-
ment is completed. In this regard, the poten-
tial carry-over of antibiotic residues to
humans is a concern. This has led to the
banning of some feed-delivered antibiotics,
especially in the EU, with consequently
increased emphasis on the use of ‘natural’
ingredients, such as herbal extracts, in
animal feeds to replace them. Changes in the
volume and composition of manure may be
important in regions that have strict environ-
mental controls, such as The Netherlands.
Increasing the lean content of carcasses
makes economic sense only if the premiums
offered to the producers for lean are greater
than the cost of producing the extra lean. In
some situations, such as for fresh pork cuts, a
low fat content is desirable, while for some
processed products a higher fat content is
desirable.
3.11 Dietary Chromium and Insulin
Chromium is an essential trace mineral that is
active in biological systems as the trivalent
form (Cr3+). It has been shown to have
antioxidant properties and to stabilize pro-
teins and nucleic acids. Chromium, as part of
a 70 kDa protein, has been shown to enhance
RNA synthesis in mice. However, the major
role of dietary chromium is to increase the
sensitivity of cells to insulin, perhaps by facil-
itating the binding of insulin to its receptor
on the cell surface. Chromium is an essential
component of an organometallic complex
called glucose tolerance factor (GTF), which
also contains nicotinic acid, glutamic acid,
glycine and cysteine. The exact structure of
the GTF insulin-potentiating complex has not
been determined. The biologically active in
vivo form of Cr, known as the low molecular
weight chromium-binding substance
(LMWCr), may be a Cr-containing oligo-
polypeptide.
Insulin
Insulin is a polypeptide hormone produced
by the β cells in the islets of Langerhans in the
pancreas. Its primary role is to regulate blood
glucose levels by increasing the uptake of
glucose into tissues and storage as glycogen
or lipid. It also plays a key role in promoting
amino-acid uptake in species where little
fluctuation in blood glucose is seen, such as
in functional ruminants and carnivores.
Insulin consists of two polypeptides, an A
chain of 21 amino acids and a B chain of 30
amino acids, that are linked by disulphide
bridges (see Section 1.2). The amino-acid
sequence of insulin is very similar among
vertebrates, with minor changes mainly at
positions 8, 9 and 10 of chain A and position
30 of the B chain. As a result, insulin isolated
from one species is active in another. Insulin
is synthesized as proinsulin, with the active
molecule formed from cleavage of the
23-amino-acid C peptide. There is a high
degree of species variability in the C-peptide
sequence.
Insulin acts on the liver to increase glu-
cose uptake and formation of glucose-6-phos-
phate and to activate glycogen synthetase. In
adipose tissue, glucose is converted to gly-
cerol and combined with free fatty acids to
form triacylglycerol. Lipid synthesis is
increased by stimulation of citrate lipase,
acetyl-CoA carboxylase, fatty acid synthase
and glycerol-3-phosphate dehydrogenase. In
muscle, insulin stimulates the uptake of glu-
cose and amino acids and stimulates glyco-
gen and protein synthesis. Protein catabolism
is also decreased. Insulin also has a direct
vasodilatory effect to increase blood flow and
nutrient supply to muscles. 
Rapid growth and leanness in domestic
animals is related to enhanced sensitivity of
muscles to insulin and enhanced glycolytic
metabolism of muscles. Decreased insulin
sensitivity results in increased basal levels of
insulin and increased carcass fat with
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decreased growth rate. For a review on the
insulin signalling pathways, see Nystrom
and Quon (1999).
Glucagon
Glucagon is a peptide hormone that is pro-
duced in the α cells of the pancreas islets and
acts to increase blood glucose by increasing
glycogenolysis or gluconeogenesis. Glucagon
is a single-chain polypeptide of 29 amino
acids that is identical in sequence across all
mammals and highly conserved across all
species.
The effects of glucagon are opposite to
those of insulin. In the liver, it stimulates
glycogenolysis and gluconeogenesis from
amino acids and glycerol, to maintain suffi-
cient levels of blood glucose. This is particu-
larly important during prolonged fasting,
exercise or during neonatal life. Glucagon
stimulates lipolysis in adipocytes.
Chromium improves the function of
insulin to reverse the effects of clinical hyper-
glycaemia by increasing the uptake of glu-
cose into tissues for lipogenesis and
glycogenesis. Chromium also increases the
effects of insulin in stimulating uptake of
amino acids and protein synthesis in muscle. 
The signs of chromium deficiency are
related to impaired insulin function and
include impaired glucose tolerance, elevated
levels of insulin, cholesterol and triacylgly-
cerols in plasma, glucosuria, impaired
growth and decreased longevity and fertility.
Chromium supplementation is effective in
humans receiving parenteral nutrition or
with type 2 (insulin independent) diabetes.
Chromium supplementation is also effective
in animals under various forms of stress,
such as newly arrived feedlot cattle and first
lactation dairy cows. 
Mechanisms of action
The insulin receptor (see Section 1.3) consists
of extracellular α-subunits and intracellular
β-subunits held together by disulphide
bonds. Insulin binding to the α-subunit caus-
es autophosphorylation of the β-subunit and
activates its tyrosine kinase. Insulin activates
a phosphatase enzyme that dephosphory-
lates and activates glycogen synthetase. 
Detection of glucose levels in plasma by
the pancreatic islet cells, as well as uptake
and release of glucose by tissues, involves
glucose transport proteins (GLUTs) in the cell
membrane. These proteins catalyse the trans-
port of glucose down concentration gradients
and into target cells. There are five glucose
transporter isoforms, GLUT1–4 and GLUTX1
(which is involved in early blastocyst devel-
opment), along with a fructose transporter,
GLUTS.
The GLUTs differ in tissue distribution
and kinetic properties and play a key role in
glucose homeostasis. GLUT1 is present at
high levels in erythrocytes and in endothelial
cells lining the blood vessels in the brain.
GLUT3 is present in neurones, and together
with GLUT1, allows the brain to take up ad-
equate glucose. GLUT2 is a low-affinity
transporter that is part of the glucose sensor
system in pancreatic cells and is involved in
absorbing dietary glucose across the basolat-
eral membranes of intestinal epithelial cells.
GLUT2 is also important in the transport of
glucose out of the liver and kidney and into
the blood. GLUT4 is the major insulin-
responsive isoform found in adipose tissue
and striated muscle. It is normally located in
intracellular storage compartments and is
translocated to the plasma membrane in
response to insulin. When insulin levels
decline, GLUT4 is recycled back into intracel-
lular storage. 
The mode of action of chromium in glu-
cose metabolism has not been firmly estab-
lished. Chromium may be involved in
stabilizing insulin, or affecting the interaction
of insulin with its receptor. The LMWCr com-
plex has also been shown to increase the
activation of the insulin receptor phos-
photyrosine kinase (PTK) in the presence of
insulin. The increased PTK activity increases
the translocation of the GLUT4 from the
Golgi apparatus to the cell membrane. This
improves glucose uptake in adipose tissue
and skeletal muscle. 
Chromium also has been reported to be
involved in stabilizing nucleic acids and
stimulating RNA and protein synthesis, but
the mechanism behind these effects has not
been established.
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Physiological effects
The potential physiological responses to
chromium are summarized in Fig. 3.28.
Supplementing newly arrived feedlot cattle
with dietary chromium is reported to
decrease morbidity and lower plasma corti-
sol, but the response is variable. The immune
response is also improved, as measured by
the blastogenic response of peripheral blood
mononuclear cells cultured with T-lympho-
cyte mitogens. The beneficial effects of
chromium were not seen when calves were
given a long-acting antibiotic shortly after
arriving at the feedlot. In growing cattle,
chromium supplementation improves glu-
cose metabolism by enhancing tissue
responses to insulin as well as improving
immune status. For a review on the effects of
chromium on health and performance, see
Borgs and Mallard (1998).
Chromium supplementation is effective
in first-lactation dairy cows in the transition
period, but not in multiparous cows.
Supplemental chromium given through late
gestation and into the first weeks of lactation
tends to improve milk yield in the first 4–6
weeks of lactation. The metabolic stress dur-
ing transition is also lowered, with decreases
in levels of blood ketone bodies. There is also
improved cell-mediated immune response in
lactating cows via changes in production of
cytokines. The specific role of chromium in
cattle undergoing stress has not been estab-
lished.
The effectiveness of chromium in pigs is
quite variable. However, when given as a
dietary supplement ranging from 0.5 to 5.0
mg kg–1 diet, chromium has been shown,
under some circumstances, to alter metabo-
lism in pigs to improve growth rate, increase
lean muscle mass and decrease fat content in
carcasses and improve reproductive perform-
ance.
Supplemental chromium chloride at 20
mg kg–1 increases the rate of glucose utilization
by livers of chicks and poults. There is some
evidence of improved growth rate and feed
efficiency and decreased mortality and serum
and yolk cholesterol from chromium supple-
mentation in poultry. Research with rabbits has
shown that the cholesterol and plaque contents
in the aorta are decreased with supplemental
chromium. Chromium supplementation has
also been reported to alter glucose metabolism
in fish, and to increase weight gain, energy dis-
position and liver glycogen. 
For a comprehensive review of the role
of chromium in animal nutrition, see NRC
(1997).
Dose
The response of animals to chromium sup-
plementation of practical diets is variable,
since some diets may already have adequate
levels of chromium. The chromium status of
the animals can also vary, so that in some sit-
uations the animal’s requirement for chromi-
um is increased. Thus, diets must be deficient
in chromium or the animal must require
additional dietary chromium before supple-
mentation of diets with chromium can be
effective. A chromium intake of between 50
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Fig. 3.28. Potential physiological responses to chromium.
and 200 µg day–1 is recommended for adult
humans, but because there is no accurate
measure of chromium status, daily chromi-
um requirements for animals are difficult to
define and no recommended dietary intake
has been made.
Trivalent chromium has been used as a
dietary supplement in the form of chromium
picolinate (CrPic), chromium nicotinate
(CrNic) and high-chromium yeast, which are
absorbed more efficiently than inorganic
chromium chloride. The efficacy of dietary
chromium may be affected by inefficient
absorption of chromium, particularly if it is
not complexed with an organic molecule
such as picolinate. The absorption of chromi-
um is inversely related with dietary intake,
ranging in humans from 2% absorption at
10 µg day–1 in the diet to 0.5% absorption
with >40 µg day–1 in the diet. Absorption is
increased in diabetes, possibly because dia-
betics are deficient in chromium.
Factors affecting the bioavailability of
dietary chromium in feeds and the relative
bioavailability of chromium from different
supplements are not well understood. The
low bioavailability of inorganic chromium
may be due to the formation of insoluble
chromic oxide, binding to chelating agents in
feeds, and slow conversion to the biological-
ly active form. Measurements of the total
chromium content of feeds are therefore
poorly related to the amount of biologically
active chromium. 
Plasma levels of chromium range from
0.01 to 0.3 µg l–1 and are lower during infec-
tions and after glucose loading. Chromium is
transported in the blood bound to β-globu-
lins and is transported into tissues bound to
transferrin or as GTF. Turnover of chromium
follows a three-compartment model with
half-lives of 0.5, 6 and 83 days. Plasma levels
of chromium are not a good indicator of tis-
sue chromium levels, since these different
chromium pools do not seem to be in equilib-
rium. Uptake of chromium by tissues
decreases with age. 
Chromium is excreted mostly in the
urine, with 24 h excretion rates of 0.22 µg
day–1 in humans. Excretion increases after
glucose loading and is higher in diabetics.
Stress and exercise also increase chromium
excretion, with several times more chromium
excreted after extreme trauma.
Safety issues
Chromium toxicity is primarily associated
with exposure to hexavalent Cr6+ salts, which
are strong oxidizing agents used in alloying
and tanning and in the production of
corrosion-resistant paints. Workers exposed
to these compounds suffer from dermatitis,
cancer, gastroenteritis, nephritis and hepati-
tis. Hexavalent Cr6+ is more soluble, more
readily absorbed and is at least five times
more toxic than Cr3+. The LD50 for Cr
3+–nico-
tinic acid complex injected intravenously is
60 mg kg–1 BW in rats. The lethal single dose
of Cr6+ in young rats is 130 mg kg–1 BW, while
as much as 650 mg kg–1 BW of Cr3+ produced
no toxicosis. There is no information on
chromium toxicity in swine. Feeding a diet
containing 2000 mg kg–1 CrCl3 decreased
growth rate of chicks, while levels of 1000 mg
kg–1 had no effect on growth. The concentra-
tions of trivalent chromium that are typically
added as dietary supplements for most food-
producing animals are assumed to be safe
and non-toxic. However, aside from CrPic,
chromium has not been approved as a feed
additive for livestock, due to the lack of
information on the dietary requirements for
chromium and its role as an essential nutri-
ent. The NRC (1980) set maximum levels of
chromium oxide at 3000 p.p.m. and chromi-
um chloride at 1000 p.p.m. for livestock feeds. 
3.12 Effects of Stress on Meat Quality
Pale, soft, exudative and dark, firm, dry
meat
Pale, soft, exudative (PSE) meat is a potential
problem with poultry (chicken and turkey)
and with pork. The PSE condition has been
most extensively studied in pigs and can be
caused by pre-slaughter stress, which
induces a rapid post-mortem breakdown of
muscle glycogen and subsequent increase in
anaerobic glycolysis to form lactate. This
increases the temperature of the muscle and
dramatically decreases muscle pH, which
denatures the sarcoplasmic reticulum pro-
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teins and decreases water-binding capacity of
the tissue. An increased level of metabolites
in the cells also increases the osmotic pres-
sure, which causes water to move into the
cells from the extracellular space. The muscle
of pigs becomes pale, watery (exudative),
sour-smelling and loose-textured. There is
increased water (drip) loss and decreased
water binding capacity during storage, lead-
ing to decreased shelf-life and poor consumer
appeal.
The water-binding capacity of meat is
affected by pH. It is lowest at the isoelectric
point of meat between 5.0 and 5.1, since the
protein has no net charge and the solubility of
the proteins is at a minimum. Thus, as the pH
of meat declines after slaughter, the water-
binding capacity also decreases. In PSE pork,
the exudate fills the spaces between the mus-
cle fibre bundles and contributes to the soft
texture of the pork. The paleness of meat is
caused by the increased scattering of light
within the meat due to protein denaturation.
The pale colour of PSE pork takes at least
1.5 h to develop, and the development of pale
colour may continue up to 4 days post-
slaughter.
Stress can also cause dark, firm and dry
(DFD) meat when levels of muscle glycogen
are drastically depleted before slaughter. This
limits the amount of lactate that is formed
post-mortem and results in a high pH in the
meat. The high pH results in increased water-
holding capacity.
The initial pH taken at 45 min after
slaughter and the ultimate pH taken at 24 h
after slaughter can be used to predict PSE and
DFD meat (Fig. 3.29). A pork carcass with a
pH of 6.0 at 45 min would have a rapid rate of
glycolysis and a strong possibility of becom-
ing PSE. At 24 h, normal pork has a pH of
between 5.4 and 5.7, PSE pork can have a pH
below 5.0 and DFD pork has a pH of greater
than 6.0. For further details, see Swatland
(1994).
PSE poultry meat is a problem since it is
unsuitable for further processing due to
excessive colour variation, defective water-
holding capacity and poor binding ability,
which reduce product yield and texture. PSE
pork is also less suitable for the production of
cured and processed products. 
PSE pork was first described as a post-
slaughter quality defect related to stunning
technique, temperature of scalding water,
duration of scalding and time until the car-
cass was chilled. A survey of US packing
plants in 1992 showed that only 16% of hams
were the desirable reddish-pink, firm, non-
exudative (RFN) quality. Fifty-eight per cent
of hams were reddish pink, soft, exudative
(RSE), 16% were pale, soft and exudative
(PSE) and 10% were classified as dark, firm
and dry (DFD). The method of restraint and
stunning dramatically affects the incidence of
PSE meat. Stunning with carbon dioxide pro-
duces the lowest incidence of PSE, followed
by electrical stunning without restraint, with
the highest incidence when electrical stun-
ning with restraint was used. High-voltage
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Fig. 3.29. Effects of muscle pH on dark, firm, dry (DFD) and pale, soft, exudative (PSE) meat.
(330–700 V) stunning increased PSE and
blood splash compared to low-voltage (70 V)
stunning. Carbon dioxide stunning is consid-
ered to be both humane and efficient and is
increasingly used in Europe. Handling of
hogs in holding pens, truck-loading tech-
niques, mixing of animals, crowding, temper-
ature, travel time and access to feed and
water are also important. 
Drip loss in PSE pork is about 1.70% of
trimmed carcass weight compared to 0.77%
for normal pork and drip loss increases with
storage. For an estimated incidence of 18% of
PSE carcasses, with an extra shrink loss of
5–6%, this amounted to US$95 million loss to
the US pork industry in 1972. 
DFD meat is a problem with beef, pork
and probably also with poultry. In beef, DFD
meat is referred to as dark-cutting meat and
is most severe in young bulls, due to their
aggressive behaviour, which reduces muscle
glycogen stores. In poultry there is some evi-
dence that cyanosis is due to DFD meat.
Cyanosis is the fourth leading cause of con-
demnation of chickens in Canada and cyan-
otic meat is condemned because little is
known about its safety and quality. It is
thought to be caused by chronic hypoxia
from overcrowding, but may be related to
general shipping stress. 
Porcine stress syndrome
Porcine stress syndrome (PSS) is a genetic
defect that leads to malignant hyperthermia
(MH) in the live pig and the formation of
pale, soft, exudative (PSE) pork. The syn-
drome can be traced to early 20th century
Germany and is particularly prevalent in the
Piétrain breed. This breed may have begun
by inadvertently selecting animals with the
PSS mutation due to their exceptional muscle
development.
PSS pigs that are stressed develop hyper-
thermia (body temperature >41°C) and take
rapid, shallow breaths (dyspnoea). The skin
becomes blotchy and the muscles tremble
and become rigid or weak. The animal may
die from acidosis, hyperkalaemia, vasocon-
striction and cardiac arrest. Survival depends
on cooling the animal and providing ade-
quate oxygen. These effects are due to rapid
muscle metabolism, which increases oxygen
consumption up to threefold and produces
heat. The endocrine stress response is also
stimulated (see below), which exacerbates
the metabolic response.
In PSS pigs, the muscle pH can drop to
6.0 in less than an hour due to excessive lac-
tic acid accumulation, and the muscle tem-
perature can rise to above 40°C, resulting in
PSE meat. The DFD condition could be pro-
duced in PSS pigs that survived the initial
stress response, but were slaughtered with
very low levels of muscle glycogen. This
would result in low levels of lactic acid in the
meat and an ultimate pH greater than 6.0.
PSS and PSE are not the same thing. PSS
is a genetic defect of pigs while PSE is a non-
specific meat condition that may occur in
meat from any animal source with accelerat-
ed post-mortem glycolysis. However, PSE
meat is more prevalent in carcasses of pigs
that suffer from PSS, with 60–70% of PSS pigs
developing PSE meat, depending on post-
mortem handling. Stress factors that can trig-
ger PSS include breeding, high temperatures,
crowding/mixing, transportation to the abat-
toir, vaccination, castration, moving within
the abattoir, and oestrus. Although PSS pigs
are more susceptible to developing PSE meat,
pigs that are free from the genetic defect can
produce PSE meat as well. An examination of
PSE loins for the PSS genotype showed that
3.6% were homozygous and 29% were het-
erozygous for the recessive stress gene, while
the remainder had a normal genotype. This
indicates that, while a high proportion of PSS
pigs produce PSE meat, PSE meat can also be
produced in normal pigs.
PSS is a genetic susceptibility to stress
that is due to changes in calcium metabolism
in the muscle (Fig. 3.30). Intracellular Ca2+
levels in relaxed muscle are 104 times lower
than in the extracellular fluid. During muscle
contraction, Ca2+ that is stored in the sar-
coplasmic reticulum in the muscle cell is
released through a calcium release channel
(CRC, also known as the ryanodine receptor
for its binding of the plant alkaloid, ryan-
odine) and intracellular Ca2+ is increased ten-
fold. Relaxation occurs as the Ca2+ is pumped
back into the sarcoplasmic reticulum. The
CRC is a large protein (molecular mass
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564,743 Da). It is activated by phosphoryla-
tion and is under negative feedback control
from intracellular Ca2+. It is also inactivated
by calsequestrin (a protein that stores Ca2+
within the sarcoplasmic reticulum) and the
action potential, which causes membrane
depolarization and is measured by a voltage
sensor that is physically connected to the
CRC. Mg2+, calmodulin and repolarization of
the membrane that is detected by the voltage
sensor inactivate the CRC. Non-physiological
activators of the CRC include halothane,
ryanodine and caffeine.
The PSS defect is due to a substitution of
a single nucleotide (position 1843 of the ryr-1
gene) that causes a single amino-acid replace-
ment (cysteine instead of arginine) in amino
acid 615 in the CRC. The mutation causes the
CRC to be more sensitive to biochemical acti-
vators, making it easier to open and more dif-
ficult to close. This in turn makes skeletal
muscle contraction easier to activate and
more difficult to relax (Fujii et al., 1991).
Testing for PSS
PSS pigs were first reliably identified by the
halothane challenge test, which was devel-
oped in 1974. In this test, 2–3-month-old pigs
are given 3–5% halothane in oxygen through
a face mask. PSS-susceptible pigs develop
extensor muscle rigidity when exposed to
halothane gas. This is analogous to malignant
hyperthermia in humans. PSS is inherited as
an autosomal recessive trait and the
halothane challenge test is highly sensitive
for homozygotes, but only 25% of heterozy-
gotes are detected. The response in the test is
increased if the pigs are stressed by fighting
or rough handling. Skeletal muscle from
PSS-susceptible pigs, as well as from malig-
nant hyperthermia-sensitive people, is more
sensitive to drug-induced contraction. This
forms the basis for caffeine and halo-
thane contraction tests using muscle biopsy
specimens.
Following the development of the
halothane challenge test, it was found that
PSS was rarely found in Hampshire, Duroc,
Large White and Yorkshire breeds, while it
was prevalent in Piétrain, Landrace and
Poland China pigs. The incidence of PSS
found in Landrace pigs at different locations
in the 1970s suggested that the defect spread
from Germany and Belgium. Haplotype
analysis of the ryr-1 gene suggests that the
PSS mutation arose from a single founder
animal. It is now found in virtually all other
domestic breeds used for intensive pork pro-
duction worldwide and in more that 25% of
the breeding stock in Europe and North
America. In the early 1990s, the PSS mutation
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Fig. 3.30. Defect in calcium metabolism leading to porcine stress syndrome (PSS). CRC, Calcium
release channel; SR, sarcoplasmic reticulum.
was found in 97% of Piétrain, 80% of Poland
China, 37% of Landrace, 22% of Large White,
Duroc and Hampshire and 17% of Yorkshire
pigs. The spread of the mutation is due to the
relatively small number of breeding pigs that
are providing the genetics for the slaughter
pigs, the introduction of new breeding stock
in genetic improvement programmes and the
fact that there is increased carcass lean in ani-
mals with the PSS mutation, which resulted
in it being selected for in ‘improved’ pig
genotypes. In North America, there has also
not been any direct penalty to producers for
carcasses that have PSE.
Canadian researchers have developed
a PCR-based test that identifies the gene
mutation in pigs (Fig. 3.31). DNA is first iso-
lated from blood, muscle, semen or other tis-
sues, with the preferred procedure being a
dried blood sample on filter paper. A 659 - bp
portion of the ryr-1 gene that includes the
mutation is then amplified by PCR and the
amplified DNA is subjected to restriction
fragment length polymorphism (RFLP)
analysis. This involves digesting the DNA
with the restriction endonuclease BsiHKAI,
which cuts the amplified DNA at a site com-
mon to both normal and mutant genes as
well as at the mutation site itself. The number
and position of DNA fragments that are
found after agarose gel electrophoresis is
used to identify the PSS genotype (O’Brien et
al., 1993).
However, PSS has not been eliminated.
The DNA test is costly, therefore some pro-
ducers do not test their herds. There are no
economical incentives for producers to test
their herds. PSS pigs that survive to slaughter
have higher lean yield, and a higher lean
yield is also found in pigs that are heterozy-
gous for the mutation. Thus, it may be advan-
tageous to control the frequency of the
mutation, and to raise heterozygous animals
rather than to completely eliminate it.
The PSS mutation results in improved
carcass characteristics and feed conversion in
heterozygous animals. Landrace pigs that are
heterozygous for the mutation have 5% less
back fat and 2.8% increased lean yield, while
heterozygous Yorkshire pigs have 5.7%
improved feed conversion, 6.3% decreased
back fat and 4.1% increased lean yield com-
pared to non-mutant pigs. The increased lean
and decreased fat may be a direct consequence
of the increased sensitivity of the muscle to
contraction and increased metabolic activity of
the muscle in heterozygous pigs. This may act
directly as a stimulus for muscle hypertrophy
and mobilization of fat in PSS pigs.
The ryr-1 gene is also expressed in brain,
while two other CRC genes, ryr-2 and ryr-3,
are expressed in smooth muscle and brain.
The PSS mutation does not, therefore, affect
cardiac or smooth muscle. The presence of
the PSS mutation in the brain may mean that
the central nervous system is more sensitive
to stress in mutant animals. Regional differ-
ences in levels of neurotransmitters in the
brain have been reported in affected pigs, but
these may be secondary effects from the
altered muscle metabolism.
PSS is analogous to malignant hyper-
thermia (MH) found in humans, dogs and
horses. Although MH is due to a single muta-
tion in pigs, there are many different muta-
tions that can cause MH in humans. MH is
also 5000- to 25,000-fold less common in
humans than in pigs. This is because modern
domestic pigs are highly inbred and the PSS
mutation has likely been selected for due to
the improvements in carcass composition
and feed conversion associated with it. 
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Fig. 3.31. DNA test for porcine stress syndrome
(PSS).
Endocrine factors that affect PSS pigs
and PSE pork
During stress, secondary responses of the
endocrine system occur with adrenaline and
cortisol (see also Section 6.3 for a discussion
of stress). The adrenal catecholamine, adren-
aline is synthesized from noradrenaline in the
adrenal medulla. The catecholamines act as
short-term response hormones to cause vaso-
constriction and other changes for the ‘fight
or flight’ response. There are both α-adrener-
gic receptors, which lead to vasoconstriction
and β-adrenergic receptors, which stimulate
vasodilation (see Section 3.5). Arterial and
venous systems contain mostly α-receptors,
while skeletal and cardiac muscle contain
both α- and β-receptors. Noradrenaline stim-
ulates α-receptors and causes vasoconstric-
tion, while adrenaline stimulates both α- and
β-receptors. The overall vascular response of
an organ to catecholamines thus depends on
the relative amounts of adrenaline and nor-
adrenaline and the ratio of α- to β-adrenergic
receptors present. In skeletal muscle, high
levels of catecholamines result in vasocon-
striction.
During the stress response (Fig. 3.32),
adrenaline levels in PSS pigs rise quickly and
adrenaline acts to increase the activity of
glucagon. Glucagon and adrenaline work via
a cAMP-dependent pathway to stimulate
glycogenolysis, which is the breakdown of
glycogen stores. Glycogen is converted to
glucose-6-phosphate during glycogenolysis,
and during glycolysis, glucose-6-phosphate
is converted to pyruvate. After the pig is
slaughtered, pyruvate is converted to lactate
under anaerobic conditions. Lactate builds
up in muscle to cause a dramatic decrease in
muscle pH, leading to PSE pork.
Adrenaline causes vasoconstriction and
a hypoxic condition results in the muscle of
PSS pigs, due the lack of oxygenated blood.
This causes lactate to accumulate from anaer-
obic glycolysis. In a live pig under anaerobic
conditions, the excess lactate would be shunt-
ed in the blood to the liver. This lactate would
then be converted back to glucose; this is
known as the Cori cycle. Under aerobic con-
ditions, pyruvate from glycolysis is convert-
ed to acetyl -CoA which enters the TCA cycle. 
Cortisol is a glucocorticoid steroid hor-
mone produced in the adrenal cortex and is a
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Fig. 3.32. Hormonal and metabolic responses to stress.
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long-term stress hormone. Its major target
tissue is the liver, and other important
target tissues are the lymphoid cells, thymus
gland and kidney. Cortisol affects carbo-
hydrate metabolism by promoting gluco-
neogenesis from body proteins, enhancing
fatty acid mobilization and oxidation,
increasing plasma cholesterol and triacyl-
glycerol levels and glycogen deposition in the
liver. This affects water and electrolyte distri-
bution in tissues by opposing water shift into
the cells. 
Gonadotrophin secretion is also affected,
as cortisol inhibits GnRH stimulation of LH
release. In the gastrointestinal tract, pro-
longed high levels of cortisol encourage the
development of ulcers. The inhibition of
prostaglandin synthesis is possibly involved
in this process. Cortisol also has effects on
immunity and inflammation (see Section 6.3).
Cortisol is involved in placental endocrine
function. Maternal cortisol levels are higher
and the placenta contains cortisol receptors.
Cortisol promotes the secretion of chorionic
gonadotrophin, which is a hormone required
for the maintenance of pregnancy. How-
ever, increased production of cortisol by the
fetus acts as a trigger for parturition (see
Section 5.1).
The effects of cortisol are more pro-
nounced in PSS pigs. When the pig is
stressed, cortisol levels rise. Because of the
problems with calcium sequestration in PSS
pigs, the animal’s muscles continue to con-
tract. Cortisol levels remain high for extend-
ed periods and this causes the proliferation of
gluconeogenesis from body proteins. When a
pig is stressed during transportation or upon
entry into the abattoir, cortisol levels will be
high. Cortisol has permissive effects on cate-
cholamines; therefore adrenaline will more
readily convert glycogen to glucose. Upon
death, glucose will be utilized by anaerobic
glycolysis to produce lactate in the muscles,
leading to PSE meat.
Thyroid hormones may also play a role
in the development of PSE meat. Thyroid
hormones normally stimulate heat produc-
tion by increasing aerobic metabolism.
Removing the thyroid glands from pigs
decreases the rate of post-mortem glycolysis,
while supplementing pigs with thyroid hor-
mones increases the rate of pH decline in the
muscles.
Manipulations to reduce the incidence of
PSE
Reducing stress prior to slaughter will reduce
the incidence of PSE meat. Adequate pen
space should be provided in the holding pens
at the slaughter plant (0.6 m2 per 115 kg pig).
All pigs must have room to lie down, and
during hot weather the animals can be wet
down with sprinklers. Two to 4 hours of rest
should be allotted prior to stunning. Animals
should be handled and driven quietly, with
minimal electric prod usage. Overcrowding
and exposure to unfamiliar animals should
be avoided. The animals should have room to
turn so they can enter the race more easily.
Pigs must always have access to water.
Supplementing animals with electrolytes and
feeding a high-quality protein such as casein
may also reduce the stress response. 
Rapid cooling of the carcass would
reduce the formation of PSE conditions, since
it would reduce the denaturation of sar-
coplasmic proteins caused by the excessive
heat from the rapid metabolism. Injection of
sodium bicarbonate has been shown to
reduce the rate or extent of post-mortem pH
decline. Injection of 10% by weight of 0.3 M
sodium bicarbonate at 15 min after death
improved colour, reduced drip loss and
increased the ultimate pH of longissimus and
biceps femoris muscles. Including 0.7% NaCl
along with the sodium bicarbonate improved
juiciness and flavour. Injection at 24 h after
death improved drip loss but not the colour
defect (Kauffman et al., 1998).
Summary and Conclusions
In this chapter, a number of methodologies
have been described for manipulation of the
growth rate, carcass composition and meat
quality of meat animals. Some of these meth-
ods, such as the use of anabolic steroids and
antimicrobials, have been used for many
years to improve growth rate, performance
and lean yield. The use of uncastrated male
pigs has also been used for a long time in a
few countries, but has yet to be a universally
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accepted procedure for pig production. Other
technologies, such as the use of soma-
totrophin or β-agonists and reducing the inci-
dence of PSS, have been used for a shorter
period of time. Other endocrine systems,
such as leptin, control of appetite with CCK
antagonists, and use of various dietary
PUFAs are only now being considered for
use. A thorough understanding of the un-
derlying biology is necessary for develop-
ment of effective methods by which to
manipulate these endocrine systems. In a
number of cases, this has allowed the devel-
opment of specific receptor agonists or antag-
onists that affect only the appropriate
components of the endocrine system, to pro-
duce the desired results without adverse
side-effects.
Manipulation of Growth and Carcass Composition 119
Questions for Study and Discussion
Section 3.2 Anabolic Steroids
1. Describe the use of anabolic steroids in meat animal production and in horse racing.
2. Describe methods used to distinguish between the anabolic and androgenic effects of various
steroids. Give examples of structural changes that have been used to optimize these effects.
3. Describe the direct and indirect mechanisms of action of anabolic steroids.
4. Discuss potential safety issues with the use of anabolic steroids.
Section 3.3 Use of Intact Male Pigs
1. Discuss the advantages and disadvantages of raising intact male pigs for pork production.
2. Describe the metabolism of the boar taint compounds, androstenone and skatole.
3. Discuss potential methods to control boar taint.
Section 3.4 Somatotrophin
1. Outline the effects of ST on carcass composition.
2. Discuss the control of pulsatile ST release.
3. Describe the direct metabolic effects of ST.
4. Describe the indirect effects of ST via IGF-I.
5. Outline potential methods to manipulate ST.
Section 3.5 β-Adrenergic Agonists
1. Describe the role of the sympathetic nervous system and catecholamines.
2. Describe the types of β-AA receptors and their interaction with various β-AA compounds.
3. Outline the metabolic effects of β-AA that result in changes in carcass composition.
4. Comment on the safety concerns for β-AA use.
Section 3.6 Thyroid Hormones
1. Describe the synthesis and metabolism of thyroid hormones.
2. Discuss the metabolic effects of thyroid hormones.
3. Describe the role of thyroid hormones in growth and development.
Section 3.7 Dietary PUFA
1. Discuss the effects of PUFA and their metabolites on gene expression.
2. Describe the metabolic pathways of LA, ALA and GLA leading to eicosanoid production.
3. Outline the metabolic effects of CLA isomers.
4. Describe the potential applications of dietary PUFA.
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Section 3.8 Leptin
1. Describe the mechanism of action of leptin and the model systems used.
2. Outline the role of leptin as an adipostat.
3. Describe the effect of leptin on uncoupling proteins and heat generation.
4. Describe the role of leptin in regulation of reproduction.
Section 3.9 CCK and Appetite
1. Describe the structure of CCK, gastrin and their receptors.
2. Describe the role of CCK and NPY in regulating appetite.
3. Outline potential applications of CCK in controlling feed intake.
Section 3.11 Dietary Chromium
1. Describe the role of chromium in the glucose tolerance factor and its effects on insulin activity.
2. Outline the potential physiological roles of dietary chromium.
3. Discuss the effective dose and potential safety concerns of dietary chromium.
Section 3.12 Effects of Stress on Meat Quality
1. Discuss the post-mortem factors that lead to the development of PSE and DFD meat.
2. Describe the genetic defect leading to PSS and testing procedures for PSS-susceptible pigs.
3. Discuss the endocrine responses that lead to PSE.
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4.1 Mammary Gland Development
and Milk Production
Introduction
The endocrine effects on milk production are
important in the growth and development of
the mammary gland (mammogenesis), the
initiation of lactation (lactogenesis) and the
maintenance of lactation (galactopoiesis).
Metabolic diseases related to lactation, such
as ketosis and milk fever, are also affected by
endocrine factors.
The mammary gland or udder is a skin
gland located outside the abdominal cavity.
In cows, the right and left sides of the udder
are entirely separate, with no common blood
supply. There is also no internal crossover of
the milk duct system among the individual
udder quarters, so that substances injected
into the teat and duct system of one quarter
will only be found in that quarter. Sheep and
goats do not have the four quarters of the
udder that cows have.
Milk is synthesized in small, sack-like
structures called alveoli (Fig. 4.1). Groups of
alveoli are organized into lobules, and groups
of lobules are organized into lobes. The
epithelial lining of the alveolus is surrounded
by myoepithelial cells, which contract in
response to the hormone oxytocin to squeeze
the milk out into small ducts. The small ducts
connect with larger ducts, which deliver the
milk to the cistern within the gland for stor-
age. There is no direct innervation of the
secretory system to affect milk delivery.
Mammary gland development
The number of milk-synthesizing cells is one
of the major factors that determines the milk
yield capacity of the mammary gland.
Factors that affect mammary development
during rearing can affect the number of milk-
producing cells and thus affect the future
milk yield capacity of the mature cow. 
Mammary gland development is related
to reproductive development, which occurs
in distinct phases during fetal life, puberty,
pregnancy and lactation (Fig. 4.2). At birth,
the non-epithelial tissues and basic structures
of the mammary gland, including the con-
nective tissue and blood and lymph vessels,
have already formed. However, the secretory
and glandular tissue is still rudimentary. At
2–3 months of age until shortly after puberty
is completed in cattle, the mammary gland
undergoes an allometric growth phase in
which it grows faster than other parts of the
body. During this period, the fat pad and
mammary ducts grow rapidly but no alveoli
are formed. At puberty, the mammary glands
of heifers weigh about 2–3 kg, with 0.5–1 kg
of parenchymal tissue that consists of 10–20%
epithelial cells, 40–50% connective tissue and
30–40% fat cells. Increased growth rate due to
feeding high-energy diets near puberty can
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lead to permanently reduced milk yield
potential. This is due to excess fat deposition
in the mammary gland and decreased growth
of parenchyma. This may not occur when a
high-energy and high-protein diet is fed, so
that dietary protein does not limit mammary
gland development. Higher body-weight
gain after puberty and during pregnancy has
no effect on mammary growth and potential
milk yield. For more information, see Sejrsen
et al. (2000).
Very little mammary growth occurs after
puberty until pregnancy. In early pregnancy,
the mammary ducts grow and there is exten-
sive lobulo-alveolar development from mid-
pregnancy. The growth rate is exponential,
with the majority of the growth occurring in
the last trimester of pregnancy. The growth
and development during this period deter-
mine the number of milk-secreting cells and
thus the extent of milk production. Cell num-
bers continue to increase even after parturi-
tion. Increased nursing intensity increases
mammary growth during lactation. The lac-
tating mammary gland in dairy cattle weighs
15–25 kg, with the parenchyma consisting of
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Fig. 4.1. Diagram of mammary gland structure.
Fig. 4.2. Mammary gland changes during development.
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40–50% epithelial cells as ducts and alveoli,
15–20% lumen, 40% connective tissue and
almost no fat cells. 
During lactogenesis, the alveolar secre-
tory cells are activated. The amount of rough
endoplasmic reticulum, Golgi and mitochon-
dria increases in alveolar cells. The activities
of enzymes associated with lactation, such as
acetyl-CoA carboxylase and fatty acid syn-
thase, are increased, along with the transport
systems of the substrates for milk synthesis,
including amino acids and glucose. Casein
micelles and fat droplets accumulate in the
cytoplasm and are released into the lumen of
the alveolus.
There is a two- to sixfold increase in
blood flow to the mammary gland, starting
2–3 days postpartum. However, the decrease
in production that normally occurs later in
lactation is not due to decreased blood flow.
Mammary duct development increases
by around 8% in each oestrous cycle and then
regresses during metoestrus and dioestrus.
After the first pregnancy, cell numbers can be
higher for subsequent lactations. Milk yield
increases until the cow is 8 years old, with
mature cows typically producing 25% more
milk than 2-year-old heifers. For more infor-
mation on mammary cell changes during
pregnancy and lactation, see Knight and
Wilde (1993).
Involution and the dry period
As lactation progresses in dairy cattle, the
number of mammary cells decreases due to
apoptosis, resulting in decreased milk yield.
Pregnancy also decreases milk yield, possibly
due to the effects of oestrogen produced by
the placenta on mammary function. The
decrease in milk yield eventually results in an
end to lactation and mammary gland involu-
tion. In contrast with other milk proteins, the
synthesis of lactoferrin is increased during
involution; lactoferrin may act as a non-
specific disease-resistance factor. The level of
the lysosomal enzyme N-acetyl-β-D-glucos-
aminidase also increases in the mammary
gland during involution. There is a decrease
in the size of the alveoli and lumen during
involution, but general alveolar structure is
maintained in bovine mammary gland. In
rodents, there is extensive tissue degenera-
tion and disintegration of the alveolar struc-
ture through apoptosis during mammary
gland involution.
A dry period is required between the end
of lactation and calving so that milk yield in
the next lactation will not be reduced. To
induce the dry period, the amount of grain
and water supplied to the cow is first limited
to reduce milk production, and then milking
is stopped 45–50 days before the expected
date of parturition. A shorter dry period sig-
nificantly reduces subsequent milk produc-
tion. The early dry period is the time of the
highest incidence of new intramammary
infections. This may be due to the presence of
a large volume of milk in the gland that
is conducive to bacterial growth, leakage
from the teats or the lack of teat-end disinfec-
tion. The concentration of total leucocytes
increases in mammary secretions during this
period. 
About 3–4 weeks prepartum, the mam-
mary gland begins the transition from the
non-lactating to the lactating state. Transport
of IgG into the colostrum begins 2 weeks
prior to parturition and the concentrations of
the major milk components increase dramat-
ically 3–5 days prepartum.
Model systems for studying mammary
gland development and function
In vitro cell culture systems 
Bovine mammary epithelium cells can be iso-
lated and cultured in a collagen matrix to
form a three-dimensional structure.
Mammary tissue can be obtained from preg-
nant cows, minced and dispersed in a mix-
ture of collagenase and hyaluronidase. The
epithelial cells are purified by density gradi-
ent centrifugation. Alternately, a cloned
mammary cell line can be used, such as the
MAC-T3 (mammary alveolar cell transfected
with large T antigen).
Whole animal studies
An in vivo model for studying endocrine
effects on the mammary gland is the method
of close arterial infusion into the mammary
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gland. This can be accomplished without
general anaesthesia or deep surgical dissec-
tion, which minimizes the stress to the ani-
mal. The arterial supply to the two
contralateral sides of the mammary gland
can be catherized separately, so that one side
of the gland can be used as the treatment and
the other side for the control.
The catheter is placed into the saphenous
artery and inserted up to the external iliac
artery, which supplies the ipsilateral mam-
mary glands via the external pudendal artery,
and the hind limb via the femoral artery. The
position of the catheter is determined by real-
time ultrasound imaging. Evans blue dye
injected through the catheter appears exclu-
sively in the ipsilateral vein (Maas et al.,
1995).
Test compounds can also be infused into
one half of the udder via the streak canal. The
contralateral half of the udder is the control
and receives the vehicle alone. This method
tests the activity of compounds that are
infused into the internal milk secretory sys-
tem of the udder rather than delivered to the
mammary gland via the blood.
Mammary gland function can be
assessed by biopsy of mammary tissue from
the live animal or by imaging the mammary
tissue using magnetic resonance imaging
(MRI).
Hormones and mammary gland develop-
ment (mammogenesis)
A number of autocrine and paracrine factors
are important in mammary growth and
development (Table 4.1). Mammary epithelial
cells grow into the fat pad, and the develop-
ing structures will only be formed when the
fat pad is present. This may involve specific
fatty acids from the fat pad.
Oestrogen stimulates mammary duct
growth, and oestrogen and progesterone act
synergistically to stimulate lobule–alveolar
development. Progesterone is elevated
throughout gestation and oestrogen is partic-
ularly elevated during the latter half of preg-
nancy. Thus, mainly ductal and lobular
growth occur during the first half of preg-
nancy, with lobule–alveolar growth occurring
during the second half of pregnancy.
Prolactin and growth hormone (ST) are need-
ed for the steroid hormones to be effective.
Prolactin binds to a receptor on the mamma-
ry epithelial cell, which induces dimerization
of the receptor and activates Janus kinase 2
(JAK2). JAK2 phosphorylates and activates
members of the STAT family of transcription
factors (see Section 1.3), which then activate
certain genes involved in differentiation of
terminal end buds of the mammary ducts.
Levels of prolactin, ST and insulin decrease
during gestation.
Placental lactogen is a peptide hormone
produced by the placenta and is structurally
related to prolactin and/or ST, depending on
the species. It binds to the prolactin receptor
in rodents to stimulate mammogenesis dur-
ing pregnancy. Levels of placental lactogen in
the cow are very low in maternal blood, so it
has little effect in cattle.
Mammary-derived growth inhibitor
(MDGI) is a 14.5 kDa protein that is produced
by mammary epithelial cells. It acts in an
autocrine manner to inhibit cell growth and
especially to induce differentiation in mam-
mary epithelium. MDGI levels increase in
mammary gland 2 weeks prior to parturition
and are high in lactating dairy cows. MDGI
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Table 4.1. Hormone effects on mammary development and milk production.
Stage of development Stimulated by Inhibited by
Mammary development Oestrogen/progesterone, prolactin, placental MDGI, TGFβ
lactogen, ST/IGF-I, EGF, FGF, TGFα, MCSF,
HGF, Crypto-1
Lactogenesis Prolactin, oestrogen, glucocorticoids, insulin Progesterone
Galactopoiesis Thyroid hormones, prolactin, milk removal, ST Glucocorticoids, oestrogen
Crypto-1 (or Cr-1) is also known as teratocarcinoma-derived growth factor (TDCF-1).
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has been shown to be the same as the fatty
acid binding protein isolated from heart (H-
FABP). FABP is important in intracellular
transport and metabolism of fatty acids, cell
differentiation and signal transduction.
Epidermal growth factor (EGF) stimu-
lates mammogenesis, but not in cattle.
Fibroblast growth factors (FGFs) may be
involved in the growth of mammary stromal
cells such as fibroblasts. Transforming
growth factor-α (TGFα), hepatocyte growth
factor (HGF) and macrophage colony stimu-
lating factor (MCSF) have also been implicat-
ed in stimulating mammogenesis. TGFβ
inhibits mammogenesis in mice and may also
be effective in cattle. See Section 4.3 for more
information of the EGF family of growth fac-
tors.
ST stimulates the growth of ducts during
mammary development near puberty and
lobulo-alveolar growth during pregnancy.
Injection of ST between 8 and 16 months of
age increases growth of the parenchyma and
total mammary cell numbers in cattle. This
occurs via the action of insulin-like growth
factor-I (IGF-I) produced either by the liver or
locally in the mammary stroma. The negative
effects of high feeding level on mammary
growth near puberty may be due to increased
local production of IGFBP-3, which binds
IGF-I to inhibit it. 
Oestrogen stimulates proliferation of
stromal cells in the mammary gland and stro-
mal cells produce IGF-I. Insulin has little
effect on mammogenesis in vivo, but adminis-
tration of very high levels of insulin can
mimic the effects of IGF-I. Cortisol targets the
endoplasmic reticulum and Golgi apparatus
in the differentiation of the lobule–aveolar
system in cattle. This is necessary so that pro-
lactin can later induce the synthesis of milk
proteins. For a review of hormonal effects on
mammary growth and lactation, see Tucker
(2000).
Hormones and initiation of lactogenesis
There is considerable species variability in
the effects of hormones on lactogenesis (the
start of milk production) and galactopoiesis
(the maintenance of milk production).
Prolactin, oestrogen and glucocorticoids
initiate lactation, provided there is a well-
developed lobule–alveolar system.
Oestrogen stimulates the release of prolactin
from the anterior pituitary and increases the
number of prolactin receptors in mammary
cells. There is a surge of prolactin several
hours before parturition. If this surge is
blocked with bromocriptine, milk yield is
reduced. Prolactin increases the translation of
milk protein mRNAs, swelling of Golgi
membranes and milk protein secretion, along
with synthesis of lactose and milk fat.
Injections of glucocorticoids into non-
lactating cows with well-developed lobule–
alveolar systems induce the onset of lacta-
tion. Milk production is increased if prolactin
is also present, and there is a synergy
between glucocorticoids and prolactin in ini-
tiating lactation. Glucocorticoids bind to
receptors in mammary tissue to increase the
development of the rough endoplasmic reti-
culum and other ultrastructural changes to
increase the secretion of α-lactalbumin and
β-casein. Binding to the corticosteroid bind-
ing globulin (CBG) reduces the activity of
glucocorticoids in serum. During the peripar-
turient period, levels of the CBG decrease
and free glucocorticoid levels increase, which
might explain the lactogenic effects of gluco-
corticoids. Glucocorticoids also suppress the
immune system, which may contribute to the
increased incidence of mastitis during early
lactation. 
Insulin is important in stimulating glu-
cose uptake and the expression of milk pro-
tein genes required for lactogenesis. IGF-I
also stimulates cell division leading up to lac-
togenesis.
The importance of the lactogenic com-
plex of the hormones insulin, prolactin and
glucocorticoids has been demonstrated using
in vitro culture of bovine mammary tissue.
The specific hormones that are involved in
regulating lactogenesis vary among different
species. 
Progesterone inhibits the initiation of
lactogenesis, but has no effect on milk yield
once lactation is established. Progesterone
has been suggested to work by increasing the
mammary threshold to prolactin, by altering
the secretion of prolactin from the pituitary
or acting as a glucocorticoid receptor antago-
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nist. The level of progesterone is high during
gestation and serves to inhibit lactogenesis
until just before parturition. The level
decreases about 2 days before parturition to
remove the inhibition of milk synthesis.
ST does not appear to be involved in the
onset of lactation in cattle. ST was not lacto-
genic when added to slices of mammary tis-
sue cultured in vitro or when given to late
pregnant cattle in the dry period.
Lactation can be induced hormonally in
non-pregnant cattle that have been dry for at
least 30 days. They are injected for 7 days with
high levels of oestrogen plus progesterone,
followed by increasing prolactin and finally
treatment with glucocorticoids. After 3 weeks
the cows are milked, since milk removal is
important in stimulating mammary growth
and inducing lactation. This method is not
effective in all cows and the level of milk pro-
duction is lower than if the cow gave birth
and started lactation naturally.
Milking different quarters of the udder
in dairy cattle at different times prepartum
changes the composition of the milk from
each quarter at parturition. This suggests that
local factors within each quarter of the gland
also affect the final activation of milk secre-
tion. The matrix in which the cells are grown
also affects mammary cellular functions. The
basement membrane is a component of the
extracellular matrix and contains proteins
such as collagen, laminin and proteoglycans.
Epithelial cells in all tissues are in contact
with the basement membranes, which allows
the cells to develop polarity and secrete milk
components at the apical surface of the cell.
Mammary cells grown in tissue culture on a
collagen matrix can also be induced to form
three-dimensional structures resembling
alveoli.
Maintenance of lactation (galactopoiesis)
Hormonal effects
Thyroid hormones are required for maximal
milk production. During lactation there is
decreased conversion of thyroxine (T4) to the
active hormone triiodothyronine (T3) in liver
and kidney, but increased conversion to T3 in
the mammary gland. This would enhance the
priority of the mammary gland for metabo-
lites compared to other body tissues. Surgical
thyroidectomy or treatment with radioactive
iodine, which is sequestered in the thyroid
gland to destroy thyroid function, decreases
milk yield. Administration of thyroid hor-
mones or iodinated casein (thyroprotein)
causes a temporary increase in milk produc-
tion. However, milk yield after treatment
with iodinated casein is below normal, so
there is no net benefit.
High levels of exogenous glucocorti-
coids and oestrogen decrease milk produc-
tion in an established lactation. Physiological
levels of glucocorticoids stimulate milk pro-
duction in rats, but the results are ambiguous
in ruminants. There is no change in CBG dur-
ing lactation in cattle, and corticoids are not
limiting to milk yield.
Prolactin is required for the maintenance
of milk production in rats and rabbits, with
decreases in milk yield of 50% or more after
bromocriptine administration. Decreasing
prolactin by bromocriptine administration is
much less effective in ruminants, except for
the lactating ewe. Suckling induces a three-
fold release of prolactin over 30 min after
milking, which is much less dramatic than
the peripartum prolactin surge associated
with lactogenesis. Milking is thought to
increase prolactin secretion by decreasing
prolactin inhibiting factor (PIF) release from
the hypothalamus. There is a correlation
between milk yield and prolactin in blood
5 min after milking, but milk yield and pro-
lactin levels before or 1 h after milking were
not correlated.
Prolactin levels increase with increasing
temperature and photoperiod. Prolactin lev-
els are also affected by stress, so blood sam-
ples must be taken carefully. Increasing the
photoperiod from 8 to 16 h day–1 increased
milk yield by 6–10% in cattle. Increasing pho-
toperiod also stimulated release of prolactin
and IGF-I, but the galactopoietic effect of
these hormones has not been proven. 
Cows can be pregnant and lactating at
the same time. Administration of bovine pla-
cental lactogen increases milk yield, but little
endogenous placental lactogen is normally
released into the maternal circulation, so it
will usually have a nominal effect. 
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Milk removal
Milk removal from the mammary gland is
necessary for the maintenance of lactation.
Milk secretion rate is less affected by long
milking intervals in high-producing dairy
cows than in low-producing cows. Increasing
milking frequency from 2 to 3 or 4 times per
day can increase milk yield to a similar extent
as treatment with bST (see below). The rate of
milk secretion increases only in the part of the
gland that is milked more frequently. Since all
sides of the udder are exposed to the same
systemic hormones, this suggests that local
autocrine factors within the individual parts
of the mammary gland affect milk produc-
tion.
The increased milk production is not
simply due to manipulation of the gland, but
requires actual removal of the milk. A 7.6 kDa
milk whey protein isolated from goats’ milk
has been proposed as a feedback inhibitor of
lactation. This protein acts in an autocrine
manner to reduce the rate of milk secretion,
stimulate the degradation of newly synthe-
sized casein and reduce prolactin receptor
numbers on mammary epithelial cells.
Acute accumulation of milk in the mam-
mary gland also increases intra-mammary
pressure, which activates sympathetic nerves
to decrease mammary blood flow and limit
the supply of hormones and nutrients to the
gland.
Effect of bST
The effects of ST on growth and carcass com-
position are discussed in Section 3.4. The
development of recombinant DNA technol-
ogy made possible large-scale production of
bST for use in improving the efficiency of
milk production in dairy cattle. ST is not
galactopoietic in rats but it is the major galac-
topoietic hormone in cattle. Blood levels of ST
decrease with advancing lactation.
Recombinant bST was approved for use in
dairy cattle prior to 1990 in the former Soviet
Union, Brazil, Mexico, South Africa, Bulgaria
and the former Czechoslovakia, and in the
USA in 1994. bST has also been shown to
increase growth rate in lambs and to increase
milk production in ewes and buffalo.
bST increases milk yield by 10% when
administered in early to mid-lactation, and
by 40% in late lactation. The percentage
increase depends on the dose, formulation,
nutrition programme, herd health and, most
importantly, management and environmen-
tal factors. Similar increases in milk yield are
found in all breeds. Various effects of parity
have been reported. It may be more cost
effective to administer bST after peak lacta-
tion, when the effect of treatment is greatest.
Treated cows become more persistent in milk
production, so milk yield decreases at a slow-
er rate than untreated cows after peak pro-
duction (Fig. 4.3). This also extends the
calving interval and results in fewer calves
being born per year. Increasing ST by treat-
ment with growth hormone releasing hor-
mone from the anterior pituitary is as
galactopoietic in dairy cattle as treatment
with ST directly.
During the early transition phase of bST
treatment, there is a delay of a few weeks in
increasing the voluntary feed intake,
although milk yield increases immediately.
This puts the cow in negative energy balance,
so body fat stores are mobilized and body
condition scores are reduced. There may be a
slight increase in the milk fat content during
this time and a slight decrease in milk protein
due to a limited supply of amino acids.
Adequate body condition score should be
achieved prior to calving.
Cows treated in the long term with bST
increase their nutrient intake to support the
increased milk production. The absolute
nutrient requirements for maintenance and
130 Chapter 4
Fig. 4.3. Effect of bST on milk production.
chap04.qxd  10/10/03  7:47 AM  Page 130
the nutrient requirements per unit of milk
produced by the dairy cow are not changed
by bST treatment. However, the increased
milk production results in an overall increase
in feed efficiency, since the requirements for
maintenance are a smaller percentage of the
overall requirements. Cows treated with bST
are like genetically superior cows at the same
level of milk production and should be fed
according to the level of milk production. 
Inadequate nutrition will decrease the
response to bST. Using more grain can
increase the energy density of the ration, but
dietary buffers are then needed to maintain
pH balance in the rumen. Feeding ruminally
inert fat such as the calcium salts of long-
chain fatty acids (Megalac®) also increases
the dietary energy. Sufficient levels of high-
quality rumen undegradable protein are also
needed. The diets needed by bST-treated
cows are more expensive, but the income
from milk production is increased over feed
costs. For more information on the effects of
bST on nutrient requirements of dairy cattle,
see NRC (1994). For a more general review on
the effects of bST, see Burton et al. (1994).
Mechanism of action
ST does not bind to receptors in the bovine
mammary gland, but acts by partitioning
additional nutrients to the mammary gland
during lactation for the increased synthesis of
lactose, protein and fat. Insulin normally
increases the utilization of acetate by adipose
tissue for lipid synthesis and thus is involved
in partitioning nutrients away from milk syn-
thesis and towards body tissues. Levels of
insulin in blood are negatively correlated
with milk yield. Especially during early lacta-
tion, adipocytes become less sensitive to
insulin, and ST acts on the adipocytes to
make more energy from fat available to the
mammary gland. Activities of acetyl-CoA
carboxylase and fatty acid synthase are
decreased in adipose tissue by ST treatment.
This increases the level of non-esterified fatty
acids (NEFA) in plasma, which can be oxi-
dized by peripheral tissues or used for the
synthesis of milk fat. Insulin also encourages
glucose sparing from peripheral tissues and
increased the glucose available for milk pro-
duction by the mammary gland. The lipo-
lytic effects of bST are most prominent during
the first two-thirds of long-term treatment
during lactation.
ST also stimulates secretion of IGF-I
from the liver, which increases proliferation
and survival of mammary cells. However,
IGF-I infusion into mammary glands is not
galactopoietic, so these mitogenic responses
of IGF-I may not be important in the galac-
topoietic effects of ST. However, IGF-I may
compete with insulin for binding to the
insulin receptor in peripheral tissues, thus
contributing to the insulin resistance caused
by ST. There are at least six binding proteins
for IGF-I, which either inactivate or enhance
the activity of IGF-I or have biological activi-
ties of their own. These proteins are present
in the blood as well as in the interstitial
spaces of the mammary gland. 
Delivery
The Monsanto Corporation has developed
and markets bST, using the trade name
Posilac®. Recombinant produced bST has up
to eight amino acids added to the amino ter-
minus, depending on the manufacturing
method. This has resulted in four different
recombinant bST products, Somagrebove®
(American Home Products), Somavubove®
(Pharmacia and Upjohn), Sometribove®
(Monsanto) and Somidibove® (Elanco). 
bST undergoes deamidation in solution,
with a tenfold increase in deamidation from
5°C to 37°C. Covalent crosslinks also form
between bST molecules and result in
hydrophobic aggregates that precipitate at
neutral pH and high protein concentrations.
This can cause extremely slow and incom-
plete release of bST from a sustained release
formulation. Aggregation can be reduced
somewhat using detergents such as Tween 20
or hydroxypropyl-β-cyclodextrin and sor-
bitol, but the high protein concentrations
needed for prolonged release of more than 1
month are still a problem.
bST can be injected daily, or more com-
monly every 2 weeks using a prolonged
release formulation. Suspensions of bST in oil
have been made for sustained release and to
stabilize the molecule by excluding water.
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Aluminium monostearate has been used as a
dehydrating or gelling agent with bST dis-
persed in oil at 10–50% by weight.
Microparticles of bST have also been made
using waxes, stearates, fatty acid anhydrides,
sucrose, sodium sulphate, polysorbate 80 or
sodium benzoate and dispersed in a carrier
vehicle. Once injected, the microparticles are
dissolved and the bST released over time (see
Section 2.4). Implants have been made of
compressed pellets of bST powder, with exip-
ients such as polyanhydride, polycaprolac-
tone, polyesters, cholesterol and
ethylcellulose to slow the release of bST.
Implants can suffer from problems of incom-
plete release of bST from their interior, the
necessity of sterilizing them and problems
with placing them. For more information, see
Foster (1999).
Safety concerns of bST use
bST only slightly alters milk composition by
altering the nutrient requirements of the cow.
It increases milk production and also the
problems normally associated with high milk
production. These include increased somatic
cell counts and mastitis. These are thought to
be a result of the increased milk yield rather
than a direct effect of bST. There is also some
evidence of increased lameness in bST-
treated cows. This might be due to negative
effects of bST on connective tissue and bone
development (see Section 3.4).
Cows treated with bST can take longer to
come into oestrus after parturition than
untreated cows, particularly if their body
condition is not adequate. Adequate nutrition
should be provided to replenish body condi-
tion during late lactation or during the dry
period. There is no effect on the number of
services required per cow once the animal
starts cycling, and levels of GnRH, FSH and
LH are unchanged by bST treatment.
Delaying bST treatment until after peak lacta-
tion or until conception has occurred can
counteract the negative effects on reproduc-
tion in dairy cows.
bST is thought to have no oral activity in
adult humans and is destroyed by digestion;
however, young infants can absorb intact
proteins. Bovine IGF-I has the same sequence
as human IGF-I, but levels in milk are only
increased by abnormally high doses of bST
and are not above those found in human
breast milk. Both bST and IGF-I will be at
least partially denatured by heat during pas-
teurization. It is estimated that by 1992, over
41,000 cows were treated with bST in scienti-
fic studies. The Food and Drug
Administration of the USA reviewed more
than 120 studies prior to approval of bST.
Factors affecting milk composition
The genetics and nutrition of dairy cows
affect the composition of milk. There are large
differences in milk fat content among differ-
ent breeds of dairy cows, ranging from 5.1%
for Jersey to 3.7% for Holstein-Friesian cows.
Likewise, Jerseys produce milk with 3.8%
protein compared to 3.1% protein for milk
from Holstein-Friesian cows. Milk fat and
protein content increase in the later stages of
lactation, and frequency of feeding and
method of feeding also affect milk composi-
tion. Undoubtedly, hormones are involved in
the underlying mechanisms for these differ-
ences in milk composition. All components of
milk can be altered to some degree. The
amount of fat and the fatty acid composition
of milk fat are most easily altered, followed
by the protein content, with the lactose con-
tent of milk being the most difficult to
change. Lactose is the most important osmo-
tic component of milk, so changes in lactose
synthesis are accompanied by changes in
water volume and thus milk yield. For a
review of the biological potential to alter milk
composition, see Kennelly and Glimm (1998).
Milk protein 
The primary purpose of milk proteins is to
provide a source of readily digestible pro-
teins with a balanced amino-acid content for
the young. However, the digestion of milk
proteins produces a wide array of bioactive
peptides that modulate digestive and meta-
bolic processes. This includes peptides with
effects on nutrient uptake (phosphopeptides,
casomorphins), immune function (im-
munopeptides, casokinins, casomorphins)
and neuroendocrine function (casokinins).
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Peptides with antimicrobial properties that
are active against bacteria, yeast and fungi
are produced by proteolysis of lactoferrin
and casein. Antihypertensive peptides that
inhibit the angiotensin-converting enzyme to
reduce blood pressure are derived from
casein. Antithrombotic peptides that inhibit
platelet function are derived from casein and
lactotransferrin. Casein phosphopeptides
form a complex with calcium ions and pro-
vide a passive means for increased calcium
absorption in the small intestine, as well as
recalcification of dental enamel. Im-
munomodulatory peptides that affect the
immune system and the cell proliferation
response are derived from casein.
Casomorphins are opioid peptides derived
from casein. They are absorbed from the
intestine to produce analgesic effects and
induce sleep. They also inhibit intestinal peri-
stalsis and motility, modulate amino-acid
transport, and stimulate the secretion of
insulin and somatostatin. Thus, there is a lot
of potential for producing functional ingredi-
ents and high value-added products from
milk. Many of these proteins could be sal-
vaged from by-products of the manufacture
of dairy products. For more information, see
the review by Clare and Swaisgood (2000).
Increasing dietary protein or decreasing
the degradation of dietary protein in the
rumen increases the protein content in milk.
Most additions of fat to the diet decrease milk
protein content. Infusion of glucose along
with increasing insulin in blood increases the
protein concentration in milk. This may pro-
vide a method for manipulating the composi-
tion of milk.
Milk fat
The largest proportion of milk lipids is in the
form of triglycerides, along with lesser
amounts of diglycerides and monogly-
cerides. The fatty acid composition of can be
altered to produce a more desirable product.
For example, increasing the content of C18:0,
and particularly C18:1, and decreasing the
content of C14:0 and C16:0 may help to
reduce plasma cholesterol and would result
in a softer butter. Conjugated linoleic acid
occurs predominantly in meat and dairy
products. It has been shown to reduce the
growth of many types of tumours and to
reduce the risk of atherosclerosis (see Section
3.7). Altering the fatty acid profile of milk has
also been reported to lower plasma choles-
terol in people consuming the product.
Increasing the fat content has traditionally
been a focus in dairy breeding programmes.
However, altering milk composition through
breeding strategies is effective only in the
long term. 
Volatile fatty acids produced in the
rumen, especially acetate, are the major pre-
cursors for synthesis of milk fat. Acetate pro-
duction is increased with high-fibre diets,
while low-fibre diets increase the production
of propionate, which is a precursor for glu-
cose and lactose synthesis. Milk fat content is
decreased as the proportion of concentrate is
increased in dairy rations, particularly in late
lactation. Milk fatty acids are either derived
from dietary long-chain fatty acids (50%),
microbial synthesis or from body stores of fat
(5–10%), or are synthesized directly from
acetate and β-hydroxybutyrate by the mam-
mary epithelial cells (40–45%). Microbial
action in the rumen produces branched-chain
and odd-carbon-number fatty acids, as well
as products of biohydrogenation of polyun-
saturated dietary fatty acids. Hormones
affect the delivery of nutrients to the mam-
mary gland and the activities of the acetyl-
CoA carboxylase and fatty acid synthase
enzymes involved in fat synthesis in the
mammary gland. 
The mammary gland cannot produce
fatty acids longer than 16 carbons. The bal-
ance between fatty acids synthesized in the
mammary gland and those available from the
diet or microbial synthesis can be altered by
dietary means. Feeding sources of unsatur-
ated fatty acids, such as sunflower and saf-
flower supplements, increases the content of
unsaturated fatty acids, particularly C18:1,
and lowers the content of C16:0 in milk.
Levels of eicosapentaenoic acid (EPA) and
docosohexaenoic acid (DHA) in cows’ milk
can be increased to the levels found in human
breast milk by including a fish-meal-contain-
ing supplement in the diet of dairy cattle. For
information on bioactive lipids in milk, see
Molkentin (1999).
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Metabolic diseases related to
lactation
Ketosis
Ketosis results from a high demand for glu-
cose for milk synthesis at a time when the
cow is in negative energy balance. This usu-
ally occurs in early lactation when the cow
may not obtain sufficient feed to produce
enough propionate for glucose synthesis.
This leads to the catabolism of fat and protein
and the overproduction of ketone bodies and
the accumulation of fat in the liver. From
4–12% of dairy cows develop clinical symp-
toms of ketosis, including depressed appetite,
milk yield and body weight, increased milk
fat, acetone breath, ketonaemia, ketonuria
and fatty liver.
An imbalance in the insulin/glucagon
ratio, abnormal liver function, adrenal corti-
coids, thyroxine and mineral and vitamin
deficiencies have been implicated in causing
ketosis. Moderate levels of body fat prepar-
tum and increasing feeding rapidly postpar-
tum are desirable, but appetite and intake are
normally depressed postpartum. Treatments
are aimed at increasing body glucose. This
includes intravenous glucose infusion,
preferably in combination with polypropyl-
ene glycol, which is converted to propionate.
Administration of cortisone or ACTH can
raise blood glucose but may be detrimental in
the long term.
Milk fever
Milk fever (parturient paresis) is an econo-
mically important metabolic condition that
occurs at the onset of lactation and can
reduce the productive life of a dairy cow.
Clinical symptoms include reduced appetite
and rumen motility, inhibition of urination
and defecation, lateral recumbency and even-
tual coma and death if left untreated. Cows
recovering from milk fever have a greater
incidence of ketosis, mastitis, dystocia,
retained placenta, displaced placenta and
uterine prolapse than cows that have never
had milk fever. 
Milk fever is due to a severe drop in
blood calcium, which disrupts neuromuscu-
lar function. The concentration of calcium is
12 times higher in milk than in blood. A cow
producing 10 l of colostrum requires about
23 g of calcium, which is about nine times the
total plasma pool of calcium, while a cow in
early lactation milking 40 l day–1 requires
56 g of calcium. Calcium in plasma is derived
from the diet and from bone storage reserves.
At parturition, the cow must bring more than
30 g of calcium per day into the plasma pool.
However, it takes about 14 days to condition
the effective release of calcium from bone,
and the early postpartum cow may not
receive enough dietary calcium due to a
depressed appetite. This can result in low
blood calcium (hypocalcaemia) of less than
6.5 mg 100 ml–1, compared to 10 mg ml–1 for
normal blood calcium, and can cause milk
fever. 
HORMONES INVOLVED. Blood calcium levels are
increased by the coordinated actions of the
calcitrophic hormones parathyroid hormone
(PTH) and 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] and decreased by calcitonin
(Fig. 4.4). PTH is secreted from the parathy-
roid gland in response to low blood calcium;
first causing increased calcium reabsorption
from the glomerular filtrate in the kidney and
then calcium resorption from bone. The total
soluble calcium in bone fluids of the typical
cow is estimated at 6–10 g and this is
increased by an additional 6–8 g during
metabolic acidosis. PTH stimulates the rapid
transport of the calcium from the bone fluids
to the extracellular fluid.
PTH also induces the 1α-hydroxylase
enzyme in the kidney that activates vitamin
D to 1,25(OH)2D3. The 1,25(OH)2D3 stimu-
lates the synthesis of calcium transport pro-
teins that move calcium across the intestinal
epithelial cells, and the magnesium-depend-
ent Ca-ATPase that pumps the calcium out of
the cell into the plasma. The 1,25(OH)2D3 also
acts synergistically with PTH to increase the
release of bone calcium and increase the renal
reabsorption of calcium.
Calcitonin release from the thyroid
increases calcium deposition in bone by
inhibiting the effects of PTH. Calcitonin also
stimulates the excretion of calcium and phos-
phorus in the kidney.
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PREDISPOSING FACTORS. Cold stress in subzero
temperatures can induce hypocalcaemia.
Milk fever is more prevalent in over-fat cows
(fatty liver) than in thin cows, as mobilization
of fatty acids can affect blood calcium levels. 
Some breeds of cows, especially Channel
Island, Swedish Red and White, and Jersey
breeds, are more susceptible to milk fever. A
lower number of intestinal receptors for
1,25(OH)2D3 are present in Jerseys than in
age-matched Holsteins. The decreased recep-
tor number would limit the effectiveness of
1,25(OH)2D3 in stimulating the reabsorption
of calcium. 
The incidence of milk fever increases
dramatically in third and greater lactations.
Older cows have increased milk production
and greater demands for calcium. However,
the ability to resorb calcium from bone and
transport calcium across the intestinal epithe-
lial cells, as well as the synthesis of
1,25(OH)2D3, decrease with age. This is due
to a decrease in the intestinal receptors for
1,25(OH)2D3 and an increase in the activity of
the C24-hydroxylase enzyme that inactivates
1,25(OH)2D3. 
TREATMENT AND PREVENTION. Treatment of
milk fever consists of supplementing blood
calcium levels until the bone and intestinal
transport systems adapt to provide the neces-
sary calcium. The intravenous infusion of
23% calcium borogluconate is most widely
used, but this can result in high plasma calci-
um if administered too quickly, causing car-
diac arrest. About 25% of cows treated this
way require additional treatment. Calcium
and phosphorus supplements can also be
given around parturition in the form of calci-
um carbonate, calcium chloride gels, or dical-
cium phosphate. A paste of calcium
propionate has been used to give a more sus-
tained calcium release and to provide propi-
onate as a gluconeogenic precursor. 
Stimulating calcium turnover from bone
before calving can reduce the incidence of
milk fever. This is done by feeding limiting
amounts of dietary calcium (100 g day–1, or
70 g day–1 for small breeds) for 2 weeks
before calving. Insufficient dietary magne-
sium reduces calcium mobilization from
bone, while excess dietary phosphorus can
interfere with vitamin D metabolism and
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cause milk fever. Dry cow rations need to be
balanced for calcium (0.39%), phosphorus
(0.24%) and magnesium (0.23%).
Injection of vitamin D3 or its synthetic
analogues within 8 days prepartum may also
be effective in preventing milk fever.
However, cows treated with vitamin D com-
pounds, including 1α-dihydroxyvitamin D3,
develop hypercalcaemia and are unable to
produce endogenous 1,25(OH)2D3 due to
inhibition of the 1α-hydroxylase enzyme.
More active and longer-lasting vitamin D
analogues, such 24-F-1,25(OH)2D3, have been
developed as an experimental implant, but
are not used commercially. 
PTH infusions or infections can prevent
milk fever, with about 20 times more PTH
needed for intramuscular than intravenous
treatment. A sustained release of PTH via an
implant has been suggested.
Anionic salts such as ammonium chlor-
ide and magnesium sulphate also stimulate
the release of calcium from bone. These salts
are rather unpalatable, and must be mixed
with feed in two daily feedings and not fed
for more than 3–4 weeks. Hydrochloric acid
that has been diluted and mixed with
molasses can also be used as a source of
dietary anions, but HCl is dangerous to han-
dle and corrosive to machinery. Adding
anions reduces the dietary cation–anion dif-
ference (CAD) to reduce the pH of the blood
and urine. The CAD can be calculated as:
CAD = (0.38Ca2+ + 0.3Mg2+ + Na+ + K+) –
(Cl– + 0.6SO4
2–)
This takes into account the average absorp-
tion of the different ions in cattle.
A CAD of –50 to –100 mEq kg–1 of diet,
or urinary pH of between 5.5 and 6.2, has
been suggested as optimal. Mild acidosis
increases tissue responsiveness to PTH,
resulting in increased resorption of calcium
from bone and increased synthesis of
1,25(OH)2D3. This may be due to improved
function of PTH receptors at lower pH.
An alternative approach to increasing
dietary anions is to lower the levels of dietary
cations. This is particularly important if the
CAD of the diet is greater than 250 mEq kg–1,
as it will be difficult to add enough anions to
lower the CAD to –100 mEq kg–1 without
seriously affecting the palatability of the feed.
Potassium is the cation present in highest
amounts in ruminant forages, and growing
conditions that produce consistently low lev-
els of potassium in forages would be benefi-
cial in reducing the cation content of the feed. 
The strategies for preventing milk fever
can be summarized as follows. If the dietary
CAD is below 250 mEq kg–1 of feed, anions
can be added to the diet to produce mild aci-
dosis and increase the sensitivity of the PTH
receptors. If the CAD is above 250 mEq kg–1
feed, calcium gels can be administered to
increase the passive absorption of calcium.
PTH, vitamin D analogues or low calcium
diets can also be given to increase the activity
of the calcitrophic hormones and increase the
available calcium. For more information, see
Horst et al. (1997).
4.2 Egg Production
This section covers endocrine factors that reg-
ulate sexual differentiation and development,
the rate of follicular development and egg
production, and the formation of the egg
shell in poultry. 
Sexual development
Female chickens have a unique reproductive
structure since they have only one functional
ovary. During embryonic development, birds
start out with two undifferentiated gonads.
As the male matures, it develops two func-
tional testes, while in the female the left
ovary matures and the right ovary regresses.
The reason why only one ovary develops is
not known, but it may be related to weight
constraints for flight and the restraints
imposed by the additional nutrient require-
ments of the organ. However, these factors
are not important in laying hens.
Interestingly, some species of wild birds, par-
ticularly hawks, develop two functional
ovaries and oviducts. A line of Rhode Island
Red chickens with two oviducts has also been
described (Wentworth and Bitgood, 1988).
This does suggest that it may be possible for
two functional ovaries and oviducts to devel-
op in chickens. This has the potential to
increase egg production, although the physio-
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logical and metabolic constraints of produ-
cing twice as many eggs may make this
impossible. More likely, egg production may
increase slightly and might be more pro-
longed, with ovulation alternating between
the two ovaries.
The control of sex is also important, since
the broiler industry prefers males for their
improved growth rate and improved lean
yield, while the layer industry uses only
females. Millions of chicks are therefore
culled because they are not the desired sex.
Various hormonal and physical manipula-
tions can somewhat alter the sexual pheno-
type and produce pseudo-sex-reversed birds,
but no reliable method has yet been found to
permanently alter the phenotypic sex of com-
mercial poultry.
Hormonal effects
During embryonic development, the primor-
dial germ cells (PGCs) settle in the urogenital
ridge region of the embryo around 3 days of
incubation. Up to 5–7 days of incubation, the
gonads are bipotential, meaning that they can
form either ovaries or testes. The undifferen-
tiated gonad is composed of an inner med-
ulla, which produces androgens, and an outer
cortex, which produces oestrogens. Sex dif-
ferentiation and regression of the right ovary
begins 6.5 days after hatching. In developing
genetic females, the gonads produce mostly
oestrogens, while androgens predominate in
the genetic male. The major hormone present
then determines the pattern of gonadal
development, with oestrogen playing a key
role. Steroid hormones also play a role in the
development of secondary sex characteristics
as the birds mature. Androgens stimulate
comb growth, spur growth, male feathering
and copulatory behaviour, while oestrogens
cause female feathering patterns and inhibit
male phenotypic and behavioural expression.
Gonad development in fish and reptiles
can be altered by treatment with exogenous
sex steroids; androgens induce the formation
of functional testes, while oestrogens induce
the formation of functional ovaries. The sen-
sitivity of fish and reptiles to exogenous hor-
mones is the basis of several assays for
endocrine disruptor chemicals (EDCs, see
Section 6.4). Mammalian gonads are insensi-
tive to exogenous hormone treatment, while
the gonads of birds are intermediate in
response. Treatment with an aromatase
inhibitor prevents the synthesis of oestrogen
and causes the development of a functional
male phenotype, although the female growth
pattern is not altered. Removal of the left
ovary or natural regression of the left gonad
after infections or tumours induces the right
gonad to develop as a semi-functioning testis
and for a male phenotype to develop.
Castrated males continue to grow like males,
while genetically male embryos treated with
oestrogen at 4 days of age develop a transient
female phenotype. 
The aromatase enzyme is expressed in
the medulla of the left and right gonads of
female embryos, but not in male embryos.
The oestrogen receptor is expressed in the left
gonad and not the right gonad of both sexes,
but the expression in males is restricted to a
very early stage of development. The lack of
an oestrogen receptor in the right gonad
could explain why the right gonad does not
develop as an ovary. The oestrogen receptor
is transiently present in the left male gonad,
which explains why the left gonad can be sex
reversed in the male by administration of
oestrogen. The oestrogen receptor does not
normally play a role in the male, since the
aromatase gene is not expressed and oestro-
gen levels would normally be low.
Genetic effects
In birds, the female is the heterogametic sex
(ZW), while the male is homogametic (ZZ).
The mammalian Y and avian W chromo-
somes are both small and contain very few
genes. It is possible that gonadal differentia-
tion is controlled by the ratio of sex chromo-
somes to autosomes, also known as
chromosomal dosage, as occurs in Drosophila.
Alternatively, major sex determining genes
may be present on the W chromosome that
triggers the development of the ovary. This
gene, termed ASW for avian sex-specific W
linked, has recently been cloned and mapped
to the W chromosome. It is related to the HIT
(histidine triad) family of proteins and the
putative protein kinase C inhibitor (PKCI).
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The mode of action of ASW has not been
determined, but it may act to induce the for-
mation of the ovary in an analogous manner
to the SRY gene on the mammalian Y chro-
mosome, which leads to the development of
testes (see Section 5.1). In mammals, female is
the ‘default sex’, and the activity of the SRY
gene is required to cause the undifferentiated
gonad to form a testis. Conversely, in birds
the default is the formation of the male testis.
The SRY gene has not been found in birds,
but the SOX9 gene, which is related to SRY, is
expressed at day 6 of incubation in the testis,
while expression in the ovary is weak. SOX9
may have a role in testis function, but in con-
trast to mammals it is expressed after the
AMH gene (see below), so it is not likely to
play a role in sex determination. For further
information, see Capel (2000).
Both Müllerian and Wolffian ducts are
present during early development before sex-
ual differentiation has occurred. When an
ovary is present and the synthesis of oestro-
gen occurs, the Müllerian ducts develop into
oviducts, uterus and cloaca, and the Wolffian
ducts regress. In the presence of a testis, the
Wolffian ducts develop into seminal vesicles,
ductus deferens and epididymis, and
Müllerian ducts regress. The development of
the Müllerian ducts is inhibited by anti-
Müllerian hormone (AMH, also known as
Müllerian inhibiting substance, MIS) that is
produced by the developing testis. AMH in
chicken has been cloned and is a 644-amino-
acid glycoprotein that is a member of the
TGFβ family. It may also inhibit aromatase
activity. The action of AMH is inhibited by
oestrogen, and the lack of oestrogen receptors
in the right ovary results in regression of the
right Müllerian duct. AMH may be con-
trolled by SOX9 as well as by other genes
encoding transcriptional factors involved in
sexual determination, including DAX1, SF1,
WT1 and possibly DMRT1 (see Section
5.1). DAX1 is expressed at similar levels
in both male and female gonads during
differentiation and may be more important in
regulation of steroidogenesis. SF1 is
expressed by day 3.5 of incubation and,
in contrast to mammals, is higher in female
than in male gonads, with expression up-
regulated in developing ovaries after
the onset of differentiation. WT1 is ex-
pressed at similar levels in male and female
gonads. DMRT1 is expressed at 3–4 days
of incubation in the genital ridge and
Müllerian ducts. It is located on the Z chro-
mosome and is expressed in higher levels in
ZZ embryos than in ZW embryos, making it
a good candidate for sex determination in
birds. For more information on sexual differ-
entiation in birds, see Shimada (2002), and for
information on the control of spermatogene-
sis, see the review by Thurston and Korn
(2000).
A more complete understanding of the
pattern of gene expression during sexual dif-
ferentiation may lead to methods for reliably
altering the phenotypic sex of poultry.
Regulation of follicular development and
egg production
Commercial chickens (pullets) begin to lay
eggs as they approach sexual maturity at
18–20 weeks of age. However, not all hens
begin to lay eggs at the same time. Egg pro-
duction increases to a maximum of about
90% of hens producing an egg every day over
about 2 months, as all the hens come into lay,
and then gradually decreases as the hens get
older. An ideal production curve would be
when maximum egg production is reached
immediately and then maintained indefinite-
ly (Fig. 4.5). 
Follicular development is under the con-
trol of the pituitary gonadotrophins, but the
precise mechanisms are not well understood.
Multiple follicles begin to mature at the same
time in the avian ovary. A high percentage of
small follicles do not grow to a fully differen-
tiated stage, but undergo atresia and are
resorbed. Those that grow to 10 mm in diame-
ter are recruited to the stage of accumulating
yellow yolk. Between 4 and 8 yellow growing
follicles are present at any time, and these are
arranged in a hierarchy of size, based on their
stage of maturation. 
Follicular growth and yolk deposition
have been studied by feeding birds gelatin
capsules containing fat-soluble dyes, such as
Sudan black or Sudan red. As the yolk is
deposited in the growing follicle, the dye
forms a coloured ring. This can be seen by
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slicing the yolk after the egg has been hard-
boiled.
Before recruitment as yellow follicles,
the numerous small follicles produce de-
hydroepiandrosterone (DHEA), androstene-
dione and oestrogens (Fig. 4.6). Following
recruitment, the yolk-filled follicles produce
progesterone as well as decreased quantities
of oestrogens. As the follicles continue to
mature, they lose the ability to produce
androgens and oestrogens and the largest fol-
licle produces large quantities of proges-
terone. This surge of progesterone stimulates
the release of LH, which acts by positive feed-
back to increase progesterone production by
the largest follicle, which ultimately results in
ovulation. Plasma levels of LH and proges-
terone peak 4–6 h prior to ovulation. LH
stimulates steroidogenesis in all follicles,
with androgens and oestrogens produced by
the small follicles.
Ovulation is caused by a surge in LH
concentrations and the timing of ovulation is
controlled by the circadian rhythm, which is
normally set by the light–dark cycle. In the
absence of a light–dark cycle, eggs are laid at
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Fig. 4.5. Changes in egg production of laying hens with age.
Fig. 4.6. Regulation of follicular growth and maturation.
Progesterone
chap04.qxd  10/10/03  7:47 AM  Page 139
all times throughout the day, although some
hens may establish a circadian rhythm from
other environmental cues. As little as 1.25 h
of darkness is sufficient to establish the circa-
dian rhythm from the photoperiod. The tran-
sition from light to dark is important and
eggs are laid 12–18 h after darkness begins. 
The length of the ovulatory cycle and fol-
licular maturation can range from 23 to 28 h
in different birds. However, hens in normal
production are kept on a light–dark cycle of
14L–10D totalling 24 h, which fixes the peri-
od of time that LH is released and ovulation
can occur. Birds that take longer than 24 h to
mature a follicle will therefore not always
have a follicle ready for ovulation when lev-
els of LH have peaked. This results in a non-
egg-laying day or a pause in the sequence or
‘clutch’ of eggs that are laid. If hens are kept
on a 28-h day, virtually all hens will be able to
mature a follicle in this period and one egg
will be laid for each light–dark cycle. A bird
that has a rate of follicular development that
is less than 24 h will not ovulate the mature
follicle until the LH surge. Selection for birds
with rapid rates of lay, using short 22-h photo-
schedules, has been used to increase the rate
of egg production, but lower egg weights
were obtained. For more information on fac-
tors affecting the ovulatory cycle of hens, see
the review by Etches (1990).
There are two forms of GnRH in the
chicken (Table 4.2), with GnRH-I being the
most prevalent. Immunization against
GnRH-I but not GnRH-II inhibits ovulation.
Mammalian GnRH is also active in chickens. 
As the hen ages, there is decreased
gonadotrophin production from the anterior
pituitary gland in response to the GnRH. This
results in a reduced number of follicles reach-
ing the final stages of maturity, so that a
mature follicle is not always available for
ovulation and the rate of lay decreases.
However, since fewer follicles are develop-
ing, they receive a proportionally greater
amount of yolk, causing an increase in egg
size. 
FSH is involved in maintaining the hier-
archy of size in the developing follicles and
the rate of follicle atresia. Levels of FSH are
decreased by inhibin, which is produced by
the four largest preovulatory follicles (F1–F4),
in particular the largest F1 follicle. Inhibin is
a gonadal glycoprotein that is a member of
the transforming growth factor-β (TGFβ)
family of peptides (see Section 5.1). It is com-
prised of two subunits, α and β, while activin
is a related protein that is comprised of two
β-subunits and has opposite physiological
effects on FSH. Inhibin reduces the secretion
of FSH from the anterior pituitary gland
without affecting LH production. It has also
been shown to have paracrine effects in the
ovary, acting as a competitive FSH receptor
antagonist in mammals. Follistatin is a solu-
ble protein that binds and inhibits activin; it
also binds inhibin with less affinity but its
physiological role with inhibin is not com-
pletely understood. The IGFs also have
important effects on the control of reproduc-
tive function in the ovary. They appear to act
as paracrine/autocrine regulators of follicu-
lar growth and differentiation.
Application
The expression of inhibin in the F1–F4 folli-
cles and plasma levels of inhibin are higher in
hens that lay at a low rate compared to those
that lay at a high rate. The α-subunit of inhib-
in has been cloned and sequenced, and this
information has been used to develop inhibin
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Table 4.2. Structure of mammalian GnRH, chicken GnRH-I and chicken GnRH-II (from Etches, 1990).
Amino-acid number
1 2 3 4 5 6 7 8 9 10
mGnRH Pyro-Glu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2
cGnRH-I Pyro-Glu His Trp Ser Tyr Gly Leu Gln Pro Gly-NH2
cGnRH-II Pyro-Glu His Trp Ser His Gly Trp Tyr Pro Gly-NH2
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conjugates for immunization of hens.
Immunization against inhibin increased the
number of follicles that were recruited into
the preovulatory hierarchy in chickens and
advanced the onset of lay and increased the
rate of egg production in Japanese quail
(Moreau et al., 1998).
Eggshell formation
Poor eggshell quality, resulting in cracked
shells, is a major source of losses to the layer
industry. Poor shell quality occurs due to
environmental factors, such as temperature
and stress, as well as nutritional factors, such
as the availability of dietary calcium and lev-
els of minerals such as phosphorus and chlo-
ride. Poor shell quality along with decreased
egg production is a major cause of culling in
older hens. The egg shell is also important for
successful development of the chick embryo,
as it provides protection from damage, infec-
tion and desiccation, and provides a source of
calcium for skeletal development. The devel-
opment of a thicker shell is undesirable, since
this would reduce the exchange of gas and
water and make it more difficult for the
embryo to hatch. Rather, it is the mineraliza-
tion process, which involves both shell
matrix proteins and calcium salt crystals, that
affects shell strength.
After ovulation, the ovum is fertilized in
the infundibulum and then albumin is added
in the magnum. The shell membranes are
added further along in the isthmus (Fig. 4.7).
Then about 6 g of calcium carbonate (calcite)
and a thin layer of calcium phosphate
(apatite) are laid down in the 18 hours while
the egg is in the shell gland or uterus. The egg
shell consists of an organic matrix (3.5%) and
mineral layers (95%). The molecular con-
stituents involved in the mineralization
process have been studied, with the goal of
improving eggshell quality, since the struc-
tural organization within the mineral layer is
the most important factor affecting shell
strength.
The egg shell is divided into six layers
(Fig. 4.8). The innermost layers are the mem-
branes that enclose the yolk and albumin.
The outer membrane is anchored to the first
calcified (cone) layer. This is followed by the
palisade layer, which consists of an array of
crystals arranged perpendicular to the shell
surface and then a vertical layer of crystals.
An organic cuticle covers the outer surface of
the egg shell and contains the majority of
shell pigments.
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Fig. 4.7. Diagram of the reproductive tract of poultry.
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Shell matrix
The matrix is composed of a mixture of pro-
teins and polysaccharides that directs the
nucleation and controls the growth of crystals
in the mineral layer, thus affecting the
mechanical strength of the shell. The shells of
eggs at the end of a hen’s laying cycle can still
contain the same amount of calcium, but
eggshell strength can be decreased due to poor
structural organization in the mineral layer.
Some of the proteins involved in regulat-
ing mineralization are acidic and are located
at the interface between the crystal and the
matrix, while others are found within the
crystals. Crystal growth is initiated by depo-
sition of calcium carbonate on organic aggre-
gates that are present on the outer surface of
the eggshell membranes. Crystal structure is
affected by protein–mineral interactions and
competition for space from crystals growing
from adjacent centres of nucleation. The shell
membranes are necessary for shell deposition
and affect the pattern of mineral growth. This
has been shown in experiments in which
replacement of part of the shell of a snail by
eggshell membranes resulted in an avian pat-
tern of mineral formation in the snail shell.
Several proteins are secreted into the
uterine fluid and are present in the egg shell,
including ovocleidin-17 (OC17, a specific
uterine protein), osteopontin (OPN, a bone-
matrix phosphorylated glycoprotein), serum
albumin, ovalbumin, lysozyme and ovo-
transferrin. OPN is expressed in the shell
gland and secreted into the lumen only dur-
ing the period of shell calcification. OPN syn-
thesis is induced by the mechanical strain of
the egg in the gland and it is not expressed if
the egg is removed prematurely from the
shell gland. The eggshell matrix also contains
proteoglycans, primarily keratan sulphate
and dermatan sulphate. These macromol-
ecules influence the organization of crystal
growth by controlling the size, shape and ori-
entation of calcite crystals. They are present
in uterine fluid at different concentrations,
depending on the stage of shell calcification,
while levels of calcium and bicarbonate
remain high. Changes in matrix shell proteins
have also been shown during the growth of
shells from molluscs and echinoderms.
Functional studies of shell-matrix pro-
teins have involved studying the effects of
these proteins on delaying calcium carbonate
precipitation and affecting the size, shape
and orientation of crystals formed in vitro
from a supersaturated salt solution. Soluble
extracts of egg shells, or uterine fluid collect-
ed towards the completion of the shell, delay
precipitation and cause aggregation of the
crystals. Uterine fluid in which the large mol-
ecules are removed by ultrafiltration has no
effect on crystal formation. For further infor-
mation on the eggshell matrix, see the review
by Nys et al. (1999).
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Fig. 4.8. Diagram of the various layers in the shell.
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Calcium metabolism
The average egg shell contains 2.3 g of calci-
um and, at a rate of production of 250 eggs
year–1, the hen turns over 580 g of calcium
each year. Few species of animals turn over
this much calcium as a percentage of body
weight. The calcium used for shell formation
comes from the blood. Plasma calcium level
rises from 100 µg ml–1 before the onset of lay
to 200–270 µg ml–1 throughout egg produc-
tion. Most of the calcium in plasma is associ-
ated with organic complexes, very-
low-density lipoprotein (VLDL) and vitel-
logenin, with only 20% of the calcium present
in an ionized form. 
An adequate supply of calcium is essen-
tial for proper shell formation, with normal
layer rations containing 3.5% calcium.
Calcium is needed during the night when
shell formation occurs. Feed intake increases
in the 2 hours before the onset of darkness,
and hens will readily pick out large particles
of oyster shell or limestone pellets, and store
these in the gizzard, where soluble compo-
nents will be leached by the HCl present. The
passage of calcium through the digestive
tract can be regulated to optimize the absorp-
tion of calcium. A coarse particle size of calci-
um improves shell quality by increasing the
period when calcium is available from the
diet. High levels of saturated fatty acids in
the diet lead to the formation of calcium
soaps and decrease calcium bioavailability.
High levels of dietary phosphorus decrease
calcium availability, with 0.3% available
phosphorus being adequate for normal
performance and bone integrity. Feeding a
calcium-deficient diet results in decreased
plasma LH, decreased egg production and
ovary regression by 6–9 days. 
The additional calcium that is required
for shell formation is mobilized from storage
in bone (Fig. 4.9). The calcium required for
the formation of a single egg shell is equiva-
lent to about 10% of the total calcium stored
in the skeletal system and, in the absence of
adequate dietary calcium, the bones can be
demineralized to cause ‘cage layer fatigue’
and bone breakage. Calcium storage in bone
develops as oestrogen levels increase at sexu-
al maturity and is in a labile form of calcium
phosphate, called medullary bone, that is
present in the long bones. Vitamin D stimu-
lates the mobilization of calcium from bone
by osteoclasts, as well as calcium uptake from
the intestine, by increasing the synthesis of
the calcium-binding protein calbindin.
Vitamin D3 is converted into 25-hydroxy-
cholecalciferol in the liver and then further
hydroxylated to the active form 1,25-hydroxy-
cholecalciferol in the kidney. If blood cal-
cium levels decrease, parathyroid hormone
(PTH) is released from the parathyroid
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Fig. 4.9. Calcium mobilization in birds.
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glands. PTH stimulates osteoclast activity
directly and also increases the 1-hydroxyla-
tion of 25-hydroxycholecalciferol in the kid-
ney, which increases the removal of calcium
from bone. Calcium deposition in bone
occurs by osteoblasts, which have increased
activity when the shell is not being deposited.
During shell formation, the uterine cells
secrete a fluid into the shell gland that is
supersaturated with calcium and bicarbon-
ate. The changes that occur in the uterine
fluid during calcification are summarized in
Table 4.3. Sodium and chloride levels are
high in the uterine fluid at the beginning of
calcification and then decrease by 18 h as they
are reabsorbed by active transport into the
uterine cells. The level of potassium increases
and the pH decreases during calcification.
Calcium absorption from the blood and
secretion in the uterine fluid occurs by active
transport via a calcium-ATPase pump and a
Ca2+/Na+ exchanger (Fig. 4.10). A calcium-
binding protein, calbindin, is present in the
uterine cells and this protein is identical to a
vitamin D-dependent protein found in the
intestine. Calbindin may be involved in Ca2+
transport or in protecting the cells from high
levels of intracellular calcium. Levels of cal-
bindin increase in uterine cells at sexual
maturity in response to oestrogen stimulation
of oviduct development and are not depend-
ent on vitamin D. Calcium secretion and lev-
els of calbindin mRNA vary during the
ovulatory cycle and increase during shell for-
mation. Shell deposition only occurs when
the presence of a yolk in the uterus is
synchronized with ovulation. This suggests
that hormonal factors linked to ovulation
and follicular maturation regulate calbindin
synthesis.
Bicarbonate is produced by the action of
carbonic anhydrase in the uterine cells (Fig.
4.10). The level of carbonic anhydrase
increases with oviduct development and also
at the onset of egg production. A vitamin D
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Table 4.3. Summary of ionic changes in uterine
fluid shell formation.
Start of End of
calcification calcification
Na 144 80
Cl 71 45
K 12 60
Ca 6–10
Bicarbonate 60–110
PCO2 100
pH 7.6 7.1
Values are reported in mmol l–1, except for PCO2,
which is in mmHg.
Uterine glandular
cellPlasma Uterine
fluid
CO2
H+
Na+
HCO3
CaCO3
Shell
formation
CO2 + H2O
Carbonic
anhydrase
H+ HCO3– HCO3
Ca2+
Calbindin
Ca2+
Cl–
Ca2+
Ca-ATPase
–
–
Fig. 4.10. Ionic fluxes through uterine glandular cells (after Nys et al., 1999).
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response element is present in the carbonic
anhydrase II gene; however, the activity of
carbonic anhydrase is associated with the
development of the oviduct induced by sex
steroids, so the exact hormonal regulation of
carbonic anhydrase remains to be estab-
lished. 
Chloride levels greater than 0.2% affect
shell quality negatively, particularly for older
hens. High environmental temperature
decreases shell quality because of reduced
calcium consumption as well as increased
respiration rate, which causes respiratory
alkalosis and reduces the CO2 and CO3
2–
available for shell formation. Supplying car-
bonated water, sodium bicarbonate and vita-
min C may also improve shell quality,
particularly in hot environments. Increasing
the concentration of CO2 in the air also
improves shell quality, but this is not practi-
cal in commercial egg production.
Applications
The levels of plasma hormones, such as
parathyroid hormone (PTH) as well as PTH-
related peptide, oscillate during the egg cycle
and may be involved in regulation of matrix
protein synthesis. However, the hormonal
control of matrix protein synthesis has not
been established. Further work in this area
could lead to biochemical markers for
eggshell mineralization and shell quality.
Hens with poor eggshell quality tend to
have lower plasma levels of 1,25-hydroxy-
cholecalciferol, and this could possibly be
used in genetic selection programmes for
improved shell quality.
4.3 Wool Production and Endocrine
Defleecing
Introduction
This section describes various dietary and
endocrine manipulations that can be used for
defleecing sheep. The endocrine factors
(cytokines) that are involved in the function
of wool and hair follicles, in particular the
epidermal growth factors, are discussed.
The traditional method of mechanical
shearing of sheep is labour intensive, requires
considerable skill, is time consuming and is a
major annual cost to a wool-growing enter-
prise. Simple, low-cost and effective methods
for defleecing sheep would thus provide con-
siderable benefits. Some ancestral breeds of
sheep, such as the Wiltshire Horn, naturally
shed their wool seasonally. Shedding occurs
during the spring and early summer when
daylength is increasing. Wool growth in
modern domestic breeds varies seasonally,
possibly due to similar mechanisms. Changes
in the cellular activity in the mature wool fol-
licle affect the rate of fibre production and
fibre diameter. Follicles undergo a growth
cycle, which consists of periods of fibre
growth (anagen) followed by follicle regres-
sion (catagen), quiescence (telogen) and re-
initiation of fibre growth (proanagen). This
cyclic growth is regulated by growth factors.
The matrix cells of the dermal papilla at
the base of the follicle produce the keratin
proteins that are the main components of the
wool fibre (Fig. 4.11). At least five areas are
potential targets for the action of defleecing
agents. These are:
1. The follicle bulb in which active cell divi-
sion is occurring.
2. The keratogenous zone where cells pro-
duced in the bulb grow and are modified to
form the wool fibre and root sheath.
Oxidation of thiols in proteins occurs here
and RNA and DNA are degraded and
resorbed at the top of this zone.
3. The zone of final hardening of the wool
fibre, where oxidation of the thiol groups is
completed.
4. The inner root sheath, which forms the
outer cuticle of the fibre.
5. The intercellular cement in the fibre.
Defleecing methods
Copper deficiency results in wool with low
intrinsic strength, and zinc deficiency results
in partial or complete shedding of the wool.
Chelating agents such as EDTA can be given
to reduce the available copper and zinc and
to cause defleecing, but the doses required
are near lethal. Single oral doses of various
thallium salts (10–14 mg kg–1 BW) or the anti-
cancer drug cyclophosphamide (25–30 mg
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kg–1 BW), which arrests cell division, can
cause defleecing, but these compounds are
toxic. Hair loss in mice is induced by the
selenium-containing amino acids, seleno-
cystathione and selenocystine, but these
compounds have not been tested in sheep,
due to their cost and toxicity. 
Producing imbalances in available
amino acids can also weaken the wool fibres.
This can be done by infusion of an amino-
acid mixture without lysine or methionine
into the abomasum. Infusion of methionine
into wheat-fed sheep leads to distortion and
partial degradation of the wool fibres.
Abomasal infusion of a complete amino-acid
mixture or infusion of methionine into
roughage-fed or grazing sheep increases
wool growth.
Intravenous infusion (80 mg kg–1 BW
for 2 days) or oral doses (400–600 mg kg–1
BW) of the amino acid mimosine (Fig. 4.12) to
sheep decreases wool growth and causes
defleecing. Mimosine, which is present in
high levels in the tropical legume Leucaena
leucocephala, arrests cell division in the follicle
bulb and wool fibre growth for 10–12 days
within 2 days after dosing. The rate of
regrowth and fibre diameter is increased after
defleecing. Lower doses cause a partial break
in the fibres without shedding the fleece. The
analogue isomimosine is also effective in
defleecing. Mimosine is effective under con-
trolled laboratory conditions, but is not com-
pletely reliable in practice. A large dose is
needed for defleecing (16 g for a 40 kg sheep),
which is difficult to administer, close to the
lethal dose and the effectiveness is influenced
by the nutrition of the sheep. For more infor-
mation on chemical defleecing, see Reis and
Panaretto (1979).
Hormones from the thyroid, adrenal,
pineal, pituitary and gonads can affect hair
and wool loss in mammals. Administration
of ACTH, cortisol and cortisone has been
shown to inhibit wool growth, but long-term
exposure to high levels of hormone is need-
ed. Shedding is induced in Merino sheep
with synthetic corticosteroids such as dexa-
methasone given at 8.5 mg kg–1 BW0.75 (meta-
bolic body weight) and flumethasone given
at 1.3 mg kg–1 BW0.75 as a constant intra-
venous infusion over 8 days. Plasma levels of
dexamethasone and flumethasone were
40–50 and 8 µg ml–1, respectively, from this
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Fig. 4.11. Diagram of epidermis and follicle anatomy.
Fig. 4.12. Structure of mimosine, an amino acid
that causes defleecing.
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treatment. This dose is expensive and the
extent of shedding varies among animals and
differs in various anatomical areas on the ani-
mals.
Endocrine defleecing can be accom-
plished in modern breeds of sheep using epi-
dermal growth factor (EGF). This process,
known as Bioclip®, was developed by CSIRO
Animal Production and The Woolmark
Company in Australia, and has been market-
ed by Bioclip Pty Ltd in Australia since 1998.
In the first stage, known as donning, sheep
are prepared by removing undesirable fleece,
such as head and shank wool or stained
wool, to improve the quality of the final wool
that is harvested. The sheep are then fitted
with a fleece retention net and injected with
EGF in the inguinal (inside back leg) region.
Doffing occurs at day 14–18 after EGF treat-
ment, when the net is removed along with
the wool. The sheep are then treated with a
protective coat until day 28, when there is
sufficient wool regrowth to protect the sheep
from climatic extremes. Reported costs for
using Bioclip® are Aus$4.50 per animal,
which includes $0.90 in preparative work.
Endocrine defleecing has the advantages
of improving wool quality by eliminating
second cuts on the wool, thus reducing the
variability in fibre length, the amount of short
fibres and mechanical damage, and improv-
ing carding yield. The ends of the wool fibres
are more rounded and thus the wool is softer
and more comfortable than wool harvested
by mechanical shearing. The defleecing
process does not affect non-wool fibres, such
as kemp and hair fibres, which remain on the
sheep and do not contaminate the final fleece.
This improves the processing and dyeing of
the wool yarn. Avoiding shearing cuts to the
skin also decreases the contamination of the
wool with skin pieces and increases the value
of the sheep leather. 
Model systems used to study function of
follicles
A simplified in vitro model system to study
follicular function is the microdissection of
follicles from skin samples followed by
growth in culture (for example, see Bond et
al., 1998). In vivo model systems in which the
follicle activities are exaggerated, such as
synchronized cycles of shedding sheep, can
also be used. Whole animals can be treated
with growth factors and depilation (removal
of wool) force measurements then used to
determine whether the strength of the wool
fibres has been affected. Skin samples can be
removed from the animal after treatment and
various cell parameters can be measured.
Growth factor expression can be knocked out
or growth factors can be overexpressed in
transgenic animals. Naturally occurring
mutations that affect fibre growth, such as
angora, waved and rough, can also be studied
to determine the role of growth factors in
these phenotypes.
Growth factor effects on hair and wool
follicles
A large number of growth factors have been
implicated in the regulation of wool follicle
function (Table 4.4). These factors act locally
within the follicle to regulate cell function in
an autocrine or paracrine manner. Growth
factors bind to cells within the wool follicle
bulb to affect cell proliferation and ker-
atinocyte differentiation, which affect the rate
of growth and characteristics of the wool
fibre. Growth factors also bind to the extra-
cellular matrix (ECM), which consists of
fibrous proteins, glycoproteins and proteo-
glycans. Growth factors influence ECM syn-
thesis and degradation or are activated by
ECM components and affect the wool folli-
cles embedded in the ECM. 
Growth factors affect the morphogenesis
of wool follicles in the fetus and also the pro-
liferation and differentiation of cells in the
mature follicles. The development of follicles
in the fetus determines the density, size and
form of follicles, which affects the extent of
wool production and wool fibre characteris-
tics in the adult. 
Insulin-like growth factors
The insulin-like growth factors are single-
chain polypeptides of about 70 amino acids.
They act as mitogens, morphogens and differ-
entiation and cell-cycle progression factors.
ST stimulates IGF-I production by the liver,
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as discussed in Chapter 3. IGF-II is present in
higher amounts than IGF-I in sheep plasma
and skin, but its role is less well understood.
Insulin-like growth factors stimulate ker-
atinocyte proliferation and prolong the
growth phase of hair follicles. IGF-binding
proteins have been found in the dermal
papilla, suggesting that they may modulate
the effects of IGF on fibre growth. Mice with
null mutations for IGF-I and IGF-II have
hypoplasia of the epidermis and reduced fol-
licle density. Conversely, mice overexpress-
ing IGF-II had skin hypertrophy, while
transgenic sheep expressing IGF-I had
improved wool production. However, whole-
body or skin-patch infusions of IGF-I in
sheep had no effect on wool growth. 
Fibroblast growth factors
The key members of the FGF family involved
in the maintenance and control of fibre
growth are acidic FGF (FGF-1), basic FGF
(FGF-2), keratinocyte growth factor (KGF or
FGF-7) and FGF-5. Basic FGF is found in the
outer root sheath of the wool follicle and is
associated with the ECM between the outer
root sheath and the dermis. It may provide a
mitogenic stimulus for the follicle bulb cells.
Acidic FGF is concentrated in the upper bulb
cells and is associated more with cell differ-
entiation than proliferation. It appears to reg-
ulate fibre differentiation by affecting the
expression of particular keratin genes and the
pattern of differentiation of cells in the folli-
cle. KGF is synthesized within the dermal
papillae, while its receptor is present in
epithelial follicle cells in the bulb. Treatment
with KGF stimulates hair growth in mice,
while KGF knockout mice have matted and
greasy coats, similar to the naturally occur-
ring rough mutation. KGF is thus important
for normal fibre development. FGF-5 is local-
ized to the outer root sheath and is increased
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Table 4.4. Growth factors affecting follicular function (after Nixon and Moore, 1998).
Growth factor Receptor(s) Function
Insulin like growth IGFR-I, insulin receptor Required for follicle growth in culture; expression
factor-I (IGF-I) varies with follicle cycle
Insulin-like growth IGFR-I and II IGF-II mRNA and receptor present in follicles
factor-II (IGF-II)
Acidic fibroblast FGFR-1 Associated with differentiating keratinocytes
growth factor (FGF-1)
Basic fibroblast FGFR-2 Associated with basement membrane of follicle;
growth factor (FGF-2) inhibits hair growth in mice
Keratinocyte growth FGFR-2 Dermal papilla to germinal matrix communication
factor (FGF-7 or KGF)
Fibroblast growth FGFR-1 Cycle-dependent expression in peripheral follicle
factor-5 (FGF-5) cells
Transforming TGFβR-I and II Follicle regression and inhibition of cell
growth factor-β (TGFβ) proliferation
Epidermal growth EGFR Inhibits cell proliferation in wool follicle and
factor (EGF) causes catagen in follicle and fibre weakness
Transforming growth EGFR Mutants have enlarged follicles and wavy fur
factor-α (TGFα)
Hepatocyte growth Keratinocyte growth and motility
factor (HGF)
Parathyroid hormone PTHR Antagonists stimulate hair growth in mouse
related protein (PTHrP)
Platelet derived growth PDGF-Rα and β Mitogenic in connective tissue sheath of hair
factor (PDGF-A and -B) follicles
Vascular endothelial Autocrine action in human dermal papilla cells
growth factor (VEGF)
chap04.qxd  10/10/03  7:47 AM  Page 148
during anagen and decreased after catagen.
Gene knockout resulted in an exceptionally
long coat, analogous to the angora mutation.
FGF-5 thus appears to be involved in follicle
regression. 
Transforming growth factor-β
The TGFβ family includes three isoforms of
TGFβ along with bone morphogenic proteins
(BMPs) and the inhibins and activins. They
are synthesized as a large precursor that is
cleaved to form a 112-amino-acid growth fac-
tor and a binding protein. TGFβ receptors are
serine/threonine kinases (see Section 1.3).
Binding of the growth factor to the Type II
receptor results in phosphorylation and acti-
vation of the associated Type I receptor. The
receptors are located in the follicle matrix and
outer root sheath. TGFβs regulate cell growth
and differentiation, and are some of the earli-
est signals found during development of skin
and hair follicles. They generally inhibit
growth by suppressing mitosis of epithelial
cells, inducing differentiation or inducing
apoptosis. The roles of the individual TGFβs
are not clear, but they are involved through-
out follicle morphogenesis. Transgenic
overexpression of BMPs in the outer root
sheath and TGFβ1 in the epidermis result
in decreased epithelial cell proliferation
and follicle formation. TGFβs also regulates
cell proliferation in follicles during the
hair growth cycle, with highest levels at
catagen.
EGF family of growth factors
Skin and hair follicles synthesize a number of
the EGF family of peptide growth factors
(Table 4.5), including EGF, transforming
growth factor-α (TGFα), amphiregulin and
heparin binding (HB)-EGF, which all bind the
EGF receptor. Members of the EGF growth
factor family have a 36–40-amino-acid con-
served motif and three disulphide bridges,
which form three peptide loops. EGF stimu-
lates cell proliferation, while TGFα may be
the fetal ligand for the EGF receptor and
results in a transformed phenotype by regu-
lating cell migration and differentiation.
Amphiregulin contains a putative nuclear
translocation signal and stimulates the
growth of normal keratinocytes and fibro-
blasts while inhibiting growth of several
breast cancers. Heparin-binding EGF has an
N-terminal extension and can bind the extra-
cellular matrix. Cripto is another member of
the EGF family of growth factors. It induces
branching morphogenesis in mammary
epithelial cells and inhibits the expression of
various milk proteins.
EGF stimulates the proliferation of cell
types of ectodermal or endodermal origin.
EGF consists of 53 amino acids but it is also
active as a 150-amino-acid prohormone when
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Table 4.5. EGF superfamily of growth factors.
EGF type Receptor type Function
EGF ErbB1 (EGFR) Promotes mitosis in mesodermal and ectodermal tissue
TGFα ErbB1 Transforms normal cells; proposed fetal ligand for EGFR
Amphiregulin ErbB1 Stimulates growth of normal fibroblasts and keratinocytes;
inhibits growth of carcinoma
Neu differentiation ErbB3 and ErbB4
factors (NDF)
neuregulins and
hereregulins
Betacellulin ErbB1 and ErbB4
Epiregulin ErbB1 and ErbB4
Heparin-binding EGF ErbB1 and ErbB4
Urogastrone Inhibits secretion of gastric acid
Cripto Mammary gland development
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it is anchored to the cell membrane with the
EGF sequence located in the extracellular
space. The EGF peptide is identical to uro-
gastrone, which is a peptide isolated from the
urine of pregnant women that blocks the
secretion of gastric juices. A major site of EGF
production is the salivary gland, and produc-
tion is stimulated by androgens. EGF is
released in the saliva and is thought to play a
role in wound healing in animals that lick
their wounds. The studies using EGF to
inhibit wool growth used EGF prepared from
submaxillary glands of adult male mice.
The activity of EGF is determined with a
bioassay that measures its effectiveness in
causing precocious incisor eruption and eye-
lid opening in newborn mice. EGF was first
named based on the thickening and kera-
tinization of the epidermis on the back and
eyelid caused by injection of salivary gland
extracts.
EGF RECEPTOR. The EGF receptor (EGFR) is a
180 kDa polypeptide that is part of a larger
family of receptors known as ErbB, which are
the receptors for the v-erb-B oncogene (see
Table 4.5). The EGFR was identified in 1980 as
the first member of the tyrosine kinase recep-
tor type (see Section 1.3). Shortly afterward,
the receptors for insulin, IGF-I and PDGF
(platelet-derived growth factor) were also
shown to be tyrosine kinase receptors. The
free receptor is a single polypeptide chain.
Binding of EGF to the receptor causes the
receptor to form a dimer, which is in many
cases a heterodimer of different receptor sub-
types. Whether a homodimer or heterodimer
is formed and which receptors are involved,
dramatically affects the signalling properties
of the receptor. 
When the dimer is formed, the catalytic
site of one chain phosphorylates a number of
tyrosines in the adjacent chain. These phos-
photyrosines serve as recognition sites for
binding of signalling proteins that have a
SH2 (src homology region 2) region. An
example of these signalling proteins is phos-
pholipase C (PLCγ1), which is activated by
binding to the receptor, thereby increasing
calcium mobilization and activating protein
kinase C. PLCγ1 also has a SH3 domain,
which allows it to bind to the cytoskeleton
and provide access to the phosphatidyl-
inositol substrate in the cell membrane. EGFR
signalling is involved in regulating cell devel-
opment and motility, protein secretion,
wound healing and tumorigenesis. For more
information, see the review by Wells (1999).
EFFECTS OF EGF ON FOLLICLES. EGF reduces hair
growth in mice by reducing the number of
proliferating cells in the follicle bulb and
reducing the rate of follicle development.
Mice treated with EGF produce hair that is
shorter, finer and wavy. Inactivation of the
TGFα gene in knockout mice also produces a
wavy coat, while overexpression of this gene
results in a thickened epidermis and stunted
hair growth.
EGF treatment of sheep produces differ-
ent effects in the follicle than in the surround-
ing epidermal cells. EGF treatment causes
weakening in the unhardened wool fibres
and a partial disruption of fibre growth in the
inner root sheath cells in the keratogenous
zone of the follicle bulb. A gradual inhibition
of mitotic activity then occurs in the bulb cells
over a period of 2–3 days, with a catagenic
regression of the follicle. This is followed by
asynchronous regeneration of the follicles 4–8
days after infusion of EGF. However, EGF has
the opposite effect on cells in the epidermis
and sebaceous gland, where cell proliferation
is increased by 2 days after infusion of EGF.
The mechanism behind the contrasting
effects of EGF in the follicles and epidermis is
not known. It may be the result of a massive
disruption in the normal homeostatic mecha-
nisms that regulate the activities of the differ-
ent cell types in the skin. 
Subcutaneous injections or intravenous
infusions of 3–5 mg of EGF caused a transient
regression of the wool follicles from the
actively growing stage, and resulted in shed-
ding of the entire fleece. Treatment with
1–3 mg of EGF resulted in a zone of weakness
in the wool fibres 3-4 weeks later but the
fleece was not shed. The weakness of the
wool fibres is assessed by measuring the
depilation force, which is the force required
to pluck wool staples from the midback
region of the sheep.
Following treatment with EGF, there
were changes in the regrowth wool. The con-
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tent of high-sulphur proteins increased from
19% to 30%, while the content of high-
tyrosine proteins decreased from 12% to 5%.
There were also alterations in the proportions
of other components. The maximum change
in composition was observed around 4
weeks, with the composition returning to
normal by 10 weeks. The effects were dose
dependent and were similar to those seen
when chemical defleecing agents were used.
This suggests that the changes in wool
composition are characteristic of wool grow-
ing from newly regenerated or regenerating
follicles.
Commercial use of EGF for endocrine
defleecing uses Met-EGF®, which is a geneti-
cally engineered form of EGF produced in a
recombinant E. coli expression system pre-
pared by Pitman-Moore Ltd, New South
Wales, Australia. It results in easy and consis-
tent fleece removal. 
OTHER EFFECTS OF EGF. Other effects of EGF
are the requirement of sufficient time for
regrowth of the wool, food rejection and
anorexia, decreased gastrin secretion and
gut motility, and an increase in abomasal
pH. There can be erythema around the
eyes and muzzle, and some rupturing of
dermal blood vessels. In pregnant ewes,
there can be a delayed onset of oestrus,
abortions, increased GH and placental lacto-
gen, decreased thyroxine, but no effect on
pregnancy rate or lambing. In rams, there
can be decreased sperm motility for about 12
weeks and increased plasma cortisol. Because
of the negative effects of EGF on repro-
duction, it is recommended that producers
wait for 5 weeks after using EGF before
breeding.
Summary of growth factors affecting fibre
growth
FGF-5 and TGFβ have been identified
as markers of catagen, and they inhibit
follicle growth. EGF and FGF can influence
fibre characteristics. Fibre curvature may be
controlled by factors that result in an
asymmetric distribution of keratinocytes
in the follicle bulb. Infusion of EGF stimu-
lates epidermal thickening and also in-
duces catagen in wool follicles prior to fleece
shedding. For practical applications, it is eas-
iest to treat all sheep about 12 weeks prior to
breeding. EGF treatment does produce a vari-
ety of behavioural and physiological side-
effects.
Continued research on the ultrastructure
of wool follicles and the detailed mechanisms
of the effects of different growth factors is
needed. Information on the cellular mecha-
nisms affected by EGF infusion is incomplete.
The side-effects of Met-EGF and the reasons
why Met-EGF is less variable need to be stud-
ied further. For further information, see
Steensel et al. (2000) and Stenn and Paus
(2001).
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Questions for Study and Discussion
Section 4.1 Mammary Gland Development and Milk Production
1. Describe the structure of the mammary gland. Outline the structural changes that occur during
sexual development, pregnancy and the drying off period. What model systems are used to study
mammary gland function?
2. Describe the endocrine factors that regulate mammogenesis.
3. Describe the endocrine factors that regulate the initiation of lactogenesis.
4. Describe the factors that regulate galactopoiesis. Describe the role of bST in increasing milk pro-
duction.
5. Describe factors that can affect the content of milk protein and milk fat.
6. Describe factors affecting ketosis and milk fever. What methods are used to control these meta-
bolic diseases of lactation?
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Section 4.2 Egg Production
1. Describe factors regulating sexual differentiation and gonad development in birds.
2. Describe the hormonal regulation of follicular development in poultry.
3. Describe the structure of the egg shell and the role of the shell matrix.
4. Discuss the regulation of calcium metabolism in shell formation.
Section 4.3 Wool Production and Endocrine Defleecing
1. Describe various nutritional and endocrine methods for defleecing sheep. What are the advantages
and disadvantages of each method?
2. Describe the model systems that can be used to study the function of wool follicles.
3. Outline the roles of growth factors, particularly IGFs, FGFs and TGFβ, in wool follicles.
4. Describe the roles of the EGF family of growth factors and their receptors in the function of wool
follicles.
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5.1 Manipulation of Reproduction in
Mammals
This section focuses on the potential for the
endocrine manipulation of reproduction,
with a particular emphasis on females, since
with the advent of artificial insemination this
is usually the limiting factor in animal pro-
duction systems. Unifying concepts are first
presented, followed by discussion of species-
specific information, as appropriate. This
information is then used as background for
understanding currently available methods
of manipulating the system and for devising
potentially useful methods for future applica-
tion.
The process of sexual differentiation and
maturation is first described, including the
sexual differentiation of different tissues, the
genes that are involved in these processes
and the regulation of meiosis in germ cells. A
description of the regulation of the oestrous
cycle, pregnancy and parturition and the
induction of puberty follows this.
Opportunities and possibilities for the
manipulation of the oestrous cycle are then
discussed. This includes a description of the
different hormonal preparations that are
available, methods for detection of oestrus,
the induction and synchronization of oestrus
and the techniques of superovulation and
embryo transfer. This is followed by a discus-
sion of methods for maintaining pregnancy
or inducing parturition. Finally, problems
that occur during the postpartum interval,
inducing puberty and advancing cycling in
seasonal breeders are discussed.
Sexual differentiation and maturation
Sex determination is controlled by the genet-
ic sex of the animal, which is fixed at the time
of conception. In the process of sex differenti-
ation, the genetic sex directs the development
of either ovaries or testes, which then deter-
mines the phenotypic sex as the animal
matures. Usually, a male genotype will pro-
duce a male phenotype and a female geno-
type will produce a female phenotype.
However, in some fish and reptiles the phe-
notypic sex can differ from the genotypic sex
due to environmental factors such as temper-
ature. The administration of sex steroids at a
critical point during development can also
permanently alter the phenotypic sex in some
species.
There is usually one pair of sex chromo-
somes, either XX/XY or ZW/ZZ for
female/male determination. In the XX/XY
system, the female is the homogametic sex,
while in the ZW/ZZ system, the male is the
homogametic sex and the female is the het-
erogametic sex. The ZW/ZZ system is found
in birds, reptiles and some fish and amphib-
ians. Other systems of polygenic sex determi-
nation involving multiple chromosomes with
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sex determining genes are also known in
some lower vertebrate species. Polygenic sex
determination produces male:female ratios
that are different from the 1:1 ratio seen with
pure sex chromosome systems.
Differentiation of the gonads and ducts
Sex differentiation relates to the development
of the phenotypic sex from the genetic sex.
This includes the migration of primordial
germ cells, the development of gonadal
ridges and the differentiation of the gonads
into ovaries or testes, which is controlled
by sex-determining genes. In the absence of
sex-determining genes on the Y chromo-
some to initiate testis formation, the
undifferentiated gonads in the early embryo
develop into ovaries and lead to a female
phenotype. In mammals, organization of
spermatic cords during testicular develop-
ment begins earlier in gestation than organi-
zation of the primordial follicles during
ovarian development.
In the undifferentiated stage of gonadal
development, both Wolffian and Müllerian
ducts are present and these later develop into
the male or female accessory sex organs. The
Müllerian ducts differentiate to form the
Fallopian tubes, uterus and vagina, while the
Wolffian ducts form the epididymis, ductus
deferens and seminal vesicles. The Sertoli
cells of the fetal testes produce anti-Müllerian
hormone (AMH, also known as Müllerian
inhibitory substance, MIS), which is a glyco-
protein related to the TGFβ family of pep-
tides. AMH acts locally to induce regression
of the Müllerian ducts and to inhibit the
expression of aromatase, but is not required
for testis determination (see also Section
4.2 for information on sexual development in
birds). The development of male external
genitalia is dependent on androgens pro-
duced by the testis. In the absence of andro-
gens, the female phenotype develops.
Testosterone is converted to the ultimate
androgen, dihydrotestosterone (DHT), by the
5α-reductase enzyme to stimulate the differ-
entiation of male genitalia. In addition to the
androgenic effects of testosterone and DHT,
these steroids also produce anabolic effects
on various tissues (see Section 3.2).
Differentiation of the brain
The undifferentiated mammalian brain is
inherently female, but androgens act on the
brain to programme male behaviour and
activity of the hypothalamus in controlling
pituitary function. Sexual differentiation is a
permanent change due to gonadal steroids,
which alters the sensitivity of a behaviour to
activation by sex steroids later in life. Sexual
differentiation of behaviour includes both
masculinization, which is the development of
male behaviours such as mounting and copu-
lation, and defeminization, which is the loss
of sexual receptive behaviour, lordosis and
the surge of luteinizing hormone (LH) in
response to oestradiol. The release of pitu-
itary trophic hormones, such as soma-
totrophin and the gonadotrophins, is
pulsatile in females and more uniform or
tonic in males (see Section 3.4).
The neonatal testis produces androgens
that act at a critical time in development to
programme or ‘imprint’ a male pattern of
function in the hypothalamus. This critical
period, which is species specific, may be
related to the stage of neuronal development
in the hypothalamus and can be affected by
thyroid hormones. Generally speaking, in
animals with longer gestation periods that
are more developed at birth, the critical peri-
od occurs prenatally, while for those with
shorter gestation periods that are less mature
at birth the critical period extends into the
early postnatal period. The sexual dimorphic
development of the brain results in perma-
nent differences in ‘hard wiring’ of the brain.
This includes differences in neuronal growth,
cell death, synthesis of neurotransmitters, the
synaptic connections of nerve cells, and in the
size of particular regions, such as the sexual-
ly dimorphic nucleus of the preoptic area
(POA). The POA is involved in regulating the
release of gonadotrophins due to feedback
from oestrogen and progesterone.
The effect of androgens on the differenti-
ation of the hypothalamus actually occurs via
oestrogens, which are synthesized from
testosterone by the aromatase enzyme in the
brain (see Section 1.2). The administration of
dihydrotestosterone, which cannot be aroma-
tized, does not masculinize the brain; howev-
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er, exogenous oestrogens will have this effect.
The fetal female brain is protected from the
minor levels of circulating oestrogens by the
fetoneonatal oestrogen binding protein
(FEBP) that is present in high levels in the cir-
culation. FEBP has a high specific binding
affinity for oestrogen and prevents it from
reaching the brain. Synthetic oestrogens that
have a low affinity for FEBP will also mas-
culinize the brain. In birds, oestrogen results
in a female pattern of brain differentiation,
while androgens are important in the control
of song in male birds. While oestrogens are
required for ovary development in non-
mammalian vertebrates, they are not
required for the initial differentiation of the
reproductive tract in mammals. 
The development of a number of other
tissues is also sexually dimorphic. For exam-
ple, there are marked sex differences in
steroid metabolism in the liver, and this can
affect the metabolism and clearance of drugs,
hormones and xenobiotics. In rats, the pat-
tern of steroid metabolism in the liver is reg-
ulated by the pattern of growth hormone
secretion from the pituitary, and removal of
the pituitary results in a male pattern of
steroid metabolism. The pattern of growth
hormone secretion is due to imprinting of the
hypothalamus by exposure to androgens
during neonatal life. A pulsatile pattern of
growth hormone release occurs in male rats
and can be mimicked by intermittent injec-
tions, while a more constant release of
growth hormone occurs in females and can
be mimicked by a constant infusion tech-
nique. Growth hormone regulates the expres-
sion of various steroid metabolizing
cytochrome P450 (CYP) genes in the liver, by
a mechanism that does not appear to involve
IGF-I. For more information, see the article by
Gustafsson (1994) and other articles in the
book by Short and Balaban (1994).
Sex differentiation in cattle, sheep and
pigs
Sexual differentiation occurs prenatally in
sheep and cattle, but is completed postnatal-
ly in swine. The pattern of secretion of testic-
ular steroids differs among cattle, sheep and
swine. Boars have three periods of elevated
steroids during development, while rams
and bulls have only two. 
Differentiation of the gonads in cattle
occurs from day 45 to day 70 of gestation.
Female fetuses that are treated with exoge-
nous testosterone show masculinization of
the gonads. Sexual differentiation of the brain
in cattle occurs after day 60 of gestation, as
treatment with exogenous testosterone before
this sensitive period does not affect brain
function later in development. Steroid syn-
thesis in female ovaries is low from day 70 to
day 85, while levels of androstenedione are
high in male fetuses until day 100, thus pro-
viding steroid precursors for male program-
ming of the hypothalamus.
Testosterone production by the fetal
testis in sheep increases from day 35 of gesta-
tion to a peak at day 70. Masculinization of
the gonads occurs from day 35 to day 45,
while male differentiation of the brain occurs
from day 50 to day 80. The reduced steroid
production by the ovary from day 45 to day
80 protects the female brain from masculin-
ization. Male lambs need additional exposure
to sex steroids during the critical period from
4 to 8 weeks after birth in order for male sex-
ual differentiation to be completed. 
Boars have three periods of enhanced
testicular development. Levels of testos-
terone are increased from day 35 to day 40 of
gestation and differentiation of the gonads is
complete by day 45. The second period
occurs shortly after birth, when the number
of Leydig cells increases. During this early
postnatal period, the testis is actively produ-
cing steroids due to a lack of negative feed-
back control of steroids on LH secretion in
males at this time. The third period of testic-
ular development occurs at puberty when
spermatogenesis occurs. Boars castrated
within the first 2 months after birth show
female behaviours after treatment with
oestrogen as adults, including receptivity to
mature boars. However, males castrated after
6 months of age show little female behaviour
after oestrogen treatment. This suggests that
male programming of the brain in boars
occurs during the prepubertal period at 3–5
months of age. 
Over 90% of female twins from mixed-
sex pregnancies in cattle are freemartins and
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the syndrome is also known in goats, sheep
and pigs. A freemartin is a sterile XX/XY
chimera produced from a female twin that
has a placenta that is fused with a male twin.
The blood systems of the embryos are joined
through vascular anastomoses in the fused
placenta of the twins. This allows the transfer
of AMH, androgens and possibly blood cells
from the male to the female fetus, interfering
with development of the ovaries and para-
mesonephric ducts. The gonads of the
freemartin range from modified ovaries to
testes-like structures that can be retained in
the abdomen. The hypothalamus is also
masculinized by exposure to androgens and
the animal can display male patterns of
behaviour. 
The risk of freemartinism is greatly
increased in sheep with litters of four or more
lambs. Placental fusion occurs rarely in mice,
and a band of connective tissue separates the
two placentas and prevents the formation of
a freemartin. This may be a protective mech-
anism that has evolved in litter-bearing
species and may explain the very low inci-
dence of freemartins in pigs. For more infor-
mation on sex differentiation in cattle, sheep
and pigs, see the review by Ford and
D’Occhio (1989).
Sex-determining genes
The key sex-determining genes SRY (sex-
determining gene on Y) and SOX9 (SRY box)
have been identified in mammals. These
genes are involved in testis formation and in
the development of the male phenotype. In
the absence of the SRY gene, ovaries develop.
SRY is located on the short arm of the Y chro-
mosome and codes for a protein called the
testis-determining factor (TDF), which has an
80-amino-acid HMG (high-mobility group)
domain that can bind to and bend DNA. This
region also binds calmodulin (see Section 1.3)
and contains nuclear localization signals.
Mutations in the HMG domain are found in
some XY sex-reversed individuals. In mice,
the TDF also has a large glutamine-rich
repeat domain that is involved in transcrip-
tional activation. SRY is implicated in the dif-
ferentiation of Sertoli cells, the migration of
primordial germ cells from the mesonephros
to the genital ridges and the proliferation of
cells within the genital ridges. The exact role
of SRY in testis differentiation is not known,
but SRY is thought to trigger each of these
events, possibly by activating a secondary
gene, such as SOX9. 
SOX9 is up regulated in the genital
ridges of male embryos and down regulated
in females. The SOX9 protein has an HMG
domain and two transcription activation
domains and binds to the AMH promoter to
increase the expression of the AMH gene. The
expression of SOX9 may be reduced by the
anti-testis gene DAX1 (DSS-adrenal hypopla-
sia critical region of the X chromosome),
which is expressed more in females than in
males. Steroidogenic factor 1 (SF-1) also plays
a role in regulating SOX9 expression and in
the activation of AMH gene expression by
SOX9. In mammals, levels of SF-1 are main-
tained in males but not in females after
gonadal differentiation has begun. Since the
AMH gene is not required for testis differen-
tiation, SOX9 and SF-1 proteins must act on
other genes besides AMH during testis differ-
entiation. The DMRT1 (DM domain related
transcription factor 1) gene is related to sex-
determining genes in other species and is
expressed in the developing testis in XY
males. It is also present on the chicken Z chro-
mosome and is a good candidate for a sex-
determining gene.
The WNT genes code for growth and dif-
ferentiation factors that appear to play a role
in the development of the ovaries and
oocytes. WNT-4 may act as a suppressor of
Leydig cell function in females and is neces-
sary for the formation of Müllerian ducts.
WNT-4-deficient females show a partial sex
reversal. WNT-7α is involved in the further
development of the Müllerian ducts to form
the oviduct and uterus. For more information
on genes that affect sex differentiation, see
the reviews by Haqq and Donahoe (1998),
Heikkila et al. (2001) and Koopman et al.
(2001).
Regulation of meiosis in germ cells
Male gametes, or spermatozoa, are produced
from a continuously replenishing population
of spermatogonia. Meiosis begins in male
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germ cells at puberty and continues through-
out the reproductive life of the animal. This
ensures an abundant supply of male gametes
for fertilization. In contrast, the process of fol-
liculogenesis in females produces only a
restricted number of oocytes, with meiosis
occurring during specific stages of develop-
ment. The fetal ovary contains all the avail-
able oocytes at birth, as a pool of primordial
follicles that are arrested in the late prophase
or diplotene stage of meiosis. These follicles
begin to grow again as the female nears
puberty and ovulation begins. An under-
standing of the factors that regulate meiosis
in germ cells could lead to applications for
controlling fertility.
During development of the gonads, the
fate of the germ cells depends on the sur-
rounding cells in the tissue. Oocytes in the
cortex of the developing ovary are the first to
reach the diplotene stage and be enclosed in
follicles. In the testis, the prespermatogonia
are enclosed in testicular cords when the
testis differentiates, and meiosis does not
begin until puberty. Meiosis in both sexes is
thought to be triggered by meiosis activating
substance (MAS), and to be prevented within
the testicular cords by meiosis preventing
substance (MPS). MAS is found in preovula-
tory follicular fluid and in adult testis, and
can activate meiosis in both male and female
germ cells and across various species
(humans, cattle, mice). MAS has been identi-
fied as two steroids in the cholesterol biosyn-
thesis pathway (Fig. 5.1), namely
4,4-dimethyl-5α-cholest-8,24-diene-3β-ol and
4,4-dimethyl-5α-cholest-8,14,24-triene-3β-ol.
When oocytes surrounded by cumulus cells
are treated with FSH, MAS is produced by
the cumulus cells and acts in a paracrine
manner to stimulate meiosis in the oocyte.
Growth differentiation factor 9 (GDF-9),
a member of the TGFβ family, is an oocyte-
specific factor made throughout folliculogen-
esis. GDF-9 is required for the development
of follicles but not for oocyte growth and dif-
ferentiation in mice.
It may be possible to control fertility
with MAS analogues. These compounds
should not affect the normal synthesis or
actions of steroid hormones. MAS agonists
would be expected to increase the production
of spermatogonia and the maturation of
oocytes, while MAS antagonists would act as
contraceptive agents. Inhibition of the 14α-
reductase or stimulation of 14α-demethylase
(CYP51) would increase levels of MAS in tis-
sues. For more information, see the reviews
by Byskov et al. (1998) and Albertini and
Carabatsos (1998).
Regulation of the oestrous cycle 
In this section, the natural mechanisms regu-
lating the oestrous cycle are presented. This
information is expanded in a later section that
describes methods for manipulating the cycle.
Reproductive performance in dairy cattle
has decreased with increasing milk produc-
tion in dairy herds. Information on factors
affecting the development of follicles, oestrous
behaviour, ovulation and corpus luteum
development and regression may be used to
devise methods for improved reproductive
performance. In dairy cattle, the goal is to
manipulate the reproductive cycle to maxi-
mize milk production. In beef cattle, the goal is
to maximize the number of calves produced
by rebreeding the female within a set interval.
The production of one calf per year for dairy
and beef cows is considered optimal. Similar
optimal goals for sows and ewes would be 30
piglets or two lambs per year, respectively.
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Fig. 5.1. Cholesterol biosynthesis pathway and
formation of meiosis activating substance (MAS)
(Byskov et al., 1998).
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Overview of the oestrous cycle
In the absence of pregnancy, the mature
female undergoes a continuous series of
reproductive cycles (Fig. 5.2) in which a
group of ovarian follicles mature (follicular
phase), the female becomes receptive to mat-
ing (oestrus or heat), and the dominant folli-
cle ovulates and a corpus luteum (CL) is
formed (luteal phase). The number of follicles
ovulated and the CL formed is a characteris-
tic of a species or sometimes a strain within a
species. If fertilization of the egg and implan-
tation of the embryo does not occur, the CL
regresses (luteolysis) and the cycle repeats
itself. The cycle lasts for approximately 21
days for cattle, pigs and goats, from 19–25
days for horses and 16–17 days for sheep.
Follicular development
The maturation of ovarian follicles is driven
by the gonadotrophic hormones luteinizing
hormone (LH) and follicle stimulating hor-
mone (FSH) that are released from the anteri-
or pituitary (Fig. 5.3). The release of the
gonadotrophic hormones is driven by
gonadotrophin releasing hormone (GnRH)
produced by the hypothalamus. GnRH is
delivered to the anterior pituitary via the
hypothalamic–hypophyseal portal blood ves-
sels (see Section 1.4). Both GnRH and the
gonadotrophins are released in a pulsatile
manner, with the pulse frequency and ampli-
tude dramatically affecting biological activi-
ty. Variations in the frequency of pulsatile
GnRH release have differential effects on LH
and FSH production. Many external factors
affect the activity of the pulse generator in the
central nervous system and thus affect the
activity of the reproductive system. The fac-
tors include nutrition, stress, suckling, pres-
ence of males, season and visual and
olfactory cues.
LH and FSH are glycoprotein hormones
that are each comprised of two peptide
chains, a common α-chain of 90 amino acids
and a β-chain that is hormone specific. Pig
LH-β has 119 amino acids and pig FSH-β has
107 amino acids. The gonadotrophins have
multiple roles, including controlling the
development of ovarian follicles, ovulation,
and formation and function of the corpus
luteum, and regulating the production of
gonadal hormones. In the male, LH stimu-
lates steroidogenesis in Leydig cells and FSH
binds to Sertoli cells. Inhibin, activin and fol-
listatin (activin binding protein) are pro-
duced by the gonads and regulate the release
of FSH by the pituitary. Inhibin and activin
are members of the TGFβ family of polypep-
tides. Inhibin reduces the production of FSH,
while activin increases FSH production inde-
pendently of GnRH. Follistatins are a family
of monomeric glycoproteins that bind to
activin and prevent the stimulation of FSH
production. For more information on inhibin,
activin and follistatin, see Findlay (1993) and
for activin and its receptor, see Peng and
Mukai (2000).
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Fig. 5.2. Outline of the oestrous cycle.
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At birth, the mammalian ovary contains
a large number of primary follicles (about
500,000 in cows) that gradually grow and
mature as the animal matures. These primary
follicles consist of an oocyte surrounded by a
single layer of granulosa cells and interstitial
tissue, which keep the ovum suspended in the
first stage of meiotic division. As the follicle
grows, the oocyte increases in diameter and is
surrounded by a zona pellucida. The number
of layers of follicular cells also increases and a
second mass of theca cells develops. The vast
majority of follicles will undergo atresia after
maturation, since only a limited number of
ovulations occur (over a 15-year period a cow
can ovulate at most only 300 follicles). Growth
of the follicles up to 3 mm in diameter is inde-
pendent of FSH, while FSH is required for
growth of the follicles from 3 to 10 mm in
diameter. A group of follicles produce activin
and are ‘recruited’ to begin maturation due to
a transient increase in FSH. The size of this
group can vary from 50 follicles in pigs to
5–10 in cattle and 1–4 in horses. The granulosa
cells of the larger developing follicles produce
oestradiol, using androgens that are produced
by the theca cells. The granulosa cells of the
large developing follicles also produce inhi-
bin, while the other developing follicles pro-
duce follistatin, which together inhibit the
release of FSH from the pituitary.
IGF-I activity also increases as the folli-
cles develop, due to decreased levels of IGF-
binding proteins. IGF-I may play a more
important role in the growth of small follicles
to recruitment, rather than in the growth of
large follicles. Treatment with exogenous
somatotrophin increases IGF-I and the num-
ber of small follicles, and also increases the
number of corpora lutea in cattle and large
follicles in pigs. Somatotrophin acts both by
increasing cell proliferation and decreasing
apoptosis and atresia of follicles.
As FSH levels decline, one follicle (or
more in litter-bearing species such as pigs)
acquires LH receptors on its granulosa cells
and becomes the dominant follicle. Growth
of this dominant follicle to a preovulatory fol-
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Fig. 5.3. Hormonal regulation of the oestrous cycle.
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licle is dependent on pulses of LH. The
growth of the other subordinate follicles is
depressed due to the lack of FSH and they
undergo atresia. If there are insufficient pul-
ses of LH, the dominant follicle also under-
goes atresia, while a surge in LH results in its
ovulation. A new wave of follicular growth
(Fig. 5.4) occurs about every 10 days in cattle,
so there will be 2–3 follicular waves during
each oestrous cycle. Sheep have 3–4 waves,
goats have 4–5 waves and horses have 1–2
waves in each cycle. Waves of follicular
growth start before puberty and continue even
throughout most of pregnancy, although dur-
ing these times the follicles do not ovulate and
become atretic. There is apparently little evi-
dence for waves of follicular growth in pigs.
Prolificacy in sheep is due to large genet-
ic differences in ovulation rate among differ-
ent breeds of sheep. Increased ovulation in
the Booroola breed is due to a single gene,
while in the Finn and Romanov breeds,
increased ovulations are due to multiple
genes. Waves of follicular development occur
in all genotypes. The increased ovulation rate
in Finn ewes is due to an extended period of
follicular recruitment, which allows follicles
to be maintained from one wave to the next.
Oestrus and ovulation
The dominant follicle produces oestradiol,
which acts on the brain to induce oestrous
behaviour or ‘heat’. Oestradiol also stimu-
lates the production of oestradiol receptors in
the hypothalamus and pituitary. Oestradiol
then acts by positive feedback on the pitu-
itary to increase LH production, while re-
ducing FSH levels by negative feedback. This
leads to a surge in LH release that culminates
in rupture of the follicle and release of the
ovum (ovulation) and formation of the cor-
pus luteum (CL or yellow body) on the ovary. 
Luteal phase
The CL develops from the follicle after ovula-
tion and is present during a large part of the
oestrous cycle known as the luteal phase.
After ovulation, the theca cells degenerate
and the granulosa cells hypertrophy and
luteinize to form lutein cells. The lutein cells
produce progesterone, which inhibits GnRH
secretion by the hypothalamus and thereby
decreases pulsatile LH release. The CL grows
rapidly and progesterone production increa-
ses at the beginning of the cycle (days 3–12 in
the cow and days 2–8 in the ewe and sow)
and then remains constant until day 15–16,
when regression (luteolysis) begins unless
fertilization occurs. The presence of a func-
tional CL during the luteal phase of the cycle
prevents ovulation, and any follicles that
mature during the luteal phase will undergo
atresia (except in the mare). Elevated levels of
cortisol can also block or delay the preovula-
tory LH surge.
Oestrogen acts on the uterus to increase
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Fig. 5.4. Waves of follicular growth and development.
Follicle recruitment
Atretic follicles
Ovulation
occurs
Selection of
dominant follicle
chap05.qxd  10/10/03  7:49 AM  Page 161
the number of receptors for oestrogen and
oxytocin. If fertilization and implantation do
not occur, high levels of progesterone and
oxytocin from the ovary stimulate the uterus
to secrete prostaglandin F2α (PGF2α). PGF2α
causes regression of the CL by interfering
with LH action on the CL and increases the
production of oxytocin by the ovary. A new
follicular phase then begins as the follicles
mature to ovulation. For more information on
follicular development and reproductive
cycles in farm animals, see the reviews by
Wiltbank (1998) and Driancourt (2001).
Pregnancy
If fertilization occurs, the embryo implants in
the uterine endometrium and produces pro-
teins that prevent regression of the CL. A func-
tional CL is necessary for the maintenance of
pregnancy in all farm animals. For pigs, about
four embryos are required to sustain a preg-
nancy. In sheep, cattle and goats, a group of
antiluteolytic proteins are produced by the
conceptus. These were named trophoblast pro-
tein-1 (TP-1) and later renamed interferon-τ
(IFN-τ) due to the sequence similarity with
type-I interferon. IFN-τ decreases the produc-
tion of PGF2α by the uterus. The decrease in
PGF2α suppresses luteolysis, so the CL is main-
tained and continues to produce progesterone.
Progesterone is required for the mainten-
ance of pregnancy and is produced by the
ovary, placenta and adrenal gland. The rela-
tive importance of these sources depends on
the species and the stage of gestation.
Progestogens alter the ionic permeability of
the muscles of the myometrium to decrease
the excitability of the cells and they also serve
as precursors for the synthesis of other
steroids. The placenta secretes increasing
amounts of oestrogens during the second and
third trimesters. High levels of progesterone
and oestrogen reduce GnRH release from the
hypothalamus and LH release by the pituitary.
Supplementing with exogenous progesterone
may be useful in maintaining pregnancy.
Parturition
The increased production of corticosteroids
by the fetus signals the beginning of parturi-
tion, and reducing the production of cortisol
using corticotrophin releasing hormone
(CRH) receptor antagonists (see Section 6.3)
delays parturition. Increased levels of corti-
costeroids stimulate the production of oestro-
gens by the placenta. Oestrogens stimulate
the production of PGF2α by the uterus and
increase the number of oxytocin receptors in
the uterus. Oxytocin is released by the poste-
rior pituitary in response to the fetus entering
the birth canal. Oxytocin increases the pro-
duction of PGF2α and both hormones
increase contractions in the uterus. 
Puberty and seasonality
An animal reaches the puberty stage of sexu-
al maturation when it is able to display com-
plete sexual behaviour and produce and
release gametes. During the onset of puberty,
both the amplitude and frequency of LH
pulses from the pituitary increase because the
hypothalamic–pituitary axis becomes less
responsive to negative feedback from oestra-
diol. Regular oestrous cycles then begin in
females with the maturation of the hypothal-
amic–pituitary axis.
The onset of puberty is influenced pri-
marily by reaching a target age and weight,
although the age at puberty varies with the
breed, nutritional status and environmental
effects such as photoperiod and temperature.
Puberty occurs at around 6–7 months of age
in sheep, goats and pigs and at around 12
months of age in cattle.
There are seasonal effects on reproduc-
tive efficiency in cattle, but cattle are not con-
sidered to be true seasonal breeders. Season
plays a role in the induction of puberty in cat-
tle, with heifers born in the autumn reaching
puberty before those born in the spring.
Animals born in the autumn are from 6–12
months of age when spring arrives, and the
increased photoperiod during the spring
stimulates the hypothalamic–pituitary–ovari-
an axis. Seasonal differences in photoperiod
can affect the period of postpartum anoestrus
by 10–35 days. Cows calving in the period of
lengthening photoperiod from late spring to
early autumn have a shorter period of
anoestrus than animals that calve in the win-
ter, when the photoperiod is decreasing.
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The domestic pig is capable of producing
piglets throughout the year, although there is
reduced fertility in the late summer and early
autumn. During this time, the seasonal
breeding European wild boar is in seasonal
anoestrus. Seasonal infertility results in a
reduced farrowing rate, delayed puberty in
gilts and a prolonged weaning to oestrus
interval.
True seasonal breeders include sheep,
goats and horses, as well as buffaloes, which
are important in Asia, and caribou and rein-
deer, which are raised in northern regions.
Sheep, goats and deer are short-day breeders,
with increased reproductive activity during
the shorter days in the autumn, while horses
are long-day breeders, with increased repro-
ductive activity during the longer days
in the summer. Seasonal differences in
anoestrus in wild species allow the birth of
young when food is abundant and survival
of the young is more likely. During the anoe-
strous period, low levels of oestradiol inhibit
the secretion of LH from the pituitary. The
development of follicles can continue in some
species during the period of anoestrus, but
the levels of LH are insufficient for the final
stages of follicular development. In other sea-
sonal breeders, follicular development ceases
during the anoestrous period. Testis size and
sperm production is also reduced in rams
during the non-breeding season. Season
affects the time to reach puberty in sheep,
with ewe lambs born in the autumn not
showing oestrus until after the summer
anoestrus.
During the breeding season, the negative
feedback of oestradiol on LH secretion is
reduced. The change in photoperiod increa-
ses LH pulse frequency, and FSH levels
increase to stimulate the production and mat-
uration of large, active follicles. Eventually, a
dominant follicle develops and ovulation
occurs. The first oestrus that occurs in mares
during the spring transition period after the
winter anoestrus is typically erratic and long
in duration and it is difficult to determine the
time of ovulation.
Seasonal differences in photoperiod
are detected by the pineal gland, which
receives light impulses from the retina of the
eye by way of the optic nerve. The pineal
gland releases melatonin (N-acetyl-5-
methoxytryptamine, Fig. 5.5) during periods
of darkness, but not during light periods, and
the pattern of melatonin release regulates the
pulsatile release of GnRH from the hypothal-
amus. In this way, the pattern of melatonin
release regulates seasonal rhythms in both
short- and long-day breeders, with increased
melatonin inhibiting GnRH release in long-
day breeders and stimulating GnRH release
in short-day breeders. Melatonin does not act
directly on the GnRH neurones, but acts indi-
rectly through other neurones that finally
synapse on the GnRH neurones. Melatonin
affects the negative feedback of steroids on
GnRH secretion. For more information on
melatonin and its effects, see the reviews by
Malpaux et al. (1999) and Zawilska and
Nowak (1999).
Regulation of LH production
Dopamine is involved in the negative feed-
back of oestrogen on neurones that produce
GnRH (Fig. 5.6), and injection of dopamine
antagonists (pimozide, domperidone, per-
phenazine, sulpiride) increases LH secretion
in seasonally anoestrous ewes and mares.
Opioids, such as β-endorphin, are also
involved in the reduced gonadotrophin
secretion in seasonally anoestrous mares,
and administration of the opioid antagon-
ist naloxone advances the first ovulation
of the year. Opioids are also thought to
reduce the production of GnRH in cycling
animals following ovulation, while gluta-
mate, nitric oxide (NO), carbon monoxide
and neuropeptide Y stimulate neurones that
produce GnRH.
NO is a gaseous chemical messenger that
acts locally in tissues and is involved in vas-
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Fig. 5.5. Structure of melatonin.
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cular relaxation, activation of the immune
system, platelet function and as a neurotrans-
mitter. NO is synthesized from arginine by
the calcium-sensitive enzyme, nitric oxide
synthase (NOS). NOS exists in a number of
different tissue-specific isoforms, including a
neuronal nNOS, an inducible iNOS in
immune cells and endothelial eNOS. NO is
involved in the LH surge mechanism and
also acts in the ovary to affect steroidogene-
sis, ovulation and luteolysis. NO is produced
by nNOS in specific neurones and diffuses to
adjacent GnRH neurones. In the GnRH neu-
rones, NO activates soluble guanylate cyclase
to increase levels of cGMP, and cyclooxyge-
nase to increase synthesis of prostaglandins
(PGE2α), which leads to increased release of
GnRH. Leptin acts via increased NO in the
hypothalamus and pituitary to increase
release of LH. Glutamate and noradrenaline
(norepinephrine) neurones also stimulate NO
production. In the ovary, the activity of NOS
increases during the preovulatory LH surge,
stimulating prostaglandin production and
the inflammatory process at ovulation. For
more information, see the review by
Dhandapani and Brann (2000).
Regulation of steroidogenesis
Primarily, LH and FSH regulate the produc-
tion of steroid hormones by ovarian cells,
although somatotrophin also plays an impor-
tant role. Somatotrophin may act by potenti-
ating the effects of gonadotrophins through
upregulation of gonadotrophin receptors.
Somatotrophin increases the synthesis of
some steroidogenic enzymes during the fol-
licular and luteal phases to increase the secre-
tion of oestradiol and progesterone.
Somatotrophin increases the synthesis of
steroid acute regulatory protein (StAR),
which is responsible for translocating choles-
terol into the mitochondria. It also increases
the synthesis of cytochrome P450scc
(CYP11A), which catalyses the side-chain
cleavage step of cholesterol to form preg-
nenolone; CYP17, which converts pregnen-
olone and progesterone to androgens; and
aromatase (CYP19, CYParom), which con-
verts testosterone to oestrogen. These effects
are mediated in part by increased production
of IGF-I and in part by direct action of so-
matotrophin. Somatotrophin can be pro-
duced by ovarian tissue, to act locally, as well
as by the pituitary.
Reducing the enterohepatic circulation
can decrease levels of steroid hormones.
Steroid hormones are metabolized in the liver
and eliminated in the bile as conjugates with
sulphate or glucuronic acid (see Section 1.2).
These conjugates can be removed by bacter-
ial metabolism in the intestine and the free
steroids reabsorbed into the circulation.
Increasing the liver metabolism of steroids,
by treating with inducers of cytochrome
P450, such as phenobarbital, or decreasing
the absorption of steroids from the intestine,
using binding agents or mineral oil, will
increase the elimination of steroids and lower
plasma steroid levels.
Manipulation of the oestrous cycle
During the normal reproductive cycle, a
group of ovarian follicles matures during the
follicular phase, the female becomes recep-
tive to mating during oestrus, the dominant
follicle ovulates and a corpus luteum (CL) is
formed during the luteal phase. The repro-
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ductive cycle can be manipulated in a num-
ber of ways to improve reproductive efficien-
cy (Fig. 5.7). In the cycling female, luteolysis
can be induced, oestrus and ovulation can be
induced or regulated, and the number of fol-
licles that ovulate can be increased. The preg-
nant female can be treated to either maintain
pregnancy or to induce parturition. The non-
cycling female can be treated to induce
cycling, as in inducing puberty and ending
seasonal anoestrus. For more information,
see Wright and Malmo (1992).
Hormone preparations for manipulating
reproduction
A number of hormone preparations are com-
mercially available for the manipulation of
fertility. This includes GnRH analogues,
gonadotrophin preparations, synthetic
progestogens, oestrogens, corticosteroid, and
prostaglandins. In the United States, only
GnRH and its analogues and PGF2α and its
analogues are approved for use on lactating
dairy cows, although other hormonal treat-
ments can be used in heifers and beef cattle.
The commercially available GnRH and
gonadotrophin preparations are summarized
in Table 5.1. Natural GnRH is a decapeptide
(5-oxo-Pro-His-Trp-Ser-Tyr-Gly-Leu-Arg-
Pro-Gly), also known as gonadorelin. Potent
analogues with higher receptor-binding
affinities and longer half-lives include
deslorelin ([D-Trp6]-GnRH) and buserelin
([D-Ser(tBu)6, Pro9 NEt]-GnRH). Treatment
with 2.5 mg of GnRH IV produces pulses of
LH, while increasing the dose to 250 µg pro-
duces a surge in LH release that can cause
ovulation of mature follicles.
Pregnant mare serum gonadotrophin
(PMSG), also known as equine chorionic
gonadotrophin (eCG), has primarily long-
acting FSH activity, but also some LH
activity, and is used for oestrus induction and
superovulation in cows and sheep. A number
of FSH preparations of pituitary origin are
available. Human chorionic gonadotrophin,
isolated from the urine of pregnant women,
has LH activity and is used to induce ovula-
tion of mature follicles. LH from pituitary
origin is also available. PG600 is a combina-
tion of PMSG and hCG that is used for
puberty induction in gilts.
The commercially available progesto-
gens, oestrogens and corticoids are summa-
rized in Table 5.2 and the structures of orally
active progestogens are given in Fig. 5.8. The
main progestogen is progesterone, which
primes the brain for oestrous behaviour after
oestrogen exposure, suppresses the secretion
of GnRH and is required for the maintenance
of pregnancy. Progestogens are used in treat-
ment programmes to induce or synchronize
ovulation. Pretreatment with progestogens is
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Fig. 5.7. Opportunities for manipulation of the oestrous cycle.
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necessary for the development of LH recep-
tors in preovulatory follicles and for normal
luteal function after ovulation is induced
with GnRH or LH.
Synthetic progestogens that can be given
orally include melengestrol acetate (MGA), 6-
methyl-17-acetoxy-progesterone (MAP) and
6-chloro-8-dehydro-17-acetoxy-progesterone
(CAP). Subcutaneous implants of progesto-
gens, progesterone-releasing intravaginal
devices (PRIDs) and controlled internal drug
releasing devices (CIDRs) are popular meth-
ods for producing a sustained release of
progesterone over a 7–10 day period.
Intravaginal sponges containing MAP are
used in ewes. Altrenogest is used in mares
and fluorogestone acetate (FGA) is used to
induce oestrus in ewes.
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Table 5.1. GnRH and gonadotrophin preparations.
Biological name
Category Hormone or activity Commercial name and company
GnRH Gonadorelin Natural GnRH Cystorelin® (Elf Sanofi), Factrel®,
(Ayerst) and Fertagyl® (Intervet)
Deslorelin ([D-Trp6]-GnRH) Ovuplant® (Ayerst)
Buserelin ([D-Ser(tBu)6,
Pro9 NEt]-GnRH)
Nafarelin
GnRH antagonists Nal-Glu, Cetrorelix
Gonadotrophins PMSG/eCG Long-acting FSH Equinex® (Ayerst) and Folligon®
activity, some LH (Intervet)
activity
Pituitary FSH FSH-P® (Schering) and Folltropin-v®
(Vetrapharm), Ovagen® (ICP),
NIH-FSH-S8®
hCG LH activity Chorulon® (Intervet)
Lutropin-V Pituitary LH Lutropin-V® (Vetrepharm)
PMSG and hCG PG600® (Intervet)
combination
Table 5.2. Progestogens, oestrogens and corticoids.
Biological name
Category Hormone or activity Commercial name and company
Progestogens Orally active MGA, MAP (Provera), CAP,
progestogens Altrenogest® (Regu-Mate® from
Hoechst), fluorogestone acetate,
Levonorgestrel®, Desogestrol®
Norgestomet Progestogen implant Synchro-mate-B® (Ceva laboratories)
Oestrogen Long-acting oestrogen ECP (Upjohn)
Corticosteroids Flumethasone, Short-acting analogues
dexamethasone
Dexamethasone Long-acting analogues
trimethylacetate,
triamcinolone acetonide
MGA, melengestrol acetate; MAP, 6-methyl-17-acetoxy-progesterone; CAP, 6-chloro-8-dehydro-
17-acetoxy-progesterone; ECP, oestradiol cypionate.
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Oestrogens are luteolytic and are given
before progestogen treatment in programmes
to synchronize oestrus. Synthetic oestrogens
are available that are metabolized more slow-
ly than oestradiol. Corticosteroids can be
used for induction of parturition. Short-
acting analogues include flumethasone and
dexamethasone, and long-acting forms
include dexamethasone trimethylacetate,
triamcinolone acetonide and suspensions of
flumethasone or betamethasone (Fig. 5.9).
Several steroid hormone antagonists
have been developed (Table 5.3). Steroid hor-
mone antagonists bind to the normal ligand-
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Fig. 5.8. Structures of some orally active progestogens.
Table 5.3. Hormone antagonists.
Biological name Commercial name
Category Hormone or activity and company
Antiprogestogen Registered for veterinary use Aglepristone® (Virbac)
Onapristone
(ZK98299)
Aglepristone
(RU46534)
Oestrogen Tamoxifen, Type I oestrogen antagonists with mixed
antagonists clomifene antagonist–agonist effects
Type II anti-oestrogens with no agonist ICI 164,384,
effects ICI 182,780
Antiandrogens Cyproterone acetate, flutamide
Norgestomet
Altrenogest17-Acetoxy-6-methylprogesterone (MAP)
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binding domain of a receptor, but they induce
a different conformation of the receptor
which results in decreased hormone-depend-
ent gene expression. Antiprogestogens (Fig.
5.10) include mifepristone, aglepristone and
onapristone; the binding affinity varies with
species and tissue type. The hydrophobic
side-chain at C17 is thought to be responsible
for high-affinity binding to the receptor,
while the additional side-group at C11 causes
a change in conformation of the receptor that
inhibits the activity. Antiprogestogens can be
used to prevent implantation of the fertilized
ovum, to cause resorption or abortion of
established pregnancies or to hasten parturi-
tion at the end of pregnancy.
Anti-oestrogens and anti-androgens
(Fig. 5.11) are used to treat hormonal-respon-
sive cancers in humans, such as breast and
prostate cancer. Tamoxifen and clomiphene
have mixed antagonist–agonist effects,
depending on the species and tissue type.
For example, in humans tamoxifen acts
as an anti-oestrogen in the mammary gland
and an oestrogen agonist in the uterus.
Type II anti-oestrogens include ICI 164,384
and ICI 182,780, which are 7α-alkyl-amide
analogues and do not have oestrogen agonist
activity. 
Anti-androgens, such as cyproterone
acetate and flutamide, inhibit the develop-
ment of secondary sex glands in laboratory
animals and male sexual activity in some
species. Daily treatment with cyproterone
acetate has been shown to prevent taint in
boars (see Section 3.3). For more information
on steroid hormone antagonists, see
Hoffmann and Schuler (2000). 
Prostaglandin F2α and its analogues
(Table 5.4 and Fig. 5.12) are used for their
luteolytic action (regression of the CL) or
stimulation of the myometrium to induce
parturition. This includes PGF2α itself, avail-
able as dinoprost, as well as a number of
synthetic prostaglandins. Synthetic pros-
taglandins have fewer side-effects, such as
sweating and abdominal cramps, than
PGF2α. Similarly, sows injected with PGF2α
to induce parturition have increased nest-
building behaviour, while if cloprostenol is
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Fig. 5.10. Structures of some synthetic antiprogestogens.
Fig. 5.11. Structures of some oestrogen and androgen antagonists.
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used to induce parturition, nest-building
behaviour does not increase.
Use of hormone agonists to control
fertility
GnRH analogues, progestins and androgens
can act synergistically by negative feedback
to reduce the release of gonadotrophins from
the pituitary and thereby reduce fertility. The
orally active progestogen melengestrol
acetate (MGA) is used for suppressing
oestrus and improving the rate of gain and
feed efficiency in heifers. GnRH agonists (e.g.
deslorelin, nafarelin, Table 5.1) have a higher
affinity for GnRH receptors and a longer half-
life in the circulation than GnRH itself.
Chronic treatment with GnRH agonists ini-
tially causes a dramatic increase in the release
of LH and FSH, followed by the down regu-
lation of GnRH receptors on pituitary
gonadotroph cells and inhibition of pulsatile
LH release. The lack of LH blocks ovulation,
but the ovary is still responsive to exogenous
LH. Implants of GnRH agonists have been
developed and can be used to prevent preg-
nancy in heifers under extensive manage-
ment systems for up to 10 months. The
procedure can also be used to control the time
of ovulation by injection of LH in animals
treated with GnRH agonist, which allows
artificial insemination (AI) at a fixed time.
This approach can be used to optimize ovula-
tion rate and recovery of embryos in multiple
ovulation and embryo-transfer protocols.
Bulls implanted with GnRH agonists
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Table 5.4. Prostaglandins.
Category Hormone Commercial name and company
PGF2α Dinoprost Lutalyse® (Upjohn)
Synthetic Cloprostenol Estrumate® (Mallinckrodt)
prostaglandins Fenoprostalene Bovilene® (Syntex)
Alphaprostol Alfavet® (Hoffman–La Roche)
Fluprostenol Equimate® (Miles)
Prostalene Synchrocept® (Syntex)
Fig. 5.12. Structures of some prostaglandin F2α analogues.
chap05.qxd  10/10/03  7:49 AM  Page 170
have higher levels of testosterone for the
duration of treatment. However, males of
other species, such as the pig, have decreased
levels of testosterone after treatment with
potent GnRH agonists, which overstimulate
the pituitary gland and shut down
gonadotrophin release. GnRH antagonists
(e.g. Nal-Glu and Cetrorelix, Table 5.1) have
been used to reduce sperm counts in humans,
but these peptides must be injected. Orally
active non-peptide GnRH antagonists have
also been developed and could be potentially
used as contraceptive agents in livestock or
captive animals.
Treatment of males with high levels of
androgens reduces the secretion of LH and
FSH by negative feedback on the pituitary,
and thus androgens can act as contraceptive
agents. For example, treatment of boars with
testosterone propionate is reported to
decrease the intensity of boar taint, and
testosterone analogues are being investigated
as male contraceptives in monkeys and
humans. Testosterone itself is rapidly degra-
ded by the liver and is thus not practical for
use as a contraceptive agent. Testosterone
esters, such as testosterone enanthate and
testosterone undeconate, are effective in
reducing sperm counts in humans. The
7α-methyl derivative of 19-nortestosterone,
which cannot be reduced by the 5α-reductase
enzyme, prevents dihydrotestosterone-like
effects such as prostate hyperplasia.
Combinations of testosterone esters and
progestins (medroxyprogesterone acetate,
Levonorgestrel® or Desogestrol®, Table 5.2)
are more effective contraceptive agents in
humans. Implants of the progestins MGA or
Levonorgestrel® are used to control fertility
in zoo mammals. The use of a ‘male pill’ con-
taining the anti-androgen cyproterone acetate
with testosterone undeconate has also been
studied in humans. For more information, see
Amory and Bremner (2000).
Transdermal patches can be used as an
alternative to weekly injections or daily oral
dosing for delivering combinations of andro-
gens and progestins for contraceptive pur-
poses, but can result in skin irritation. Other
complications from some steroid contracep-
tives include weight gain and a decrease in
serum HDL-cholesterol.
Methods for detection of oestrus
During oestrus or ‘heat’, the female will
accept a male, and during ‘standing heat’ will
stand to be mounted. In pigs, this lordosis
can be more easily detected by pushing for-
ward on the rear of the sow. The efficiency of
detection of oestrus in cattle can be less than
50%, so either methods to improve heat
detection, or strategies to control the time of
ovulation can be used to improve conception
rates.
OESTROUS BEHAVIOUR. Cows need adequate
space to display mounting behaviour, with
softer footing such as grass, dirt or straw.
Mounting behaviour is decreased on concrete
floors or floors that are too slippery or
too coarse. Cows with sore feet or legs have
less mounting activity. Cows that are them-
selves in heat or have recently been in heat
are most likely to mount a cow in heat. As the
number of cows in heat increases up to 3–4,
the number of mounts per cow increases
dramatically. 
The extent of mounting can be used as
an indicator of oestrus. The tail-head area
can be scarred and dirty from mounting by
herd mates. A more accurate measure is to
use brightly coloured enamel-based paint on
the tail-head and to cover the paint strip with
a contrasting colour of chalk. The extent of
cover of tail paint and chalk is scored using a
scale of 5, for no signs of oestrus and full
presence of paint and chalk, to 0 for standing
oestrus and absence of paint and chalk.
Pressure-activated heat mount detectors that
change colour from the weight of the mount-
ing animal can also be fixed to the tail-head.
There are more sophisticated pressure sen-
sors available that either display the frequen-
cy of mounting behaviour directly or send
signals to a remote device that records the
mounting behaviour. Vasectomized teaser
bulls, which can be fitted with a chin ball
marking harness, are particularly useful in
detecting heat when there are only a few
cows in heat. Cows or heifers treated with
testosterone or oestradiol can also be used as
an alternative to vasectomized bulls.
Standing heat can often be brief in dura-
tion and is not always observed since it
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occurs mostly in the early morning and late
evening, but various secondary signs can be
used to detect oestrus. During oestrus, vagi-
nal mucus is discharged that is clear and
stringy, and the vulva is reddened, but this
can be difficult to detect in cows. Blood stains
on the tail or vulva are indicative of a recent
heat. Cows in heat are restless, bellowing and
trailing other cows. Pedometers fixed to the
leg of the cow can be used to measure an
increase in walking activity as a measure of
oestrus. Feed intake and milk yield can also
decrease during oestrus. Changes in perineal
odours occur near oestrus and these can be
detected using trained sniffer dogs or poten-
tially using an ‘electronic nose’, which has
electronic sensors that change electrical char-
acteristics when exposed to volatile com-
pounds.
Follicular development can be estimated
by palpating the ovaries via the rectum or
using real-time ultrasound equipment with a
transducer placed in the rectum. Pregnancy
can be confirmed by this type of examination
at about 40 days after breeding. For more
information on the detection of oestrus in cat-
tle, see the review by Diskin and Sreenan
(2000).
MILK PROGESTERONE. The level of progesterone
in milk can be used to evaluate oestrus and
pregnancy in dairy cattle. The level of prog-
esterone rises slowly for the first 4–6 days
after ovulation and reaches a maximum at
days 10–17. It falls sharply at day 18–19 in
non-pregnant cows due to luteolysis, but
remains elevated in pregnant cows since the
CL continues to function. 
The accuracy of pregnancy diagnosis
using milk progesterone is only about 80%,
due to factors such as errors in oestrus detec-
tion, differences in cycle length, uterine dis-
ease, ovarian cysts and early embryonic
mortality. It can more reliably be used to deter-
mine if a cow is not pregnant. This involves
comparing progesterone levels in milk sam-
ples taken at the time of insemination to pro-
gesterone levels in milk at 21–24 days later. 
A high level of progesterone in milk can
confirm the lack of oestrus and that a cow
should not be inseminated. This can be partic-
ularly useful in high-producing cows or cows
under heat stress, when there are poor out-
ward signs of oestrus. A low progesterone
level suggests that the cow might be near
oestrus, but does not confirm that it is at the
optimum stage for insemination. Low proges-
terone levels can also be due to inactive
ovaries or the presence of follicular cysts.
Luteal cysts can be distinguished from follicu-
lar cysts by a high level of progesterone. The
presence of a functional CL can be confirmed
by accompanying high progesterone levels in
cows that will be used as embryo transfer
recipients.
Milk progesterone can be evaluated
using commercially available kits for on-farm
use and could potentially be measured with
an on-line system during milking in the
future.
Induction and synchronization of oestrus
Synchronization of oestrus involves manipu-
lating the ovarian cycle in order to mate the
female at a predetermined time. This allows
for greater management control of reproduc-
tion, improved reproductive efficiency and a
predetermined parturition time. Synchro-
nizing oestrus reduces the number of checks
required for determining when it is present
and increases the intensity of oestrus when a
group of cows are in oestrus at the same time.
Timed artificial insemination (AI) can also be
used on all cows in a dairy herd at the same
time when protocols designed to bring all
cows into oestrus within a narrow window of
time are used. Oestrus synchronization is
also necessary for embryo-transfer pro-
grammes. 
Effective methods for the synchroniza-
tion of oestrus are also necessary in order for
AI to be used in the beef cattle industry,
although AI is used to a much smaller extent
in beef cattle than in dairy cattle. This is
because of the extensive nature of beef cattle
operations, while dairying is an intensive
operation. Increased used of AI would allow
the use of superior genetics in the beef indus-
try, as has been done in the dairy industry for
some time. Fertility is the most important
trait for beef cattle, since beef breeders get
most of their income from calves born into
the herd.
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The fertility of the first oestrus after par-
turition (‘foal-heat’ in mares) is low, and the
timing of ovulation can be erratic, so animals
can be treated with luteolytic agents at this
time to induce regular oestrus. Oestrogen (as
oestradiol cypionate, Table 5.2) is also used to
induce oestrus in ‘jump’ mares used as
teasers for semen collection from stallions. 
Methods for oestrus synchronization
must produce a high proportion of females in
heat at a predetermined time, maintain high
rates of fertility and have no undesirable
side-effects. In addition, they should be easy
to perform and be of low cost. 
STRATEGIES FOR SYNCHRONIZING OESTRUS. The
presence of a functional CL during the luteal
phase of the cycle prevents ovulation.
Progesterone produced by the CL delays the
maturation of LH-dependent follicles and
primes the brain for oestrous behaviour. In
the absence of pregnancy, prostaglandin F2α
causes luteolysis and decreases progesterone
levels. This restores the LH pulse frequency
and amplitude, allowing the subsequent
development of the dominant follicle, lead-
ing to oestrus, ovulation and normal luteal
function. Treatment of animals having a func-
tional CL with prostaglandin F2α will thus
result in oestrus and ovulation a few days
thereafter. 
Schedules for oestrus synchronization
have been devised based on PGF2α, a combi-
nation of PGF2α and GnRH and a combina-
tion of progestins and PGF2α.
Prostaglandin F2α-based systems. Injection
of PGF2α will induce regression of the CL and
not adversely affect subsequent oestrous
cycles. However, PGF2α is not effective on
newly established CL, and cows injected on
days 1–5 of the oestrous cycle are non-
responsive. There are a number of waves of
follicular development in each oestrous cycle,
and cows injected on days 7 or 15 of the
oestrous cycle have a highly developed folli-
cle ready to ovulate after CL regression.
PGF2α treatment on days 7 or 15 will there-
fore induce oestrus 3 days after injection. A
practical approach (Fig. 5.13) is to inject
PGF2α twice, 14 days apart, so that the cows
will be responsive to PGF2α at least at the sec-
ond injection and come into oestrus shortly
thereafter. Alternatively, cows can be injected
at the beginning of 1 week and those that
come into oestrus later in the week are insem-
inated. The remaining cows are injected with
PGF2α at 14 days after the first injection and
then inseminated when oestrus is detected or
at the latest 4 days after the last injection of
PGF2α. However, not all cows respond to
PGF2α treatment, particularly before day 12
of the oestrous cycle. Improved synchroniza-
tion of oestrus is obtained with an additional
injection of PGF2α 2 weeks before the initial
injection. Cows are rebred 21 days after the
first insemination if they are seen to be in
oestrus. This decreases the number of days
open and the net cost per cow. However, this
process requires detection of oestrus, keeping
accurate records and the identification of
individual animals.
GnRH and the Ovsynch® protocol. Treatment
with PGF2α results in regression of the CL,
but does not synchronize the growth of folli-
cles or affect the preovulatory surge of LH.
Injection of GnRH at 7 days before treatment
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with PGF2α synchronizes follicular growth
and oestradiol secretion with luteolysis and
improves the timing of oestrous behaviour.
The Ovsynch® protocol (Fig. 5.14) utilizes
GnRH and PGF2α in a procedure that allows
for AI without oestrus detection in lactating
dairy cows. The protocol can be used at any
point in the oestrous cycle and is particularly
useful when the efficiency of oestrus detec-
tion is poor. The Ovsynch® protocol without
oestrus detection results in pregnancy rates
that are similar to multiple treatments with
PGF2α every 14 days and insemination at
detection of oestrus. In addition, the
Ovsynch® protocol reduces the number of
days postpartum to first insemination and
the number of days open.
The initial treatment with GnRH will
ovulate a dominant follicle if it is present and
initiate a new follicular wave, or a new follic-
ular wave may be occurring spontaneously.
The injection of PGF2α given 7 days later will
cause regression of the CL. A second injection
of GnRH is given 48 h later and will cause the
dominant follicle that has grown from the
first injection of GnRH to ovulate. Cows are
inseminated 16–20 h later so that capacitated
sperm are present at the time of ovulation. In
some cases, cows will be in oestrus shortly
after treatment with PGF2α and these cows
should be inseminated at that time.
The Ovsynch® protocol does not
improve conception rates in heifers com-
pared to insemination at detected oestrus.
However, the Ovsynch® protocol does
remove the difficulty of detecting oestrus and
therefore reduces the number of days open in
heat-stressed cows. It is also useful in treating
cows with either ovarian or follicular cysts
without identifying the type of cyst, since the
GnRH treatment will remove the follicular
cyst and PGF2α treatment will remove the
luteal cyst (see below). Cows with inactive
ovaries in which follicular development has
ceased do not respond well. 
Progestin-based systems. Treatment with a
progestin for 7 days before treatment with
PGF2α improves the synchronization and
detection of oestrus and conception rates.
Short-term exposure to progestins will also
induce the onset of oestrous cycles in a pro-
portion of anoestrous cows and heifers. Early
use of progestins for oestrus synchronization
utilized treatments in excess of 14 days.
These resulted in abnormal follicular growth
and decreased fertility, and were linked to
deleterious effects on sperm transport and
viability in the reproductive tract of ewes.
Short-term treatment with progestin of less
than 10 days’ duration is now used along
with a treatment to cause regression of the
CL, such as PGF2α or oestrogen (Fig. 5.15).
Progestin is normally administered to
dairy cows using implants (CIDR or PRID).
For beef cattle, norgestomet is available in the
Synchro-Mate-B® implant or melengestrol
acetate (MGA) is given in the feed (Table 5.2).
The implant is placed at the base of the ear
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Fig. 5.15. Progestin-based protocols for oestrus
synchronization.
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and an injection of oestradiol valerate and
norgestomet is given when the implant is
inserted. The CL regresses spontaneously
while the implant is present. The injection of
oestrogen and progestin is designed to cause
early regression of the CL in cows in the early
stage of the cycle. Alternatively, MGA can be
fed to beef cattle for 14 days, followed by an
injection of PGF2α 17 days later. The treat-
ment with MGA will initiate oestrus in anoe-
strous females and synchronize oestrus in
cyclic females, but will result in a low-fertility
oestrus in the 7 days after MGA is with-
drawn. The PGF2α treatment occurs in the lat-
ter part of the next oestrous cycle, which will
cause a high rate of CL regression and syn-
chronization of oestrus. This procedure
induces oestrus in about 80% of yearling
heifers and is used for this purpose.
However, since the protocol takes about 34
days to achieve synchronized oestrus, it can-
not be used with postpartum cows that
calved late in the season without affecting the
start of the new breeding season.
A number of protocols have been devel-
oped using progestins to induce puberty and
synchronize oestrus in beef heifers. A pro-
gestin treatment (norgestomet implant) can
be used between the GnRH treatment and the
PGF2α treatment (GnRH–P–PGF). A further
modification of an additional GnRH treat-
ment 48 h after the PGF2α treatment
(GnRH–P–PGF–GnRH) induces a final LH
surge and a highly synchronous time of
oestrus, which allows the use of timed AI
without oestrus detection. Another approach
uses an initial injection of oestrogen and a
progestin implant (CIDR) for 7–8 days, fol-
lowed by an injection of PGF2α when the
CIDR is removed and a second injection of
oestrogen 24–48 h later (E–CIDR–PGF–E).
The first oestrogen injection will cause regres-
sion of FSH-dependent follicles and the CIDR
implant with progestin induces turnover of
LH-dependent follicles. Once these follicles
become atretic, a new wave of follicular
development begins. The injection of PGF2α
will cause any CL present to regress, and the
final oestrogen injection will induce oestrus
and ovulation. The induction of puberty and
oestrus is more effective the closer the ani-
mals are to a naturally occurring oestrus.
Controlled breeding programmes result
in significant financial savings to dairy pro-
ducers. The additional costs for drugs and
labour are more than offset by the savings
from decreased labour for oestrus detection,
lower costs from fewer days open and fewer
replacement heifers needed. Producers can
also control the time of calving, to take
advantage of seasonal variations in pricing
and constraints to production. Beef cattle pro-
ducers can use controlled breeding pro-
grammes to induce puberty and synchronize
oestrus in heifers by the start of the breeding
season, so they will calve early and improve
lifetime production. For more information on
the manipulation of the oestrous cycle in
dairy and beef cattle, see the reviews by
Thatcher et al. (1998) and Day (1998).
Synchronization of oestrus in pigs can be
accomplished by treatment with progestogen
for 14–18 days (Altrenogest® in the feed,
Table 5.2) and then breeding at oestrus. 
Ewes during the breeding season can be
injected with PGF2α twice 9 days apart and
then treated with an intravaginal sponge im-
pregnated with MAP (Table 5.2) for 12 days.
Ewes will exhibit oestrus 48–72 h after the
removal of the sponge. In the non-breeding
season, PMSG treatment (Table 5.1) is also
necessary to induce ovulation.
Superovulation and embryo transfer
A number of in vitro techniques can be used
to improve reproductive efficiency and
increase the contribution of valuable females
to the gene pool. Large numbers of oocytes or
embryos can be collected from female donors
and transferred to recipient females.
Immature oocytes can be matured in vitro,
fertilized, grown to the blastocyst stage and
then transferred to recipient females.
Multiple ovulation and embryo transfer
(MOET) involves the recovery of multiple
embryos after superovulation and transfer of
the embryos to synchronized recipients of
lesser genetic merit. To induce superovula-
tion, FSH or PMSG is given in the middle of
the cycle (days 8–14 in cattle) to increase the
number of follicles that mature into domi-
nant follicles, and to reduce the regression of
follicles. A single injection of PMSG (which
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has a longer half-life than FSH), or twice-
daily injections of FSH for 2 days, is required.
This is followed by treatment with PGF2α on
day 3 to induce luteolysis, and then twice-
daily FSH injections are continued to induce
superovulation until day 4, when oestrus
occurs. Twice-daily inseminations are given,
starting 12 h from the start of oestrus. Sperm
transport can be reduced by superovulation,
particularly when PMSG is used, so insemi-
nations directly into the uterus can be used to
improve fertility. Embryos are collected by
flushing the uterus non-surgically at 6–8 days
after oestrus in cattle and horses, but surgical
recovery is used for pigs, sheep and goats.
Embryos are assessed for the stage of devel-
opment and for evidence of physical damage,
and good-quality embryos can then be trans-
ferred to recipients or frozen. Recipient ani-
mals should be checked for the presence of a
CL, since a CL is required to maintain the
pregnancy after transfer of the embryos.
The ovulation rate and number of trans-
ferable embryos can be improved by treat-
ment with anti-PMSG serum at oestrus or
after the LH surge has occurred. This sup-
presses the second wave of follicular devel-
opment and reduces the number of follicular
cysts. A low LH content in the FSH prepara-
tion is desirable, since LH interferes with fol-
licular development. The presence of a large
dominant follicle reduces the number of folli-
cles that will mature and ovulate in response
to exogenous gonadotrophins. There is also
the possibility that the animals will produce
antibodies against the non-homologous
gonadotrophins that are used for superovula-
tion, so that later treatments with
gonadotrophins will not be successful.
IN VITRO PRODUCTION OF EMBRYOS. Large num-
bers of embryos can also potentially be pro-
duced from immature oocytes that have not
yet committed to atresia. The pig ovary has
over 200,000 primordial follicles, while the
cow has about half that number. Oocytes can
be collected at slaughter, or by aspiration of
immature follicles from both mature and
immature females. This allows the produc-
tion of embryos from donors with poor fertil-
ity or those that do not respond to
superovulation. This is particularly useful for
the recovery of genetic material from slaugh-
tered animals. It also has potential for the
conservation of rare breeds. Oocytes can also
be recovered from young prepubertal
females, thus shortening the generation time
and increasing the number of potential
offspring from valuable individuals.
After recovery, the oocytes are matured and
fertilized in vitro and grown to the blastocyst
stage before freezing or transfer to a recipient
animal. 
The efficiency of blastocyst production
from in vitro production systems is highly
variable and lower than with oocytes recov-
ered after insemination. Blastocyst produc-
tion depends on the quality of the gametes
used and human technical skills. Culture con-
ditions are also important, and the optimum
culture conditions vary among different
species. Good-quality oocytes that are sur-
rounded by intact cumulus cells and have a
homogeneous-looking cytoplasm should be
used. In vitro maturation (IVM) of oocytes
includes both nuclear maturation, seen as the
development of a metaphase II spindle, and
cytoplasmic maturation, which allows the
formation of a male pronucleus after fertiliza-
tion. IVM has been performed using a num-
ber of different systems, including
co-culturing the oocytes with oviductal
epithelial cells or granulosa cells, or supple-
mentation of media with follicular or oviduc-
tal fluid. Defined culture media have also
been used, and are preferred since they
reduce the potential for contamination with
bacteria and viruses from cells in co-culture.
Adding gonadotrophins (LH and FSH) along
with epidermal growth factor (EGF) or IGF-I
to the maturation medium can stimulate
oocyte maturation in defined media. One-
third of porcine oocytes that are treated with
EGF (10 mg ml–1) develop to the blastocyst
stage after in vitro fertilization (IVF).
A major problem with IVF of porcine
oocytes is polyspermy, which occurs when
several sperm penetrate each oocyte and the
oocyte then fails to develop properly past the
blastocyst stage. This is rarely observed with
in vivo insemination prior to ovulation, since
there is a limited number of sperm arriving
simultaneously at the oocyte and the zona
pellucida effectively blocks the penetration of
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more than one sperm. The success of fertil-
ization is seen ultimately in cleavage of the
oocyte. Both fresh and frozen–thawed sperm
have been used for IVF in cattle and swine.
Sperm cells can be sorted to some degree into
separate pools of X- and Y-bearing sperm and
used to produce offspring of the desired sex.
Alternatively, a few cells can be removed
from an embryo and the sex can be deter-
mined using X- and Y-specific DNA probes
with PCR.
Embryos are a convenient and cost-
effective form for providing new genetics to
animal production systems. Since embryos
can be produced that are free of disease, they
are especially suitable for international trade.
Embryo recovery and transfer can also be
used to eliminate disease by repopulating
herds with uninfected animals. Embryos
that are recovered from infected animals can
be treated with trypsin and washed to
remove bacteria and viruses so they are free
of the disease, since the zona pellucida pro-
tects the embryo from infection. The embryos
are then transferred to clean individuals to
produce uninfected animals at birth. For
more information on embryo production and
transfer in cattle and pigs, see Marquant-
Leguienne and Humblot (1998) and Day
(2000).
Maintenance of pregnancy
The embryonic loss rate, which is the differ-
ence between the fertilization rate and birth
rate, is between 30 and 40% in cattle.
Embryonic loss is also the major factor affect-
ing litter size in pigs. The highest rate of
embryo loss occurs during the time of mater-
nal recognition of pregnancy. A single treat-
ment with PGF2α between 18 and 28 days
postpartum can improve uterine involution
and may reduce the number of services to
conception. The fertility and pregnancy rate
from oestrus induced by PGF2α is about 10%
higher than naturally occurring oestrus, pos-
sibly due to improved quality of the ova with
the shorter period of luteolysis.
Treatment with GnRH once between 11
and 13 days after insemination may delay
luteal regression or cause ovulation of the
dominant follicle in the next wave and form
an accessory CL. This will increase proges-
terone production and improve the rate of
implantation of the embryo and maternal
recognition of pregnancy. Treatment with
hCG on day 15 improves pregnancy in heat-
stressed cows but not normal cows. Direct
treatment with progestogens after insemina-
tion can also increase the secretory function
of the uterine endometrium and improve the
implantation of the embryo.
Pregnancy rates can be increased in
mares by delaying the postpartum oestrus.
This is accomplished using progestogen
treatment either alone or in combination with
oestrogen, starting immediately after foaling.
Administration of PGF2α can also be used to
induce the next oestrus after foal heat.
Early embryonic mortality is increased
with very poor body condition, high temper-
atures in the first week after mating and
severe stress.
Induction of abortion/parturition
Progesterone is required for the maintenance
of pregnancy and the CL, placenta and adren-
als produce the progesterone at different
times during pregnancy. In the mare and
ewe, progesterone is produced in the latter
half of pregnancy by the placenta, while in
the cow, sow and goat the CL persists
throughout pregnancy and produces proges-
terone. Parturition is the process of delivering
a fetus and placenta from a pregnant uterus.
It is triggered by the fetus, which releases
corticosteroids due to activation of the
fetal hypothalamic–pituitary–adrenal axis
as the fetus matures. The fetal corticoster-
oids increase oestrogen production and
decrease progesterone production by the
placenta, which in turn stimulates
prostaglandin production by the uterus.
Oestrogen also increases the number of oxy-
tocin receptors and sensitizes the uterine
myometrium for contractions. In CL-depend-
ent species, the prostaglandin causes regres-
sion of the CL and removes the source of
progesterone.
Treatment with corticosteroids can thus
induce parturition if a functional placenta
exists. Prostaglandin treatment is needed
to induce parturition when there is a non-
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functional placenta, as in the case of fetal
mummification.
Abortion is induced in animals entering
feedlots, after inappropriate matings and due
to pathologic pregnancy. Up to 5 months of
pregnancy, abortion is induced in cattle using
PGF2α, while combinations of PGF2α and cor-
ticosteroids are used late in gestation. Calves
born more than 3 weeks premature have poor
viability.
Feeding inhibitors of prostaglandin syn-
thase, such as aspirin or indomethacin, can
reduce the levels of prostaglandins. This
approach may be useful for inhibiting oestrus
or maintaining pregnancy. In postpartum
ewes, indomethacin treatment increased LH
pulse frequency and amplitude and resulted
in an early return to oestrus.
Oxytocin is also used to induce parturi-
tion, for the expulsion of a retained placenta
and the acceleration of uterine involution. It
is also used to induce contraction of the
myoepithelium cells in the mammary gland
and cause milk let down. Bromocryptine is
used to inhibit prolactin secretion and pre-
vent spurious lactation. 
Postpartum interval
There is normally a period of 30–76 days of
anoestrus before the first oestrus occurs post-
partum in cattle, with dairy cattle ovulating
sooner than beef cattle. Ovarian cycling can
be limited by inadequate LH pulse frequency,
so that follicles do not mature properly. There
can also be a decrease in the normal preovu-
latory LH surge from positive feedback by
oestradiol. The decreased LH production is
due to reduced function of the hypothala-
mus–pituitary axis. The first ovulation post-
partum often results in a CL that regresses
early and results in a short cycle of 8–10 days.
This may be due to the need for progesterone
priming of the follicles for normal CL func-
tion after ovulation. Progesterone priming of
the brain is also necessary for normal
oestrous behaviour that is induced by oestra-
diol. 
In order to shorten the period of anoe-
strous, the frequency of LH pulses has to be
increased so that the follicles will reach the
final stages of maturity. The presence of con-
tinuous low levels of progesterone, that do
not affect pulsatile LH release but prevent the
LH surge, results in large, persistent follicles
containing ageing oocytes. Other factors,
such as high blood cortisol levels, may also
block the LH surge. Persistent large follicles
can form ovarian cysts, which can be treated
by injection of GnRH. Luteal cysts that pro-
duce high levels of progesterone can also
form and can be treated by injection with
PGF2α. In addition to limitations on ovula-
tion, the uterus of the postpartum cow
requires 30–40 days to complete involution,
so cattle should not be bred before 60 days
after calving.
The duration of postpartum anoestrus is
affected by nutrition, suckling, seasonal fac-
tors and the presence of males. Some animals,
particularly seasonal breeders, are very non-
responsive to treatments designed to induce
the ovarian cycle and are said to be in ‘deep
anoestrus’. 
Suckling more than 2–3 times per day, or
increased frequency of milking, increases lev-
els of endogenous opioid peptides in the
brain. This decreases the production of
GnRH by the hypothalamus and the release
of LH by the pituitary. The decrease in LH
prevents the final maturation of the follicle to
the preovulatory stage and increases the
number of days to first oestrus and ovulation.
However, suckling also improves uterine
involution and increases the conception rate.
Sows need to nurse for about 10 days or they
will develop follicular cysts, persistent
oestrus and have poor uterine involution.
Removing the piglets or exposure to a boar
will stimulate follicular growth in sows.
Cystic ovarian disease
About 30% of postpartum cows develop
ovarian cysts, which are structures greater
than 2.5 cm in diameter that last more than 10
days and are follicular or luteal in origin.
Follicular cysts are more common than luteal
cysts and are associated with a high level of
production, reduced nutrient status, uterine
infections, increased age, stress and season,
with a higher incidence in the autumn and
winter. They are caused by inadequate LH
response to oestradiol and failure of ovula-
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tion and are associated with anoestrus post-
partum. Stress-induced release of ACTH and
corticosteroids can also reduce LH release
and cause cyst formation. 
High levels of progesterone in the blood
or milk can indicate the presence of luteal
cysts. Follicular cysts can be treated with
hCG or GnRH to induce luteinization of fol-
licular cells, and luteal cysts can be treated
with PGF2α to cause luteolysis.
Effects of nutrition
The nutrient (energy) balance of the animal is
the difference between the availability of
nutrients from body reserves and feed intake,
and the nutrient requirements of the animal
for lactation, metabolism, growth and activi-
ty. A reduced energy balance can delay
puberty and increase the period of postpar-
tum anoestrus. This may be signalled by a
low level of blood glucose, which increases
the negative feedback by oestradiol on GnRH
release by the hypothalamus and decreases
the level of LH. The level of IGF-I is also
decreased during negative energy balance,
which, together with decreased LH, con-
tributes to decreased follicular growth and
maturation. Poor nutrition results in a
reduced size of follicles and more rapid
turnover of the dominant follicle. Oestrous
cycles in mature cycling pigs can be disrupt-
ed in severe and prolonged feed restriction,
while less severe conditions will delay puber-
ty and increase the period of postpartum
anoestrus.
Undernutrition results in a decrease in
plasma levels of insulin, IGF-I and leptin, and
an increase in growth hormone. IGF-I acts
with the gonadotrophins to stimulate follicu-
lar development, and a low level of IGF-I in
follicular fluid is associated with a low ovula-
tion rate. Insulin stimulates nutrient uptake
and prevents apoptosis in granulosa cells,
reduces atresia of follicles and increases ovu-
lation rate. Leptin (see Section 3.8) may act to
signal the reproductive system that sufficient
body fat is present to support a pregnancy.
Leptin treatment has been shown to increase
sexual development and levels of LH and
FSH in male and female rodents. Levels of
leptin are correlated with size of the fetus,
and appropriate levels of leptin are required
for the maintenance of pregnancy.
Dairy cattle are normally in a period of
negative energy balance during the postpar-
tum transition period, when maximum milk
production is reached before maximum feed
intake has occurred. The time to first ovula-
tion postpartum is a function of the number
of days the cow is in the lowest energy bal-
ance; this averages about 33 days in Holsteins
in the USA. There is also a period of negative
energy balance in beef cattle, even though
milk production is much lower than in dairy
cattle. Improved feed intake or body condi-
tion score will stimulate puberty in young
animals and decrease the period of anoestrus
in older animals.
Correcting the negative energy balance
and improving body condition score will
reduce the period of anoestrus in transition
dairy cows. These factors contribute to an
increase in conception rates after 60 days
postpartum. Follicular growth is decreased in
lactating cows compared to dry cows.
Treatment with bST stimulates the growth of
smaller follicles, while feeding the calcium
salts of long-chain fatty acids stimulates
growth of the largest follicles. Feeding high-
energy diets and a high-quality protein also
shortens the time to first ovulation in transi-
tional mares that have a low amount of body
fat and low body condition score. For more
information on the effects of nutrition on
cycling in beef heifers, see Schillo et al. (1992)
and for pigs, see Prunier and Quesnel (2000).
Effects of stress
Seasonal periods of heat stress above 32°C
increase the length of the oestrous cycle and
can reduce plasma levels of oestradiol before
oestrus, and thereby decrease the intensity
and duration of oestrus. This lowers fertility
and oestrus detection rates. Injection of
GnRH at oestrus has been suggested as a
method to improve the LH surge and ovula-
tion rate. Progesterone production by the CL
is also decreased during heat stress. 
Elevated body temperature also increas-
es embryonic mortality. Heat stress decreases
feed intake, growth rate and milk production.
It can also lower libido and sperm quality in
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males, resulting in lower fertility. More subtle
changes in temperature may also play a role
in the timing of the circannual reproductive
rhythm of seasonal breeders. Bulls also show
seasonal effects on fertility, with improved
sperm production during long days and
decreased sperm production during high
temperatures. Other forms of generalized
stress (see Section 6.3) can also contribute to
the intensity of seasonal infertility.
Inducing puberty
Exposure to a male increases the pulsatile
release of LH and decreases the age at which
puberty is reached in cattle, sheep, goats and
pigs. The presence of a male also shortens the
period of anoestrus by acting on the hypo-
thalamus to reduce the negative feedback of
oestrogen on LH release. The ‘ram effect’ is
used to induce ovulation in ewes. Male sheep
and goats produce pheromones in sebaceous
glands that are released on the hair. Male pigs
release sex pheromones in the saliva that
induce puberty and cause oestrous females to
stand for mating. Further details are given in
Section 6.2. In addition to male pheromones,
visual, auditory and tactile cues are less
important components of the male effect on
stimulating female reproduction.
Growth hormone plays an important
role in sexual maturation and may accelerate
puberty by activating the LH pulse generator
or potentiating the action of androgens.
Advancing cyclicity in seasonal breeders
In seasonal breeders, such as sheep and hor-
ses, regular oestrous and ovulation cycles can
be induced at the beginning of the breeding
season. The official date of foals for each
breeding season is set as 1 January by many
breeding associations, so it is advantageous
to breed mares early in the year to have an
age advantage over foals born later in the
season. Increasing the photoperiod using
artificial lighting is used to induce oestrus in
mares. About 14–16 hours of light exposure
for 8–10 weeks is used, starting at the begin-
ning of December to induce oestrus by the
middle of February. Supplemental lighting is
given at the beginning and end of the natural
daylight. A 1–2-hour light period 9.5 h after
the beginning of the dark period has also
been suggested as a method to induce
oestrus, suggesting that this light-sensitive
period plays an important role in sensing cir-
cannual changes in photoperiod (see also reg-
ulation of egg production, Section 4.2).
Melatonin is involved in the regulation
of circadian rhythms, including the
sleep–wake cycles in humans. In the absence
of external signals, these rhythms would be
free running, but they are normally synchro-
nized to the endogenous melatonin and
photoperiod signals. Administration of
exogenous melatonin or inhibition of mela-
tonin synthesis by exposure to bright light
can be used to entrain these physiological
rhythms to new signals. This can be used to
treat sleep–wake disorders in workers on dif-
ferent shifts, from changes in time zone (jet
lag), in blind individuals who are unable to
perceive light and in elderly people with
insufficient melatonin production. In
amphibians, fish and some reptiles, mela-
tonin causes aggregation of melanin granules
in melanocytes, resulting in blanching of the
skin. Seasonal anoestrus can be reduced
using melatonin for short-day breeders or
increased lighting through artificial lighting
programmes for long-day breeders.
A decrease in thyroid hormones occurs
during seasonal anoestrus in ewes, but thy-
roid hormones do not seem to be involved in
seasonal anoestrus in mares. Melatonin also
inhibits prolactin release in ewes and admin-
istration of exogenous prolactin decreased
the time to first ovulation in seasonally anoe-
strous mares. 
Exogenous melatonin can be given to
ewes by injection or feeding to mimic the
effects of short days and stimulate gonadal
activity. Long treatment periods are needed
and a commercial implant of melatonin
(Regulin®, Schering Pty Ltd) is available.
Boluses of slow-release melatonin that
remain in the rumen for extended periods of
time can also be used.
Mares can be treated with progestogens
(injection of progesterone in oil or feeding
Altrenogest® for 10–15 days) to induce
oestrus. Progestogen treatment suppresses
LH release and may allow LH stores to
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increase in anoestrous mares, so that suffi-
cient LH will be released to induce ovulation
after progestogen treatment has ended. The
effects of progestogen treatment are additive
to the effects of artificial lighting in inducing
oestrus. Treatment with progestogens is more
effective in mares during the latter part of the
transition period when larger follicles are
present, compared to the early transition
period when there are only small follicles.
Oestradiol treatment can be used together
with the progestogen treatment, to further
reduce the variation in follicular develop-
ment and ovulation. Treatment with
dopamine antagonists (domperidone, 1.1 mg
kg–1 orally or sulpiride 0.5 mg kg–1 intramus-
cularly, see Fig. 5.6) reduces the negative
feedback on LH release and results in earlier
time of ovulation in mares, especially when
combined with light treatment. The period of
treatment is longer for mares that are in deep
anoestrus compared to mares in transition. 
There is an extended period of oestrus in
mares, with ovulation occurring from 1 to 10
days after oestrus begins. Oestrus can be
induced using PGF2α as described above for
cattle, but the time of ovulation is still vari-
able. The most effective method is treatment
with progestogen/oestradiol followed by
PGF2α to remove any persistent CL. Ovu-
lation of large preovulatory follicles (35 mm
in diameter) is then induced with hCG.
The GnRH analogue deslorelin (Table 5.1)
can also be used as an implant to shorten the
time to ovulation in mares. For more infor-
mation, see Pratt (1998) and Nagy and Daels
(2000).
Immunological control of reproduction
Immunization against inhibin increases ovu-
lation rate in sheep and horses by increasing
FSH levels. Immunization against oestradiol
or androstenedione can also be used in sheep
to increase the ovulation rate by removing
the negative feedback of gonadal steroids on
the hypothalamus and pituitary. A commer-
cial product (Fecundin®, Glaxo Animal
Health) uses a dextran adjuvant that can be
given as a single injection and produces a
moderate antibody response. Synchro-
nization of oestrus is not necessary, but oth-
erwise fertilization rates and embryo survival
rates can be decreased. In anoestrus ewes, fol-
licular development is stimulated and multi-
ple ovulations occur when the ewes are
exposed to a ram.
Immunization against GnRH produces a
form of non-surgical castration by neutraliz-
ing the effects of GnRH and inhibiting the
production of gonadotrophins and gonadal
steroids. This effect is temporary if passive
immunization is used. GnRH is available for
antibody binding while it is in the hypothala-
mic–pituitary portal blood vessels on its way
from the site of production in the hypothala-
mus to the anterior pituitary gland. In order
to generate antibodies, GnRH, or a GnRH
analogue, is coupled to a large molecule, such
as albumin, keyhole limpet haemocyanin
(KLH) or diphtheria or tetanus toxoid (see
Section 2.1). Adjuvants other than Freund’s
complete adjuvant are used commercially,
since Freund’s causes severe local inflamma-
tion at the injection site.
Immunization against GnRH in males
reduces testicular size and function and can
be used to control aggression, reduce the inci-
dence of male-associated odours and reduce
fertility. A commercially available vaccine
(Vaxstrate®), based on a carboxyl-GnRH ana-
logue coupled to ovalbumin that was
designed for beef heifers, is also effective in
male goats and sheep. Bull calves immunized
against GnRH had less carcass fat, increased
loin eye area and improved weight gain and
feed conversion efficiency compared to
steers. This is probably due to the increased
exposure to testicular steroids in immunized
calves compared to castrates. Immunized
lambs produced carcasses that were similar
to those of castrates but had similar back fat
to intact control lambs. Immunized bucks
and boars had decreased odour score but
similar carcass weights as controls. A tandem
repeat of GnRH linked to KLH produced a
more consistent immune response in boars.
The effects of immunocastration on carcass
composition depend on the vaccination pro-
tocol and age of the animal. Immunization
protocols have been developed that consis-
tently reduce boar taint and also do not
adversely affect the improved feed efficiency
of intact boars or the lean content of boar
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carcasses compared to that of castrates (see
Section 3.3). For more information on immu-
nization against GnRH in males, see
Thompson (2000).
The fertility of females can be reduced by
vaccination with a key target protein that per-
manently affects the reproductive integrity of
the ovary. The zona pellucida (ZP) is a glyco-
protein matrix surrounding the oocyte that
has receptor sites for sperm binding. If the ZP
is masked or altered, fertilization will not
occur. Vaccination with purified ZP glycopro-
teins produces antibodies that inhibit sperm
binding and penetration of the ZP and results
in immunocontraception. Antibody titres
normally fall over a period of time after vac-
cination and this can lead to an eventual
increase in fertility in mature animals that
have been immunized against important
reproductive proteins such as ZP glycopro-
teins. Immunosterilization will result if the
immune reaction causes irreversible damage,
such as the atrophy of follicles or the destruc-
tion of oocyte/granulosa cell complexes. For
more information, see Fayrer-Hosken et al.
(2000).
5.2 Endocrine Manipulations in
Aquaculture Fish
Fish are an important part of the human diet,
and fish meal is an important commodity as a
component of animal feeds. Aquaculture is
increasingly needed since natural sources are
unable to supply the demand for this com-
modity. Improved reproductive manage-
ment, growth performance and feed
efficiency of aquaculture systems can be
achieved by endocrine manipulations. 
Control of reproduction
Sex is determined by the presence of sex
chromosomes (either XX/XY or ZW/ZZ) in
most species of fish of commercial interest.
Sex differentiation in fish can occur by direct
differentiation of the primordial gonad into
either a testis or an ovary. This occurs in ‘dif-
ferentiated’ species such as the medaka, coho
salmon, common carp and European sea
bass. In ‘undifferentiated’ species, such as the
guppy, hagfish and European eel, the gonad
first develops as an ovary-like structure and
then forms a testis in some of the fish. 
The incubation temperature of reptile
eggs determines the gonadal sex. At higher
temperature, the increased synthesis of
oestrogen by the aromatase enzyme down-
regulates steroidogenic factor 1 (SF-1) expres-
sion and results in the female phenotype.
Conversely, when oestrogen production is
reduced, SF-1 expression increases and males
are produced. This sexual dimorphism in
SF-1 expression is reversed in mammals com-
pared to birds and reptiles. Changes in
oestrogen synthesis in response to tempera-
ture occur first in the brain and later in the
gonads.
Sex reversal
Exogenous steroids can be used for sex rever-
sal in many fish, amphibians and reptiles.
Exposing the young fry to exogenous hor-
mones can readily alter the phenotypic sex of
fish. Sex control is used in aquaculture to pro-
duce the sex of fish that grows more rapidly;
this is female in the salmonids and the
cyprinids, while it is male in the cichlids.
Sexual maturation in males is inhibited in
production systems in order to reduce prob-
lems with poor carcass quality and aggres-
sive and territorial behaviour in sexually
mature fish. Both males and females are ster-
ilized to allow larger fish to be reared and to
prevent poor feed efficiency, as nutrients are
normally diverted into gonadal growth as the
fish matures. In sea ranching, rearing sterile
fish prevents interbreeding with wild fish
stocks by captive fish that escape.
Sex steroids regulate the differentiation
of the gonads in fish. Oestrogens are respon-
sible for ovarian differentiation; treatment of
genetic female salmon with an aromatase
inhibitor will cause them to develop into
functional males. Environmental factors can
also affect sexual differentiation by inducing
or repressing the activity of certain genes,
such as that coding for aromatase. Similarly,
treatment of genetic female chickens with
aromatase inhibitors early in development
results in the development of testes rather
than ovaries (see Section 4.2). Similarly, treat-
ment of genetic male marsupials with oestro-
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gen early in development causes the devel-
opment of ovaries. 
Fish can be directly feminized by treat-
ment of a group of sexually undifferentiated
fish with oestrogen, but half of these pheno-
typic females will have a male genotype.
There may also be some concern from con-
sumers about the direct use of steroid treat-
ment in fish destined for human
consumption.
HORMONAL TREATMENTS FOR SEX REVERSAL.
Acute administration of hormones to fish can
be achieved by injection of the hormone
(intramuscularly or into the body cavity), or
immersing the fish in water containing the
hormone. Feeding hormone-treated food, or
implantation of silastic capsules, cholesterol
pellets or osmotic minipumps has been used
for chronic administration of hormones.
Addition of hormone to the water is useful
for treatment of larval stages, when the hor-
mone can be absorbed via the gills or integu-
ment. Rearing density is important with this
method. Administration of the hormone in
the feed can be used once external feeding
has begun and this avoids disturbing fragile
larvae.
Oestrogenic compounds, particularly
oestradiol, are used for feminization of fish,
while 17α-methyl testosterone is used for
masculinizing fish. High doses or long expo-
sure times to the hormone result in steriliza-
tion. In Atlantic salmon, doses of >20 mg kg–1
of 17α-methyltestosterone for the first 600
degree days of feeding result in sterilization.
A number of endocrine disruptor chemicals
have also been shown to affect sexual devel-
opment in fish (see Section 6.4). Other oestro-
genic compounds, such as DES, are not used
since they are carcinogenic in humans. In the
European Union, Council Directive
96/22/EC regulates the use of sex steroids for
sex control in finfish aquaculture.
Treatment with oestrogens can some-
times alter male secondary sex characteristics
without complete sex reversal. High levels of
oestrogen can also reduce survival and
growth rate. Salmonids require the lowest
exposure (a combination of dose and treat-
ment duration) to steroids for sex reversal,
while cyprinids require considerably more
exposure. In many species of salmonids,
steroids are administered by immersion of
the newly hatched fry in water containing the
steroid. This likely allows the steroids to
accumulate in the yolk sac, where they will
continue to affect the developing fish until
day 20.
Exogenous steroid hormones are most
effective during the ‘labile period’ of sexual
development, when the gonads are still
undifferentiated. The timing of this labile
period is species specific and somewhat
dependent on the hormone used and the
dose. For example, the labile period for
oestrogen occurs before the labile period for
androgens. Treatment times as short as hours
have been used. In coho and chinook salmon,
one or two 2-h immersions in steroids
(400 µg l–1) during the alevin stage at 8–13
days after hatching is sufficient to cause sex
reversal. In tilapia, 30–40 p.p.m. of 17α-
methyltestosterone is given in the food for 30
days at the swim-up stage to produce all
male fish for grow out. Treatment outside the
labile period requires higher doses of hor-
mone or longer periods of treatment to
achieve sex reversal. The optimum treatment
protocols for sex reversal use the minimum
dose of natural hormone during the labile
period, so that the shortest exposure time,
and consequently the least effect on survival
or growth rate, can be used.
Steroids are metabolized and cleared
through the liver (see Section 1.2) and this
occurs rapidly, so levels of exogenous
steroids would be undetectable a few days
after treatment. Treatment of fish with
steroids for sex reversal differs from use of
steroids in beef cattle for weight gain (see
Section 3.2). Cattle are usually treated with
synthetic steroids, the treatment is continued
for months and ends very near slaughter. In
contrast, fish are usually treated with natural
steroids, the treatment is short term and treat-
ment ends long before the fish are marketed,
even with the direct method for sex reversal.
However, it is likely that indirect methods for
sex reversal would be more acceptable to
consumers than direct methods.
INDIRECT METHODS. All-female fish can also be
produced in two generations using an indi-
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rect feminization procedure (Fig. 5.16). This
indirect procedure does not involve direct
treatment of the fish used for consumption.
In this procedure, a group of genetic females
are first masculinized by treatment with
androgens. These ‘neomales’, which carry
only X chromosomes, are identified using
sex-specific DNA probes and bred with nor-
mal females. The resulting offspring are all
female. The stock is maintained by masculin-
izing a small number of fish to provide more
neomales. The untreated fish are grown out
and marketed or used as female brooding
stock. Thus, the indirect method of producing
all-female stock is more time consuming but
does not expose the marketable fish to
steroids. It is used commercially for the cul-
ture of several salmonids, including rainbow
trout and chinook salmon, and is applicable
to fish species with the XX/XY sex determi-
nation system.
All-male stocks can also be produced
by indirect treatment with oestrogens (Fig.
5.17). Sexually undifferentiated fish are
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first treated with oestrogens and the ‘neo-
females’ (genetic males but phenotypic
females) are bred with normal males. One
quarter of these progeny will be YY
‘supermales’. These YY males are identified
and bred with normal females to produce
100% XY male progeny. YY males have been
produced in a number of species, including
medaka, goldfish, rainbow trout and Nile
tilapia, but are not viable in other species. In
ZW/ZZ sex determination systems, as in the
black molly, oestrogen treatment of undiffer-
entiated fish produces ZZ neofemales. These
are bred to normal ZZ males to produce all
male offspring.
Sterile fish can be produced by in-
ducing triploidy. Triploids can be produced
indirectly by crossing tetraploids with
diploids, or directly by preventing the extru-
sion of the second polar body after fertiliza-
tion. Direct triploid production accom-
plished by heat, pressure or anaesthetic
chemical treatment. For example, triploids
can be induced in Atlantic salmon eggs by
exposure to 30°C for 6–10 min at 20–30 min
after fertilization. Pressure treatment is more
costly but less variable and can be used to
produce triploids over a wider period of time
than heat treatment. Exposure of eggs to
hyperbaric nitrous oxide gas also produces
triploids, but the treatment must begin
immediately after fertilization and is inter-
mediate in effectiveness between heat and
pressure treatment. For more information,
see Piferrer (2001).
Induction of spawning
Environmental and hormonal manipulations
can be used to manipulate spawning time
(Fig. 5.18). Most fish spawn seasonally in the
wild in response to environmental cues that
occur with the seasons. In temperate and sub-
tropical species, changes in water tempera-
ture and photoperiod dramatically affect
gonadal growth and spawning. This allows
the progeny to be produced in the spring,
when the conditions for their survival are
more favourable. However, in captivity, it is
necessary to control spawning time in order
to provide marketable fish throughout the
year. In the red drum, the age to sexual matu-
rity can be reduced by more than half by rear-
ing the fish at high water temperatures. In
salmonids, photoperiod is the main environ-
mental cue for gonadal maturation and
spawning. The annual cycle of temperature
and photoperiod can be condensed into a few
months to stimulate gonadal growth and
spawning. The change in the direction of the
photoperiod (from short days to long days
and vice versa) is more important than the
actual daylength. Exposure of rainbow trout,
which normally spawn in late autumn, to
long days early in the cycle followed by short
days in late spring, will advance spawning
time by 3–4 months.
In addition to environmental cues,
spawning can be induced by treatment with a
crude preparation of fish gonadotrophin or
hCG, but species-specific preparations of
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gonadotrophins may be needed in some
cases. Thyroid hormone also acts in synergy
with gonadotrophins to promote the final
maturation of oocytes. GnRH can also be
used to induce spawning and it has several
advantages over gonadotrophins, since it is
not species specific and is an easily synthe-
sized small molecule. More active GnRH ana-
logues have also been developed, and a
number of slow-release delivery systems are
being investigated. These compounds are
also orally active, but the dose required is 10
times higher than that required by injection.
The most potent GnRH analogue is the
salmon GnRH analogue [D-Arg6, Pro9 NEt]-
sGnRH (sGnRH-A), although analogues of
mammalian GnRH (mGnRH) such as
[D-Ala6, Pro9 NEt]-mGnRH (GnRH-A) are
also very active. The increased activity of
these analogues comes from a combination of
increased binding affinity to receptors on
pituitary gonadotrophs and increased
hydrophobicity and resistance to enzymatic
degradation.
In some species, dopamine acts as a
GnRH antagonist to prevent the release of
gonadotrophins from the pituitary gonado-
trophs. Treatment with dopamine receptor
antagonists, such as domperidone, in combi-
nation with GnRH-A improves the induction
of spawning in some species, such as
salmonids, but not in others, such as sciaenids.
Syndel Laboratories, Vancouver, Canada, has
marketed a formulation of sGnRH-A and
domperidone under the name Ovaprim®.
Oestradiol acts by positive feedback to
increase the production of gonadotrophins
by the pituitary. Injection of testosterone,
which is aromatized to oestradiol, has been
used to increase the production of
gonadotrophins. Oestradiol is also a potent
inducer of vitellogenesis in the liver, which
provides the components for yolk in the
growing oocytes. For more information on
the manipulation of spawning in fish, see the
reviews by Peter and Yu (1997) and Mylonas
and Zohar (2001).
Effects on growth and nutrient utilization
Increasing growth rate and feed efficiency is
particularly important in aquaculture, due to
the long production cycle of cold-water fish.
This cycle normally lasts for years, with a
consequently greater risk of loss of fish from
disease or accidental release. In contrast, pro-
duction cycles for poultry, swine and cattle
are much shorter. Feed costs account for 50%
or more of the cost of production in aquacul-
ture, so improvements in feed efficiency can
dramatically reduce operating costs. 
Various dietary components can have
dramatic effects on hormone levels, but it is
difficult to measure these effects since
changes in one component of the diet are
often linked to changes in other dietary com-
ponents. Endocrine systems can be regulated
at a number of points, including neuroen-
docrine signalling, synthesis and secretion of
the hormone, transport in the blood, metabo-
lism in peripheral tissues, receptor binding,
and metabolism and clearance of the hor-
mone (see Chapter 1). Both CCK and NPY
(see Section 3.9) have been identified in fish
and probably play a major role in how nutri-
tional status affects endocrine function in
fish.
Steroid hormones, particularly andro-
gens, can increase growth rate but they are
not used commercially. Thyroid hormones
are important in larval development in verte-
brates. The yolk of newly fertilized eggs from
salmonids and striped bass contain high lev-
els of thyroid hormones and supplementing
eggs or larvae with additional T3 improves
growth and survival of the larvae and finger-
lings. Thyroid hormones are involved in the
regulation of growth and energy utilization
and they may play a permissive role in
growth to potentiate the anabolic effects of
insulin and growth hormone. Food depriva-
tion decreases the levels of thyroid hormones
and reduces the conversion of T4 to T3.
Dietary protein and carbohydrate affect thy-
roid hormone production. Carbohydrate
stimulates the secretion of T4, while protein
increases the conversion of T4 to T3.
Restricted growth rate seen at high stocking
densities is accompanied by decreased plas-
ma thyroid hormones.
Fish growth follows a pattern that is
related to daylength. Long daylength stimu-
lates growth, in part because the fish has
more time to forage for food, but also due to
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melatonin production by the pineal gland.
Melatonin production is regulated by expo-
sure to light and can affect the production of
growth hormone and thyroid hormone
metabolism. This affects the rate of growth
and sexual maturation.
Growth hormone is the most potent
growth promoter in teleost fish. Growth hor-
mone acts in synergy with androgens and
thyroid hormones to increase growth.
Growth hormone release from the pituitary is
increased during food deprivation or when
low protein diets are fed, and this is thought
to be due to direct effects of glucose and
amino acids on the pituitary. However, in
these situations IGF levels decline, so that
growth hormone directly stimulates lipolysis. 
Exogenous recombinant growth hor-
mone from chicken or cattle injected into
salmon improves growth and feed conver-
sion efficiency. Somatotrophin analogues
have also been developed that have increased
potency and stability. Somatotrophin and its
analogues are also active orally in fish, but
the dose required is higher than that given by
injection. Immersing trout fry for 30 min in a
solution of homologous growth hormone
also dramatically improved growth.
Transgenic salmon have also been produced
that express high levels of growth hormone
and have a dramatically increased growth
rate. For further information on genetic
manipulations in aquaculture, see Hulata
(2001).
Insulin and glucagon regulate lipid and
carbohydrate metabolism as well as growth
in fish. The level of insulin is increased in
faster-growing fish, but it is not clear whether
insulin stimulates growth or whether the
increased level of insulin is a consequence of
increased feed intake. Under natural pho-
toperiod and temperature changes, fish show
an active period of feed intake and growth
rate during times of increased temperature
and photoperiod. The level of insulin is high-
est during the times of rapid growth and low-
est in coldest weather, when feeding activity
is lowest. During short-term food depriva-
tion, glucagon and glucagon-like peptides
stimulate gluconeogenesis to maintain blood
glucose levels. Injection of glucose into fed
brown trout decreases levels of glucagon but
does not affect the level of insulin, although it
is increased by the amino acid arginine.
Applications
Periods of feed restriction or ‘nutritional
stress’ can be used to increase feed conver-
sion efficiency and lean growth. Lipolysis
and gluconeogenesis are increased during
feed restriction as the level of growth
hormone increases and insulin and thyroid
hormones are decreased. After feed restric-
tion, animals enter a phase of compensatory
growth, when levels of anabolic hormones
are increased to promote somatic growth
rather than storage of energy reserves as fat.
This results in improved lean growth and
feed efficiency and decreased fat deposition.
Compensatory growth after feed restriction is
also seen in other species, such as poultry.
Levels of many hormones in fish change
with a circadian rhythm. The circadian
rhythm of hormone release can also vary
with an annual cycle and be dramatically dif-
ferent in winter than in summer. The release
of metabolism-related hormones, such as
insulin, is also affected by the composition of
the diet, including the quality and propor-
tions of protein, carbohydrate, fats and vita-
mins and minerals. The time of feeding, as
well as the amount of feed given, can affect
the amplitude of the daily rhythm of thyroid
hormone, particularly T4, as well as insulin
and growth hormone. The time of day when
fish are fed can thus dramatically affect
growth and feed conversion efficiency, due to
differences in levels of hormones. It is thus
advantageous to determine when the hor-
mone levels in the fish are optimal for growth
and how different dietary nutrients affect
hormone levels. This will allow the develop-
ment of feeding strategies to promote anabol-
ic hormone production. The goal is to feed
fish at the optimal feeding rate and time of
day to provide nutrients when the animal is
physiologically best able to deal with them.
This approach will achieve the best feed con-
version efficiency and growth rate. However,
in a practical commercial setting, it may be
impossible to feed all fish at the optimal rate
and time of day. For more information, see
the review by MacKenzie et al. (1998).
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Stress and effects on the immune system
As with all commercial animal production,
poor husbandry practices and suboptimal
environmental conditions can cause
increased levels of stress. Long-term stress
can reduce growth performance and repro-
ductive success and increase the susceptibili-
ty to disease. Fish respond to increased stress
by activation of the adrenergic system to pro-
duce catecholamines, and the hypothalamic–
pituitary–interrenal (HPI) axis to produce
glucocorticoids. These responses are similar
to those described for other commercial ani-
mal species (see Section 6.3). Chronic stress
reduces the production of sex steroids and
impairs gonadal growth, gamete viability
and reproductive performance. Levels of
growth hormone are increased by stress, but
growth rate is decreased due to decreased
sensitivity of the target tissues. Chronic stress
can also decrease the levels of thyroid hor-
mones and reduce feeding activity, which,
together with the catabolic effects of cortico-
steroids, decreases growth rate.
Physical stress increases the oxygen
demand for fish by more than 50%. This
becomes more of a problem at high tempera-
tures due to lowered oxygen content of the
water and the accumulation of toxic levels of
ammonia produced as nitrogenous waste
and carbon dioxide from respiration.
Respiratory stress can result in high mortali-
ty rates in extreme situations. The hormonal
responses to stress also reduce the ability of
the fish to maintain osmoregulation, which
causes a loss of electrolytes in freshwater fish
and an increase in electrolytes in marine fish.
Stress also increases the susceptibility of
fish to a variety of viral, bacterial, fungal and
protozoan pathogens. As occurs in mammals,
the endocrine system and immune systems in
fish interact with each other (see Section 6.3).
Cortisol, growth hormone, prolactin, repro-
ductive hormones, melanotrophins and some
pro-opiomelanocortin (POMC)-related pep-
tides influence immune responses in fish.
Cortisol is the major corticosteroid pro-
duced by the interrenal gland in teleost fish.
Stress or cortisol administration decreases the
resistance of fish to infection by bacteria and
fungi. The decreased immune response
includes decreased phagocytosis and lym-
phocyte mitogenesis and decreased activity
of antibody-producing cells and levels of
IgM. 
Growth hormone is involved not only in
the regulation of somatic growth, but also in
osmoregulation and gonadal steroidogenesis
in fish. Prolactin is also involved in growth
and development, osmoregulation and repro-
duction. Both prolactin and growth hormone
are also involved in the stimulation of
immune responses in fish. They stimulate
lymphocyte maturation and differentiation,
activate phagocytes and natural killer cells
and stimulate antibody production.
The major steroids produced by the
ovaries of female fish are testosterone and
androstenedione, while males produce pri-
marily 11-ketotestosterone and 11-β-hydroxy-
testosterone. In rainbow trout, oestradiol
stimulates, while 11-ketotestosterone decrea-
ses lymphocyte proliferation. Testosterone
reduces the number of antibody-producing
cells, as does cortisol, and these steroids act
synergistically to inhibit antibody produc-
tion. High levels of the gonadal steroids are
present in salmonids during their freshwater
migration and maturation, and this is linked
to immune deficiencies and increased infec-
tions during this time.
Skin colour in fish is controlled by the
pituitary hormones α-melanocyte stimulat-
ing hormone (αMSH) and melanin concen-
trating hormone (MCH), which act on
melanocytes. αMSH darkens the skin by
causing dispersion of melanin granules,
while MCH concentrates the melanin to
decrease skin colour intensity. Both hor-
mones have also been implicated in the regu-
lation of the HPI axis, feeding and
osmoregulation in fish. Early studies showed
that fish kept in dark tanks are more vulnera-
ble to infections, and this is due to the actions
of the melanotrophins. αMSH inhibits fever
and inflammation by inhibiting the synthesis
of the pro-inflammatory cytokines IL-1, IL-6,
IL-8 and TNFα, and stimulating the release of
the anti-inflammatory cytokine IL-10. MCH
stimulates the proliferation of leucocytes and
reduces the inhibitory effects of cortisol on
mitogenesis. Other POMC-derived peptides,
including ACTH and β-endorphin, have also
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been implicated in modulating the immune
response of fish. For more information on the
effects of hormones on the immune system in
fish, see Harris and Bird (2000).
Applications
Although it is impossible to completely elim-
inate stress in commercial aquaculture, the
negative effects of stress can be minimized.
Appropriate stocking densities should be
used and water quality should be main-
tained. Adequate time (days to weeks)
should be allowed for recovery from stress
from routine procedures such as netting,
grading and transporting, and multiple
stresses should be avoided. Manipulations
should be done in colder water temperatures.
Dilute salt solutions can be used for fresh-
water fish to limit osmoregulation problems.
Withdrawal of food for a few days before the
stress minimizes contamination of the water
from fecal matter and feed and reduces
respiratory stress through increased oxygen
availability. Anaesthetics (MS222, phen-
oxyethanol, etomidate) can be used to mini-
mize the stress response. 
The magnitude of the stress response
varies dramatically between different breeds
and strains of fish. Genetic selection for fish
with reduced cortisol response to stress may
alleviate some of the negative effects of stress.
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Questions for Study and Discussion
Section 5.1 Manipulation of Reproduction in Mammals
1. Outline the role of endocrine factors in the differentiation of gonadal structures and the brain.
2. Describe the differences in the pattern of sexual differentiation in cattle, sheep and pigs.
3. Describe the endocrine factors that regulate meiosis in germ cells.
4. Describe the hormonal changes during the different phases of the oestrous cycle.
5. Describe the hormonal regulation of follicular development.
6. Describe the hormonal changes during pregnancy and parturition.
7. Discuss the effects of seasonality on sexual maturation and breeding.
8. Describe the opportunities for manipulation of the oestrous cycle. What hormone preparations are
available for this purpose?
9. Outline methods for detection of oestrus in cattle.
10. Describe methods for synchronizing oestrus in cattle.
11. Discuss methods for maintaining or ending pregnancy.
12. Describe factors that affect the resumption of oestrus postpartum.
13. Outline methods for inducing cycling in seasonal breeders.
14. Discuss the potential for the immunological control of reproduction.
Section 5.2 Endocrine Manipulations in Aquaculture
1. Describe the direct and indirect methods for the use of hormones in sex reversal of fish.
2. Discuss methods for inducing spawning.
3. Describe the potential for the hormonal manipulation of growth and nutrient utilization in fish.
4. Discuss the effects of stress on productivity of farmed fish.
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6.1 Control of Broodiness in Poultry
Broodiness, also known as incubation behav-
iour, occurs when birds spend an increasing
amount of time in the nest to incubate eggs.
Food and water consumption decrease dra-
matically and egg production ceases due to
regression of the ovary and oviduct.
Broodiness is decreased in battery-type cages
and increased in ‘welfare friendly’ produc-
tion systems that allow full nesting behaviour
to be expressed, such as modified cages,
aviary and free-range systems. Broodiness is
a natural behaviour that allows the hen to
incubate and hatch out a clutch of eggs.
However, broodiness is a problem in modern
production systems, since when a hen
becomes broody it ceases to lay eggs due to
the regression of the reproductive system. 
Broodiness can be controlled by manipu-
lation of the environment to remove the stim-
uli that encourage nesting behaviour. This
includes regular removal of eggs and use of
uniform lighting to discourage birds from
nesting in dim corners. Adequate numbers of
nest boxes should be provided and these
should be closed at night. The arrangement
or appearance of the nest boxes should also
be changed regularly to prevent the birds
from becoming attached to a familiar nest
site. Hens that are in the early stage of per-
sistent nesting can be transferred to a pen
designed to make nesting uncomfortable,
such as one with wire floors and strong
updrafts of cold air.
Altering hormone function can be used
to control broodiness (Fig. 6.1). Nesting
behaviour begins just before an egg is laid
and is stimulated by the interaction of oestro-
gen and progesterone. After birds have been
in lay for a few weeks, nesting behaviour
may become prolonged and advance to
become broodiness. An extensive brood
patch can develop on the breast, designed to
improve heat transfer from the hen to the
developing embryos. Prolactin acts in concert
with the ovarian steroids to increase vascu-
larization and feather loss in the brood patch.
Stimulation of the brood patch by the eggs or
a familiar nest site maintains the high levels
of prolactin release, and once broodiness is
established oestrogen and progesterone are
no longer needed. Prolactin also decreases
the secretion of LH, which results in regres-
sion of the ovary and the cessation of egg lay-
ing. 
The secretion of prolactin by the anterior
pituitary gland is controlled by the avian pro-
lactin releasing hormone, a 28-amino-acid
peptide originally isolated from the gut and
also known as vasoactive intestinal peptide
(VIP). VIP is released from the hypothalamus
and binds to specific receptors on lactotroph
cells in the anterior pituitary. VIP release is
increased by serotonin or dopamine, and
turnover of these neurotransmitters is
increased in the hypothalamus of broody
birds. Dopamine may also act directly on the
anterior pituitary to inhibit prolactin secre-
tion.
The prolactin receptor gene has been
suggested as a candidate gene for the control
192
6
Effects on Animal Behaviour,
Health and Welfare
©CAB International 2003. Applied Animal Endocrinology (E.J. Squires)
chap06.qxd  10/10/03  8:14 AM  Page 192
of broodiness and it has been mapped to the
Z chromosome. However, there are no differ-
ences in the amounts of the prolactin receptor
between White Leghorns, which do not
become broody, and bantam hens, which
commonly develop broodiness behaviour. It
may be that differences in the expression of
the various isoforms of the receptor are
important.
Applications
Broodiness occurs where the birds are kept
on the floor, and affects broiler breeders,
especially the dwarf strains, egg-layer multi-
plier flocks and especially turkeys.
Broodiness is affected by genotype, and is
present in most species of laying fowl except
White Leghorn. 
Administration of pharmacological
doses of progesterone or oestrogen disrupts
broodiness, but this delays the return to lay.
Treatment with anti-oestrogens (clomiphene
citrate and tamoxifen) produced inconsistent
results. Further treatments to disrupt broodi-
ness have been directed at either increasing
gonadotrophin secretion or decreasing pro-
lactin secretion. Treatment with gonado-
trophins returns broody turkeys to lay but is
too expensive to be of practical use.
Treatment with synthetic GnRH is also
impractical since the anterior pituitary
becomes non-responsive to GnRH after pro-
longed treatment. Treatment with a
dopamine receptor blocker, pimozide, does
not prevent broodiness. Decreasing the syn-
thesis of serotonin with p-chlorophenyl
alanine (PCPA) decreases the production of
prolactin, but does not return turkeys quickly
back into lay. Use of the dopamine agonist,
bromocryptine, delays the resumption of egg
laying.
Passive immunization against prolactin
in bantam broody hens results in increased
LH. Subsequent cloning of chicken prolactin
allowed the active immunization of hens
against recombinantly derived prolactin cou-
pled to β-galactosidase. This procedure
decreases broodiness without affecting egg
production, and is more effective if it is initi-
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ated before egg laying begins. The peptide
sequences of chicken prolactin and turkey
prolactin are practically identical, so this
should also be effective in turkeys.
Alternatively, hens can be immunized against
VIP. Injection of antibodies against VIP
decreases the prolactin level to baseline and
decreases broodiness. Active immunization
of turkeys with synthetic turkey VIP conju-
gated to keyhole limpet haemocyanin (KLH)
decreases the prolactin level and broodiness.
Active immunization protocols to decrease
broodiness require regular booster injections
at 3–5-week intervals to maintain sufficient
antibody titres. For more information, see the
review by Sharp (1997).
6.2 Applications of Pheromones
The use of chemical signals is an important
method for many diverse species to commu-
nicate between and within a species, and
between a species and its environment. An
appreciation of the use of chemical signals in
animals began in the 19th century, but it was
not until the 1930s that experimental evi-
dence showed that volatile chemicals were
involved. For further information on
pheromones, see the Scientific American text
by Agosta (1992) and the symposium pro-
ceedings by Johnston et al. (1999). For an
interesting discussion of the evolution of
pheromones and their receptors, see Stoka
(1999).
Naturally occurring compounds that are
used by organisms to perceive and communi-
cate with other organisms and the environ-
ment are collectively known as
semiochemicals. They include pheromones,
allomones and kairomones. The word
pheromone, used by Karlson and Butenandt
in 1959, is derived from the Greek pherein, ‘to
transfer’, and hormon, ‘to excite’, and refers to
a chemical messenger released to the exterior
of one individual to stimulate a response in
another individual of the same species.
Pheromones are thus hormones that are used
external to the animal. Allomones are emitted
by a species to control other species for its
advantage. For example, when different
species compete for the same resources,
repellant allomones emitted by one species
can reduce the number of individuals present
from another species. Kairomones are emit-
ted by a species to its disadvantage and typi-
cally as a result of efforts to overcome
stresses. For example, pears release ethyl-2,4-
decadieoate, which is a highly potent attrac-
tant to the codling moth, Cydia pomonella,
which is a serious insect pest of walnuts,
apples and pears.
The field of chemical communication
and semiochemicals has concentrated mainly
on insects, although several vertebrate
pheromones have now been identified.
Current research on pheromones is involved
in determining receptor function and signal
transduction mechanisms, and developing
natural product analogues.
Types of Pheromones
Pheromones are divided into two types,
depending on their effect on the recipient.
Signalling pheromones transfer specific
information to induce changes leading to a
prompt behavioural response in the recipient.
They include sex attractants, which either
lead to aggression or are involved in
courtship or copulatory behaviour. Alarm
pheromones prompt organisms to evacuate
an area. Aggregation pheromones bring oth-
ers to a food source or a suitable habitat, or
bring others to a sexual partner. Dispersion
pheromones maintain optimal separation
between animals and maintain separation
between territorial social groups. Priming
pheromones induce physiological changes
that may have a long-term influence on the
recipient, such as the induction of puberty or
the termination of anoestrus.
Chemistry of pheromones
The chemical structures of several
pheromones are known, but in most cases the
existence of a pheromone is implied from
behavioural studies when the chemical struc-
ture of the pheromone has not yet been estab-
lished. Most of the work comes from studies
on insects, with much less work on
pheromones from vertebrates. Pheromones
are organic compounds or mixtures of organ-
ic compounds. They may contain functional
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groups, such as carbon–carbon double bonds,
or carbonyl, hydroxyl, carboxyl and ester
groups. Most volatile pheromones are
molecules with 5–20 carbon atoms and
include hormones or their breakdown prod-
ucts. 
There are several examples of very simi-
lar, or even identical, compounds being
active as pheromones in different species. In
insects, it is common for closely related
species to use similar mixtures of compounds
as pheromones, but the ratios of the compo-
nents are different or other components are
included to give species specificity. In other
cases, the same pheromone is used for similar
species that have different timing of their
reproductive cycle, so there is no confusion.
In other cases, widely different species utilize
the same pheromones. For example, (Z)-7-
dodecenyl acetate is a sex attractant for Asian
elephants as well as the turnip looper and
cabbage looper and many species of butter-
flies and moths. 
A family of low molecular weight solu-
ble proteins known as lipocalins (Fig. 6.2) acts
as carriers for pheromones and are important
for their delivery and detection. Members of
the lipocalin family include odorant-binding
proteins (ODPs) that are produced by glands
in the nasal cavity to concentrate volatile
odorant molecules and improve their detec-
tion. Major urinary proteins (MUPs) present
in the urine and saliva of rodents act to stabil-
ize and control the release of volatile
pheromone deposits. Aphrodisin is a
pheromone-related protein in the vaginal dis-
charge of hamsters. These lipocalin proteins
have a common three-dimensional structure
called a β-barrel, which is made of eight
antiparallel β-sheets enclosing the hydropho-
bic binding pocket that binds the pheromone.
In addition to binding pheromones, some of
the pheromone-binding proteins have been
shown to have pheromonal properties of
their own, whether or not a volatile
pheromone is bound. Other lipocalins bind
lipophilic compounds such as retinol and
retinoic acid. For more information on
lipocalins, see the review by Flower (1996).
Pheromone production and release
The communication system for pheromones
requires a mechanism for emitting the
pheromone, a medium through which
pheromones can be transmitted and a mech-
anism for receiving the pheromone. Phero-
mones are usually emitted by glandular
organs equipped with specialized structures
for their release. In insects, most pheromone
glands are composed of groups of modified
epidermal cells. The glands may be complex
and associated with internal reservoirs.
Chemical signals can be quite volatile
and carried for a long distance in air or water
by diffusion and passive transport. These sig-
nals would provide an immediate message
that would last for a short time. For example,
a sex attractant released into the environment
would indicate that a member of the opposite
sex is available for mating. In insects, wing
fanning disperses the highly volatile
pheromones. In male sheep and goats, a
primer sex pheromone produced in the skin
evaporates from the hair or wool. In fish, free
steroids are released from the gills. Many
species secrete pheromones in the urine.
Some chemical signals can be persistent, sta-
ble and non-volatile. This can occur by bind-
ing a volatile compound to a protein or using
more stable chemical signals of larger molec-
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ular weight. These signals would be deposit-
ed and remain after the animal has left to pro-
vide a signal for the longer term. This would
be useful for marking territory or indicating
the location of a food source.
Detection of pheromones
The perception of pheromones is through
taste and smell receptors. Insects detect
pheromones through different hair-like pro-
jections (sensilla) on the antennae.
Chemosensory systems can be extremely sen-
sitive. For example, the antennae chemore-
ceptors of the male silkworm moth, Bombyx
mori, can detect concentrations of the female
sex pheromone bombykol as low as 1 mol-
ecule in 1017 in air. This allows a male moth to
locate a female that is several miles down-
wind, at night. Similarly, a steroid that
induces moulting in crabs, and also acts as a
sex attractant, is active at 10–13 M.
Pheromones are active over a limited concen-
tration range and are ineffective when the
levels are too high.
In mammals, odorants are detected in
the olfactory sensory neurones in the epitheli-
um that lines the nasal cavity. Most mammals
also have a second olfactory organ known as
the vomeronasal organ (VNO) that is
involved in pheromone detection. The VNO
is a tubular cavity in the nasal septum, lined
with sensory epithelium and vomeronasal
glands, which secrete a fluid into the lumen.
The lumen of the VNO is connected to the
nasal cavity by narrow ducts, which allows
the movement of secretions between the two
compartments. During the ‘lip curl’ Flehmen
response in male courtship behaviour in cer-
tain mammals, including cats, ungulates, bats
and marsupials, fluid containing female
pheromones is sucked into the VNO and the
pheromones are detected. A 70 kDa odorant-
binding glycoprotein (vomeromodulin) is
expressed in the VNO and presumed to be
involved in the binding of pheromones.
There are three distinct families of olfac-
tory receptor molecules that are all G-protein-
coupled receptors. The odour receptor (OR)
gene family, which is expressed in the olfac-
tory epithelium, consists of about 1000 genes
that code for receptor proteins that vary dra-
matically in amino-acid sequence and can
bind a wide variety of ligands. The other two
families of receptors are expressed in the
VNO; these are the V1R family of about 35
members and the V2R family of 150 mem-
bers, which are presumably involved in
detection of pheromones. All of the olfactory
receptors have seven transmembrane
domains and the V2Rs have a very large N-
terminal extracellular domain. Each olfactory
neurone expresses only one OR and each OR
can recognize multiple odorants. The detec-
tion of odours involves the combined
response of a large number of signals from
individual neurones with different receptor
molecules. This allows the discrimination of a
very large number of odorants. On the other
hand, it is hypothesized that the V1Rs and
V2Rs only respond to individual
pheromones. It has been suggested that V1Rs
react with lipophilic and volatile odorants,
while the V2Rs react with proteins. The acti-
vation of specific receptor molecules initiates
the endocrine and behavioural response to
pheromones. This mechanism provides for
the specific recognition of a defined number
of pheromones.
In mammals, ligand binding to odour
receptors (ORs) stimulates adenylyl cyclase to
increase cAMP and opens cyclic nucleotide-
gated cation channels, causing membrane
depolarization and generating an action
potential in the neurone. Alternatively, a sec-
ond pathway exists for V1R and V2R recep-
tors and ion channels that are specific to the
vomeronasal organ. In this system, phospho-
lipase C is activated to increase IP3 and trigger
the opening of an ion channel, causing an
action potential (see Section 1.3). Insect
pheromones are bound by specific
pheromone-binding proteins to interact with
a G-protein-coupled odorant receptor and
increase the IP3 second messenger.
Phosphorylation of the receptors and high
levels of cGMP reduce the signal transduction
mechanism. For more information on odour
and pheromone receptors, see Buck (2000).
Vertebrate pheromones
In vertebrates, various bodily secretions, such
as vaginal secretions and urine, have
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pheromonal effects. Pheromones have been
implicated as indicators of the reproductive
status of females and in the induction of
behaviours resulting in mating, in aggressive
behaviour towards intruder males, in the
inhibition of oestrus cycling in group-housed
females and in the induction of oestrus by
exposure to males. An individual or group
can use pheromones or chemical signals to
mark its territory. These signals are deposited
from urine, or specialized anal or suprapubic
glands.
There is also evidence that individuals
can be identified based on odour that is
directly related to the composition of the
major histocompatibility complex (MHC)
genes. Odorants may be bound directly by
proteins encoded by MHC genes, released
into serum and concentrated in urine. It is
possible that recognition of MHC types may
be used to prevent inbreeding in communal
populations. It may also be the basis of the
Bruce Effect, in which pregnancy is terminat-
ed in rodents by exposure of the female to a
male that is genetically different from the
inseminating male. 
Due to the flexibility of mammalian
behaviour and its dependence on a number
of factors, behavioural responses to olfactory
signals may be less obvious than in insects.
For example, a mammal could respond quite
differently to a pheromonal signal depending
on its emotional state. Various tactile, visual
or auditory cues from the male or female may
also affect the response. Repeated exposure
to the pheromone can cause the animal to
become habituated and then not respond to
the pheromone. These factors can make the
identification of the pheromone, and the role
that pheromones play in vertebrate behav-
iour, very difficult to determine.
Rodents
Most detailed studies of reproductive
pheromones have been done with rodents.
The female Syrian golden hamster in oestrus
leaves a pheromone trail to attract a male.
The attractant pheromone is dimethyl disul-
phide, but the later stages of courtship and
copulation are stimulated by a protein
pheromone known as aphrodisin, which is a
member of the lipocalin family. Aphrodisin,
present in the vaginal secretions of the
female, is licked by the male and detected in
the vomeronasal organ.
The major urinary protein (MUP) in the
mouse is another member of the lipocalin
family and is analogous to α-2u globulin in
the rat. MUP is thought to function in
pheromone transport in male urine but also
has pheromonal properties of its own. In fact,
the hexapeptide N–Glu–Glu–Ala–Arg–Ser–
Met, which is a truncated form of MUP, accel-
erates puberty in female mice. Male mouse
urine contains sec-butyldihydrothiazole and
dehydro-exo-brevicomin (Fig. 6.3) bound to
MUP, and these compounds stimulate
aggression in other males, female attraction,
and synchronization and acceleration of
oestrus. The pheromonal property of these
compounds is also illustrated by the fact that
a similar compound, exo-brevicomin, is a
male attractant produced by the female west-
ern pine beetle.
Six small organic compounds have also
been identified in female mouse urine that
delay the onset of female puberty. Rats
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produce a maternal pheromone, deoxycholic
acid, in the faeces that attracts the young back
to the maternal nest.
Pigs
Oestrous sows detect pheromones released
by boars. These pheromones are the steroids,
5α-androstenone and 3α-androstenol
(Fig. 6.4), which are members of the 16-
androstene steroid family, responsible for
boar taint (see Section 3.3). These steroids are
synthesized in the testis and subsequently
removed from the bloodstream by
pheromone-binding proteins (lipocalins) in
the salivary gland. Arousal of the boar results
in profuse salivation and release of the
pheromones and binding proteins with the
saliva. 5α-Androstenone is one of the first
vertebrate pheromones available as an
aerosol preparation (Boar Mate®).
The boar pheromones cause the sows to
‘stand’ for mating, so the sow resists forward
pressure (lordosis) when in oestrus. These
pheromones may also establish dominance
hierarchies and decrease fighting of males in
regrouping situations. In addition to these
signalling actions, boar pheromones have a
priming action and increase the onset of
puberty in prepubertal gilts. Boar exposure
should occur after 140 days of age, since
earlier boar exposure actually increased the
age at puberty. This may be due to a habitua-
tion of the boar presence when the gilt is
physiologically unable to respond.
Androstenone or boar exposure also decreas-
es the time from weaning to first oestrus in
sows. 
There is some evidence to suggest that
the 16-androstene steroids are active in
humans and are found in trace amounts in
human sweat. In vitro synthesis of the
steroids has been demonstrated in human
testis microsomes. The 16-androstene
steroids have also been found in various tis-
sues in camels. Androstenone is also found in
truffles, and pigs have traditionally been
used to hunt for these underground fungi.
Androstenone is also present in caviar, celery
and young parsnips.
There is some evidence that pheromones
that signal alarm are released in the urine of
pigs undergoing stress, but the chemical
nature of these pheromones has not been
investigated (Amory and Pearce, 2000). Sows
also produce a maternal pheromone that
stimulates feeding behaviour and post-
weaning weight gain in piglets (McGlone
and Anderson, 2002).
Cattle
The cervicovaginal mucous and urine from
oestrous cows stimulates sexual activity in
bulls. Higher levels of n-propyl-phthalate
and 1-iodoundecane have been found in
oestrous urine, but these compounds have
not been proven to act as pheromones.
Detection of olfactory cues as a method for
detecting oestrus in cows would benefit the
dairy and beef industries (Section 5.1).
The olfactory cues could potentially be
detected using trained animals (e.g. sniffer
dogs), and recently electronic sensors have
been used experimentally for this purpose.
There is also evidence that cows produce
pheromones that regulate the oestrous cycle
of other cows.
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Exposure to bull urine has been shown
to accelerate puberty and shorten the calving
season in heifers. Bull pheromones could
therefore be used to increase the pregnancy
rate of first-season heifers and concentrate
the calving season in beef heifers. Exposure
of cows to a bull also decreases the time to
conception after calving.
Sheep and goats
Rams sniff odours from vaginal secretions to
detect oestrus in ewes. Oestrous ewes also seek
out rams, suggesting that rams emit a sig-
nalling pheromone. The introduction of a male
also aids in the termination of seasonal
anoestrus and synchronization of oestrus in
sheep and goats. A primer pheromone is pro-
duced in the sebaceous glands of male sheep
and goats; the production of this pheromone is
induced by testosterone. The pheromone is
released from the male hair or wool and stim-
ulates the neuroendocrine system in females to
increase the frequency of pulsatile LH release
and induce ovarian function and cycling.
Fish
The existence of chemical signals for fish has
been demonstrated since 1932, but the com-
pounds responsible have only been identified
in the past 10 years. Most of the work has
been done with goldfish as a model system.
About 10 h before spawning, female goldfish
produce large quantities of di- and tri-
hydroxy-4-pregnen-3-one, testosterone and 4-
androsten-3,17-dione (Fig. 6.5). These steroids
act first as hormones to promote oocyte matu-
ration in the female then are released into the
water to act as primer pheromones, increasing
the production of gonadotrophins in males.
This stimulates the formation of milt (sperm
and seminal fluid) and increases aggression in
males. The steroids are released as conjugates
with glucuronide and sulphate in the urine
(see Section 1.2) and free steroids are released
from the gills.
Prostaglandin F2α and its metabolite 15-
keto-PGF2α are associated with follicular rup-
ture and ovulation in females. When they are
released into the water, they stimulate
aggression among males and courtship
behaviour towards females. This is an unusu-
al application for prostaglandins, as they nor-
mally have only local hormonal effects. Thus,
for fish the distinction between hormones
and pheromones is very blurred.
Injured fish release an alarm pheromone
to trigger anti-predator behaviour in other
fish. In ostariophysian (order Cypriniformes)
fish, the alarm pheromone has been proposed
to be hypoxanthine-3-oxide (Fig. 6.6), which
is produced by alarm system cells in the skin.
However, this result has been questioned due
to the high levels of the pure compound that
are needed to produce the alarm response.
Nothing is known about the chemical
structure of alarm pheromones in non-
ostariophysian fishes.
Other 
Female Asian elephants release (Z)-7-
dodecenyl acetate in their urine to signal
Effects on Animal Behaviour, Health and Welfare 199
Fig. 6.5. Primer pheromones produced by female goldfish.
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that they are ready to mate. Female 
garter snakes use a mixture of long-chain
fatty acids, ranging from 29 to 37 carbon
atoms, as a mating pheromone. Squalene
is used as a male recognition pheromone
in garter snakes. The foul-smelling musk
of skunks is produced by scent glands
near the anus. The active ingredients
are trans-2-butene-1-thiol, 3-methyl-1-
butanethiol and trans-2-butenyl methyl
disulphide. 
Nepetalactone is the active component
of catnip that induces behaviour similar to
the mating ritual in domestic cats, lions and
tigers. A synthetic feline facial pheromone
product (Feliway®) has been marketed. It is
claimed to reduce stress in cats and thus
reduce urine spraying and territorial marking
in this species.
Insect pheromones
Much more is known about the chemical
nature of insect pheromones than
pheromones in vertebrates. Bombykol (Fig.
6.7), the sex attractant produced by the
female silkworm, was the first pheromone to
be chemically identified by A. Butenandt and
co-workers in 1959. The limited equipment
and analytical techniques available at that
time made this a very difficult task.
Milligram quantities of pure material were
required for structural determination, and
sensitive bioassays needed to be developed
to guide the purification work, so the struc-
tural identification took over 20 years to
accomplish. Since this work was completed,
the structures of many other insect
pheromones have been elucidated. The
majority of the lepidopteran female sex
pheromones are long-chain alcohols, acetates
and aldehydes.
Insects use sex pheromones to attract a
mate, aggregation pheromones to indicate to
others the site of a good food source, and
alarm pheromones to indicate attack by a
predator. In some cases, insects do not syn-
thesize pheromones de novo, but use plant-
derived compounds as starting materials for
the synthesis. For example, the sex attractant
pheromone of danaid butterflies, danaidone,
is made by male butterflies from
pyrrolizidine alkaloids obtained from plants.
Similarly, aggregation pheromones of dark
beetles are composed of mixtures of com-
pounds such as exo-brevicomin, which are
derived from the plants they infest.
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The queen bee produces queen
mandibular pheromone (QMP), which main-
tains order in the hive, suppresses ovary
development in worker bees and prevents
the rearing of new queen bees. It also stimu-
lates worker bees to build new comb, rear
more bees, forage and store food. Queen bee
pheromone is a mixture of several com-
pounds (Fig. 6.8), mainly 9-oxodec-2-enoic
acid (9-ODA) and 9-hydroxydec-2-enoic acid
(9-HDA). QMP also contains methyl p-
hydroxybenzoate (HOB) and 4-hydroxy-3-
methoxyphenylethanol (HVA); levels of HOB
and HVA differ among different bee species.
Worker bees release an attractant
pheromone (Fig. 6.9) from the Nasonov gland
to keep the colony of bees together and help
disoriented workers find the nest. It is
released when swarming or forming a clus-
ter, when marking the location to the nest or
marking the location of water. The attractant
pheromone is comprised of seven closely
related compounds derived from the essen-
tial oils of fragrant plants. The most biologi-
cally active of these is citral, which is a
component of the fragrance of oranges. Oleic
acid from dead and decomposing bees acts as
a chemical message to eliminate the dead bee
from the hive.
Alarmed bees produce alarm and
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Fig. 6.8. Components of the queen bee pheromone.
Fig. 6.9. Attractant, alarm and aggression pheromones from bees.
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aggression pheromones to elicit a colony
defence response from other workers. A
major component of the alarm pheromone is
isopentyl acetate, which is a component of
the sting material as well as acting as a tar-
geting pheromone to guide other bees to the
sting site. 11-Eicosinenol also induces sting-
ing and, mixed together with isopentyl
acetate, is as effective as natural sting ex-
tract in causing a bee to engage in stinging
behaviour.
Ants also have alarm and attractant
pheromones as well as trail pheromones that
they use to mark the trail to a food source.
Different species of ants use different chemi-
cals as trail pheromones, which reduces com-
petition for the food.
Applications
Pheromone research has applications in pest
control, insect management (e.g. honey bees)
and the manipulation of reproduction in
domestic animals and humans. Once the
chemical composition of a pheromone is
known, it can be synthesized chemically in
amounts that can be used commercially. For
reviews on the commercial use of
pheromones and other semiochemicals, see
Jones (1998) and Copping and Menn (2000).
Pest control
Agricultural damage from insects amounts
overall to a loss of about 13% of the potential
crop, with much greater losses in some
instances. The use of chemical insecticides to
control insect pests results in water pollution,
pesticide residues in food and damage to
non-target species, some of which are benefi-
cial for agriculture. Insects also carry viruses,
bacteria and parasites that cause diseases
such as malaria, bubonic plague, yellow
fever, typhus and others. The use of specific
agents to effectively control targeted insect
pests would be of great benefit and is an
important part of integrated pest manage-
ment (IPM) programmes.
In the USA, pesticides have to be
approved by the Environmental Protection
Agency (EPA), and pheromone-based pesti-
cides have to pass a much simpler set of
guidelines than conventional chemical pesti-
cides. This saves a lot of money and time in
the approval of pheromones. This is not the
case in the EU, where the same criteria apply
to chemical pesticides, plant extracts and
pheromones. Pheromones are natural prod-
ucts and therefore cannot be patented. They
are effective in small amounts, and individ-
ual pheromones are specific for one particu-
lar species. This makes pheromones less
attractive commercially compared to broad-
spectrum chemical insecticides, which are
typically patentable and needed in large
quantities.
Pheromones are generally used as a
blend of several chemical components. Some
45 pheromones are listed as biopesticides and
these are used for mass trapping, as monitor-
ing agents, mating disrupters and aggrega-
tion pheromones, and as the mite alarm
pheromone. Some plant-derived compounds
attract insects to a good food source and
these can be used together with attractant
pheromones from insects. 
POPULATION MONITORING. The most important
use of pheromone-baited traps is for popula-
tion monitoring. Pheromone-baited traps can
be used qualitatively and quantitatively to
detect the presence and density of insects.
Traps work at low population levels, and
thus can provide information on whether
pests may be infecting an area or a particular
crop. This information is then used to regu-
late the amount of chemical pesticides that
are used and to ensure that they are being
used at the most effective times. For example,
the pea moth pheromone (dodecadienol
acetate, Fig. 6.10) is usually used in traps
designed to monitor the size of the moth pop-
ulation, so that conventional insecticides can
be used during the vulnerable larval stages.
Traps can also be used after spraying to
determine whether the treatments were effec-
tive. Population monitoring using
pheromone-baited traps is also useful for eco-
logical studies and surveys, and for quaran-
tine detection of non-indigenous insects.
MATING DISRUPTION. Pheromones are used at
high concentrations for mating disruption.
This high concentration of pheromone masks
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natural trails left by the species and may
divert insects from natural sources, so they
are unable to find a mate as effectively. High
levels of pheromones may also cause adapta-
tion of antennae receptors and habituation of
the CNS, so insects no longer respond to the
pheromone. About 30 pheromone-based
products that act as mating disruptors are
registered by the US EPA to control 11 lepi-
dopterous pest species. For example, high
levels of the pink bollworm sex pheromone
(gossyplure, Fig. 6.11), placed indiscriminate-
ly, make it impossible for the males to follow
the pheromone trails left by the females and
thus mating is disrupted.
MASS TRAPPING. Mass trapping is a powerful
and highly specific method for pest control,
particularly for those insects that respond to
aggregation pheromones. The appropriate
number of traps per unit area must be used to
achieve control. Generally, it is not effective
enough to completely eliminate insect infes-
tations. It is also possible to add an insecti-
cide to the trap to kill the insects that are
attracted to the pheromone. For example, the
Japanese beetle pheromone is used in traps
designed for lure-and-kill. In addition to the
pheromone, which attracts the male beetles, a
floral scent is included to attract the females.
These traps are not 100% effective, but they
do reduce beetle populations to more accept-
able levels. Another example is the use of the
aggregation pheromone of the spruce dark
beetle (Fig. 6.12) to attract the beetles to about
four baited trees per hectare. These trees are
then attacked and the heavily infested trees
are then removed and destroyed. Another
example is the use of the mite alarm
pheromone (farnesol) along with an insecti-
cide. This reduces feeding of the mites and
increases their activity and susceptibility to
the insecticide. 
To summarize pheromone use for pest
control: pheromones account for much less
than 1% of the total pesticide market. They
have key roles in pest monitoring systems for
speciality crops where the timing of insecti-
cide use is important, as with boring insects.
Pheromones have been used successfully for
mating disruption, but they are specific for
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Fig. 6.10. Structure of pea moth pheromone.
Fig. 6.11. Structure of pink bollworm sex
pheromone.
Fig. 6.12. Two pheromones used for mass trapping.
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one species and this is a major problem if
more than one insect species is involved.
Mass trapping is not effective to remove all of
the insects and it is usually only the males
that are trapped. Aggregation pheromones
are useful in specialized areas such as
forestry, where part of the crop can be sacri-
ficed for the remainder, but there are not
many suitable crops and insect pests for other
applications.
Insect management
Pheromones can also be used as part of inte-
grated resource management (IRM) pro-
grammes for beneficial organisms. For
example, queen mandibular pheromone
(QMP) can be used in the management of
honeybee colonies. It can be used to create
a pseudoqueen when shipping queenless
packaged bees and to improve queen rearing
success inside the hive. QMP can also be
sprayed on flowering crops (fruit trees) to
attract honeybees and improve pollination.
The honeybee Nasonov orientation
pheromone can be used to reduce the loss of
bees due to swarming and to trap bees in
food processing plants and other areas where
they are undesirable.
Reproduction control in mammals
Signalling pheromones produced by females
can be present at oestrus and pre-oestrus and
can serve as attractants or inducers of sexual
activity. Male pheromones can be used to
detect oestrus for correct timing of AI to
increase conception rates (e.g. Boar Mate®).
Primer pheromones can be used to induce
puberty in young females, end seasonal
anoestrus, and improve conception rates (see
Section 5.1). 
Groups of females tend to be synchro-
nized with respect to ovulation. This has been
described in rodents, humans and also poten-
tially in cattle. Pheromones may have appli-
cations in contraception and in the treatment
of infertility. Compounds such as the 16-
androstene steroids are also being marketed
and are advertised to act as aphrodisiacs in
humans to increase the sex-drive of potential
partners.
6.3 Effects of Stress
What is stress?
A stressor is any environmental change that
disrupts homeostasis, and stress refers to a
state in which the homeostasis of the animal
is threatened or perceived to be threatened.
Neutral stress results in responses that are
neither harmful nor beneficial to the animal.
Distress causes the animal to respond in a
way that can negatively affect its well-being
or reproduction and which may cause patho-
logical damage. The response to stress may
have evolved as a mechanism for coping with
threats to the survival and well-being of the
animal by adjusting several systems within
the body to maintain homeostasis. When
these adjustments fail to compensate for the
stress, or when the response is excessive or
inappropriate, pathological changes and
damage to the animal can occur. 
Stress cannot be totally avoided in a
complex real world. However, not all stress is
harmful and some stimuli are necessary and
beneficial to the animal. The well-being of
animals in a captive environment can actual-
ly be better than in a natural state, since in the
natural state predators, starvation, disease
and natural disasters can threaten animals.
The conditions in the captive environment
should be adjusted to maximize the well-
being of the animals and not simply to mimic
the natural environment.
The effects of stress are ultimately con-
trolled at the level of the hypothalamus, and
are mediated by changes in behaviour and
neuroendocrine effects via the sympathetic
nervous system and the hypothalamic–
pituitary–adrenal axis. These effects are sum-
marized in Fig. 6.13.
Stress can cause changes in behaviour
that may simply involve the animal moving
away from a threat. When this is not possible,
the animal may fight to remove the threat or
try to cope by hiding or developing tonic
immobility or other coping behaviours. If
behaviour is to be used to assess animal well-
being, a thorough knowledge of species-spe-
cific behaviours and the normal behaviours
of the animals is necessary. Coping or abnor-
mal behaviours are recognized as being not
goal oriented and of no obvious benefit to the
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animal. They include behaviours that are
seen in captivity but not in natural settings,
such as self-mutilation or repetitive stereo-
typic behaviours, as well as behaviours that
are seen in the natural setting but are per-
formed with abnormal frequency or in an
abnormal setting. 
Hormonal responses to stress
Hormone signalling plays a vital role in reg-
ulating homeostasis, and virtually every
endocrine system responds in some manner
to specific stressors. This includes hormonal
regulation of metabolism, reproduction,
growth and immunity. Rapid endocrine
responses are mediated by the sympathetic
nervous system activation of the adrenal
medulla (SA system). Longer-term effects
are due to changes in hypothalamic sig-
nalling and pituitary function, with the best
known of these being the activation of gluco-
corticoid production by the adrenal cortex
(HPA axis). For more information on the neu-
roendocrine responses to stress, see Matteri et
al. (2000).
The adrenal gland in mammals consists
of two separate organs, the adrenal medulla
on the interior of the gland, and the cortex,
which surrounds the medulla on the outside
of the gland. The medulla produces the
catecholamines, adrenaline, noradrena-
line and dopamine. The cortex is comprised
of the zona glomerulosa, which produces
mineralocorticoids (predominantly aldos-
terone), and the zona fasciculata and zona
reticularis, which produce glucocorticoids
and androgens. 
SA system
Efferent motor neurones carrying informa-
tion from the central nervous system can be
divided into two main systems, the somatic
or voluntary system that controls voluntary
movements in skeletal muscle, and the auto-
nomic system that controls smooth and car-
diac muscle and various glands. Neurones of
the autonomic nervous system belong to
either the sympathetic or parasympathetic
pathway, which generally act in opposition to
each other. The neurones of the parasympa-
thetic pathway contact the target organs via
cholinergic receptors that use acetylcholine as
the neurotransmitter. The sympathetic neu-
rones use noradrenaline as the neurotrans-
mitter at the target organs and thus have
adrenergic receptors. There are two types of
adrenergic receptors, the α-receptors, which
are selectively blocked by the drug phenoxy-
benzamine, and β-receptors, which are
blocked by propanolol (see Section 3.5).
The sympathetic and parasympathetic
pathways act in opposition to one another,
with the balance between these two systems
regulating body systems. The parasympa-
thetic pathway predominates in the relaxed
state to lower the heart rate and maintain
housekeeping tasks such as digestion. When
the animal is threatened, the sympathetic
pathway predominates (Fig. 6.14) and stimu-
lates the release of adrenaline from the adre-
nal medulla (see Sections 3.5 and 3.12). The
locus ceruleus region in the brainstem con-
tains nerve fibres that secrete noradrenaline
(LUC-NE) and are also stimulated by stress.
Adrenaline and noradrenaline inhibit the
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Fig. 6.13. Scheme of overall responses to stress.
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storage of glucose and fatty acids, inhibit pro-
tein synthesis and stimulate the release of glu-
cose, amino acids and free fatty acids from
muscle, fat tissue and liver. Heart rate is
increased, with blood flow redistributed to the
skeletal and heart muscles, and anabolic
processes, such as digestion, growth, repro-
duction and immune function, are sup-
pressed. This is a rapid hormonal response
that occurs in seconds to support the animal in
the ‘fight or flight’ response (see Section 3.5.)
HPA axis
Neuroendocrine hormones regulate repro-
duction, shift metabolism, influence growth,
affect immunity and alter behaviour. The
neuroendocrine hypothalamic–pituitary–
adrenal (HPA) axis response involves the
release of corticotrophin releasing hormone
(CRH, a 41-amino-acid peptide also known
as corticotrophin releasing factor, CRF) by the
hypothalamus (Fig. 6.15). CRH stimulates the
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Fig. 6.14. Sympathetic nervous system response to stress.
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Fig. 6.15. HPA axis response to stress.
chap06.qxd  10/10/03  8:14 AM  Page 206
anterior pituitary to release adrenocorti-
cotrophic hormone (ACTH) and subsequent-
ly cause the release of glucocorticoids by the
adrenal cortex. Vasopressin also increases the
release of glucocorticoids by potentiating the
effects of CRH on the pituitary to increase the
release of ACTH and also release peptides
derived from pro-opiomelanocortin (POMC),
such as β-endorphin. These opioid peptides
have an analgesic effect and reduce the stress
response by inhibiting the release of CRH.
The major glucocorticoid produced in
humans, pigs, cattle, sheep and fish is corti-
sol, while in rats and birds the major gluco-
corticoid is corticosterone.
Cortisol acts by negative feedback on the
hypothalamus and pituitary to decrease the
production of CRH and ACTH. The HPA
response occurs more slowly (minutes to
hours) and has a more general effect on the
animal than the SA response. ACTH is secre-
ted in a pulsatile manner throughout the day
and is thought to enhance attention, motiva-
tion, learning and memory retention. Both
ACTH and CRH suppress reproduction. 
The LUC-NE system is also involved in
the stress response, as noradrenaline increas-
es general brain activity and stimulates the
release of CRH (Fig. 6.14). CRH, in turn, stim-
ulates the release of noradrenaline, which
acts both locally and systemically. CRH
receptors are present in several areas of the
brain involved with cognitive function and
emotion. Injection of CRH into the brain of
rats produces anxiety behaviour and wake-
fulness and decreases appetite and sexual
receptivity. Elevated levels of CRH in the
hypothalamus have been linked to depres-
sion in humans. CRH thus acts as a neuro-
transmitter and plays a role in the behaviour-
al response to stress. The response to CRH
depends on previous experience and type of
stressor as well as the genetic disposition of
the animal. For more information, see the
review by O’Connor et al. (2000).
CRH AND CRH RECEPTORS. The effects of CRH
on behaviour can be assessed using CRH
receptor antagonists. The first CRH receptor
antagonists used were the peptide fragments
of CRH, namely α-helical CRH9-41 and D-Phe-
CRH12-41. These peptide antagonists do not
cross the blood–brain barrier and had to be
injected into the brain to block stress-induced
behaviours. CRH is a member of a family of
neuropeptides that includes the mammalian
CRH analogues, urocortin and the amphibian
peptides, sauvagine and urotensin I (Table
6.1; see also the review by Lovejoy and
Balment, 1999). The peptide antagonists anti-
sauvagine-30 and astressin have been devel-
oped based on the structure of this family of
peptides (Fig. 6.16). A number of non-peptide
receptor antagonists that readily cross the
blood–brain barrier have also been devel-
oped (see reviews by Christos and Arvanitis,
1998; McCarthy et al., 1999).
CRH acts via two classes of receptors,
CRHR1 and CRHR2 (α,β, and γ forms), all of
which are G-protein-coupled receptors. There
is also a CRH-binding protein that is thought
to regulate the concentration of free extracel-
lular CRH. CRHR1 is linked to increased
anxiety-like behaviour and is localized in
the brain cortex and cerebellum. CRHR2α is
localized in the lateral septum and paraven-
tricular and ventromedial nuclei of the hypo-
thalamus; CRHR2β is found in heart, skeletal
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Table 6.1. Naturally occurring CRH-like peptides.
Hormone Species/source Function
Urotensins Fish Ion balance
Sauvagine Amphibians Osmoregulation in skin, binds to CRHR1 and
CRHR2
Urocortin Lateral hypothalamus, peripheral 40-fold higher affinity for CRHR2, decreased
tissues (lymphocytes, GI tract) gastric emptying and food intake
CRH Neuropeptide Release of ACTH by anterior pituitary, behavioural
changes
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muscle, and in the choroid plexus and cere-
bral arterioles in the brain; and CRHR2γ is
localized in the amygdala. These receptors
have been cloned and expressed in mam-
malian cells and these cells have been used in
a bioassay system to screen for non-peptide
antagonists for specific receptors. 
Sauvagine (a CRH-like peptide isolated
from frog skin) binds to both CRHR1 and
CRHR2 receptors. Specific CRHR1 receptor
antagonists include NBI 27914, CP 154,526
from Pfizer (Fig. 6.16), and antalarmin, which
differs from 154,526 only by a methyl group
on the pyrollopyrimidine moiety. These oral-
ly active compounds reduce anxiety behav-
iour, act as antidepressants and decrease the
production of stress hormones, and can delay
parturition. Other antagonists include DMP-
696 by Dupont and NBI-30775 from
Neurocrine Biosciences, which reduce stress
behaviour but do not affect the HPA axis.
NBI-30775 has a high affinity for CRHR1 but
not CRHR2 and reduces the severity of
depression in humans without affecting the
production of cortisol, and would therefore
be unlikely to cause serious endocrine side-
effects, such as adrenal insufficiency. 
Urocortin is a CRH-related peptide pro-
duced by the lateral hypothalamus as well as
by peripheral tissues, including lymphocytes
and the gastrointestinal tract. It binds CRHR2
with 40-fold greater affinity than CRHR1 and
is thus considered the natural ligand for
CRHR2. Antisauvagine-30 is a specific pep-
tide antagonist for CRHR2 but not CRHR1.
Studies in transgenic mice have linked acti-
vation of CRHR2 to reduced signs of anxiety,
suggesting that CRHR1 and CRHR2 have
opposite effects on stress behaviour. This is
important for allostasis, which is the adap-
tive response to stress by changes in hor-
mones and autonomic responses. CRHR1
present in the pituitary gland is critical for
the rapid initiation of corticosteroid release in
response to stress, while CRHR2 is thought to
be involved in the proper recovery of the
response that may be independent of the neg-
ative feedback by glucocorticoids (Coste et
al., 2001). For example, injection of CRH into
the brain results in increased blood pressure
and heart rate, as is seen during stress. In
contrast, CRH or urocortin given systemical-
ly causes vasodilation and decreases blood
pressure. Urocortin also decreases gastric
emptying and food intake (Wang et al., 2001).
For more information on the action of CRH
analogues, see the review by Eckart et al.
(1999).
Role of various hormones in stress
responses
Glucocorticoids stimulate gluconeogenesis in
the liver by increasing the synthesis of the
enzymes involved in converting amino acids,
glycerol and lactate into glucose and increas-
ing the mobilization of amino acids from
muscle. Glucocorticoids also decrease the
rate of glucose transport and utilization by
cells. This increases blood glucose levels by
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Fig. 6.16. Structure of CRH and CRHR1 receptor antagonist
NH2-I-I-E-M-L-K-N-S-H-A-Q-Q-A
L-Q-E-A-R-A-M-E-L-V-E-R-L-L-H
F-T-L-D-L-S-I-P-P-E-E-E-S-COOH
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as much as 50% above normal. Cellular pro-
tein levels are also decreased by glucocorti-
coids in all cells except the liver, due to
increased protein catabolism and decreased
protein synthesis. Although labile proteins
are first depleted, prolonged exposure to high
levels of glucocorticoids can cause muscle
weakness, decreased size of lymphoid tissue
and impaired immune function. However,
the rate of synthesis of liver protein and plas-
ma proteins made in the liver increases as
part of the acute-phase response, which
occurs in response to infection.
Glucocorticoids increase the mobilization of
fatty acids from adipose tissue and increase
their utilization for energy. Long-term expo-
sure to high levels of glucocorticoids may
suppress growth and accelerate the ageing
process by increasing protein catabolism and
causing hyperglycaemia.
Glucocorticoids affect the expression of
many genes involving various aspects of
metabolism and development. They are per-
missive for the actions of many hormones,
including potentiating the synthesis and
actions of catecholamines in increasing
hepatic gluconeogenesis. Glucocorticoids
have immunosuppressive and anti-inflam-
matory effects. They also increase gastric
secretion, which can lead to the development
of gastric ulcers. Glucocorticoids also
decrease reproductive efficiency by blocking
the effects of LH on the gonads. For further
information, see Sapolsky et al. (2000).
DHEA (dehydroepiandrosterone) and
DHEA sulphate are also produced by the
adrenal cortex in response to ACTH and are
normally secreted in synchrony with cortisol.
However, in critical illness and acute trauma,
such as burns, levels of DHEA and DHEAS
decrease while cortisol levels increase. The
stress of increased physical exercise tends to
increase levels of DHEA and DHEAS. The
role of these steroids in the stress response is
not clear, but DHEA is thought to enhance
immune function and to be correlated with a
sense of well-being in humans. Further infor-
mation can be found in a review by Kroboth
et al. (1999).
Short-term stress increases the secretion
of GH in non-rodents, but reduces the secre-
tion of IGF-I, thus diverting energy from
growth to survival. GH acts as an antagonist
to insulin in peripheral target tissues to spare
blood glucose, while decreased production of
IGF-I reduces growth. Stress also increases
levels of IGF-binding proteins. The increased
GH may be caused by increased glucocorti-
coids. The mechanism of decreased IGF-I
during stress is not established, but lower
numbers of GH receptors and decreased sig-
nal transduction in the liver have been demon-
strated during undernutrition or exposure to
cold temperatures. Under long-term stress,
growth hormone release is suppressed.
Levels of prolactin increase within a few
minutes in response to acute stimuli and then
decrease. Passive, rather than active, coping
responses to stress increase prolactin. The
increased prolactin may be due to production
of β-endorphin, which decreases levels of
dopamine, which normally acts as prolactin
inhibitory factor (PIF) to inhibit prolactin
release. Vasoactive intestinal peptide (VIP)
and thyrotrophin releasing hormone (TRH)
also directly stimulate prolactin release. The
role of prolactin in the stress response is not
clear, but it has been suggested to modulate
immune function.
Acute psychological stress increases TSH
secretion from the pituitary and increases
release of T3 and T4 from the thyroid in non-
rodents, to increase the metabolic rate. Cold
temperature increases the activity of thyroid
hormones, while chronic undernutrition
decreases thyroid activity. This is due to
changes in hypothalamic TRH release, pitu-
itary thyrotroph function, thyroid hormone
production and peripheral thyroid hormone
receptors. The reduction in metabolic rate
when food supply is limited would decrease
energy usage and improve survivability.
Chronic stress reduces thyroid hormone
function and elevated levels of glucocorti-
coids inhibit the conversion of T4 to T3.
Renin is released from the kidney in
response to various forms of distress. It acts
on angiotensinogen to produce active
angiotensin, which is a powerful vasocon-
strictor. The activation of α-adrenergic recep-
tors on pancreatic β cells by the sympathetic
nervous system also suppresses insulin
release. Glucagon release is also increased by
aversive states and these effects on insulin
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and glucagon elevate the plasma glucose
level during stress.
In summary, exposure to distress
increases levels of adrenaline, noradrenaline,
corticosteroids and, in some species, growth
hormone and thyroxine. These hormones
have a catabolic function and mobilize ener-
gy reserves to allow the animal to deal with
the adverse situation. Conversely, levels of
anabolic hormones (insulin, androgens and
oestrogens) decrease with distress. Prolonged
exposure to aversive situations thus results in
decreased thyroid activity, reduced body
growth and decreased reproductive activity.
Assessment of stress
Behavioural and physiological measures
Animals can respond to stress by changes in
behaviour, changes in the autonomic nervous
system and catecholamine production, neuro-
endocrine changes in the hypothalamic–
pituitary system and changes in immune
function (Table 6.2). However, not all of these
systems are altered by any one stress and
there is no non-specific stress response that
applies to all stressors. It is thus important to
monitor a number of systems to assess the
degree of stress in animals. For further infor-
mation on the concept of stress and methods
for assessing stress, see the series of review
papers by Clark et al. (1997a,b,c).
Animals respond to stress with species-
specific behaviours as well as learned behav-
iours that are specific to the individual
animal. Species-specific behaviours have
allowed animals to survive in the wild, but
may result in a harmful response in captive
animals. Individual animals may react differ-
ently to the same stimulus, depending on
their genetic constitution and previous expe-
riences. Circadian rhythm and environmental
effects, as well as age, sex, physiological state
and population density, can also affect the
reactions of individuals to stress.
Useful behaviours for monitoring well-
being include level of activity, posture, vocal-
ization, aggressiveness, movement patterns,
feed and water intake and sleep patterns.
Animal preference tests, in which an animal
can choose between different situations or
stimuli, can also be used to assess whether a
particular stimulus is undesirable. The
amount of effort that an animal is willing to
use to avoid the stimulus is used as a meas-
ure of the degree of averseness of the stimu-
lus. In this way, preference testing may be
used to rank the suitability of housing sys-
tems, food and other environmental factors.
Physiological responses to stress include
changes in heart rate, blood pressure,
gonadal function and immune function that
could be monitored to assess the level of
stress (Table 6.2). Chronic stress results in
decreased growth, increased disease, reduced
fertility, gastric ulcers and hypertension.
Hormonal measures
The activity of the hypothalamic–pituitary–
adrenal axis, as measured by the levels of
ACTH and glucocorticoids, has been widely
used as an index of stress. However, changes
in levels of these hormones do not necessari-
ly indicate that the animal is in distress. For
example, surgical trauma can result in release
of ACTH even though the animal is anaes-
thetized and presumably unaware of what is
happening. The magnitude of the ACTH
response does not always match the degree of
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Table 6.2. Summary of potential methods for assessing stress.
Behavioural/physiological Endocrine Metabolic systems
Activity/sleep patterns Catecholamines Immune function
Posture/stereotypes ACTH/CRH, glucocorticoids Disease state
Feed and water intake Gonadotrophin/sex steroids Growth performance
Heart rate and blood pressure Cytokines Reproductive performance
β-Endorphin, renin and prolactin
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painfulness or unpleasantness of the treat-
ments. Glucocorticoid levels also depend on
the behavioural response that occurs due to
the stress. Other factors, such as the availabil-
ity of food and water, can also affect the mag-
nitude of this response. If an animal perceives
an event as threatening, it will respond
whether the event is actually threatening or
not. Glucocorticoid levels are also increased
in situations that are not unpleasant, such as
during coitus, voluntary exercise, in anticipa-
tion of regular deliveries of food, and simply
exposure to novel environments. There is a
large diurnal variation in the pulsatile release
of glucocorticoids. Sampling at the same time
every day can minimize this variation. 
Repeated regular exposure to a stress, in
which the animal can anticipate when the
stress will occur, can result in habituation and
dampening of the corticosteroid response.
For example, electric shocks delivered at
irregular intervals produce a higher cortico-
steroid response than electric shocks given at
regular intervals. In the same manner, if the
animal has a sense of control and can predict
the stress, the glucocorticoid response will be
lessened. In contrast, for highly painful and
aversive stressors, such as dehorning, the
response may increase when the stress is
repeated. The endocrine response to stress
also depends on the individual coping
responses of the animals. If the animal reacts
in an active manner in an attempt to control
the threat, it will exhibit aggression and sta-
tus control behaviours. If it is driven by
anger, the endocrine responses will be
increased levels of noradrenaline and sex
steroids, while if it is driven by fear the levels
of glucocorticoids and catecholamines will
increase and sex steroids will decrease. If the
animal reacts in a passive manner due to a
loss of control, it will exhibit defeat behav-
iours, resulting in increased glucocorticoids
and decreased sex steroids.
Glucocorticoid levels return to near nor-
mal in animals under long-term stress,
because of negative feedback of glucocorti-
coids on ACTH release. However, there may
be changes in the response of the adrenal
glands to ACTH in chronic stress. Repeated
challenge with ACTH increases the produc-
tion of glucocorticoids, so administering
ACTH or providing an acute stress to chroni-
cally stressed pigs (a challenge test) may
result in an increased glucocorticoid pro-
duction compared with that of non-stressed
pigs.
In addition to glucocorticoids, levels of
β-endorphin, renin and prolactin are affected
by stress, and plasma levels of these hor-
mones have been suggested as possible indi-
cators of animal well-being.
In summary, a number of different vari-
ables should be measured to accurately
assess animal well-being, since animals
respond in a variety of different ways to aver-
sive situations. Behaviour can be assessed
non-invasively and provide information on
the nature of the distress and the coping strat-
egy that the animal has adopted. Differences
in behaviour among animals kept in different
environments may be used to indicate that an
environment is causing distress. However,
some changes in behaviour may be difficult
to interpret. Additional criteria need to be
measured to assess the effects of long-term or
subtle aversive stimuli. 
Issues related to sampling
Measures of physiological, metabolic or
endocrine changes in blood samples tend to
be invasive and thus induce confounding
reactions in the animal. This can be more
severe in semi-domesticated or wild animals.
Levels of catecholamines can increase within
seconds after restraint, while the cortisol level
increases within a few minutes after restraint
and then remains elevated for several hours.
Sedating the animals or habituating them to
the blood sampling procedures may reduce
the effects of handling, but may result in
atypical responses. Habituation is not suit-
able, for example, for procedures involving
the stress of handling. Alternatively, less
invasive methods that reduce the degree of
handling can be used. Indwelling catheters
can be placed in blood vessels and animals
can be trained to cooperate with blood sam-
pling procedures. Remote blood sampling
equipment attached to the free-moving ani-
mal can be used for non-invasive blood sam-
pling of large animals. However, implanting
catheters requires surgery and it can be
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difficult to keep the catheters patent.
Alternative non-invasive methods
include measurements of cortisol in readily
accessible body fluids, such as saliva, milk,
urine and faeces. Salivary cortisol level is
generally correlated with blood cortisol but is
present at only about 10% of the level present
in blood. Saliva can be collected non-inva-
sively by having the animal chew on a gauze
sponge. There can be problems with contam-
ination of the sponges with feed and with
rumen fluid in cattle, but this method has
been successfully used to assess cortisol sta-
tus in swine. Cortisol is also transported from
plasma to milk, so that milk cortisol concen-
tration can be used as an indicator of stress in
dairy cattle. Urine contains both free cortisol
and cortisol metabolites, but levels are quite
low. There is also a lag time between cortisol
release and excretion. For a quantitative esti-
mate of cortisol status, a urine sample should
be collected over the entire day. Faecal corti-
sol may be useful for studies of stress in wild
animals, but factors such as lag time, volume
of faeces and rate of passage need to be
considered.
In plasma, there is an equilibrium
between glucocorticoids bound to corticoid-
binding protein (CBP, transcortin) or albumin
and free, unbound steroids. Only the free
steroids are thought to have biological activi-
ty, so increasing the concentration of CBP
would lower the activity of the glucocorti-
coids. The ratio of free to bound steroids can
be altered by changes in the amount of bind-
ing protein, particularly during chronic stress
when protein catabolism occurs. There is,
therefore, some controversy over whether the
total amount of glucocorticoids, or simply the
free steroids, should be measured to assess
the stress response. All cortisol in the saliva is
present in the free form and not bound to
protein.
Effects of stress on the immune system
and disease resistance
Overview
The immune system contains a number of
different leukocytes (white blood cells) that
play integral roles in the overall response to
an immune system challenge. This includes
granulocytes and monocytes, which are
formed in the bone marrow and protect the
body by ingesting invading organisms, by
the process of phagocytosis, to destroy them.
This is called innate immunity (Fig. 6.17).
Monocytes mature in tissues to become large
macrophages, which can combat foreign
pathogens without prior exposure to them
through disease or vaccination. The granulo-
cytes include neutrophils, which attack bacte-
ria by phagocytosis, and eosinophils, which
attach to parasites to kill them.
Other types of white blood cells include
lymphocytes and plasma cells, which are pro-
duced in the lymphoid tissues and are
involved in the immune reactions. They are
involved in acquired immunity (Fig. 6.18),
since the response is directed specifically
towards foreign agents that have been pres-
ent previously. Humoral immunity is a type
of acquired immunity that refers to the pro-
duction of antibodies by B-cell lymphocytes
(see Section 2.1), while cell-mediated immu-
nity is acquired immunity carried out by acti-
vated T cells. There are three groups of T-cell
lymphocytes, helper T cells, cytotoxic T cells
and suppressor T cells. The helper T cells (Th)
produce lymphokines (also known as
cytokines), which are peptide hormones that
include interleukins (IL) and interferons
(IFN) that act in a paracrine or autocrine
manner to stimulate other immune cells in
the process of inflammation and immune
reactions. There are two major types of Th
cells that are mutually inhibitory. Th-1 cells
produce IL-2, IFN-γ and TNF-β to promote
cellular immunity and inflammation. Th-1
cells are inhibited by IL-4 and IL-10, which
are the major anti-inflammatory cytokines.
Th-2 cells secrete IL-4, IL-10 and IL-13 to pro-
mote humoral immunity. Th-2 cells are inhib-
ited by IL-12 and IFN-γ, which are the major
212 Chapter 6
Fig. 6.17. Innate immunity (bone marrow).
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pro-inflammatory cytokines. Thus, the prod-
ucts of Th-1 cells inhibit the Th-2 cells and
vice versa. Cytotoxic killer T cells attack and
kill foreign cells or cells that have been inva-
ded by viruses. The suppressor T cells
regulate the other cells to prevent severe
immune reactions that could damage
the animal’s own tissues.
Stress from traumatic injury resulting in
bacterial or viral infection causes an inflam-
mation response and production of cytokines
by macrophages, vessel endothelial cells and
fibroblasts. Bacterial infections induce the
production of IL-1, IL-6, IL-8 and TNF-α,
while viruses induce the production of type I
interferons, such as IFN-α and -β. These dis-
tinctions are not absolute, but cytokines can
be used as markers of infection and for dis-
criminating between bacterial and viral infec-
tions (Fossum, 1998). 
Cytokines induce a sickness response,
causing fever, fatigue, loss of appetite and
decreased libido. They also stimulate an
acute-phase response, which includes the
production of hepatic acute-phase proteins,
including protease inhibitors, coagulation
factors, complement factors, transport pro-
teins and scavengers that are released into the
circulation. In addition, synthesis of acute-
phase-regulated intracellular proteins,
including transcription factors, intracellular
enzymes and cell surface receptors is also
increased. The role of the acute-phase pro-
teins is to restore homeostasis. For example,
C-reactive protein (CRP, named for its ability
to bind the C protein of pneumococci), along
with other complement proteins, binds to
bacteria in the process of opsonization and
tags the bacteria for destruction by
macrophages. Tests are available for the rapid
determination of CRP in blood, and these
tests are used to diagnose inflammation and
determine the effectiveness of treatments. 
Inflammation is the complex of changes
that occurs in injured tissue. It is character-
ized by enhanced local blood flow, increased
permeability of the capillaries, clotting of the
fluid in the interstitial spaces and swelling of
the tissue. Inflammation serves to wall off the
damaged or infected area from the remaining
tissues to contain the damage. These changes
cause the redness, heat, swelling and pain
that are associated with tissue injury. Large
number of granulocytes and monocytes
migrate to the area and are activated by lym-
phokines and tissue products such as
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Fig. 6.18. Acquired immunity (lymphoid tissue).
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histamine, bradykinin, serotonin and
prostaglandins to begin their phagocytic
actions.
Stress effects on the immune system
There is a lot of evidence demonstrating that
prolonged exposure to aversive conditions
reduces the health of animals. Many inten-
sive livestock production systems reduce the
immune response of animals and the resist-
ance to disease. For example, the stress of
shipping calves to feedlots increases their
susceptibility to bovine respiratory disease
(shipping fever). This is due in part to the
decrease in neutrophil release from bone
marrow caused by glucocorticoids. In con-
trast, shipping pigs decreases body weight
but does not reduce immune function,
although pigs with lower social status have
generally lower immune function compared
to dominant pigs.
The nervous system can directly modu-
late the activity of the immune system to
decrease disease resistance. This occurs by
the direct innervation of lymphoid tissue by
autonomic nerves, by paracrine action of
noradrenaline released from nearby nerves
on immune cells, and through the HPA axis. 
Glucocorticoids affect the immune
response in animals to lower the resistance to
infection and decrease inflammation (Fig.
6.19). Glucocorticoids affect cell-mediated
immunity by decreasing the number of lym-
phocytes and eosinophils, suppressing natu-
ral killer (NK) cell activity and decreasing the
amount of lymphatic tissue. Increased levels
of glucocorticoids can destroy thymus cells
and negatively affect T cells. There are also
negative effects on B cells, causing an inhibi-
tion of antibody formation. Adrenalectomy
prevents the negative effects of stress on the
immune response in laboratory animals.
Glucocorticoids modulate immune
responses by inhibiting the production of
type 1 pro-inflammatory cytokines, which
stimulate cellular immunity. These cytokines,
particularly interleukin 1 (IL-1), also act on
the hypothalamus to increase the secretion of
CRH, which acts on the pituitary to release
ACTH and subsequently increase the pro-
duction of glucocorticoids from the adrenal
cortex. CRH is also produced by immune
cells in the spleen or in nerve endings and
acts on immune cells at the site of inflamma-
tion. The glucocorticoids and CRH then act
by negative feedback on the immune system
to increase the formation of neutrophils and
decrease the formation of macrophages and
lymphocytes. The production of pro-inflam-
matory leukotrienes and prostaglandins by
immune cells is also decreased and the activ-
ity of pro-inflammatory transcription factors,
such as nuclear factor-κB (NF-κB) and acti-
vating protein-1 (AP-1), is inhibited by gluco-
corticoids. A polymorphism has been
identified in the human glucocorticoid recep-
tor gene that increases the susceptibility to
glucocorticoids. 
Both glucocorticoids and catecholamines
also increase the production of the type 2
anti-inflammatory cytokines IL-4, IL-10 and
IL-13 by Th-2 cells. These cytokines promote
humoral immunity and protect against extra-
cellular bacteria and parasites and soluble
toxins and allergens. Further information on
the effects of stress on the immune response
can be found in the review by Elenkov and
Chrousos (1999).
Thus cortisol reduces inflammation and
speeds up the healing process. In addition to
inhibiting the production of cytokines, corti-
sol stabilizes the lysosomal membranes and
reduces the release of proteolytic enzymes
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from lysosomes. It also decreases the permea-
bility of capillaries and reduces the loss of
plasma and the migration and activity of
white blood cells. This blocks the further
release of inflammatory materials from cells.
The reduction in cytokine production also
reduces fever. The activation of the HPA axis
and the production of glucocorticoids thus
keep the immune response in check and pre-
vent it from becoming hypersensitive and
therefore harmful.
The effects of stress on immune function
depend on the nature of the stressor as well
as the immunological function being meas-
ured. Immune system function can be evalu-
ated by in vitro measures, such as the ability
of natural killer cells to destroy virus-infected
cells and the proliferation of T and B cells
after exposure to mitogens in culture. In vivo
measures of immune function are antibody
formation after exposure to antigens and T-
cell-mediated delayed hypersensitivity and
graft rejection. The effects of stress on resist-
ance to disease can vary. Social stress in
chickens decreases the resistance to viral dis-
eases such as Newcastle disease or Marek’s
disease, but increases the resistance to bacter-
ial infections. This may be due to the action of
glucocorticoids in suppressing inflammation
from bacterial infection.
The reduction in cellular immunity, and
the accompanying inflammation, pain and
sickness behaviour, allow the animal to
respond more effectively to stressful situa-
tions in the short term. However, the chronic
depression of cellular immunity by long-term
stress decreases the ability of the animal to
fight infection by viruses, bacteria, fungi and
protozoa, and increases the possibility of ill-
ness. Thus, long-term stress is undesirable
and makes the animal more susceptible to
disease. Long-term aversive stress can also
lead to organ damage, such as cardiovascular
disease and gastric ulcers. Increased release
of free fatty acids can result in the formation
of fatty deposits on arterial walls and can
lead to atherosclerosis and hypertension.
Other changes due to long-term stress
include adrenal hypertrophy, haemorrhage,
skeletal muscle degeneration and reduced
weight of other organs, such as the spleen
and thymus.
The levels of anabolic hormones, includ-
ing GH and IGF-I, are decreased during dis-
ease, so supplementing with anabolic
hormones might reduce the catabolic effects
of disease. GH treatment of critically ill
patients increases protein synthesis, stimu-
lates the immune system and improves
wound healing. Use of insulin and anabolic
steroids also increases nitrogen retention.
Treatment of growing cattle with GH
improves the immune response to experi-
mental challenge with bacterial lipopolysac-
charide (LPS), but not to infection with
parasitic coccidia. However, treatment with
the anabolic steroids oestradiol and proges-
terone improves the response to coccidia
infection. It is thus apparent that treatment
with anabolic hormones can improve animal
responses to disease. Further research is
needed in this area.
Effects on reproduction
Animals that are suffering from chronic stress
do not have the same reproductive success as
non-stressed animals. Acute stressors may
also impair reproductive function during
critical periods of the reproductive cycle,
such as ovulation, early pregnancy and lacta-
tion. Stress decreases the secretion of GnRH
by the hypothalamus and subsequent pro-
duction of LH and FSH by the pituitary and
sex steroids by the gonads (Fig. 6.20). This
causes decreased libido and fertility rates,
lack of implantation of the fertilized ovum
and retarded growth of the embryo. Perinatal
stress during sensitive periods can demas-
culinize males and delay puberty in females.
Glucocorticoids, ACTH and CRH, as
well as vasopressin and opioids such as β-
endorphin, reduce GnRH secretion. IL-1 also
inhibits the hypothalamic–pituitary–gonadal
axis. Glucocorticoids may also directly inter-
fere with gonadotrophin secretion by the
pituitary, inhibit the production of gonadal
steroids and reduce the sensitivity of target
tissues to sex steroids. The initial rapid
release of LH is mediated via arachidonic
acid and its metabolites, while the prolonged
release of LH is regulated by protein kinase
C-dependent mechanisms. Glucocorticoids
reduce the release of LH by inhibiting the
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hydrolysis of phospholipids to release arachi-
donic acid. Glucocorticoids also affect the
feedback of gonadal steroids on the pituitary
gonadotropes. In rats, glucocorticoids pre-
vent oestrogen from sensitizing the pituitary
to GnRH and thus prevent the preovulatory
release of LH.
Glucocorticoids interact with reproduc-
tive hormones during early development of
the neuroendocrine system. Elevated cortico-
steriod levels negatively affect pregnancy rates
in gilts and the rate of sexual development of
boars. Sexual behaviour depends on the pro-
duction of gonadal hormones and may be
suppressed when a stressor interferes. Sexual
activity of low-ranking males is depressed
when dominant animals are present, due to
low production of testosterone. The stress of
low social rank in females can interfere with
LH production and prevent ovulation and
oestrous behaviour. Paradoxically, acute
stress, such as mixing with unfamiliar gilts,
can increase LH production and is used for
oestrus synchronization and induction of
early puberty. The first few days of early preg-
nancy until implantation is thought to be a
particularly stress-sensitive period.
Stress also negatively affects lactation.
Catecholamines and opioids produced dur-
ing stress reduce oxytocin production, which
negatively affects milk ejection and yield.
Nutritional stress delays the onset of
puberty, interferes with normal cycling in
females and results in hypogonadism and
infertility in males. Leptin plays a role in this
effect, and adequate levels of leptin are
required for gonadotrophin secretion (see
Section 3.8). Heat stress also inhibits
gonadotrophin secretion, due to decreased
production of GnRH and decreased sensitivi-
ty of the pituitary to GnRH stimulation.
Long-term exposure to cold temperature also
reduces LH and FSH secretion. This may be
due in part to inadequate nutrition and lack
of leptin signalling due to the increased meta-
bolic demand at cold temperatures.
The effects of stress and glucocorticoids
are not always negative. Glucocorticoids pre-
pare the fetus for birth by stimulating the
production of lung surfactants and the matu-
ration of the gut. Parturition is initiated by a
surge of cortisol from the fetus, which is stim-
ulated by the production of CRH (see Section
5.1). Infusion of the CRHR antagonist anta-
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larmin into the fetus has been shown to delay
parturition in sheep (Chan et al., 1998).
Effects on growth performance
Chronic treatment of grower pigs with gluco-
corticoids decreases growth rate.
Glucocorticoids are catabolic and adversely
affect growth performance by increasing glu-
coneogenesis and decreasing protein incor-
poration into tissues. The overall body
response to stress results in decreased growth
rate, decreased efficiency of nutrient utiliza-
tion for growth and increased energy require-
ments for maintenance (Fig. 6.21). In young
animals, a loss of growth efficiency from
stress can be offset somewhat by increased
efficiency of nutrient use for thermogenesis.
In addition to endocrine responses, stress
reduces nutrient availability by decreasing
appetite, gut motility and nutrient absorp-
tion, and by affecting the activity levels of the
animal. Nutrient use is also directed towards
fever thermogenesis and away from growth.
While poor growth and reproduction likely
indicate that the animal is in a poor state of
well-being, the reverse is not always true.
One cannot assume that if an animal appears
to perform well, it is not under some form of
stress.
Stress effects on the metabolism of differ-
ent tissues depend on the responsiveness of
the cells to the different hormones produced
during stress. GH and IGF-I produce anabol-
ic effects, and these hormones are generally
inhibited during disease. ACTH and the glu-
cocorticoids produced during stress cause
catabolic effects. Thyroid hormone regulates
the basal metabolic rate and affects nutrient
uptake by cells. In addition, changes in blood
flow to different tissues affect nutrient
availability and the exposure of the tissues to
hormones. Blood flow changes from vasocon-
striction and vasodilation are caused by
arachidonic acid metabolites (prostaglandins,
prostacyclins and thromboxanes) and nitric
oxide (NO).
Catabolism of glycogen in liver and
muscle provides glucose, resulting in tran-
sient hyperglycaemia and then hypogly-
caemia as the glycogen is depleted.
Catabolism of adipose tissue provides fatty
acids for energy production. Muscle protein
catabolism due to TNF-α and IL-1 provides
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amino acids such as glutamine that are
required by immune cells. There is a priority
of nutrient use among different tissues, so
that different body structures are differential-
ly affected by stress. For example, the loco-
motor and fast-twitch rectus femoris muscle
is relatively unaffected, but psoas major,
which is a postural muscle with slow-twitch
fibres, is catabolized in cattle during stress.
Severe stress results in the overproduction of
stress hormones and cytokines, causing dra-
matic changes in metabolism, leading to
catabolism, tissue wasting and pathological
conditions. IL-1 induces fever and reduces
feed intake. Blocking the response to the
cytokines TNF-α and IL-1 using receptor
antagonists decreases the severity of weight
loss and muscle wasting due to disease stress.
Exposure to disease organisms stimu-
lates the immune system response and
diverts nutrients away from growth. The
stress of infections also reduces appetite. This
may be due in part to the action of urocortin.
Intravenous injection of urocortin has been
shown to delay gastric emptying and reduce
food intake in rodents and marsupials. These
effects are blocked by CRHR2 receptor antag-
onists, but not by selective antagonists for
CRHR1. Low levels of infection cause
increased production of acute-phase proteins,
reduced synthesis of muscle proteins,
increased maintenance energy requirements
and decreased feed intake. Subtherapeutic
levels of antibiotics are sometimes included
in animal feed to reduce the activation of the
stress response by subclinical infections with
bacteria. Alternatively, the health status in a
herd can be improved by increasing sanita-
tion and limiting public access. For pigs, the
effects of disease can be minimized with
specific-pathogen-free (SPF) herds or select-
ing for animals with a high immune
response. For further information on the
effects of stress on performance, see von
Borell (1995) and Elsasser et al. (2000).
Summary
Stress occurs when the homeostasis of an ani-
mal is threatened, and this can have drama-
tic negative effects on the immune system,
reproduction and the growth and perform-
ance of animals. These responses are due to
the production of stress hormones, including
the HPA and SA axis (CRH, ACTH, glucocor-
ticoids and catecholamines) and cytokines, as
well as decreases in anabolic hormones (IGF-
I, GH, thyroid hormones and sex steroids).
These hormonal changes, as well as behav-
ioural and physiological changes, can be used
to assess the degree of stress that an animal is
experiencing. Altering these hormonal
responses can potentially reduce the effects of
stress. In particular, the use of specific CRH
receptor antagonists (for example, see Deak et
al., 1999) shows promise to alleviate some of
the negative aspects of stress without
adversely affecting other endocrine func-
tions. Further research in this area that pro-
duces a more complete understanding of the
endocrine and metabolic responses to stress
may lead to additional treatment strategies.
6.4 Endocrine Applications in
Toxicology 
Endocrine disruptors or modulators
The terms ‘endocrine disruptor’ or
‘endocrine modulator’ refer to chemicals that
have direct endocrine effects or indirectly
affect the normal endocrine systems of ani-
mals. The primary concern has been xenobi-
otic chemicals in the environment, including
persistent organohalogen compounds, such
as pesticides, industrial chemicals including
surfactants, and organometals. However,
other naturally occurring compounds, such
as phyto-oestrogens, are also potent
endocrine modulators.
Environmental pollutants have been
studied for their lethal and carcinogenic
effects, but many also have endocrine disrup-
tor activities. High levels of these compounds
in the Great Lakes have been linked to thy-
roid dysfunction, decreased fertility and
hatching success, metabolic and behavioural
abnormalities, altered sex ratios and compro-
mised immune systems in various animals in
this ecosystem. High levels of dioxins were
linked to decreased fish populations, and
reproductive losses and mortality in mink
that were fed fish from the Great Lakes.
Mothers with high levels of polychlorinated
biphenyls (PCBs) and dioxin had babies with
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statistically decreased mental development
and increased incidence of learning disorders
that could be detected by skilled psycholo-
gists. The developing fetus may be more sen-
sitive to the effects of endocrine disruptors
than is an adult animal. Associations between
decreased sperm counts in men and the
increased human exposure to synthetic
chemicals over the period 1938–1998 have
also been claimed, but a cause and effect rela-
tionship has not been demonstrated conclu-
sively. For more information on this issue, see
Colborn and Thayer (2000).
Natural, plant-derived compounds such
as phyto-oestrogens can also have endocrine-
modulating effects that are at least as potent
as those of man-made xenobiotic chemicals.
Many plant and herbal extracts have been
used as health aids for some time and their
use is generally unregulated. Most natural
compounds that affect endocrine function are
biodegradable, but exposure to these com-
pounds through the diet can be high.
Since it is impossible to perform chemi-
cal analysis for all potential endocrine dis-
ruptors, certain ‘indicator species’, such as
rats, have been used as bioindicators to assess
the impact of endocrine-modulating chemi-
cals in the environment. While this approach
measures actual effects of complex mixtures
of chemicals on biological systems, the results
obtained with one species have often been
extrapolated to other, unrelated species.
However, there are dramatic differences
between species in the activities of different
hormones and receptors, the ability to detox-
ify contaminants and in other factors that
control attributes, such as sex ratios. Very lit-
tle is known about the comparative
endocrinology of many species. Thus, the
effects of a potential endocrine disruptor seen
in one species may not be applicable to other
species.
Assessment of endocrine disruptor
activity
Researchers have used a number of different
assays to demonstrate the effects of potential
endocrine disruptor chemicals (EDCs). Public
concern about the effects of endocrine dis-
ruptors on wildlife and human populations
has led to the development of government
testing programmes. The US Environmental
Protection Agency (EPA) and the European
Organization for Economic Cooperation and
Development (OECD) are developing stan-
dardized testing procedures for endocrine
disruptors. This will provide standardized
protocols that produce reproducible results
that can be compared across many different
laboratories. A number of different testing
protocols with different end-points are being
validated. Testing starts with the in vitro
assessment of endocrine disruption activity,
followed by in vivo tests to determine the
effects on different development stages of the
animal model. In addition to tests with mam-
mals (rodents), tests using various wildlife
species (fish, birds, reptiles, amphibians and
invertebrates) are being considered. Testing
procedures and the endocrine end-point
being measured need to be defined carefully
and appropriate reference chemicals that pro-
duce defined effects are required to standard-
ize the procedures. For information on the
validation of assay methods for endocrine
disruptors, see Ashby (2000).
The first set of tests (Fig. 6.22) includes in
vitro screens to determine whether the test
compound has the potential to interact with
the oestrogen receptor, androgen receptor or
the thyroid receptor. This does not confirm
toxicity, but allows for priority setting for fur-
ther testing and determination of the poten-
tial mechanism of action of the chemical. The
next level of testing is short-term in vivo
assays, such as the effect on the development
of male and female sex organs and tests in
prepubertal animals, to determine effects on
thyroid activity, as well as effects on neonatal
animals from in utero exposure. Finally, in
order to fully assess the potential risk of
endocrine disruptors, multigenerational in
vivo studies should be conducted to assess
the effects on reproduction and development.
Differences among species, dose–response
effects that cover the potential range on expo-
sure, persistence in the environment, route of
exposure and potential for exposure during
critical periods of development need to be
considered. Further details on the testing pro-
grammes for EDCs being developed by the
US EPA are summarized by Fenner-Crisp et
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al. (2000) and the OECD programme is
described by Huet (2000).
Endocrine disruptors can potentially act
by:
1. Binding to hormone receptors to act as hor-
mone agonists or antagonists;
2. Altering the synthesis, transport or metab-
olism of hormones, thus affecting hormone
levels; and
3. Interfering with signalling between differ-
ent glands, such as the hypothalamus–
pituitary–endocrine gland system. 
The testing procedures are designed to inves-
tigate one or more of these potential mecha-
nisms.
In vitro assays
In vitro assays for estimating oestrogenic
activity have been developed. In one exam-
ple, a cell line is transfected with a recombi-
nant oestrogen receptor and a reporter gene
(lac-z for β-galactosidase, luc for luciferase or
gfp for green fluorescent protein) linked to an
oestrogen-responsive element. Treatment
with compounds that activate the oestrogen
receptor increases the expression of the
reporter gene. Competitive binding assays
for the oestrogen receptor, androgen receptor,
progesterone receptor and thyroid hormone
receptor have also been developed, but these
assays do not determine whether inhibition
or activation of the hormone is occurring.
Oestrogenic compounds can also stimulate
cell division and expression of oestrogen-
responsive genes, such as c-myc, pS2 and the
progestin receptor in oestrogen-responsive
cells. The human breast tumour cell line
MCF-7, T-47D or Bg-1 cells have been used
for this purpose. Oestrogenic compounds can
also stimulate synthesis of sex hormone bind-
ing globulin in HepG2 liver cancer cells.
Oestrogen receptor antagonists, such as ICI
182,780 and ICI 164,384, can be used to block
the oestrogenic effects of the test compounds
and demonstrate that specific binding to the
oestrogen receptor is occurring. 
In vivo assays
In vivo bioassays for oestrogenic activity
include determining the effect of treatment
with the test compound on immature (22–23-
day-old) female rats. Oestrogenic com-
pounds cause premature vaginal opening
and increases in ovarian and uterine weight.
The induction of oestrogen-responsive pro-
gesterone receptor and peroxidase genes,
overall DNA synthesis in the uterus and his-
tological examination to measure thickening
and mitotic activity of the vaginal epithelium
can be compared to an oestradiol-positive
control.
Oestrogen induces the production of
vitellogenin in the liver of juveniles or males
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of oviparous species, although only females
normally produce vitellogenin. Test com-
pounds can be administered in vivo by
intraperitoneal injections or added to in vitro
cultures of liver cells from fish. Other effects
of endocrine disruptors in fish are reduced
gonad size, fecundity, egg size, hatching suc-
cess, and expression of secondary sex charac-
teristics and increased time to sexual
maturity due to decreased levels of plasma
sex hormones. The effects on plasma hor-
mone levels and sperm quality and quantity
can be measured in males. The Hershberger
assay, using castrated male rats, is used to
detect chemicals that interact with the andro-
gen receptor and cause proliferation of
androgen-dependent tissues.
Thyroid-active substances can be detect-
ed using a frog metamorphosis assay with
Xenopus laevis. Measurement of tail resorp-
tion and mortality, as well as thyroid receptor
mRNA and tissue levels of T3 and T4, can be
made. 
The induction of specific behavioural
responses (e.g. lordosis in female rats and
mounting behaviour in males) can also be
measured, keeping in mind that behaviours
vary among different species. For more infor-
mation on assays for endocrine disruptors,
see the reviews by Oberdörster and Cheek
(2000) and Lister and Van der Kraak (2001).
Sources of endocrine disruptors
Particular interest has been expressed in
chemicals that affect the actions of gonadal
steroids and thus affect reproduction. This
concern may be due, in part, to the experi-
ence with the use of diethylstilbestrol (DES).
This was a synthetic oestrogen that was used
to prevent miscarriages in pregnant women,
but it was later found to have teratogenic
effects in the fetus. A large number of xenobi-
otic chemicals and plant-derived compounds
have been shown to act as agonists of steroid
hormones, particularly oestrogens. These
phyto-oestrogens and xeno-oestrogens are
typically several orders of magnitude lower
in activity than natural oestrogens. Phyto-
oestrogens are the most potent source of
environmental oestrogens, based on in vitro
activity measurements. There was concern
that exposure to these oestrogenic com-
pounds in the environment was causing
reproductive problems in wildlife. Fears that
they were also causing decreased sperm
counts in men and breast cancer in women
have not been substantiated. 
Phyto-oestrogens can also have anti-
oestrogen effects, and foods and dietary sup-
plements rich in phyto-oestrogens are
commonly used as a preventive measure
for breast and prostate cancer. For further
information on endocrine disruptors in the
food chain and environment, see Nilsson
(2000). 
Plant-derived endocrine modulators
A wide variety of oestrogenic and anti-
oestrogenic compounds has been identified
in plants (Fig. 6.23). The flavonoids are the
most widely distributed group of phyto-
oestrogens and include isoflavones in soy
and clover, as well as flavone, flavanone and
chalcone. Coumestrol is derived from
flavonoids and is one of the most potent
oestrogenic compounds in plants. It is
thought to be responsible for ‘clover disease’
in sheep, which results in lesions in the repro-
ductive organs and infertility. The
isoflavonoids genistein and daidzein are
present in high amounts in soy products,
with 60 g of soy protein providing 45 mg of
isoflavones. This dosage can significantly
affect the menstrual cycle in women.
Genistein is also a specific inhibitor of tyro-
sine protein kinases. Lignans such as entero-
lactone are present in vegetables and in high
levels in flaxseed. They have weak oestro-
genic effects and may act as anti-oestrogens
and inhibit the conversion of androstene-
dione to oestrone by the aromatase enzyme.
Sterols such as β-sitosterol are also important
phyto-oestrogens. They are present in wood
and can be released from bleached kraft pulp
mills at levels high enough to affect the
endocrine status of fish. Bacterial degrada-
tion of plant sterols present in kraft mill efflu-
ents can also produce androgenic steroids.
The oestrogenic effects of the mycotoxin zear-
alenone have been known for some time as a
cause of infertility and constant oestrus in
pigs fed Fusarium-contaminated maize.
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Thus, there is considerable exposure to
endocrine-modulating substances in feeds
and water. This can affect animal production
systems as well as interfere with rodent
bioassays designed to measure endocrine-
modulating compounds. For more informa-
tion on phyto-oestrogens, see the reviews by
Safe and Gaido (1998) and Santti et al. (1998).
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Xenobiotic endocrine modulators
Xeno-oestrogens include organochlorine pes-
ticides such as PCBs, dichlorodiphenyl-
trichloroethane (DDT) and the related
chemical methoxychlor, and bisphenol A
(Fig. 6.24). Industrial chemicals such as
nonylphenol, which is a breakdown product
of alkoxyphenol detergents, also have oestro-
genic effects. Most oestrogenic compounds
are phenols or, like methoxychlor, are activa-
ted to phenols. Methoxychlor is 200,000 times
less potent, nonylphenol is 300,000 less
potent and PCBs are 1 million times less
potent oestrogens than oestradiol. The
oestrogenic effects from organochlorines in
the diet have been estimated to be 2.5 × 108
less than the oestrogen equivalents from
isoflavonoids in foods. The most potent xeno-
biotic endocrine disruptors in mammals are
the 2-phenyl-substituted cyclic tetrasilox-
anes, such as 2,6-cis-diphenylhexamethyl
cyclotetrasiloxane, which has a potency of
one-tenth that of DES.
Tributyltin (TBT) is used as an
antifoulant in paints for the hulls of ships and
has dramatic effects on marine invertebrates.
It results in masculinization (imposex) of
females in several species of marine snails
and interferes with reproduction in bivalves,
including oysters and other molluscs. TBT
becomes associated with nerves and ganglia
and may affect the production of neurohor-
mones. TBT also interferes with shell growth
through effects on calcium channels. The
resultant decline in gastropod populations
has been reversed following restrictions on
TBT use.
Insecticides such as juvenile hormone
analogues (methoprene), which act by inter-
fering with moulting and metamorphosis,
can also interfere with the development of
important marine crustaceans, including lob-
ster, crab and shrimp.
Municipal wastewater can contain sig-
nificant levels of oestrone, oestradiol and
ethinyl oestradiol. These oestrogens can
come from pregnant women, use of oral
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contraceptives and hormone replacement
therapy. There may also be significant release
of steroid hormones in the manure from
swine production and other intensive
animal-holding facilities.
Indirect mechanisms of action
Effects on hormone metabolism
Xenobiotic chemicals can affect the activities
of the cytochrome P450 (CYP) enzymes that
are involved in the metabolism of steroid
hormones. CYP enzymes in families 1–4 are
responsible for the metabolism of both natu-
ral endogenous steroids and xenobiotic
chemicals to more polar compounds for
excretion. These families of enzymes can be
induced by exposure to xenobiotics. CYP
enzymes in families 11, 17, 19, 21 and 27 are
involved in the synthesis of steroid hormones
and these enzymes can be inhibited by xeno-
biotics. Thus, exposure to xenobiotic chemi-
cals can decrease the synthesis and increase
the degradation of endogenous steroid
hormones, resulting in decreased levels of
these hormones. Birds fed diets containing
DDT, dieldrin or PCBs showed induction of
hepatic CYP enzymes and increased metabo-
lism of steroids to more polar products.
Exposure of blue heron embryos to
tetrachlorodibenzo-p-dioxin (TCDD) in-
creased testosterone hydroxylase activity and
7-ethoxyresorufin-O-deethylase (EROD)
activity (a measure of CYP1A1) measured in
vitro. However, TCDD treatment did not
affect plasma levels of testosterone or oestra-
diol in vivo, suggesting that the animal’s
endocrine system adapts to changes in
steroid hormone degradation through feed-
back mechanisms. Ergosterol biosynthesis
inhibiting fungicides (EBI) are widely used in
agriculture and can inhibit CYP enzymes.
However, in vivo treatment of partridges with
a potent EBI did not affect levels of plasma
steroids.
Organochlorine pesticides such as
DDT are persistent in the environment and
accumulate in animals at the top of the
food chain. They can cause direct toxic
effects at high levels and act as endocrine
disruptors at lower levels. Fish from
sites with high levels of PCBs have ab-
normal gonad development and de-
creased fecundity. Toxic effects have been
shown in birds and alligators and in
mammals such as seals and mink that
eat these fish. However, it should be
noted that these animals might also be
exposed to high levels of other toxic com-
pounds, such as methyl mercury. A well-
known example of the effects of
organochlorine pesticides is the major spill
that occurred in Lake Apopka in Florida,
which resulted in distorted sexual de-
velopment and reproductive function in
alligators (Guillette et al., 1994). In
birds, organochlorine pesticides are thought
to cause eggshell thinning, resulting in
increased embryo mortality from breakage
or increased permeability of the shell.
This is thought to be the cause of the decline
in a number of raptor species in North
America and Europe. The major cause
of this problem is thought to be p,p’-DDE,
which is a major metabolite of p,p’-DDT.
Commercial DDT is made up of several
isomers, with 75–80% being p,p’-DDT.
The o,p’-DDT isomers are relatively un-
stable and are rarely found in the en-
vironment. These compounds can act as
oestrogens themselves, as well as inducing
CYP enzymes that metabolize oestrogen and
thus decrease oestrogen activity. The p,p’-
DDT isomer has also been shown to be an
androgen receptor antagonist. The levels of
organochlorines in the environment have
decreased somewhat since the use of these
chemicals was phased out in the 1970s and
early 1980s and eggshell thickness in birds
has increased. However, levels of PCBs and
TCDD are still significantly elevated in the
Great Lakes and feeding mink with carp from
Lake Michigan has been shown to adversely
affect reproduction and survival of the
young.
Xenobiotic chemicals can inhibit the
activity of the oestrogen-specific 17β-hydroxy-
steroid dehydrogenase (17β-HSD) type I
that converts oestrone to the more biological-
ly active oestradiol. A variety of flavonoid
compounds inhibit 17β-HSD type I, at con-
centrations from 0.12 to 1.2 mM. Some
flavones also inhibit the 17β-HSD type II that
catalyses the 17β-oxidation of testosterone
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to androstenedione and oestradiol to
oestrone, producing less active steroids.
Flavonoids also inhibit aromatase activity.
This anti-oestrogen activity of flavonoids
may explain the reduced incidence of breast
and prostate cancer attributed to diets high in
phyto-oestrogens. 
Effects on thyroid function
Thyroid hormones are necessary for the
development of neurones and they affect
metabolism, growth and reproduction in all
vertebrates. They are also involved in the
smoltification (conversion from a freshwater
to a saltwater habitat) of salmonid fish and
metamorphosis in flounder to form the asym-
metrical adult. They are also required in the
development of amphibians and the meta-
morphosis from the tadpole stage to the adult
frog, which is the basis for a popular bioassay
for thyroid hormone activity.
There are three major mechanisms for
the disruption of thyroid function:
1. Inhibition of the iodoperoxidase enzyme of
the follicle cells in the thyroid gland;
2. Effects on the transport of thyroid
hormones by thyroid-binding globulin,
thyroxine-binding prealbumin (transthy-
retin) and albumin; and
3. Effects on the catabolism of thyroid hor-
mones and conjugation by the UDP-
glucuronyl transferase.
Cabbage and a number of other Brassica
species contain potent anti-thyroid com-
pounds. The most important of these is
goitrin (vinyl-2-thioxazolidine), which is as
active as the drug propylthiouracil that is
used for treating hyperthyroidism.
Glucosinolates and cyanogenic glucosides
present in foods can also be metabolized by
the myrosinase enzyme present in brassica
plants, as well as by intestinal bacteria to
form thiocyanate, which is goitrogenic.
Synthetic thionamides, aromatic amines and
polyhydric phenols inhibit the synthesis of
thyroid hormones. There are dramatic
species differences in the susceptibility of
thyroid function to sulphonamides, with rats,
mice, hamsters, dogs and pigs susceptible,
while primates, guinea-pigs and chickens are
resistant. This can be explained in part by the
inhibition of thyroid peroxidase by sulpha-
monomethoxine in the rat but not in mon-
keys. Thyroid activity is also higher in rats,
due to high levels of TSH and the lack of
thyroid-binding globulin, which increases
the turnover of thyroid hormone. Sulpha
drugs also induce thyroid neoplasia in the rat
but are not human carcinogens. The rele-
vance of thyroid disruption in a rodent test
model to endocrine disruption in other
species is thus questionable.
There is evidence that levels of thyroid
hormone can be reduced in rats by exposure
to high levels of PCBs, polybrominated
biphenyls and dioxins. These effects are seen
mainly with T4, with no effect on active T3,
suggesting that the deiodinase activity
increases to maintain T3 levels. The decrease
in T4 is not due to decreased synthesis of T4,
but may be due to increased activity of the
T4-UDP-glucuronyl transferase or reduced
binding of T4 to the transthyretin binding
protein in the blood. However, these effects
on thyroid hormones are not seen in birds.
Effects on adrenal function
An example of EDCs that affect adrenal func-
tion is the consumption of liquorice.
Liquorice can affect the synthesis of adrenal
steroids and result in retention of sodium,
excretion of potassium and hypertension due
to an imbalance in the renin–angiotensin–
aldosterone system. Liquorice contains gly-
cyrrhizic acid, which is deconjugated to the
free steroid glycyrrhetic acid (Fig. 6.25) in the
intestine. Glycyrrehetic acid is absorbed from
the intestine and acts as an inhibitor of the
11β-hydroxysteroid dehydrogenase in the
kidney, which catalyses the conversion of cor-
tisol to cortisone in the synthesis of the adre-
nal corticoids. A regular intake of 50 g of
licorice provides about 100 mg of glycyrrhet-
ic acid, which is sufficient to induce clinical
signs of excess mineralocorticoid activity in
sensitive individuals.
Effects on CNS function and behaviour
Exposure to endocrine disruptors can affect
the function of the central nervous system
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(CNS) and alter behaviour. This can occur
during early development and neonatal life,
during puberty and breeding or after the
behaviour is established. Hormones direct
the organization of the CNS and reproductive
tract during early development and are then
involved in the activation of sexual dimor-
phic behaviours via the hypothalamus–
pituitary–gonadal axis at puberty and the
maintenance of behaviour during adult-
hood (see Section 5.1).
Testosterone (T), dihydrotestosterone
(DHT) and oestradiol (E2) are involved in
male programming of the CNS and develop-
ment of the reproductive tract, with the rela-
tive importance of each steroid varying
among species. Treatment of neonatal female
hamsters or rats with oestrogenic compounds
induces male mounting behaviour when
these animals were later treated with testos-
terone as adults. Masculinization of the CNS
in this way increases the size of the sexually
dimorphic nucleus in the preoptic area of the
hypothalamus. Perinatal exposure to oestro-
genic or anti-androgenic compounds pro-
duces developmental abnormalities in the
male reproductive tract. Exposure of imma-
ture female rats to the oestrogenic pesticide
methoxychlor at doses from 2 to 200 mg kg–1
day–1 induces precocious puberty within a
few days of treatment. In adult rats, xeno-
oestrogens reduce food consumption, weight
gain and sexual behaviours.
Some pesticides act by disrupting nerve
function, such as organophosphorous insecti-
cides that act as acetylcholinesterase
inhibitors and pyrethroid insecticides that
affect sodium flux. These might be expected
to act as endocrine disruptors, but this has
not been well documented. There is evidence
that endocrine disruptors impair the stress
response in fish, but not in birds. For more
information on the effects of endocrine dis-
ruptors on the CNS, see Gray and Ostby
(1998). 
Summary
In summary, particular indicator species have
been used for monitoring endocrine disrup-
tors in the environment. However, even
though endocrine-modulating chemicals can
have significant effects with in vitro systems,
many in vivo studies have shown that the
effects may not overwhelm the normal homeo-
static control mechanisms to cause adverse
effects in animals. The potential adverse
effects of endocrine-modulating compounds
depend on the potency, levels of exposure
and time during development when expo-
sure to the compounds occurred. Possible
effects on wildlife populations are sometimes
difficult to determine due to a lack of baseline
data and the presence of other environmental
effects. For example, declines in fish popula-
tions can be due to habitat destruction or
competition from other species. The ex-
posure of humans in terms of oestro-
genic equivalents from synthetic endocrine
disruptors is estimated to be much less than
that from oestrogens used for oral contracep-
tives or natural oestrogenic compounds in
foods.
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Questions for Study and Discussion
Section 6.1 Control of Broodiness in Poultry
1. Describe factors that lead to broodiness in poultry. How can broodiness be controlled?
Section 6.2 Applications of Pheromones
1. Describe the physiological roles of pheromones.
2. Describe the nature of pheromone-binding proteins and pheromone receptors.
3. Describe sex pheromones in rodents, pigs, cattle, and sheep and goats.
4. Describe pheromones used by fish.
5. Give examples of sex pheromones, aggregation pheromones and alarm pheromones in insects.
6. Describe the use of insect pheromones in pest control.
Section 6.3 Effects of Stress
1. Discuss the nature of stress. What are the behavioural and physiological responses to stress?
2. Describe the role of the SA and HPA systems in the response to stress.
3. Describe the different roles of CRH and CRH receptors in the stress response.
4. Discuss the role of other hormones in the stress response.
5. Describe behavioural, physiological and endocrine methods to assess the level of stress.
6. Describe the systems involved in innate and acquired immunity. What is the effect of stress on
these systems?
7. Describe the effects of stress on reproduction.
8. Describe the effects of stress on nutrient utilization and growth performance.
Section 6.4 Endocrine Applications in Toxicology
1. Discuss the nature of endocrine disruptor chemicals.
2. Outline in vitro and in vivo tests for endocrine disruptors.
3. Give examples of plant-derived and xenobiotic endocrine disruptors.
4. Describe the potential effects of endocrine disruptors on hormone metabolism, thyroid and adre-
nal function, and CNS function and behaviour.
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